data_1jr6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1jr6 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.187 0.518 . . . . 0.0 110.405 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.449 HD12 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.463 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.466 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.423 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.466 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.441 HD22 HG22 ' A' ' 21' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.437 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.458 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.535 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.535 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.463 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.405 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.409 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.481 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.497 HG23 HG21 ' A' ' 81' ' ' VAL . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.4 t30 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.434 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.492 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.492 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 6.0 pt . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 122.093 0.949 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 HG23 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG2' HG11 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.006 0.431 . . . . 0.0 110.587 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.498 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.474 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.419 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.301 0.572 . . . . 0.0 110.788 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.446 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.446 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.456 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.504 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.456 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.439 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 121.263 0.554 . . . . 0.0 109.957 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.491 ' CD1' HG21 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.439 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.469 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' N ' ' A' ' 23' ' ' PHE . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.471 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.541 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.403 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.503 ' CG ' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.425 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.439 ' CD1' HG13 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.428 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.487 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.459 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.487 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.453 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.503 ' CG ' ' CG ' ' A' ' 45' ' ' LYS . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.481 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.419 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.431 ' CB ' HG12 ' A' ' 63' ' ' VAL . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.448 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.921 0.867 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.484 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.053 0.454 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.432 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.526 0.679 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 114' ' ' SER . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.491 HG21 ' CD1' ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.46 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG12 ' A' ' 32' ' ' VAL . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 49.9 t . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.263 0.554 . . . . 0.0 109.765 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.497 ' CD1' HG22 ' A' ' 122' ' ' THR . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.445 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.463 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.456 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.52 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.426 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.432 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.401 HG11 ' HG2' ' A' ' 29' ' ' PRO . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.53 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.53 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.494 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.433 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.494 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG12 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.443 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.498 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.442 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.473 HG22 HG23 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.498 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.465 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.427 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.449 ' CB ' HG11 ' A' ' 63' ' ' VAL . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.465 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.945 0.879 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.429 HG23 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.427 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.426 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.426 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.076 0.465 . . . . 0.0 110.471 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.409 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.491 HG21 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.424 HD12 ' CD1' ' A' ' 40' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.6 m . . . . . 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.366 0.603 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.451 ' O ' ' N ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.497 HG22 ' CD1' ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.491 ' CD1' HG21 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 37.8 t . . . . . 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.42 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.5 m-80 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.136 0.493 . . . . 0.0 109.925 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.452 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.4 HD21 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.431 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.476 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.453 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.428 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.476 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.428 ' CG2' HG23 ' A' ' 28' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.548 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.458 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.548 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.472 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.511 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.424 ' CD2' HD11 ' A' ' 21' ' ' ILE . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.468 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.458 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.415 ' ND2' HD13 ' A' ' 74' ' ' ILE . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.48 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.496 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.511 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.474 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.466 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.424 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.496 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.427 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.8 pp . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 122.018 0.914 . . . . 0.0 110.053 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' HG12 ' A' ' 80' ' ' VAL . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.48 HG23 ' CB ' ' A' ' 62' ' ' ALA . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.47 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 120.92 0.391 . . . . 0.0 111.172 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CG2' HD13 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.407 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.323 0.582 . . . . 0.0 110.963 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.421 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.424 HG21 ' N ' ' A' ' 114' ' ' SER . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.424 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.409 ' HB2' ' O ' ' A' ' 114' ' ' SER . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.452 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.431 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.476 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.431 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 74.9 t . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 . . . . . 0 N--CA 1.501 2.099 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.463 ' CD1' HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.404 ' O ' ' HD2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.437 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.482 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.404 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.482 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.46 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.42 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' HG22 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.5 ' HA ' ' CD2' ' A' ' 38' ' ' HIS . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.5 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.526 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.411 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.429 ' HE3' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.507 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.514 ' N ' HD23 ' A' ' 58' ' ' LEU 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 35.1 t30 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.507 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.47 ' HB ' HG22 ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.547 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.433 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.537 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.537 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.47 HG22 ' HB ' ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.414 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.1 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.884 0.849 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.454 ' O ' HG12 ' A' ' 80' ' ' VAL . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.433 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.438 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.438 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.406 HD11 ' CD2' ' A' ' 65' ' ' TYR . 5.3 tp . . . . . 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.159 0.505 . . . . 0.0 110.592 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.475 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.505 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.43 HD12 HG23 ' A' ' 33' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.456 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.425 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.424 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.407 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.425 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HA ' ' CE2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.404 ' HD3' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.463 HG23 ' CD1' ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.505 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.7 t . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.429 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.479 HG21 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.479 ' HB ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.496 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.426 HD22 HG22 ' A' ' 21' ' ' ILE . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.434 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.537 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.451 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.429 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.462 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.486 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.468 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.448 HG22 HG23 ' A' ' 81' ' ' VAL . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 16.8 t30 -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.486 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.435 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.489 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.489 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.446 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.435 ' CB ' HG11 ' A' ' 63' ' ' VAL . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.404 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.3 pp . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 122.036 0.922 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.472 HG21 HD21 ' A' ' 55' ' ' LEU . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.43 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.452 HG22 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.441 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 120.928 0.394 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.486 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.469 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.415 ' CG2' HD12 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.45 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.185 0.517 . . . . 0.0 110.744 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.412 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.45 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.446 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.446 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.445 ' CG2' HG23 ' A' ' 10' ' ' ILE . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.453 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.433 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.469 ' CD2' HG23 ' A' ' 99' ' ' VAL . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.433 ' HD2' ' CG1' ' A' ' 32' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 55.9 t . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.751 0 CA-C-O 120.807 0.336 . . . . 0.0 111.155 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.465 ' CD1' ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.439 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.402 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.436 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.443 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.439 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.443 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.426 HD21 HG21 ' A' ' 21' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.412 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.453 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.488 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.525 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.487 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD23 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.464 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.442 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.432 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.475 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.445 HD21 ' N ' ' A' ' 58' ' ' LEU . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.488 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.42 ' ND2' HG23 ' A' ' 80' ' ' VAL . 21.0 t30 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.475 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.515 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.434 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.485 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.485 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.481 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.435 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.475 ' N ' HG13 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.815 0.817 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.473 HG22 HD21 ' A' ' 55' ' ' LEU . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG12 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.401 HG21 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.401 ' N ' HG21 ' A' ' 85' ' ' THR . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.002 0.429 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.434 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.488 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.447 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.482 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.387 0.613 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.439 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.432 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.405 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.443 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' HA ' ' NE ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.466 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.406 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.466 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.445 ' N ' HG22 ' A' ' 122' ' ' THR . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.488 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.447 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.082 0.468 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.477 ' CD1' HG22 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.44 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . 0.479 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.449 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.465 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.467 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.409 ' O ' ' N ' ' A' ' 23' ' ' PHE . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.467 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.465 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.411 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.415 ' C ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.451 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.451 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.494 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.422 ' O ' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.512 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.459 HG22 HG21 ' A' ' 81' ' ' VAL . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.9 t30 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.512 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.482 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.44 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.494 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.487 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.444 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.475 ' N ' HG11 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.469 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.859 0.838 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.478 HG23 ' CB ' ' A' ' 62' ' ' ALA . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.434 HG23 ' CG1' ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.44 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.444 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.19 0.519 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' HG23 ' A' ' 122' ' ' THR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.424 HD12 ' CG2' ' A' ' 33' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.498 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.423 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.477 0.656 . . . . 0.0 110.857 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.433 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.433 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.404 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.437 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.434 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.478 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 126' ' ' LYS . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.411 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.4 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.623 0.725 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.44 HD11 ' CG2' ' A' ' 122' ' ' THR . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.459 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.444 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.433 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.464 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.472 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.419 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.43 ' CD1' HD13 ' A' ' 28' ' ' ILE . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.444 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.433 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' N ' ' A' ' 34' ' ' LYS . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.436 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.426 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.516 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.516 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.423 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.483 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.496 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.489 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.45 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG21 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.0 t30 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.489 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HB ' ' CG2' ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.505 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.505 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.473 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.4 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.44 ' CB ' HG12 ' A' ' 63' ' ' VAL . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.473 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 122.009 0.909 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 80' ' ' VAL . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.478 HG21 HD23 ' A' ' 55' ' ' LEU . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.473 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.443 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.428 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.41 HD11 ' CG1' ' A' ' 82' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.031 0.443 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.484 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.404 0.621 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.437 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.404 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.484 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.44 ' CG2' HD11 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.488 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.488 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.432 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.484 ' CD2' HG22 ' A' ' 99' ' ' VAL . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.3 t . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.458 HD13 ' CG2' ' A' ' 122' ' ' THR . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.505 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.505 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.485 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.427 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.415 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.479 ' O ' ' CD2' ' A' ' 38' ' ' HIS . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.493 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.493 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.435 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.419 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.412 HD13 HG13 ' A' ' 83' ' ' VAL . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.443 ' CD ' HD11 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.493 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.41 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 28.7 t30 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.522 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.464 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.438 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.457 ' CE1' HD21 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.457 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.432 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.43 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.464 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.911 0.863 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.415 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.438 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' THR . . . . . 0.45 HG22 ' N ' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.419 ' CD1' ' CD2' ' A' ' 65' ' ' TYR . 14.6 tp . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.091 0.472 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.483 HG21 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.245 0.545 . . . . 0.0 110.984 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.407 HG22 ' N ' ' A' ' 114' ' ' SER . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.407 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.413 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.495 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.458 ' CG2' HD13 ' A' ' 10' ' ' ILE . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.456 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.456 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.454 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.435 ' N ' HG21 ' A' ' 122' ' ' THR . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.495 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.424 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 121.104 0.478 . . . . 0.0 110.619 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 HG21 ' A' ' 10' ' ' ILE . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.431 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.423 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.468 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.462 HG23 ' O ' ' A' ' 21' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.4 ' O ' ' HD3' ' A' ' 29' ' ' PRO . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.441 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.415 ' OE2' ' CG1' ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.441 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.53 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.465 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.53 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.466 HD22 ' CE2' ' A' ' 41' ' ' PHE . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.449 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.466 ' CE2' HD22 ' A' ' 39' ' ' LEU . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.486 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.438 HD21 ' CD1' ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.413 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.48 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.454 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.416 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.5 t30 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.48 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.467 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.528 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.424 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 82' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.971 0.891 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.467 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.133 0.492 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.543 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.404 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.414 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.427 0.632 . . . . 0.0 110.821 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.441 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.441 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.425 ' N ' HG23 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.431 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.419 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.493 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.419 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' CD1' ' A' ' 10' ' ' ILE . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.495 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.495 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.543 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.431 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.409 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 16.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.2 m120 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.162 0.506 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.439 HD12 ' HG2' ' A' ' 119' ' ' ARG . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.432 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.447 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.469 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.446 HG23 ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.446 ' O ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.469 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.442 HD21 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.443 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.542 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.466 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.542 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.493 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.438 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.464 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.431 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.428 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.485 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HG21 ' A' ' 81' ' ' VAL . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.496 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.454 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.487 ' CE1' HD22 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.487 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.433 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.435 ' CB ' HG11 ' A' ' 63' ' ' VAL . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.496 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.933 0.873 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.477 HG21 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.481 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.454 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.409 ' HB1' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.757 0.313 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.493 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.43 ' CD1' ' HD2' ' A' ' 131' ' ' ARG . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.449 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 121.614 0.721 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.405 HG22 ' N ' ' A' ' 114' ' ' SER . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.405 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.471 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.436 HG23 HG12 ' A' ' 10' ' ' ILE . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.407 ' HA ' ' HD3' ' A' ' 124' ' ' ARG . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.469 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.428 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 98' ' ' SER . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.435 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.0 t . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.544 0.688 . . . . 0.0 109.261 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.444 HD13 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.467 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.442 HD22 ' CB ' ' A' ' 26' ' ' LYS . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.427 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.488 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.488 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.449 HD22 HG21 ' A' ' 21' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.438 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.52 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.478 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.52 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.441 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.415 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.414 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.465 HD21 ' HB3' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.445 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.478 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.476 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.44 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.527 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.441 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.424 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.476 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 122.115 0.96 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 80' ' ' VAL . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.443 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.419 ' CB ' ' CA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.454 ' CD1' HG22 ' A' ' 73' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.242 0.544 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.436 ' CD1' HG21 ' A' ' 33' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.411 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.601 0.715 . . . . 0.0 111.198 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.438 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.413 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.424 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.438 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.45 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.42 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.445 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.445 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.443 ' N ' HG23 ' A' ' 122' ' ' THR . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.415 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.433 0.635 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.457 HD12 ' NH1' ' A' ' 119' ' ' ARG . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.41 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.403 ' O ' ' NZ ' ' A' ' 26' ' ' LYS . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.443 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.505 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.47 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.472 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.422 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.401 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.511 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.443 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.47 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' SER . . . . . 0.427 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.45 ' CD1' HG12 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 48' ' ' CYS . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.428 ' HE2' ' HA ' ' A' ' 21' ' ' ILE . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.481 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.475 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.3 t30 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.497 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.479 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.517 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.517 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.497 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.426 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.947 0.88 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 80' ' ' VAL . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 60' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.491 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.41 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.124 0.488 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.461 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.421 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 100' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.225 0.536 . . . . 0.0 110.972 . . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.431 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.431 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.401 ' O ' ' CG ' ' A' ' 121' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.457 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.41 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 32.1 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.495 1.817 0 CA-C-O 120.969 0.414 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.479 ' CG1' ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.476 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.464 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.467 HG23 ' O ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.476 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.438 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 21' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.432 HD22 ' CD1' ' A' ' 60' ' ' ILE . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.405 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.434 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.519 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.444 ' CG ' HG12 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.519 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.522 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.431 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.426 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.438 ' CD1' HG12 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.445 ' CE ' HD22 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.48 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.511 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.48 HG22 HG22 ' A' ' 81' ' ' VAL . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.452 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.426 ' HG ' ' HA ' ' A' ' 65' ' ' TYR . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.423 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.478 HG22 ' HB ' ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.455 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.799 0.809 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.431 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.452 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.034 0.445 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.489 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.529 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.437 HG23 ' CD1' ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.511 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.44 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.406 HG23 ' O ' ' A' ' 103' ' ' ASN . 1.3 p . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.44 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.354 0.597 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.471 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.488 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.402 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.467 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.467 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.433 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.529 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.479 ' NE ' ' CG1' ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.15 0.5 . . . . 0.0 110.427 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.439 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.445 HD21 ' CB ' ' A' ' 26' ' ' LYS . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.452 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.491 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.484 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.445 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.445 ' CB ' HD21 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.442 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.484 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.491 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' LYS . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.428 ' CG2' HG23 ' A' ' 28' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.497 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.457 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.497 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.483 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.436 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.483 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.437 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.422 ' O ' HD22 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.494 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.477 HG23 HG23 ' A' ' 81' ' ' VAL . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 45.8 t30 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.489 ' CE1' HD21 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.489 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.44 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.495 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 122.012 0.91 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.477 HG23 HG23 ' A' ' 60' ' ' ILE . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 14.2 tp . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.024 0.44 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.522 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.436 HD13 ' CD1' ' A' ' 40' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.419 ' OD1' ' CB ' ' A' ' 41' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.399 0.619 . . . . 0.0 111.133 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.424 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.454 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.454 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.423 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.459 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.447 ' CG2' HD13 ' A' ' 10' ' ' ILE . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.454 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.454 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.42 HG21 HG22 ' A' ' 13' ' ' VAL . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.522 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 46.2 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.139 0.495 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.43 HD21 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.455 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.456 HG21 ' O ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.409 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.434 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.41 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' HG21 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.465 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.405 HD23 HD12 ' A' ' 60' ' ' ILE . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.407 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.526 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.526 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.494 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.475 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.494 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.434 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.493 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.422 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.433 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.414 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.481 HD21 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.462 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.484 HG22 HG21 ' A' ' 81' ' ' VAL . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.411 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.483 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.442 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.493 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.437 ' CD1' ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.437 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.435 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.448 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.475 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 122.103 0.954 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.484 HG21 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.442 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.201 0.524 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.425 ' CD1' HG22 ' A' ' 33' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.426 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.546 0.689 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.434 ' O ' ' OG ' ' A' ' 114' ' ' SER . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.472 ' O ' ' N ' ' A' ' 118' ' ' ARG . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.426 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.486 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.447 ' CG2' HD11 ' A' ' 10' ' ' ILE . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.444 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.426 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.404 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.301 0.572 . . . . 0.0 110.289 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.409 ' O ' ' HD3' ' A' ' 29' ' ' PRO . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.49 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.457 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.452 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.526 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.526 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.465 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.47 HD11 HG23 ' A' ' 40' ' ' ILE . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.537 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.494 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.428 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.492 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.458 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.465 HG22 HG23 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.3 t30 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.492 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' CG ' HD13 ' A' ' 88' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.495 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.96 0.886 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 62' ' ' ALA . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.457 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.459 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.46 HD13 ' CG ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.13 0.491 . . . . 0.0 110.428 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.417 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.501 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.444 ' N ' ' CD1' ' A' ' 100' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.491 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.212 0.529 . . . . 0.0 110.648 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.432 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.403 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.4 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.432 ' CB ' ' O ' ' A' ' 115' ' ' ARG . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.518 ' O ' HD12 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.467 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.45 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.467 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.296 0.57 . . . . 0.0 109.908 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.434 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.416 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.457 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.472 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.421 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.457 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.429 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.408 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.467 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.461 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.435 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.419 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.428 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.467 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.467 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 49.9 t30 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.48 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.453 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.512 ' CE1' HD22 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.512 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.48 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 122.029 0.919 . . . . 0.0 110.29 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.429 ' CG2' HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.452 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.434 HD11 ' CB ' ' A' ' 65' ' ' TYR . 3.4 tp . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.261 0.553 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.471 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.402 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.412 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.436 0.636 . . . . 0.0 110.862 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.412 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.438 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.439 ' CG2' HD13 ' A' ' 10' ' ' ILE . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.443 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.427 ' N ' HG22 ' A' ' 122' ' ' THR . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.467 ' CD2' ' HG3' ' A' ' 119' ' ' ARG . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.434 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 42.7 t . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.151 0.501 . . . . 0.0 110.358 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.427 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.466 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.425 HD21 ' CG2' ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.438 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.476 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 21' ' ' ILE . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.435 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.545 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.474 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.48 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.431 ' HB ' ' HA ' ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.48 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.418 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.426 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.437 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.473 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.495 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.473 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.474 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.495 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.484 ' CZ ' HD22 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.484 HD22 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.434 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.436 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' CB ' HG13 ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.469 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 122.073 0.939 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 80' ' ' VAL . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.473 HG23 ' CB ' ' A' ' 62' ' ' ALA . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.409 HG21 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.513 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.451 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . 0.425 HD13 ' CB ' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.357 0.599 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.549 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.433 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.452 ' O ' ' OG ' ' A' ' 114' ' ' SER . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.403 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.469 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.406 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.425 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.443 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.435 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . 0.433 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 54.6 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.46 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.506 2.373 0 N-CA-C 112.481 0.548 . . . . 0.0 112.481 . . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.444 HD11 ' CG2' ' A' ' 122' ' ' THR . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.422 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.439 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.474 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.415 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.452 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.476 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.474 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.449 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.44 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.437 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.451 ' CD ' HG12 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.533 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.424 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CG1' HG13 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.476 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.476 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.424 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.425 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.489 HD21 ' HB3' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.464 HG22 HG21 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HB3' HD21 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.488 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.455 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.478 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.478 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.456 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.488 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.3 pp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 122.0 0.905 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.408 HG21 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.455 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 86' ' ' ASP . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.04 0.448 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.426 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.401 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.469 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.322 0.582 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.416 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.469 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.416 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.422 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.401 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.466 0 CA-C-O 120.63 0.252 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.463 HD12 ' CG2' ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.457 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.404 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.471 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.467 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.457 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.467 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.414 HD21 HG22 ' A' ' 21' ' ' ILE . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.468 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.519 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.519 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.432 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.526 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.41 ' CD2' HD12 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.422 ' CE ' HG13 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.468 HD22 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.463 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.441 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.481 ' HB2' ' CD1' ' A' ' 66' ' ' TYR . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.424 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . 0.412 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.864 0.84 . . . . 0.0 109.983 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.476 HG21 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG2' HG11 ' A' ' 73' ' ' VAL . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.104 0.478 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.486 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.491 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.422 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.473 0.654 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.434 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.403 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.44 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.418 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.463 ' CG2' HD12 ' A' ' 10' ' ' ILE . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.461 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' N ' HG22 ' A' ' 122' ' ' THR . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.491 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.7 t . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.045 0.45 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.457 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.476 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.421 ' O ' ' CD ' ' A' ' 26' ' ' LYS . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.422 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.436 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.48 ' O ' HG22 ' A' ' 21' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.466 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.446 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.447 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.521 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.521 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.42 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.434 ' CG1' HG13 ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.42 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.445 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.453 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' CD1' ' A' ' 33' ' ' ILE . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.412 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.3 t30 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.503 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.476 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.468 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.459 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.439 ' CB ' HG12 ' A' ' 63' ' ' VAL . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.503 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.427 ' O ' ' CG1' ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.933 0.873 . . . . 0.0 110.216 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 62' ' ' ALA . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.455 ' CG2' HG12 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.142 0.496 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.4 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.404 ' CD1' HG23 ' A' ' 33' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . 0.427 ' HB3' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.427 ' NE2' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.322 0.582 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.43 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.457 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.463 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.457 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.1 t . . . . . 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.461 HD13 HG21 ' A' ' 10' ' ' ILE . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.41 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.435 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.426 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.456 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.408 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.437 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.518 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 41' ' ' PHE . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . 0.488 ' CZ ' HD23 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.433 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.402 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.443 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.483 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.453 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.51 HG21 HG21 ' A' ' 81' ' ' VAL . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.444 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.483 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.497 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.44 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.516 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.448 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.464 ' CB ' HG12 ' A' ' 63' ' ' VAL . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.497 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.444 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.44 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.158 0.504 . . . . 0.0 110.733 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.471 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.434 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 100' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.446 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . 0.481 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.616 0.722 . . . . 0.0 110.91 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.481 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . 0.403 ' HB2' ' O ' ' A' ' 114' ' ' SER . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.497 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.458 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.458 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.437 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.438 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.1 t . . . . . 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.5 m120 . . . . . 0 N--CA 1.508 2.457 0 CA-C-O 120.59 0.233 . . . . 0.0 111.264 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.402 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.435 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' LEU . . . . . 0.441 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' GLU . . . . . 0.414 ' CB ' HD13 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 28' ' ' ILE . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' PHE . . . . . 0.429 ' N ' ' O ' ' A' ' 26' ' ' LYS . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . 0.42 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' ILE . . . . . 0.461 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.446 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.419 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' ILE . . . . . 0.527 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' HIS . . . . . 0.527 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.401 ' HB3' ' CG1' ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.445 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' CYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 51' ' ' LEU . . . . . 0.445 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.519 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 55' ' ' LEU . . . . . 0.509 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 58' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.464 HG22 HG21 ' A' ' 81' ' ' VAL . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . 0.509 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.463 ' CG2' HG12 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 65' ' ' TYR . . . . . 0.461 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.5 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.458 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.436 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.427 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 73' ' ' VAL . . . . . 0.484 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 74' ' ' ILE . . . . . 0.453 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.993 0.902 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 81' ' ' VAL . . . . . 0.484 HG22 ' CB ' ' A' ' 62' ' ' ALA . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 84' ' ' ALA . . . . . 0.461 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 120.968 0.413 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.445 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.477 0.656 . . . . 0.0 110.8 . . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 111' ' ' ASP . . . . . 0.46 ' O ' ' OG ' ' A' ' 114' ' ' SER . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 113' ' ' VAL . . . . . 0.422 HG21 ' N ' ' A' ' 114' ' ' SER . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 114' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.407 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 117' ' ' GLN . . . . . 0.41 ' NE2' ' HA ' ' A' ' 117' ' ' GLN . 7.6 tp60 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 119' ' ' ARG . . . . . 0.488 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 121' ' ' ARG . . . . . 0.409 ' O ' ' CD ' ' A' ' 124' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 122' ' ' THR . . . . . 0.459 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 124' ' ' ARG . . . . . 0.409 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 126' ' ' LYS . . . . . 0.481 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.481 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 128' ' ' GLY . . . . . 0.459 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 129' ' ' ILE . . . . . 0.445 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CZ ' HG11 ' A' ' 32' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 132' ' ' PHE . . . . . 0.433 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -106.91 125.5 51.09 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 110.216 179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.404 HG22 ' O ' ' A' ' 3' ' ' VAL . 27.4 m -113.29 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 13.8 p -78.34 142.98 37.31 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.306 -0.871 . . . . 0.0 110.389 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.439 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.67 148.72 85.5 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.28 -0.887 . . . . 0.0 109.5 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.439 ' HD2' HG21 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -69.12 -169.22 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 124.085 1.571 . . . . 0.0 110.751 179.456 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.532 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.68 79.44 0.08 OUTLIER Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.34 -0.85 . . . . 0.0 110.135 -179.537 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.47 -15.36 27.8 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.609 1.32 . . . . 0.0 110.579 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.402 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.09 -1.006 . . . . 0.0 110.405 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.449 HD12 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.463 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.466 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.465 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.423 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.466 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.441 HD22 HG22 ' A' ' 21' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.437 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.458 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.535 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.535 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.463 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.436 ' CD1' HG13 ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.405 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.447 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.409 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.481 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.497 HG23 HG21 ' A' ' 81' ' ' VAL . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.4 t30 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.44 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.434 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.492 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.492 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 6.0 pt -136.47 91.29 16.35 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.58 42.22 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.701 1.369 . . . . 0.0 110.421 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -120.3 -24.76 5.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.144 -0.972 . . . . 0.0 110.654 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -163.01 162.22 25.86 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.6 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -61.27 106.77 0.66 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.1 -1.235 . . . . 0.0 109.894 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.434 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.497 HG21 HG23 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.444 ' CG2' HG11 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.437 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -68.97 -19.9 64.17 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.425 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.71 -150.52 0.37 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.266 -0.896 . . . . 0.0 109.871 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.453 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 109.964 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.32 -29.44 73.16 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.661 -1.375 . . . . 0.0 109.661 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.92 19.16 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.105 -1.232 . . . . 0.0 110.769 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.472 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.5 t -90.55 -154.78 0.35 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.084 -1.01 . . . . 0.0 110.32 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.44 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.26 -32.5 7.51 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.199 -1.161 . . . . 0.0 110.199 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.99 53.94 2.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.946 -1.326 . . . . 0.0 110.587 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.498 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.439 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.474 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.441 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p -146.45 132.52 19.29 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.82 134.32 54.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.936 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.41 29.09 2.65 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.196 -0.94 . . . . 0.0 110.628 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -32.98 5.49 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.29 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.266 -1.138 . . . . 0.0 110.088 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -65.14 133.75 36.67 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.562 1.296 . . . . 0.0 110.157 179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.419 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.19 1.8 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 110.788 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.446 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.425 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.446 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.532 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.425 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.456 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.458 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.44 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.504 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.504 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.456 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.439 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.41 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.9 -65.75 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.24 96.75 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.588 -0.695 . . . . 0.0 110.007 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.09 -49.46 0.3 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.688 1.362 . . . . 0.0 110.411 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.22 23.66 4.31 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.59 167.13 10.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -1.096 . . . . 0.0 110.195 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.041 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.76 135.42 34.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.184 . . . . 0.0 110.153 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.441 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 13.6 p -113.0 104.58 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.179 -0.951 . . . . 0.0 109.899 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 78.5 p -72.3 144.66 48.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.347 -0.846 . . . . 0.0 110.487 -179.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.428 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.44 147.98 98.15 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.306 -0.871 . . . . 0.0 109.672 179.686 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.428 ' HD2' HG21 ' A' ' 5' ' ' VAL . 49.9 Cg_endo -73.35 -173.77 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 O-C-N 124.071 1.564 . . . . 0.0 111.022 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.502 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.71 76.55 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.15 -17.41 45.37 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 O-C-N 123.865 1.455 . . . . 0.0 111.048 -179.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.03 -24.52 54.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.103 -0.998 . . . . 0.0 109.957 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.491 ' CD1' HG21 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.439 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.458 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.469 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.415 ' O ' ' N ' ' A' ' 23' ' ' PHE . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.43 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.469 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.541 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.471 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.541 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.403 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.447 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.503 ' CG ' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.425 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.439 ' CD1' HG13 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.428 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.487 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.459 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.475 HG22 HG23 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.487 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.469 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.453 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.503 ' CG ' ' CG ' ' A' ' 45' ' ' LYS . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.481 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.419 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.431 ' CB ' HG12 ' A' ' 63' ' ' VAL . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.448 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 2.0 pp -137.95 115.72 9.52 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.401 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 52.2 Cg_endo -87.37 39.16 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.256 1.135 . . . . 0.0 110.97 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.17 46.88 1.42 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.928 -1.107 . . . . 0.0 110.554 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.436 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 3.8 m-80 -142.26 26.9 1.79 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.191 -0.943 . . . . 0.0 110.177 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.0 -94.92 1.12 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.79 109.06 10.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.169 -1.195 . . . . 0.0 110.164 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.446 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.466 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.484 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.84 -29.31 69.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.46 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 48.64 45.01 21.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.451 -0.781 . . . . 0.0 111.051 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.456 ' CB ' HG23 ' A' ' 93' ' ' THR . 2.5 t 33.92 -118.89 0.09 Allowed 'General case' 0 N--CA 1.505 2.282 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.55 -63.71 4.08 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -119.86 1.86 11.01 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.386 -1.067 . . . . 0.0 110.184 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.456 HG23 ' CB ' ' A' ' 90' ' ' THR . 12.3 t -67.63 -154.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.019 -1.05 . . . . 0.0 110.281 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.402 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 90.09 -41.53 2.97 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.04 57.49 4.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.178 -1.19 . . . . 0.0 111.114 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.432 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.422 ' CA ' ' O ' ' A' ' 108' ' ' LYS . 0.8 OUTLIER -147.35 113.72 5.94 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 59.1 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.17 -0.956 . . . . 0.0 110.615 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.38 28.27 5.65 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.384 -0.823 . . . . 0.0 110.704 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.83 57.17 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' A' ' 105' ' ' SER . 8.5 mmtt -96.6 156.68 36.4 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.052 -1.263 . . . . 0.0 109.764 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.67 133.81 41.18 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.625 1.329 . . . . 0.0 110.112 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.66 -177.16 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.378 -0.826 . . . . 0.0 111.128 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.411 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 114' ' ' SER . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.437 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.411 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.437 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.502 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.491 HG21 ' CD1' ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.401 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.46 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.46 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.418 ' NE ' HG12 ' A' ' 32' ' ' VAL . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 49.9 t -72.33 -61.42 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.97 147.83 33.76 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.388 -0.82 . . . . 0.0 109.953 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.37 -46.97 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.666 1.351 . . . . 0.0 110.484 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.21 -124.37 0.82 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.74 -62.1 1.58 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.232 -1.157 . . . . 0.0 110.213 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.8 ttt85 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.289 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.67 110.0 21.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -1.143 . . . . 0.0 110.325 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.401 ' O ' HG11 ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.04 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.206 -0.934 . . . . 0.0 110.021 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 17.3 p -63.83 145.14 56.35 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.378 -0.826 . . . . 0.0 110.28 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.428 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.45 98.22 Favored Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.228 -0.92 . . . . 0.0 110.147 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.428 ' HD2' HG22 ' A' ' 5' ' ' VAL . 43.5 Cg_endo -70.87 -175.86 1.58 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 124.09 1.574 . . . . 0.0 111.041 179.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.508 ' CE1' ' HB ' ' A' ' 10' ' ' ILE . 1.7 p80 -176.55 84.21 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.727 -0.608 . . . . 0.0 109.58 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.98 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.668 1.351 . . . . 0.0 110.554 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 4.3 m-80 -172.73 -36.99 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.635 -0.666 . . . . 0.0 109.765 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.508 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.426 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.445 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.463 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.456 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.52 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.426 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.427 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.463 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.443 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.432 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.401 HG11 ' HG2' ' A' ' 29' ' ' PRO . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.53 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.468 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.42 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.53 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.494 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.433 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.494 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.52 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG12 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.437 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.443 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.498 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.442 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.473 HG22 HG23 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . . . . . . . . . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.498 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.465 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.427 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.488 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.449 ' CB ' HG11 ' A' ' 63' ' ' VAL . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.465 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -136.04 99.08 11.32 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -84.46 48.02 2.33 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.762 1.401 . . . . 0.0 109.988 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.1 40.38 0.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 110.345 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -143.77 -165.45 2.11 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.14 -0.975 . . . . 0.0 110.285 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -50.32 -77.04 0.14 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -147.97 113.41 5.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.163 -1.198 . . . . 0.0 110.407 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.477 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.429 HG23 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.427 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.426 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.426 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -69.58 -16.13 63.35 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.457 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 16.8 mmt 53.23 -165.01 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.892 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.467 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.51 30.11 2.92 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 110.038 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.31 -42.09 94.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.24 14.94 11.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.221 -1.164 . . . . 0.0 110.667 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.486 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 6.6 t -80.38 -157.68 0.16 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.056 -1.028 . . . . 0.0 110.182 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 102.8 -32.84 7.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.268 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.81 56.79 3.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.113 -1.227 . . . . 0.0 110.471 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.486 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.409 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.491 HG21 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.424 HD12 ' CD1' ' A' ' 40' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.402 HG21 ' O ' ' A' ' 108' ' ' LYS . 1.6 m -143.85 121.68 11.97 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.83 43.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.173 -0.954 . . . . 0.0 110.398 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.13 30.17 5.37 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.308 -0.87 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.98 -28.87 8.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 110.001 -1.239 . . . . 0.0 110.001 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.441 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -80.89 155.39 72.97 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.055 -1.262 . . . . 0.0 109.983 179.857 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.09 136.75 45.66 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 O-C-N 123.578 1.304 . . . . 0.0 110.693 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.85 1.02 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.51 -0.744 . . . . 0.0 110.786 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.4 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.504 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.497 HG22 ' CD1' ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.491 ' CD1' HG21 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 37.8 t -77.19 -40.9 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.39 144.02 51.68 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.309 -0.869 . . . . 0.0 110.054 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.45 -55.73 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.585 1.308 . . . . 0.0 110.603 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.71 -91.33 0.41 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.01 68.16 0.89 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.233 -1.157 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.182 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.21 157.16 24.08 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -1.183 . . . . 0.0 110.175 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.95 104.48 17.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.3 -0.875 . . . . 0.0 109.67 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 p -66.68 136.96 56.32 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.415 -0.803 . . . . 0.0 110.517 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -72.99 149.03 89.63 Favored Pre-proline 0 C--N 1.303 -1.442 0 O-C-N 121.341 -0.849 . . . . 0.0 109.289 179.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -80.22 -165.56 0.35 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.027 1.54 . . . . 0.0 111.376 179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.502 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.03 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.817 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.16 60.73 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 O-C-N 123.909 1.479 . . . . 0.0 111.953 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.42 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.5 m-80 -131.92 2.6 4.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.481 -0.762 . . . . 0.0 109.925 178.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.452 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.4 HD21 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.431 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.476 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.453 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.466 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.428 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.476 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.424 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.428 ' CG2' HG23 ' A' ' 28' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.548 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.458 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.548 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.472 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.511 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.403 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.424 ' CD2' HD11 ' A' ' 21' ' ' ILE . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.453 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.471 ' HB3' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.468 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.458 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.415 ' ND2' HD13 ' A' ' 74' ' ' ILE . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.48 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.496 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.488 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.511 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.474 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.424 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.496 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.427 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.8 pp -136.94 109.54 9.15 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -86.94 46.82 1.51 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.466 1.245 . . . . 0.0 110.247 179.374 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.3 p -129.85 -9.48 4.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.069 -1.02 . . . . 0.0 111.438 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -88.92 -171.92 3.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.921 -1.112 . . . . 0.0 110.341 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.13 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -130.81 114.44 15.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.188 -1.184 . . . . 0.0 110.053 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.42 ' O ' HG12 ' A' ' 80' ' ' VAL . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.48 HG23 ' CB ' ' A' ' 62' ' ' ALA . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.47 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.446 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.86 -29.15 67.4 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.449 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.8 OUTLIER 55.62 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.827 -0.546 . . . . 0.0 110.444 179.866 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' N ' ' O ' ' A' ' 88' ' ' LEU . 0.3 OUTLIER 173.62 43.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.023 -1.048 . . . . 0.0 110.214 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.91 -46.81 90.37 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.22 28.18 2.55 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.423 -1.045 . . . . 0.0 110.138 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.42 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 3.1 t -86.29 -160.38 0.55 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.204 -0.935 . . . . 0.0 110.413 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 100.48 -31.83 8.07 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.48 73.92 0.94 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.859 -1.377 . . . . 0.0 111.172 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.414 ' CG2' HD13 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -147.38 126.25 12.72 Favored 'General case' 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.57 129.26 46.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 110.172 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.36 29.06 16.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.221 -0.924 . . . . 0.0 110.566 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.76 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.515 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.4 68.81 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.153 -1.204 . . . . 0.0 110.206 -179.863 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.7 137.45 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.555 1.292 . . . . 0.0 110.492 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.407 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.3 163.65 0.23 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.443 -0.786 . . . . 0.0 110.963 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.421 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.424 HG21 ' N ' ' A' ' 114' ' ' SER . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.424 ' N ' HG21 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.409 ' HB2' ' O ' ' A' ' 114' ' ' SER . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.502 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.431 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.476 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.431 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.401 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 74.9 t -86.7 -41.3 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.47 111.6 63.99 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.195 -0.941 . . . . 0.0 110.289 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.404 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 44.9 Cg_endo -71.54 -46.67 0.59 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.508 1.268 . . . . 0.0 110.341 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.32 129.65 6.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.84 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.256 -1.143 . . . . 0.0 110.368 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.306 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.14 102.58 14.39 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -1.174 . . . . 0.0 110.164 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.42 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 10.4 p -113.34 104.34 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.271 -0.893 . . . . 0.0 109.676 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.2 p -100.4 140.39 34.72 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 110.451 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.488 ' O ' ' CE1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -67.15 147.37 99.02 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.829 . . . . 0.0 109.108 179.596 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.6 Cg_endo -73.92 -19.56 20.55 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 124.066 1.561 . . . . 0.0 113.101 -178.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CD2' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p-80 42.78 75.77 0.6 Allowed Pre-proline 0 N--CA 1.502 2.175 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -177.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.42 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.9 Cg_endo -71.01 -175.13 1.34 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.753 1.397 . . . . 0.0 110.133 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.42 ' HB2' ' O ' ' A' ' 8' ' ' PRO . 8.5 m120 65.78 7.15 4.35 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.637 -0.664 . . . . 0.0 111.226 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.463 ' CD1' HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.45 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.404 ' O ' ' HD2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.437 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.482 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.404 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.413 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.482 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.46 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.42 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.403 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.439 ' CG2' HG22 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.5 ' HA ' ' CD2' ' A' ' 38' ' ' HIS . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.5 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.414 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.44 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.526 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.411 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.441 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.429 ' HE3' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.507 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.514 ' N ' HD23 ' A' ' 58' ' ' LEU 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.447 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 35.1 t30 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.507 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.47 ' HB ' HG22 ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.547 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.433 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.537 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.537 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.464 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.425 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.47 HG22 ' HB ' ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.414 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.1 pp -133.78 89.94 28.96 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -90.63 53.5 1.1 Allowed 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.972 1.512 . . . . 0.0 110.582 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.408 HG23 ' N ' ' A' ' 77' ' ' ASN . 5.1 t -125.66 -25.97 3.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.113 -0.992 . . . . 0.0 111.043 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.408 ' N ' HG23 ' A' ' 76' ' ' THR . 56.4 m-80 -155.25 167.68 29.55 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.991 -1.068 . . . . 0.0 110.599 -179.703 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.57 174.73 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -94.74 110.21 22.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.265 . . . . 0.0 110.194 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.454 ' O ' HG12 ' A' ' 80' ' ' VAL . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.485 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.547 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.433 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.438 ' CG2' ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.438 ' N ' ' CG2' ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.406 HD11 ' CD2' ' A' ' 65' ' ' TYR . 5.3 tp -67.44 -42.27 83.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.471 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.5 OUTLIER 49.71 23.45 0.99 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.531 -0.731 . . . . 0.0 110.447 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.462 ' CG2' ' HB ' ' A' ' 93' ' ' THR . 89.5 m 53.93 -85.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.708 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.13 -83.38 0.07 OUTLIER Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.422 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.5 p90 -97.89 37.83 1.37 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.384 -1.068 . . . . 0.0 108.557 178.159 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.477 HG22 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -137.76 -168.75 2.39 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.307 0.575 . . . . 0.0 110.328 -179.282 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.02 -17.87 4.55 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.39 75.92 3.89 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.175 -1.191 . . . . 0.0 110.592 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.477 ' CZ ' HG22 ' A' ' 93' ' ' THR . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.475 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.424 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.505 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.43 HD12 HG23 ' A' ' 33' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.456 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.421 ' CA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.45 130.53 16.36 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.3 p -107.58 134.92 49.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.105 -0.997 . . . . 0.0 110.545 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t0 55.98 32.86 20.66 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.31 -0.868 . . . . 0.0 110.94 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.39 12.46 83.81 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 179.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.448 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -123.44 156.05 64.59 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.075 -1.25 . . . . 0.0 109.607 179.698 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.91 127.76 21.29 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.549 1.289 . . . . 0.0 110.716 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.424 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.09 160.95 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 -179.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.422 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.425 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.424 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.407 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.435 ' CG2' HG12 ' A' ' 5' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.404 ' HD3' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.463 HG23 ' CD1' ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.43 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.424 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.505 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.45 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 4.7 t -84.77 -67.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.77 95.22 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.55 -0.719 . . . . 0.0 110.397 -179.734 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.28 -34.98 7.19 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.671 1.353 . . . . 0.0 110.382 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.37 -170.06 17.14 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.09 122.06 14.6 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.323 -1.104 . . . . 0.0 110.25 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.285 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 133.04 43.28 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.211 -1.17 . . . . 0.0 110.329 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.404 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.1 m -113.4 104.43 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.239 -0.913 . . . . 0.0 110.187 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.4 p -65.96 145.04 56.37 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.328 -0.858 . . . . 0.0 110.232 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.421 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.22 147.22 99.0 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.891 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.421 ' HD2' HG21 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.0 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 124.13 1.595 . . . . 0.0 111.076 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.537 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 3.3 p80 -178.9 83.02 0.21 Allowed Pre-proline 0 N--CA 1.489 1.484 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.83 89.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.732 1.385 . . . . 0.0 110.844 -179.127 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -179.98 -35.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.488 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.447 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.429 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.496 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.479 HG21 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.463 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.463 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.479 ' HB ' HG21 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.496 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.426 HD22 HG22 ' A' ' 21' ' ' ILE . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.434 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.537 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.537 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.405 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.451 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.42 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.404 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.429 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.462 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.486 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.468 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.448 HG22 HG23 ' A' ' 81' ' ' VAL . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.421 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 16.8 t30 -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.486 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.518 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.435 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.489 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.489 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.435 ' CB ' HG11 ' A' ' 63' ' ' VAL . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.462 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.404 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.3 pp -137.71 91.6 13.61 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.439 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 48.9 Cg_endo -89.37 44.89 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.633 1.333 . . . . 0.0 109.919 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.34 -21.99 4.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.252 -0.905 . . . . 0.0 111.257 -179.101 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.885 -1.135 . . . . 0.0 110.861 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.74 -177.78 0.07 OUTLIER Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.52 112.29 24.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.329 -1.101 . . . . 0.0 109.977 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.439 ' CG1' ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.472 HG21 HD21 ' A' ' 55' ' ' LEU . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.427 HG11 HG12 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.518 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.43 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.452 HG22 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.452 ' N ' HG22 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.441 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.62 -40.33 95.3 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.47 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.06 26.77 0.24 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.833 -0.542 . . . . 0.0 111.267 179.419 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.419 HG21 ' NE ' ' A' ' 121' ' ' ARG . 64.8 p 43.46 -133.45 0.57 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.561 -0.712 . . . . 0.0 110.973 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.86 -78.06 0.79 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -95.52 18.3 13.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -1.097 . . . . 0.0 109.814 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.476 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 13.3 t -98.89 -148.54 0.34 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.37 -0.831 . . . . 0.0 110.206 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 115.11 18.54 6.27 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.179 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.29 59.58 1.25 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.925 -1.338 . . . . 0.0 110.348 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.486 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.406 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.469 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.415 ' CG2' HD12 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.427 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -144.21 137.96 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.6 p -111.14 121.95 46.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.356 -0.84 . . . . 0.0 109.491 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.07 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.01 . . . . 0.0 109.405 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.24 9.62 57.06 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.794 -1.193 . . . . 0.0 110.242 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.401 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.17 155.5 73.6 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.92 -1.341 . . . . 0.0 109.865 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -67.47 160.7 46.69 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.531 1.28 . . . . 0.0 110.573 179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.45 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.13 147.61 52.07 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.349 -0.844 . . . . 0.0 110.744 -179.48 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.412 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.45 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.446 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.412 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.446 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.537 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.445 ' CG2' HG23 ' A' ' 10' ' ' ILE . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.441 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.453 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.458 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.433 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.406 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.469 ' CD2' HG23 ' A' ' 99' ' ' VAL . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.433 ' HD2' ' CG1' ' A' ' 32' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 55.9 t -94.27 -45.99 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.46 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 110.261 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.37 -21.38 23.02 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 O-C-N 123.564 1.297 . . . . 0.0 110.72 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.43 140.54 15.82 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.58 -29.35 66.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.233 -1.157 . . . . 0.0 110.272 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.237 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.83 108.06 4.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.282 -1.128 . . . . 0.0 110.235 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.424 ' CG2' ' O ' ' A' ' 3' ' ' VAL . 31.3 m -113.36 105.19 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.337 -0.852 . . . . 0.0 109.996 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.16 144.84 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.374 -0.829 . . . . 0.0 110.358 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.412 HG22 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.4 147.23 94.96 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 110.276 -179.884 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.412 ' N ' HG22 ' A' ' 5' ' ' VAL . 52.5 Cg_endo -76.36 -173.63 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 124.237 1.651 . . . . 0.0 110.985 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.508 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 3.9 p80 -177.94 83.69 0.23 Allowed Pre-proline 0 N--CA 1.489 1.51 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.83 58.51 1.6 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.487 1.256 . . . . 0.0 111.566 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.57 7.94 0.77 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.123 -0.986 . . . . 0.0 111.155 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.465 ' CD1' ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.447 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.439 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.402 ' HA ' ' HB2' ' A' ' 27' ' ' ALA . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.436 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.443 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.464 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.411 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.439 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.436 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.464 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.443 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.426 HD21 HG21 ' A' ' 21' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.412 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.453 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.525 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.488 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.431 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.525 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.487 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.485 ' CE2' HD23 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.41 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.464 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.442 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.417 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.432 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.475 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.445 HD21 ' N ' ' A' ' 58' ' ' LEU . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.488 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.42 ' ND2' HG23 ' A' ' 80' ' ' VAL . 21.0 t30 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.475 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.475 HG13 ' N ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.515 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.434 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.485 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.485 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.481 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.435 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.475 ' N ' HG13 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.65 93.6 12.31 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -79.59 60.93 8.02 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 123.757 1.398 . . . . 0.0 110.216 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.76 40.21 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.041 -1.037 . . . . 0.0 110.535 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.49 -163.51 1.58 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.199 -0.938 . . . . 0.0 109.812 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.34 -73.95 0.31 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.25 111.77 3.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -1.188 . . . . 0.0 110.315 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.431 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.473 HG22 HD21 ' A' ' 55' ' ' LEU . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.465 ' CG2' HG12 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.515 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.401 HG21 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp -63.51 -29.91 71.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.489 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.18 27.32 0.2 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.804 -0.56 . . . . 0.0 111.459 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.455 ' CB ' HG21 ' A' ' 93' ' ' THR . 61.2 p 42.06 52.58 4.35 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.779 -0.575 . . . . 0.0 111.422 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.52 -66.49 2.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -110.12 23.0 14.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.268 -1.136 . . . . 0.0 110.241 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.478 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.6 t -78.84 -148.44 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 110.15 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.433 ' N ' HG22 ' A' ' 93' ' ' THR . . . 103.54 -43.11 1.74 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.74 66.62 9.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 110.842 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.434 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.488 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.447 ' CG2' ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.482 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -143.11 140.53 30.9 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.433 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.4 p -114.31 127.69 55.99 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.356 -0.84 . . . . 0.0 109.985 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.1 t0 51.45 30.15 5.99 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.558 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.06 -32.96 5.51 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.4 mtmt -76.66 156.5 82.89 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.274 -1.133 . . . . 0.0 110.023 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -65.64 133.27 33.65 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.658 1.346 . . . . 0.0 110.381 179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -47.93 167.0 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.412 -0.805 . . . . 0.0 110.91 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.439 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.439 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.432 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.405 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.436 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.508 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' HA ' ' NE ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.466 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.409 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.44 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.466 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.445 ' N ' HG22 ' A' ' 122' ' ' THR . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.488 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.447 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t -85.91 -42.44 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.7 155.14 54.95 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.515 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.11 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.719 1.378 . . . . 0.0 110.518 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.69 74.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.62 81.42 4.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.201 -1.176 . . . . 0.0 110.245 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.282 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.9 m -87.97 150.67 23.31 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.299 -1.118 . . . . 0.0 110.368 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 17.4 m -113.18 104.45 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.28 -0.888 . . . . 0.0 109.833 179.587 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.412 ' CG2' ' O ' ' A' ' 112' ' ' ALA . 16.8 p -68.9 138.54 54.74 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.371 -0.83 . . . . 0.0 110.343 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.406 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.18 147.83 98.91 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 109.509 179.701 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.406 ' HD2' HG21 ' A' ' 5' ' ' VAL . 46.0 Cg_endo -71.5 -169.33 0.41 Allowed 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 124.142 1.601 . . . . 0.0 111.108 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.49 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.68 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.595 -0.691 . . . . 0.0 109.64 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.52 -10.58 28.25 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.68 1.358 . . . . 0.0 111.181 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -74.96 -11.24 60.07 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.973 -1.079 . . . . 0.0 110.437 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.477 ' CD1' HG22 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.44 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.479 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.449 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.465 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.467 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.409 ' O ' ' N ' ' A' ' 23' ' ' PHE . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.435 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.467 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.465 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.414 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.411 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.524 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.447 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.443 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.415 ' C ' ' CD2' ' A' ' 38' ' ' HIS . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.524 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.451 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.449 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.451 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.494 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.422 ' O ' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.498 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.512 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.498 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.459 HG22 HG21 ' A' ' 81' ' ' VAL . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.448 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.9 t30 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.512 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.475 HG11 ' N ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.482 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.44 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.494 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.487 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.444 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.402 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.475 ' N ' HG11 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.469 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.4 pp -136.34 98.3 11.39 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.429 ' O ' ' CG2' ' A' ' 76' ' ' THR . 51.0 Cg_endo -78.95 53.35 4.65 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 O-C-N 123.32 1.168 . . . . 0.0 110.192 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.429 ' CG2' ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.25 40.0 0.31 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.68 1.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.193 -0.942 . . . . 0.0 110.323 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.21 4.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.84 109.5 17.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.156 . . . . 0.0 110.136 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.448 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.478 HG23 ' CB ' ' A' ' 62' ' ' ALA . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.434 HG23 ' CG1' ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.44 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.444 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.37 -26.98 68.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.496 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 27.4 mmt 47.26 30.83 1.56 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.396 -0.815 . . . . 0.0 110.74 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.473 ' CB ' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.04 -134.95 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -178.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.29 21.03 8.03 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.679 -0.895 . . . . 0.0 109.391 178.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.473 HG22 ' CB ' ' A' ' 90' ' ' THR . 4.9 t -102.81 -155.5 0.53 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.88 . . . . 0.0 110.356 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.421 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 92.39 -33.98 4.68 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.2 59.01 5.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.973 -1.31 . . . . 0.0 110.423 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.407 ' CG2' HG23 ' A' ' 122' ' ' THR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.424 HD12 ' CG2' ' A' ' 33' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.498 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.01 136.42 22.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.417 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.1 p -113.12 126.66 55.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 110.124 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.74 35.61 19.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.773 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.24 -6.01 77.86 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.417 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.37 156.33 35.37 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.308 . . . . 0.0 110.078 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.5 129.18 21.86 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.732 1.385 . . . . 0.0 110.514 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.423 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 -51.08 152.87 2.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.484 -0.76 . . . . 0.0 110.857 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.433 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' CG2' ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.433 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.404 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.49 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.434 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.478 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.405 ' HD2' ' HB3' ' A' ' 126' ' ' LYS . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.403 ' HA ' HG22 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.411 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.4 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.5 -46.86 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.35 31.08 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.365 -0.834 . . . . 0.0 110.736 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.25 -23.75 15.23 Favored 'Trans proline' 0 C--N 1.315 -1.195 0 O-C-N 123.551 1.29 . . . . 0.0 110.726 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.61 147.05 29.2 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.49 -51.52 19.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.168 -1.195 . . . . 0.0 110.151 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.294 179.981 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.07 153.66 22.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.308 -1.113 . . . . 0.0 110.289 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 3' ' ' VAL . 33.7 m -113.42 104.52 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.235 -0.916 . . . . 0.0 110.026 179.679 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.422 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.03 143.73 57.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.312 -0.868 . . . . 0.0 110.026 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.432 HG23 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.24 149.01 86.73 Favored Pre-proline 0 C--N 1.301 -1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.579 179.656 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.521 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 41.8 Cg_endo -80.82 -57.94 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 124.229 1.647 . . . . 0.0 111.678 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.521 ' CD2' ' O ' ' A' ' 6' ' ' PRO . 17.3 p80 38.34 83.07 0.21 Allowed Pre-proline 0 N--CA 1.492 1.627 0 CA-C-O 121.129 0.49 . . . . 0.0 111.787 -178.751 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.21 58.14 2.88 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.329 1.173 . . . . 0.0 110.849 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.446 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.3 -28.0 7.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.396 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.44 HD11 ' CG2' ' A' ' 122' ' ' THR . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.459 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.444 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.433 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.464 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.472 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.419 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.43 ' CD1' HD13 ' A' ' 28' ' ' ILE . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.444 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.433 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.428 ' O ' ' N ' ' A' ' 34' ' ' LYS . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.436 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.426 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.516 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.456 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.516 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.423 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.483 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.496 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.413 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.419 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.489 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.45 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.465 HG23 HG21 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.0 t30 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.489 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HB ' ' CG2' ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.509 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.505 ' CE1' HD21 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.505 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.4 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.44 ' CB ' HG12 ' A' ' 63' ' ' VAL . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.473 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -137.8 91.77 13.34 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -86.64 55.46 3.33 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.638 1.336 . . . . 0.0 109.797 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.71 -24.69 2.69 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.176 -0.953 . . . . 0.0 111.542 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.37 158.56 40.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.847 -1.158 . . . . 0.0 110.901 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.13 162.35 0.07 OUTLIER Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.48 102.97 10.03 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.103 -1.234 . . . . 0.0 109.756 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.432 HG13 ' O ' ' A' ' 80' ' ' VAL . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.478 HG21 HD23 ' A' ' 55' ' ' LEU . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.473 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.509 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.443 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.428 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.41 HD11 ' CG1' ' A' ' 82' ' ' VAL . 0.5 OUTLIER -76.29 -30.11 57.65 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.417 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 5.7 mmt 50.87 -115.47 0.87 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.382 -0.824 . . . . 0.0 109.764 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.43 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.07 42.87 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.528 -1.358 . . . . 0.0 110.012 179.823 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.84 74.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.432 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 36.3 p90 -137.81 21.18 2.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.351 -1.087 . . . . 0.0 110.636 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.474 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 0.6 OUTLIER -100.89 -162.36 0.93 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.093 -1.004 . . . . 0.0 110.282 -179.859 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.428 ' O ' ' CB ' ' A' ' 124' ' ' ARG . . . 118.98 11.87 7.37 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.928 -1.13 . . . . 0.0 110.325 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.82 65.58 1.11 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.749 -1.442 . . . . 0.0 110.487 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.484 HG22 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.13 15.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.4 p -107.67 130.91 54.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.286 -0.883 . . . . 0.0 110.144 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.1 t70 53.84 26.67 6.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.199 -0.938 . . . . 0.0 110.109 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.77 -33.09 5.39 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.16 157.25 78.58 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.279 -1.13 . . . . 0.0 110.066 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.64 128.68 24.08 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.652 1.343 . . . . 0.0 110.358 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -46.57 146.7 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.613 -0.68 . . . . 0.0 111.241 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.437 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.404 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.404 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.422 ' OG1' ' CG2' ' A' ' 4' ' ' THR . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.484 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.441 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.44 ' CG2' HD11 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.428 ' CB ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.488 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.488 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.432 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.484 ' CD2' HG22 ' A' ' 99' ' ' VAL . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 54.3 t -73.24 -37.7 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.21 143.62 49.7 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.217 -0.927 . . . . 0.0 110.315 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -73.62 -50.2 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.695 1.366 . . . . 0.0 110.265 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.44 -54.42 0.65 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.99 -55.74 3.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.298 -1.119 . . . . 0.0 110.279 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.167 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.9 p -81.35 106.73 13.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.296 -1.12 . . . . 0.0 110.101 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.416 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.05 16.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.208 -0.933 . . . . 0.0 110.01 179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.7 p -73.16 145.3 46.45 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 110.17 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.42 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.06 147.01 60.17 Favored Pre-proline 0 C--N 1.302 -1.495 0 O-C-N 121.336 -0.852 . . . . 0.0 109.752 179.686 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.42 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.5 Cg_endo -73.16 -165.09 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 124.066 1.561 . . . . 0.0 110.931 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.543 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p80 -177.59 82.17 0.24 Allowed Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.9 81.4 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.851 1.448 . . . . 0.0 110.708 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.18 -37.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.496 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.485 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.505 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.505 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.485 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.427 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.415 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.479 ' O ' ' CD2' ' A' ' 38' ' ' HIS . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.493 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.493 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.435 ' CD2' ' HG2' ' A' ' 121' ' ' ARG . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.445 ' O ' ' HA ' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.419 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.435 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.412 HD13 HG13 ' A' ' 83' ' ' VAL . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.443 ' CD ' HD11 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.493 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.47 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.41 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 28.7 t30 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.522 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.464 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.438 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.457 ' CE1' HD21 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.457 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.432 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.43 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.464 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -136.21 92.99 15.3 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -82.82 53.4 4.4 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.705 1.371 . . . . 0.0 109.601 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.09 19.38 1.24 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.305 -0.872 . . . . 0.0 110.394 -179.271 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.35 -164.48 1.22 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.949 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.76 -77.86 0.11 Allowed Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -146.83 113.39 5.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.15 -1.206 . . . . 0.0 110.344 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.522 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.415 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.495 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.438 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' THR . . . . . 0.45 HG22 ' N ' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.45 ' N ' HG22 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.419 ' CD1' ' CD2' ' A' ' 65' ' ' TYR . 14.6 tp -61.99 -34.45 76.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.447 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 14.8 mmt 48.17 47.02 19.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 110.906 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.446 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 2.6 t 34.73 -128.05 0.09 Allowed 'General case' 0 N--CA 1.506 2.33 0 O-C-N 122.065 -0.397 . . . . 0.0 112.019 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.431 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.64 -61.49 2.04 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 33.2 p90 -121.93 3.4 9.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.459 -1.024 . . . . 0.0 109.946 178.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.446 ' CG2' ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.36 -160.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.091 -1.006 . . . . 0.0 109.819 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.34 -39.37 3.07 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.23 57.02 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.104 -1.233 . . . . 0.0 110.73 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.483 HG21 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CE1' ' A' ' 24' ' ' TYR . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.15 129.62 15.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.419 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.8 p -103.38 134.04 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.364 -0.835 . . . . 0.0 109.332 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.23 1.66 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.192 -0.942 . . . . 0.0 110.474 -179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.16 -32.73 5.71 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.419 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.7 157.36 82.15 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.354 -1.086 . . . . 0.0 110.148 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.45 130.14 25.87 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.578 1.304 . . . . 0.0 110.153 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.3 pt20 -51.73 153.99 2.2 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.455 -0.778 . . . . 0.0 110.984 -179.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.407 HG22 ' N ' ' A' ' 114' ' ' SER . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.407 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.443 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.413 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.543 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.435 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.458 ' CG2' HD13 ' A' ' 10' ' ' ILE . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.456 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.456 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.454 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.435 ' N ' HG21 ' A' ' 122' ' ' THR . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.495 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.424 ' CZ ' HG12 ' A' ' 32' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t -98.0 -30.79 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -95.72 117.74 66.32 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.555 -179.358 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.15 47.3 2.01 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.514 1.27 . . . . 0.0 110.377 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.03 -136.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.57 34.76 23.81 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -1.112 . . . . 0.0 110.235 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.055 179.821 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.25 143.44 38.94 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.235 -1.156 . . . . 0.0 110.077 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.401 HG21 ' O ' ' A' ' 3' ' ' VAL . 31.1 m -112.92 103.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.193 -0.942 . . . . 0.0 110.029 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 61.1 p -103.39 143.14 33.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.34 179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.432 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.23 149.45 98.43 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 179.468 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' HD2' HG22 ' A' ' 5' ' ' VAL . 40.8 Cg_endo -68.49 -165.3 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 124.001 1.527 . . . . 0.0 110.585 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.556 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.38 82.46 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.495 -0.753 . . . . 0.0 109.966 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.39 66.5 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 O-C-N 123.675 1.355 . . . . 0.0 109.849 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 6.6 t-20 -153.64 -34.86 0.11 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.552 -0.717 . . . . 0.0 110.619 -179.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.498 HD11 HG21 ' A' ' 10' ' ' ILE . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.431 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.423 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.468 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.462 HG23 ' O ' ' A' ' 21' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.4 ' O ' ' HD3' ' A' ' 29' ' ' PRO . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.459 ' O ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.468 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.441 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.415 ' OE2' ' CG1' ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.441 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.53 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.465 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.425 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.53 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.466 HD22 ' CE2' ' A' ' 41' ' ' PHE . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.449 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.466 ' CE2' HD22 ' A' ' 39' ' ' LEU . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.486 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.438 HD21 ' CD1' ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.413 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.48 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.454 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.465 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.416 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.5 t30 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.48 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.46 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.467 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.528 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.528 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.424 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.461 HG13 HG23 ' A' ' 82' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.0 92.51 14.09 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -83.16 51.43 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.625 1.329 . . . . 0.0 109.714 178.731 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.24 13.89 1.27 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 111.037 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -135.86 -149.9 0.35 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.044 -1.035 . . . . 0.0 109.815 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.27 174.64 0.11 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.46 114.98 2.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -1.183 . . . . 0.0 110.37 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.461 HG23 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.498 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.467 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.432 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.73 -46.46 65.85 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.426 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.0 2.13 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.341 -0.85 . . . . 0.0 110.211 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.448 HG23 ' N ' ' A' ' 94' ' ' GLY . 0.3 OUTLIER 45.46 36.26 2.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.456 -0.777 . . . . 0.0 110.83 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.84 -70.87 0.79 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.63 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 108.932 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.465 HG21 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.67 0.7 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.588 -0.695 . . . . 0.0 110.044 -179.35 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.448 ' N ' HG23 ' A' ' 90' ' ' THR . . . 126.73 -25.99 5.21 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.48 80.32 6.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -1.209 . . . . 0.0 110.694 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.465 ' CE2' HG21 ' A' ' 93' ' ' THR . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.423 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.543 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.404 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.414 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.41 HG22 ' HA ' ' A' ' 109' ' ' PRO . 3.7 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.418 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.6 p -113.97 133.66 55.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.15 -0.969 . . . . 0.0 110.175 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.2 28.78 7.46 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 110.461 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.07 4.24 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.418 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.46 75.81 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.188 -1.184 . . . . 0.0 110.056 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.41 ' HA ' HG22 ' A' ' 104' ' ' THR . 39.1 Cg_endo -66.16 135.5 40.55 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.6 1.316 . . . . 0.0 110.203 -179.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.54 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 110.821 -179.105 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.441 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.441 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.425 ' N ' HG23 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.431 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.419 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.556 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.419 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' CD1' ' A' ' 10' ' ' ILE . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.495 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.495 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.45 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.423 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.543 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.431 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.409 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 16.5 t -84.06 -68.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.1 83.04 0.23 Allowed Pre-proline 0 C--N 1.304 -1.373 0 O-C-N 121.746 -0.596 . . . . 0.0 110.254 -179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.81 -53.27 0.14 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.729 1.384 . . . . 0.0 110.515 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.34 135.77 7.11 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.95 -68.21 0.83 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.206 -1.173 . . . . 0.0 110.259 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.245 -179.928 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -91.93 137.98 31.92 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -1.162 . . . . 0.0 110.233 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.6 m -113.06 104.46 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.865 . . . . 0.0 109.904 179.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.43 ' CG2' ' HB3' ' A' ' 112' ' ' ALA . 34.8 p -92.62 144.9 24.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.485 -0.759 . . . . 0.0 110.062 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.425 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.35 147.08 98.93 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.205 -0.935 . . . . 0.0 109.73 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.432 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 46.9 Cg_endo -70.98 -167.65 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.092 1.575 . . . . 0.0 110.465 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.501 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.7 83.12 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.49 -0.757 . . . . 0.0 109.583 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.23 -13.62 28.33 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.95 1.5 . . . . 0.0 111.095 -179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 18.2 m120 -64.95 -31.25 72.39 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.082 -1.011 . . . . 0.0 110.382 -179.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.439 HD12 ' HG2' ' A' ' 119' ' ' ARG . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.432 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.447 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.469 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.446 HG23 ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.432 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.446 ' O ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.469 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.442 HD21 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.404 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.443 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.542 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.466 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.442 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.542 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.493 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.438 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.464 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.431 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.428 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.485 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.452 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.477 HG22 HG21 ' A' ' 81' ' ' VAL . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.485 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.496 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.454 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.487 ' CE1' HD22 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.487 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.433 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.435 ' CB ' HG11 ' A' ' 63' ' ' VAL . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.496 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.1 92.12 14.26 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_endo -87.73 50.94 1.99 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.617 1.325 . . . . 0.0 109.715 178.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.44 -25.64 4.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.136 -0.977 . . . . 0.0 111.283 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.1 160.34 37.22 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.884 -1.135 . . . . 0.0 110.699 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.99 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.28 111.08 13.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.238 . . . . 0.0 110.072 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.442 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.477 HG21 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.449 ' CG2' HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.481 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.454 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.409 ' HB1' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.62 -36.56 83.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.436 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 46.05 43.93 11.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.549 -0.719 . . . . 0.0 110.667 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.48 ' CB ' HG23 ' A' ' 93' ' ' THR . 1.8 t 35.34 -119.06 0.11 Allowed 'General case' 0 N--CA 1.504 2.227 0 O-C-N 122.171 -0.331 . . . . 0.0 111.691 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.413 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.92 -58.42 4.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -122.13 20.16 10.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -1.131 . . . . 0.0 110.139 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.48 HG23 ' CB ' ' A' ' 90' ' ' THR . 8.3 t -94.35 -171.46 2.52 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.214 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 119.62 5.63 10.99 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.788 -1.196 . . . . 0.0 110.512 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.82 58.56 1.32 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.684 -1.48 . . . . 0.0 110.464 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.493 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.418 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.43 ' CD1' ' HD2' ' A' ' 131' ' ' ARG . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.449 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -144.68 120.81 10.79 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.2 p -102.39 141.57 35.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 110.3 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.29 28.32 5.57 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.276 -0.89 . . . . 0.0 110.566 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.19 -13.27 57.94 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.43 ' O ' ' N ' ' A' ' 105' ' ' SER . 14.6 mttt -96.6 156.65 36.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 120.999 -1.294 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.45 130.03 27.11 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.594 1.313 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.26 168.08 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 111.176 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.405 HG22 ' N ' ' A' ' 114' ' ' SER . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.405 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.501 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.436 HG23 HG12 ' A' ' 10' ' ' ILE . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.417 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.469 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.469 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.428 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 98' ' ' SER . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.435 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 134' ' ' ALA . 7.0 t -78.1 -69.29 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.415 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.47 83.3 0.23 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.653 -0.654 . . . . 0.0 110.85 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -83.39 7.84 4.97 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.688 1.362 . . . . 0.0 110.581 179.335 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.02 -124.62 4.02 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.07 155.19 22.73 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 179.559 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.35 141.74 41.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.358 -1.084 . . . . 0.0 110.342 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.427 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 10.6 p -113.43 104.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.305 -0.872 . . . . 0.0 109.745 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.0 p -66.52 145.54 55.53 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.287 -0.883 . . . . 0.0 110.749 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.427 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.71 149.93 90.72 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.294 -0.879 . . . . 0.0 109.751 179.606 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.517 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.4 Cg_endo -79.62 -64.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 124.159 1.61 . . . . 0.0 112.533 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.539 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.88 88.78 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 CA-C-O 121.564 0.697 . . . . 0.0 110.405 -177.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.39 2.4 5.13 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 O-C-N 123.526 1.277 . . . . 0.0 112.319 -178.446 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -51.56 -25.09 6.15 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.653 -1.279 . . . . 0.0 109.261 179.08 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.444 HD13 ' CG2' ' A' ' 122' ' ' THR . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.467 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.442 HD22 ' CB ' ' A' ' 26' ' ' LYS . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.427 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.458 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.488 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.443 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.488 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.458 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.449 HD22 HG21 ' A' ' 21' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.438 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.52 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.478 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.411 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.52 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.441 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.45 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.415 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.414 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.465 HD21 ' HB3' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.445 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.478 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.409 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.476 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.476 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.44 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.527 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.527 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.441 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.424 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.476 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.1 pp -138.36 94.72 10.66 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.436 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 48.7 Cg_endo -78.73 58.01 6.63 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.691 1.364 . . . . 0.0 110.012 179.192 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.29 41.91 0.07 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.322 -0.861 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -141.03 29.36 1.85 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.154 -0.966 . . . . 0.0 110.424 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.76 -89.03 0.57 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -140.51 102.86 4.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.153 -1.204 . . . . 0.0 110.262 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.436 ' CG1' ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.49 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.443 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.499 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.434 ' HB1' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.419 ' CB ' ' CA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.454 ' CD1' HG22 ' A' ' 73' ' ' VAL . 0.6 OUTLIER -70.22 -33.43 71.67 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 2.3 tpt 53.43 -144.14 0.68 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.085 -1.01 . . . . 0.0 109.356 -179.303 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -155.55 24.86 0.4 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.923 -1.111 . . . . 0.0 110.416 179.468 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.02 -62.46 5.92 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.19 36.21 2.05 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.365 -1.079 . . . . 0.0 108.633 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.47 HG22 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.75 -167.54 1.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.712 -0.617 . . . . 0.0 110.073 -179.439 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.403 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 120.64 -24.18 7.67 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.42 73.21 10.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.003 -1.292 . . . . 0.0 110.213 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.47 ' CZ ' HG22 ' A' ' 93' ' ' THR . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.436 ' CD1' HG21 ' A' ' 33' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.411 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p -144.31 133.42 22.87 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.9 p -113.42 128.6 56.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.311 -0.868 . . . . 0.0 109.392 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.73 -141.58 0.83 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.048 -1.032 . . . . 0.0 109.533 -179.305 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.34 18.43 41.66 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.77 156.99 78.13 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.099 -1.236 . . . . 0.0 109.597 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -63.25 158.33 45.1 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.514 1.271 . . . . 0.0 110.436 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.411 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.83 164.79 11.71 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.296 -0.877 . . . . 0.0 111.198 -178.786 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.418 ' OD1' ' N ' ' A' ' 114' ' ' SER . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.438 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.413 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.424 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.438 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.45 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.475 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.405 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.445 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.445 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.403 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.435 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.445 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.443 ' N ' HG23 ' A' ' 122' ' ' THR . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.415 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.487 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 34.4 t -86.98 -41.09 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -91.14 113.07 57.06 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.301 -0.875 . . . . 0.0 109.962 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.487 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.5 -22.98 23.98 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.481 1.253 . . . . 0.0 110.751 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.33 148.16 5.02 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -90.67 -32.41 16.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.257 -1.143 . . . . 0.0 110.181 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.146 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -89.9 105.96 18.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.233 -1.157 . . . . 0.0 110.178 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.431 ' O ' ' CG2' ' A' ' 3' ' ' VAL . 31.3 m -112.84 104.46 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.346 -0.846 . . . . 0.0 109.619 179.624 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 43.8 p -90.03 143.36 26.85 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.194 -0.941 . . . . 0.0 110.82 -179.497 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.433 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.71 148.46 98.03 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.392 -0.817 . . . . 0.0 109.476 179.448 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.439 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 39.5 Cg_endo -67.57 -167.02 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 124.013 1.533 . . . . 0.0 111.104 179.33 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.557 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.31 83.2 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.712 -0.618 . . . . 0.0 109.341 -179.714 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.71 -9.6 26.01 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.91 1.479 . . . . 0.0 111.094 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 -77.94 -29.45 49.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.923 -1.111 . . . . 0.0 109.633 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.457 HD12 ' NH1' ' A' ' 119' ' ' ARG . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.41 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.403 ' O ' ' NZ ' ' A' ' 26' ' ' LYS . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.443 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.472 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.505 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.47 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.505 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.476 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.472 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.422 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.401 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . . . . . . . . . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.511 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.475 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.424 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.511 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.443 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.47 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' SER . . . . . 0.427 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' HA ' ' HD3' ' A' ' 47' ' ' LYS . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.454 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.45 ' CD1' HG12 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.4 ' HB3' ' O ' ' A' ' 48' ' ' CYS . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.428 ' HE2' ' HA ' ' A' ' 21' ' ' ILE . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.481 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.451 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.475 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.408 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.3 t30 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.481 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.497 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.479 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.517 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.517 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.497 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.426 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp -126.27 96.94 35.41 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -82.29 54.04 4.78 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.681 1.359 . . . . 0.0 109.913 179.196 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.4 t -157.0 42.45 0.34 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.245 -0.91 . . . . 0.0 110.476 -179.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -141.48 -164.95 1.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.166 -0.959 . . . . 0.0 110.175 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.44 -73.4 0.36 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -149.86 111.66 4.55 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.291 -1.123 . . . . 0.0 110.123 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.425 ' O ' HG13 ' A' ' 80' ' ' VAL . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.475 HG23 HG22 ' A' ' 60' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.491 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.496 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.479 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.41 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.63 -26.83 68.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.488 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 5.6 tpt 45.17 32.47 0.94 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.729 -0.607 . . . . 0.0 111.171 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.442 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.2 p 44.12 36.73 1.57 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.718 -0.614 . . . . 0.0 111.221 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.0 -63.99 4.65 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.2 p90 -122.28 41.1 3.49 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.383 -1.069 . . . . 0.0 109.884 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.442 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 15.4 t -91.19 -159.39 0.63 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.369 -0.832 . . . . 0.0 110.765 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.407 ' O ' ' HD3' ' A' ' 124' ' ' ARG . . . 96.48 -36.88 3.64 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.44 55.03 3.21 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.97 -1.312 . . . . 0.0 110.511 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.461 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.421 ' OG ' ' ND1' ' A' ' 38' ' ' HIS . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.442 ' N ' HD12 ' A' ' 100' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.25 130.83 16.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.415 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.0 p -112.86 127.84 56.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.868 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.45 26.95 9.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.312 -0.867 . . . . 0.0 110.526 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.79 3.32 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.54 82.09 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -1.137 . . . . 0.0 110.069 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.92 132.63 30.87 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 O-C-N 123.647 1.341 . . . . 0.0 109.902 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.68 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.256 -0.902 . . . . 0.0 110.972 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.431 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.431 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.425 ' N ' HG22 ' A' ' 113' ' ' VAL . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.401 ' O ' ' CG ' ' A' ' 121' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.557 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.442 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.442 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.41 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.405 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.406 ' O ' ' CB ' ' A' ' 134' ' ' ALA . 32.1 t -94.68 -56.99 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.406 ' CB ' ' O ' ' A' ' 133' ' ' VAL . . . 69.07 145.17 0.1 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.732 -0.605 . . . . 0.0 110.353 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.34 -55.97 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.386 0 O-C-N 123.783 1.412 . . . . 0.0 110.49 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.81 -32.47 2.44 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.29 -161.15 1.27 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -1.153 . . . . 0.0 110.262 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.7 ttt-85 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.135 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.33 10.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -1.149 . . . . 0.0 110.287 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 19.1 m -113.39 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.628 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.1 p -63.57 139.91 58.82 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.329 -0.857 . . . . 0.0 110.508 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.41 HG22 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.839 . . . . 0.0 109.702 179.681 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.414 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 46.4 Cg_endo -71.97 -165.71 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 124.094 1.576 . . . . 0.0 110.914 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.492 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.61 80.6 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.513 -0.742 . . . . 0.0 109.507 -179.602 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.14 55.21 3.95 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.747 1.393 . . . . 0.0 111.434 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.72 2.28 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.027 -1.045 . . . . 0.0 110.947 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.437 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.479 ' CG1' ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.476 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.464 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.467 HG23 ' O ' ' A' ' 28' ' ' ILE . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.476 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.438 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.467 ' O ' HG23 ' A' ' 21' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.464 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.432 HD22 ' CD1' ' A' ' 60' ' ' ILE . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.405 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.434 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.519 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.444 ' CG ' HG12 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.418 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.519 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.522 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.431 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.426 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.438 ' CD1' HG12 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.445 ' CE ' HD22 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.48 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.511 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.48 HG22 HG22 ' A' ' 81' ' ' VAL . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.472 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.452 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.488 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.426 ' HG ' ' HA ' ' A' ' 65' ' ' TYR . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.423 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.478 HG22 ' HB ' ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.455 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.5 pp -137.48 110.03 8.84 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.418 ' HA ' HG13 ' A' ' 80' ' ' VAL . 50.2 Cg_endo -87.33 40.12 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.307 1.162 . . . . 0.0 110.644 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.4 26.25 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 110.201 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.6 m-20 -135.47 27.33 3.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.237 -0.914 . . . . 0.0 110.163 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.37 -156.46 15.54 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.68 112.58 15.94 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.107 -1.231 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.45 ' O ' HG12 ' A' ' 80' ' ' VAL . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.431 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.452 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.18 -33.43 61.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.417 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.6 mmt 51.03 -106.77 0.26 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.283 -0.886 . . . . 0.0 109.988 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.456 ' CB ' HG21 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.76 41.59 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.637 -1.29 . . . . 0.0 110.424 179.74 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.43 51.12 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 179.208 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.494 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 14.2 p90 -145.48 38.32 1.13 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.66 -0.906 . . . . 0.0 109.798 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.49 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 0.5 OUTLIER -126.91 -162.41 1.15 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.324 -0.86 . . . . 0.0 110.197 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.48 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 123.48 -40.44 1.98 Allowed Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.343 179.142 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -84.45 81.09 8.99 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.135 -1.214 . . . . 0.0 110.82 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.49 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.489 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.529 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.437 HG23 ' CD1' ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.511 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.44 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.406 HG23 ' O ' ' A' ' 103' ' ' ASN . 1.3 p -147.76 129.38 15.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.5 p -113.35 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.61 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.47 -141.9 0.83 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.095 -1.003 . . . . 0.0 109.637 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 18.09 41.22 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.79 156.3 79.54 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.242 . . . . 0.0 109.713 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.67 159.79 43.43 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.625 1.329 . . . . 0.0 110.164 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.44 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.17 153.32 12.01 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.219 -0.926 . . . . 0.0 110.706 -179.28 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.442 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.492 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.422 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.488 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.402 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.467 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.467 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.433 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.529 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.479 ' NE ' ' CG1' ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.86 -46.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.19 160.97 39.15 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 110.247 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 -27.36 16.02 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.791 1.416 . . . . 0.0 110.545 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.44 79.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.92 143.37 0.56 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.278 -1.131 . . . . 0.0 110.187 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.184 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.06 150.92 20.19 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.205 -1.174 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.412 ' O ' HG21 ' A' ' 3' ' ' VAL . 21.2 m -113.32 104.69 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.366 -0.834 . . . . 0.0 110.039 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.4 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 6.2 p -66.08 145.04 56.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.336 -0.853 . . . . 0.0 110.346 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.441 HG22 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.19 147.85 95.62 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.257 -0.902 . . . . 0.0 109.828 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.474 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 38.6 Cg_endo -73.14 -64.64 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 124.13 1.594 . . . . 0.0 112.47 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.51 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 47.8 p-80 41.25 87.29 0.12 Allowed Pre-proline 0 N--CA 1.492 1.674 0 CA-C-O 121.262 0.553 . . . . 0.0 111.226 -178.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -74.91 0.74 8.49 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.454 1.239 . . . . 0.0 111.567 -179.255 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.415 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.17 4.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.805 -1.184 . . . . 0.0 110.427 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.459 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.439 HG12 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.445 HD21 ' CB ' ' A' ' 26' ' ' LYS . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.452 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.491 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.484 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.445 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.445 ' CB ' HD21 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.442 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.484 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.491 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.436 ' O ' ' N ' ' A' ' 34' ' ' LYS . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.428 ' CG2' HG23 ' A' ' 28' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.497 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.457 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.497 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.483 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.436 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.483 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.438 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.437 ' CD1' HG13 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.412 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.422 ' O ' HD22 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.494 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.477 HG23 HG23 ' A' ' 81' ' ' VAL . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.425 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 45.8 t30 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.495 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.489 ' CE1' HD21 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.489 HD21 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.44 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.495 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.1 100.49 9.61 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -88.16 36.87 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.636 1.335 . . . . 0.0 110.53 179.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.43 16.41 6.54 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.045 -1.035 . . . . 0.0 110.67 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -116.14 -165.39 1.04 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.057 -1.027 . . . . 0.0 110.09 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.78 -87.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.83 114.97 15.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -1.186 . . . . 0.0 110.391 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.425 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.477 HG23 HG23 ' A' ' 60' ' ' ILE . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.42 ' CG2' HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.494 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 14.2 tp -62.44 -23.53 66.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.479 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.4 OUTLIER 46.3 28.36 0.69 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.466 -0.771 . . . . 0.0 110.731 179.721 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.478 ' CB ' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.1 -126.34 0.11 Allowed 'General case' 0 N--CA 1.5 2.049 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 178.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.425 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.72 -51.22 3.25 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.918 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.17 23.67 4.15 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.572 -0.958 . . . . 0.0 109.428 179.066 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.484 ' OG1' ' CE2' ' A' ' 96' ' ' PHE . 3.7 t -98.92 -156.28 0.54 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.696 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.4 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 94.08 -25.01 24.13 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.277 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.17 60.94 6.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.025 -1.279 . . . . 0.0 110.814 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.405 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.522 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.436 HD13 ' CD1' ' A' ' 40' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.419 ' OD1' ' CB ' ' A' ' 41' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.406 HG21 ' O ' ' A' ' 108' ' ' LYS . 1.1 m -143.42 120.14 11.17 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.485 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.91 121.72 39.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.311 -0.868 . . . . 0.0 110.334 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.79 32.88 20.19 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.271 -0.893 . . . . 0.0 110.727 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.26 -28.2 9.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.401 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.42 155.77 51.21 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.064 -1.256 . . . . 0.0 110.137 -179.768 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.85 128.44 22.02 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.512 1.269 . . . . 0.0 110.779 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -46.35 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.569 -0.707 . . . . 0.0 111.133 -179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.424 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.424 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.418 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.454 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.454 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.423 ' HG2' ' CZ ' ' A' ' 41' ' ' PHE . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.477 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.447 ' CG2' HD13 ' A' ' 10' ' ' ILE . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.454 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.454 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.447 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.42 HG21 HG22 ' A' ' 13' ' ' VAL . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.522 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.439 ' CZ ' HG12 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.447 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 46.2 t -74.6 -31.74 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.67 134.01 25.72 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.177 -0.952 . . . . 0.0 110.061 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.51 -18.77 19.77 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.549 1.289 . . . . 0.0 110.692 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.09 -42.62 1.89 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.23 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.486 -1.008 . . . . 0.0 110.546 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.628 0 O-C-N 120.975 -1.078 . . . . 0.0 110.277 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.06 140.15 49.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -1.153 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.403 HG12 ' O ' ' A' ' 3' ' ' VAL . 7.1 p -112.83 104.8 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.303 -0.873 . . . . 0.0 109.769 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 72.2 p -62.85 141.75 58.53 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.34 -0.85 . . . . 0.0 110.376 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.428 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.86 148.88 98.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.792 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.428 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.3 Cg_endo -69.1 -171.98 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.03 1.542 . . . . 0.0 110.93 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.507 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.66 75.15 0.07 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.535 -0.728 . . . . 0.0 109.51 -179.721 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.71 -13.49 32.33 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.861 1.453 . . . . 0.0 110.691 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.5 m120 -59.85 -18.11 41.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.049 -1.032 . . . . 0.0 110.171 179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.43 HD21 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.408 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.455 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.465 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.456 HG21 ' O ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.409 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.435 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.434 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.41 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' HG21 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.465 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.405 HD23 HD12 ' A' ' 60' ' ' ILE . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.407 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.526 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.455 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.423 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.526 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.494 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.475 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.494 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.434 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.493 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.422 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.433 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.414 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.481 HD21 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.462 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.484 HG22 HG21 ' A' ' 81' ' ' VAL . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.411 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.483 ' CB ' HG23 ' A' ' 81' ' ' VAL . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.475 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.494 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.442 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.493 ' CG ' ' HG3' ' A' ' 45' ' ' LYS . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.437 ' CD1' ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.437 ' N ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.435 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.448 ' CB ' HG13 ' A' ' 63' ' ' VAL . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.475 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.2 pp -137.76 100.99 8.87 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -82.05 53.4 4.55 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.487 1.257 . . . . 0.0 110.12 178.985 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 p -149.62 22.39 0.91 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 110.925 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.19 -165.85 1.38 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.038 -1.038 . . . . 0.0 110.145 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.64 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.03 16.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.16 -1.2 . . . . 0.0 110.168 179.537 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.484 HG21 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.418 ' O ' ' HA ' ' A' ' 39' ' ' LEU . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.494 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.442 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.58 -24.51 53.5 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.365 -179.209 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.439 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.14 0.93 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.991 -1.068 . . . . 0.0 110.066 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.6 -39.55 60.89 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.15 5.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.427 -1.043 . . . . 0.0 110.436 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.476 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 0.5 OUTLIER -108.31 -171.06 1.79 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.186 -0.946 . . . . 0.0 109.843 179.666 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.441 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 121.76 -26.9 6.39 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -83.95 65.81 8.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.909 -1.348 . . . . 0.0 110.24 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.425 ' CD1' HG22 ' A' ' 33' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.426 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -141.6 127.91 19.88 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.46 50.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.299 -0.876 . . . . 0.0 110.618 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.19 34.78 24.47 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.328 -0.857 . . . . 0.0 111.257 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.8 -33.9 4.8 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.308 179.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.22 155.31 57.56 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.161 -1.199 . . . . 0.0 110.05 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.9 138.49 57.85 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.415 1.218 . . . . 0.0 110.76 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.3 156.67 0.8 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.528 -0.733 . . . . 0.0 110.948 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.434 ' O ' ' OG ' ' A' ' 114' ' ' SER . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.426 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.423 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.472 ' O ' ' N ' ' A' ' 118' ' ' ARG . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.426 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.472 ' N ' ' O ' ' A' ' 114' ' ' SER . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.507 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.447 ' CG2' HD11 ' A' ' 10' ' ' ILE . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.447 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.441 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.444 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.426 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t -79.86 -54.16 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.49 134.98 31.53 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.233 -0.917 . . . . 0.0 110.132 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.85 0.13 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 O-C-N 123.527 1.278 . . . . 0.0 110.4 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.29 -69.29 0.42 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.49 96.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.214 -1.168 . . . . 0.0 110.114 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.191 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.06 128.35 56.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.2 t -113.18 104.2 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.248 -0.907 . . . . 0.0 110.201 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 69.1 p -72.18 146.15 47.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.495 -0.753 . . . . 0.0 110.109 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.439 HG21 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.46 148.45 98.6 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.525 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 41.8 Cg_endo -80.33 -59.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 124.244 1.655 . . . . 0.0 112.413 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.525 ' CD2' ' O ' ' A' ' 6' ' ' PRO . 20.4 p80 39.31 89.25 0.08 OUTLIER Pre-proline 0 N--CA 1.493 1.683 0 CA-C-O 121.025 0.44 . . . . 0.0 111.459 -178.379 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.68 57.29 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.317 1.167 . . . . 0.0 110.9 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.404 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 -119.99 -18.78 8.07 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.242 -0.911 . . . . 0.0 110.289 179.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.518 HD12 ' O ' ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.435 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.49 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.412 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.409 ' O ' ' HD3' ' A' ' 29' ' ' PRO . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.49 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.457 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.452 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.438 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.526 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.452 ' HB3' ' O ' ' A' ' 30' ' ' LEU . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.526 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.465 ' CD2' ' CZ ' ' A' ' 41' ' ' PHE . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.47 HD11 HG23 ' A' ' 40' ' ' ILE . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.465 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.537 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.494 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.413 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.404 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.428 ' CD ' HG13 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.492 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.458 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.465 HG22 HG23 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.426 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.3 t30 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.492 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.47 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.508 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' CG ' HD13 ' A' ' 88' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.495 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.495 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.455 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.47 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -137.0 91.79 14.69 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -79.86 55.73 5.76 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.716 1.377 . . . . 0.0 110.345 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.89 0.34 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.175 -0.953 . . . . 0.0 110.457 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.97 -164.77 1.43 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.15 -0.969 . . . . 0.0 110.034 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.64 -73.58 0.35 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.179 -1.189 . . . . 0.0 110.036 179.375 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.471 HG22 ' CB ' ' A' ' 62' ' ' ALA . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.457 HG21 ' CG1' ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.508 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.459 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.46 HD13 ' CG ' ' A' ' 65' ' ' TYR . 0.8 OUTLIER -69.69 -47.0 64.77 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.456 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.11 21.89 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 110.075 -179.743 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.4 HG23 ' N ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER 62.36 -72.78 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.589 -0.694 . . . . 0.0 110.708 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.66 -98.7 0.05 OUTLIER Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.515 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 46.6 p90 -88.89 48.42 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.26 -1.141 . . . . 0.0 109.602 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.475 HG23 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.64 -146.15 0.19 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.336 -0.853 . . . . 0.0 109.941 -179.64 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.4 ' N ' HG23 ' A' ' 90' ' ' THR . . . 111.47 -30.61 7.74 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.582 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.11 80.97 9.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -1.181 . . . . 0.0 110.428 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.475 ' CZ ' HG23 ' A' ' 93' ' ' THR . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.421 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.455 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.501 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.444 ' N ' ' CD1' ' A' ' 100' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.491 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -146.91 128.91 15.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.3 p -114.37 134.6 54.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.099 -1.001 . . . . 0.0 110.406 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.03 27.02 6.97 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.245 -0.91 . . . . 0.0 110.416 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.4 -31.51 6.35 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 155.91 78.0 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.164 -1.198 . . . . 0.0 110.132 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -66.59 133.5 32.23 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.659 1.347 . . . . 0.0 110.336 -179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -47.94 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.351 -0.843 . . . . 0.0 110.648 -179.453 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.435 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.407 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.432 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.403 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.4 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.447 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.518 ' O ' HD12 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.467 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.45 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.467 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.455 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.501 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.09 -34.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.06 159.78 65.06 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.22 -0.925 . . . . 0.0 110.329 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.67 -40.98 1.24 Allowed 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.74 1.389 . . . . 0.0 110.441 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.06 88.78 0.06 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -78.47 130.77 36.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.234 -1.156 . . . . 0.0 110.335 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.316 179.941 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.5 m -111.58 155.31 23.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 110.219 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 27.5 m -113.29 104.0 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.264 -0.897 . . . . 0.0 109.889 179.629 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.423 ' CG2' ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.22 138.09 58.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.436 -0.79 . . . . 0.0 110.607 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.406 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.58 147.8 98.67 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.606 179.601 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.406 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.6 Cg_endo -69.88 -169.28 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 124.1 1.579 . . . . 0.0 111.096 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.547 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.43 82.48 0.24 Allowed Pre-proline 0 C--N 1.302 -1.476 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.595 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.83 89.24 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.658 1.346 . . . . 0.0 110.496 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.459 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.22 -33.97 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.76 -0.587 . . . . 0.0 109.908 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.472 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.434 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.416 ' CD2' ' HB3' ' A' ' 26' ' ' LYS . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.457 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.495 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.472 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.421 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.457 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.495 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.429 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.408 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.467 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.534 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.467 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.428 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.534 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.461 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.435 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.419 ' CD1' HG13 ' A' ' 83' ' ' VAL . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.428 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.467 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.467 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 49.9 t30 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 81' ' ' VAL . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.48 ' CG1' ' CG2' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.492 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.453 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.512 ' CE1' HD22 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.512 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.457 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.48 ' CG2' ' CG1' ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.427 ' CD1' ' HB2' ' A' ' 77' ' ' ASN . 1.0 OUTLIER -134.04 103.78 11.72 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -87.07 43.66 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.523 1.275 . . . . 0.0 110.304 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.66 4.59 2.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.998 -1.063 . . . . 0.0 111.091 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.427 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 1.6 m-80 -100.77 -169.15 1.67 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.282 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.42 -70.45 0.95 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -144.91 113.64 6.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.164 -1.198 . . . . 0.0 110.29 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.428 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.429 ' CG2' HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.492 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.453 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.452 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.434 HD11 ' CB ' ' A' ' 65' ' ' TYR . 3.4 tp -64.48 -32.21 73.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.458 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.83 34.84 0.95 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.461 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.5 p 47.26 -130.32 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.675 -0.641 . . . . 0.0 110.459 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.96 -85.11 1.13 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -94.43 16.98 13.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -1.142 . . . . 0.0 109.785 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.429 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.9 t -92.53 -151.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.316 -0.865 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.423 ' O ' ' CG ' ' A' ' 124' ' ' ARG . . . 94.05 -31.89 6.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.6 57.26 3.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.99 -1.3 . . . . 0.0 110.285 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.428 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.471 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.402 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.43 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -144.1 126.02 15.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.2 p -112.67 139.21 48.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.145 -0.972 . . . . 0.0 109.582 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.8 -143.55 0.73 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.051 -1.031 . . . . 0.0 109.581 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.74 26.44 12.52 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.12 156.78 67.87 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.21 -1.171 . . . . 0.0 109.821 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -65.85 162.11 36.35 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.644 1.339 . . . . 0.0 110.494 -179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.412 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -64.91 168.12 6.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.302 -0.874 . . . . 0.0 110.862 -179.307 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.412 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.438 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.423 ' OG1' ' CG2' ' A' ' 4' ' ' THR . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.414 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.547 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.461 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.439 ' CG2' HD13 ' A' ' 10' ' ' ILE . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.443 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.423 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.443 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.459 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.434 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.427 ' N ' HG22 ' A' ' 122' ' ' THR . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.467 ' CD2' ' HG3' ' A' ' 119' ' ' ARG . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.434 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 42.7 t -76.08 -60.41 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.43 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.15 146.83 35.34 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.316 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -73.97 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.312 -1.387 0 O-C-N 123.795 1.418 . . . . 0.0 110.426 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.69 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.9 82.02 3.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -1.165 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.286 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.31 50.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -1.163 . . . . 0.0 110.217 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.5 t -112.85 104.32 16.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -69.13 138.25 54.06 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.435 -0.79 . . . . 0.0 110.181 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.42 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.79 146.25 98.32 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 0.0 109.529 179.702 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -72.71 -174.3 1.45 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.997 1.525 . . . . 0.0 110.53 179.192 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.485 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.87 76.78 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.452 -0.78 . . . . 0.0 109.859 -179.626 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.23 53.96 3.6 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 O-C-N 123.763 1.402 . . . . 0.0 111.096 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -138.41 8.31 2.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.999 -1.063 . . . . 0.0 110.358 179.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.427 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.466 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.425 HD21 ' CG2' ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.438 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.476 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.476 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.429 HD21 HG21 ' A' ' 21' ' ' ILE . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.435 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.545 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.474 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.48 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.431 ' HB ' ' HA ' ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.48 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.418 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.439 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.426 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.437 ' CD1' HG13 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.473 ' O ' HD22 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.495 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.473 HD22 ' O ' ' A' ' 54' ' ' LYS . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.474 ' CD1' ' HB2' ' A' ' 34' ' ' LYS . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.495 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.469 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.503 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.462 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.484 ' CZ ' HD22 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.484 HD22 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.434 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.436 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' CB ' HG13 ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.469 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -131.29 100.34 16.9 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.68 59.8 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.609 1.321 . . . . 0.0 109.902 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' THR . . . . . 0.429 ' O ' ' HB2' ' A' ' 77' ' ' ASN . 4.7 t -135.86 61.85 1.64 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.443 -0.785 . . . . 0.0 109.288 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.429 ' HB2' ' O ' ' A' ' 76' ' ' THR . 3.2 m-20 62.7 -154.14 0.34 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.812 -0.555 . . . . 0.0 110.03 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.69 151.34 0.05 OUTLIER Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.531 -1.828 . . . . 0.0 108.531 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.4 94.04 6.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.941 -1.329 . . . . 0.0 110.238 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' HG12 ' A' ' 80' ' ' VAL . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.473 HG23 ' CB ' ' A' ' 62' ' ' ALA . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.409 HG21 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.513 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.462 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.451 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.425 HD13 ' CB ' ' A' ' 65' ' ' TYR . 2.4 tp -64.06 -47.87 78.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.432 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.2 20.61 2.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 109.943 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 94' ' ' GLY . 0.1 OUTLIER 46.85 54.65 8.81 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.393 -0.817 . . . . 0.0 110.805 179.837 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.55 -67.94 1.83 Allowed Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.12 21.74 5.63 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.308 -1.113 . . . . 0.0 109.617 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.459 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -127.99 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.433 -0.792 . . . . 0.0 109.806 -179.922 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.488 ' N ' HG23 ' A' ' 90' ' ' THR . . . 150.76 -51.02 0.53 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.408 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.31 97.41 10.78 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 110.589 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.459 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.403 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.549 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.433 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m -144.01 109.93 5.32 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.81 128.73 35.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.319 -0.863 . . . . 0.0 111.071 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.38 34.29 20.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.413 -0.805 . . . . 0.0 111.288 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.65 -14.96 54.3 Favored Glycine 0 N--CA 1.494 2.535 0 C-N-CA 119.856 -1.164 . . . . 0.0 110.301 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.464 ' O ' ' N ' ' A' ' 105' ' ' SER . 10.6 mttt -98.02 156.57 35.77 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 120.986 -1.302 . . . . 0.0 109.788 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -62.51 127.29 20.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.512 1.27 . . . . 0.0 110.508 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.49 157.43 0.06 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.452 ' O ' ' OG ' ' A' ' 114' ' ' SER . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.428 ' CG2' ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.403 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.405 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.491 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.44 ' CG ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.469 ' CG2' ' CG2' ' A' ' 99' ' ' VAL . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.406 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.425 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.443 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.443 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . . . . . . . . . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.403 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.435 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . 0.433 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 54.6 t -69.18 -55.61 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.87 159.29 45.13 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.184 -0.947 . . . . 0.0 110.299 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.419 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.9 Cg_endo -72.16 -23.12 21.62 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.697 1.367 . . . . 0.0 110.395 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.5 -64.61 0.31 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.64 -48.96 9.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.215 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . 0.419 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.128 179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 p -104.04 106.87 17.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -1.167 . . . . 0.0 110.268 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.402 ' O ' HG11 ' A' ' 3' ' ' VAL . 4.8 p -113.3 103.95 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.311 -0.868 . . . . 0.0 109.88 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.1 p -75.24 142.67 43.35 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.243 -0.911 . . . . 0.0 110.309 179.953 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.426 HG23 ' N ' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.76 146.89 97.82 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.623 179.601 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.426 ' N ' HG23 ' A' ' 5' ' ' VAL . 46.3 Cg_endo -71.98 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.116 1.588 . . . . 0.0 110.447 179.169 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.555 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.66 81.9 0.38 Allowed Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.543 179.546 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 40.1 Cg_endo -67.06 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.38 1.2 . . . . 0.0 111.021 -179.161 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.46 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER 171.79 -5.82 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 O-C-N 121.523 -0.736 . . . . 0.0 112.481 179.3 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.505 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.422 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.439 ' N ' ' HB1' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.474 HG21 ' O ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.415 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.452 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.476 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.452 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.439 ' HB1' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.474 ' O ' HG21 ' A' ' 21' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.449 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.44 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.437 ' CG1' ' HG2' ' A' ' 29' ' ' PRO . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.533 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.451 ' CD ' HG12 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.419 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.533 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.424 HD21 ' CZ ' ' A' ' 41' ' ' PHE . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.45 ' CG1' HG13 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.476 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.476 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.424 ' O ' ' HB3' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.425 ' CD1' HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.434 ' CB ' ' O ' ' A' ' 50' ' ' GLU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.489 HD21 ' HB3' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.455 ' N ' HD23 ' A' ' 58' ' ' LEU . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.464 HG22 HG21 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.414 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.489 ' HB3' HD21 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.488 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.455 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.478 ' CE1' HD22 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.478 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.456 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.422 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.488 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.433 ' CD1' ' HB2' ' A' ' 77' ' ' ASN . 1.3 pp -137.19 104.11 8.75 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -89.33 35.6 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.655 1.345 . . . . 0.0 110.589 179.341 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 6.9 t -127.81 -11.14 5.48 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.855 -1.153 . . . . 0.0 111.533 -179.167 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.433 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 8.1 m120 -104.85 -150.36 0.43 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.86 -1.15 . . . . 0.0 110.358 -179.776 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.04 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -54.88 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.139 -1.212 . . . . 0.0 110.1 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.419 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.487 ' O ' ' HA ' ' A' ' 62' ' ' ALA . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.408 HG21 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.506 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.455 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.4 ' OD1' ' N ' ' A' ' 86' ' ' ASP . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.58 -34.28 47.01 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.4 -96.15 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.713 -0.617 . . . . 0.0 110.526 179.73 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.451 ' CB ' HG23 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.1 57.1 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 120.779 -1.201 . . . . 0.0 110.713 179.924 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.03 -50.2 67.79 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 108.458 -1.857 . . . . 0.0 108.458 179.175 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.423 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 51.8 p90 -137.49 38.72 2.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.502 ' OG1' ' CZ ' ' A' ' 96' ' ' PHE . 1.3 t -98.37 -153.74 0.44 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.93 . . . . 0.0 110.659 -179.449 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' N ' ' CG2' ' A' ' 93' ' ' THR . . . 109.74 7.54 27.44 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.61 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.89 1.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.771 -1.429 . . . . 0.0 110.795 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.502 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.426 HG22 ' CD1' ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.401 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -145.15 128.7 17.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.404 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.11 134.52 54.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 -179.716 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.14 41.53 31.97 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.163 -0.961 . . . . 0.0 110.329 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.77 66.31 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.404 ' HB2' ' O ' ' A' ' 105' ' ' SER . 1.0 OUTLIER -126.55 157.56 70.41 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.206 -1.173 . . . . 0.0 109.719 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.61 123.65 12.75 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.629 1.331 . . . . 0.0 110.213 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.469 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.61 147.37 2.55 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.535 -0.728 . . . . 0.0 111.095 -179.191 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.416 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.469 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.45 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.416 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.476 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.555 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.449 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.449 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . . . . . . . . . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.422 ' CZ ' HG13 ' A' ' 13' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.401 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t -94.98 -56.03 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 63.29 146.87 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.662 -0.649 . . . . 0.0 110.227 -179.611 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.29 -52.05 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.711 1.374 . . . . 0.0 110.433 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.19 -151.69 22.35 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.917 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.44 159.19 19.41 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.27 -1.135 . . . . 0.0 110.161 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.142 -179.916 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.84 146.42 28.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -1.145 . . . . 0.0 110.408 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.449 ' O ' ' CG1' ' A' ' 3' ' ' VAL . 12.8 p -113.12 104.67 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.589 179.321 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -80.13 145.63 32.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.31 -0.869 . . . . 0.0 110.732 -179.565 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.476 ' O ' ' CE1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -74.98 148.98 85.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.348 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -71.16 -43.59 1.5 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.144 1.602 . . . . 0.0 112.843 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.4 p-80 41.26 85.35 0.16 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 122.13 -0.356 . . . . 0.0 110.786 -177.207 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.7 Cg_endo -68.29 -161.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.842 1.443 . . . . 0.0 110.132 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.483 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.09 -35.89 0.2 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.66 -0.65 . . . . 0.0 111.047 -179.159 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.463 HD12 ' CG2' ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.457 ' CD2' ' CB ' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.404 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.434 ' N ' ' HB2' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.471 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.467 ' CG2' ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.457 ' CB ' ' CD2' ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.434 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.467 ' HB ' ' CG2' ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.471 ' HA ' ' CA ' ' A' ' 19' ' ' GLY . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.414 HD21 HG22 ' A' ' 21' ' ' ILE . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.468 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.519 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.459 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.519 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.432 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.526 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.411 ' HB3' ' HB2' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.41 ' CD2' HD12 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.422 ' CE ' HG13 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.468 HD22 HG22 ' A' ' 81' ' ' VAL . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.463 ' N ' HD22 ' A' ' 58' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 HG22 HG21 ' A' ' 81' ' ' VAL . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.466 ' HB1' ' HB3' ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.477 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.441 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.481 ' CD1' ' HB2' ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.481 ' HB2' ' CD1' ' A' ' 66' ' ' TYR . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.451 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.419 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.477 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.424 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.6 pp -137.35 98.8 9.96 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -81.59 51.6 3.93 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.578 1.304 . . . . 0.0 110.421 179.261 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.91 8.94 1.92 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.976 -1.078 . . . . 0.0 111.072 -179.694 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -108.61 -165.48 1.03 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.897 -1.127 . . . . 0.0 109.923 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.1 -91.84 0.01 OUTLIER Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . 0.412 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 -124.26 113.72 18.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.151 -1.206 . . . . 0.0 109.983 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.43 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.476 HG21 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.447 ' CG2' HG11 ' A' ' 73' ' ' VAL . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.491 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.441 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.53 -23.49 66.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.512 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 32.3 mmt 49.81 37.26 12.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.406 -0.809 . . . . 0.0 110.941 179.567 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.481 ' OG1' ' CG2' ' A' ' 93' ' ' THR . 3.2 t 32.7 42.66 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.13 -38.52 88.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 179.567 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -136.21 12.43 3.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.455 -1.026 . . . . 0.0 110.76 -179.753 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.489 ' HA ' ' CE2' ' A' ' 96' ' ' PHE . 14.9 t -67.43 -158.99 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.96 -1.087 . . . . 0.0 110.468 -179.834 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.93 3.34 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.07 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.22 60.23 5.82 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.261 . . . . 0.0 110.938 -179.248 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.489 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.486 ' CB ' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.491 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.422 HG22 ' CD1' ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.49 130.37 16.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.407 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.7 p -113.97 127.67 56.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.304 -0.872 . . . . 0.0 109.916 179.309 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.98 28.96 11.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.229 -0.92 . . . . 0.0 110.488 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.13 3.93 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.772 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.407 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.87 156.6 82.44 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.321 -1.105 . . . . 0.0 109.918 179.873 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -64.8 138.97 60.57 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.52 1.274 . . . . 0.0 109.968 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.76 150.63 2.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.274 -0.892 . . . . 0.0 110.843 -178.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.434 ' OD1' ' CG2' ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.428 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.434 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.41 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.435 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.403 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.422 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.5 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.418 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.463 ' CG2' HD12 ' A' ' 10' ' ' ILE . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.452 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.461 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' N ' HG22 ' A' ' 122' ' ' THR . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.491 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.428 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 48.7 t -78.45 -61.12 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -115.97 170.75 5.35 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.258 -0.901 . . . . 0.0 110.437 -179.713 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.0 Cg_endo -74.69 -50.35 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.735 1.387 . . . . 0.0 110.327 179.95 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.03 87.07 1.67 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.08 -164.75 1.04 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.234 -1.157 . . . . 0.0 110.315 -179.943 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.264 179.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.23 138.02 31.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -1.169 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.411 ' O ' HG21 ' A' ' 3' ' ' VAL . 8.9 m -113.2 104.1 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.18 -0.95 . . . . 0.0 109.959 179.712 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.46 135.8 44.14 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.309 -0.869 . . . . 0.0 110.23 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.12 147.56 99.0 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.248 -0.908 . . . . 0.0 109.175 179.604 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.43 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.6 Cg_endo -73.66 -168.91 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.021 1.537 . . . . 0.0 110.635 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.496 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.71 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 121.633 -0.667 . . . . 0.0 109.22 -179.764 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.49 -5.86 17.94 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.805 1.424 . . . . 0.0 111.236 -179.296 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.58 -14.24 62.74 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.132 . . . . 0.0 110.449 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.457 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.476 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.421 ' O ' ' CD ' ' A' ' 26' ' ' LYS . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.422 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.466 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.48 HG22 ' O ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.432 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.498 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.436 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.48 ' O ' HG22 ' A' ' 21' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.466 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.446 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.447 ' O ' ' CE1' ' A' ' 38' ' ' HIS . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.521 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.473 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.521 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.42 HD22 ' CZ ' ' A' ' 41' ' ' PHE . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.434 ' CG1' HG13 ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.42 ' CZ ' HD22 ' A' ' 39' ' ' LEU . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.445 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.422 ' CD1' HG11 ' A' ' 83' ' ' VAL . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.415 ' O ' ' HB2' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.432 ' HE2' ' HD2' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.482 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.453 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.476 ' CD1' ' CD1' ' A' ' 33' ' ' ILE . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.412 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.3 t30 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.482 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.503 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.496 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.476 ' CD1' ' HD2' ' A' ' 45' ' ' LYS . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.468 HD22 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.459 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.423 ' O ' ' CG2' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.439 ' CB ' HG12 ' A' ' 63' ' ' VAL . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.503 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.427 ' O ' ' CG1' ' A' ' 74' ' ' ILE . 1.4 pp -136.15 95.02 13.66 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.422 ' HA ' ' CG1' ' A' ' 80' ' ' VAL . 52.7 Cg_endo -81.39 52.81 4.43 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.622 1.328 . . . . 0.0 110.887 179.889 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.982 -1.073 . . . . 0.0 110.652 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.402 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 3.0 m120 -112.54 -165.83 1.03 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.121 -0.987 . . . . 0.0 110.173 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -66.35 2.66 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.904 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -151.79 110.91 3.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.218 -1.166 . . . . 0.0 110.216 179.748 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.471 HG21 ' CB ' ' A' ' 62' ' ' ALA . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.455 ' CG2' HG12 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.496 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.25 -45.47 32.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 89' ' ' MET . . . . . 0.437 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.22 20.74 1.96 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.615 -0.678 . . . . 0.0 110.713 179.642 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.444 ' CG2' ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.09 32.7 3.08 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.207 -0.933 . . . . 0.0 110.527 179.559 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.91 -67.84 1.91 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . 0.441 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 53.2 p90 -96.68 33.96 1.75 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -1.097 . . . . 0.0 109.155 179.087 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.487 HG23 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -131.22 -151.64 0.47 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.553 -0.717 . . . . 0.0 110.303 -179.37 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.413 ' N ' HG21 ' A' ' 90' ' ' THR . . . 124.42 -35.76 3.11 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.577 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.61 80.1 9.36 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.956 -1.32 . . . . 0.0 110.872 -179.463 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.487 ' CE2' HG23 ' A' ' 93' ' ' THR . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.4 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.404 ' CD1' HG23 ' A' ' 33' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . 0.427 ' HB3' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -147.44 122.14 9.88 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 33.0 p -102.6 131.53 49.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.299 -0.876 . . . . 0.0 110.219 179.848 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 55.97 30.73 16.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.334 -0.854 . . . . 0.0 111.032 179.611 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 -29.7 8.01 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.349 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.27 154.43 59.97 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.057 -1.261 . . . . 0.0 110.14 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.85 139.21 56.18 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.535 1.281 . . . . 0.0 110.292 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.427 ' NE2' ' HB3' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -48.04 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.297 -0.877 . . . . 0.0 110.872 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.434 ' OD1' ' N ' ' A' ' 114' ' ' SER . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.43 ' CG2' ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.457 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.442 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.402 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.463 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.457 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 71.1 t -95.34 -24.09 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.04 124.65 5.47 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.266 -0.896 . . . . 0.0 110.186 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.511 1.269 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.75 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.77 83.89 2.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.4 ttt180 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.196 -179.948 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 t -84.16 106.28 15.67 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -1.179 . . . . 0.0 110.319 -179.985 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.4 ' O ' HG23 ' A' ' 3' ' ' VAL . 19.4 m -113.13 104.41 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.324 -0.86 . . . . 0.0 110.076 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 50.5 p -88.57 136.33 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.304 -0.872 . . . . 0.0 110.221 179.696 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.401 HG21 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.62 147.28 98.71 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.654 179.654 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.403 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 55.7 Cg_endo -82.01 -169.33 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 124.106 1.582 . . . . 0.0 110.862 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.74 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.158 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.7 108.82 1.32 Allowed 'Trans proline' 0 C--N 1.312 -1.367 0 O-C-N 123.844 1.444 . . . . 0.0 110.884 -179.51 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 179.69 -32.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.461 HD13 HG21 ' A' ' 10' ' ' ILE . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.41 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.435 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.426 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.474 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.456 ' CG2' ' O ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.408 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.433 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.435 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.456 ' O ' ' CG2' ' A' ' 21' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.474 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.421 ' O ' ' HB3' ' A' ' 34' ' ' LYS . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.437 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.518 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.476 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.414 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.518 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.488 HD23 ' CZ ' ' A' ' 41' ' ' PHE . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.444 ' HB ' ' CB ' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . 0.488 ' CZ ' HD23 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.433 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.402 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . 0.402 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.443 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.402 ' HB2' ' O ' ' A' ' 47' ' ' LYS . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.417 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.483 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.453 HD21 ' N ' ' A' ' 58' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.51 HG21 HG21 ' A' ' 81' ' ' VAL . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.444 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.483 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.497 ' CG2' ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.479 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.44 ' CB ' ' HB3' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.516 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.516 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.448 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.441 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.464 ' CB ' HG12 ' A' ' 63' ' ' VAL . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.497 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.439 HD13 ' ND2' ' A' ' 77' ' ' ASN . 1.1 pp -136.68 113.33 10.02 Favored Pre-proline 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' HA ' HG13 ' A' ' 80' ' ' VAL . 51.3 Cg_endo -89.31 40.97 0.51 Allowed 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.566 1.298 . . . . 0.0 110.357 178.722 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.57 47.67 1.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.068 -1.02 . . . . 0.0 110.652 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . 0.439 ' ND2' HD13 ' A' ' 74' ' ' ILE . 5.5 m-80 -148.45 27.38 0.92 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.139 -0.976 . . . . 0.0 110.275 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.71 -94.6 1.39 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.27 111.68 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.189 -1.183 . . . . 0.0 110.097 179.675 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.444 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.51 HG21 HG21 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.503 ' CG2' ' O ' ' A' ' 83' ' ' VAL . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.44 ' HB3' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.438 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.44 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -67.04 -33.86 76.45 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.5 mmt 55.09 -87.48 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.606 -0.684 . . . . 0.0 110.505 179.801 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 88' ' ' LEU . 0.0 OUTLIER -179.5 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.944 -1.097 . . . . 0.0 110.46 -179.833 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . 0.418 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 70.09 -65.38 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 38.3 p90 -128.22 13.93 6.68 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -1.213 . . . . 0.0 110.858 -179.637 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.478 ' OG1' ' CE1' ' A' ' 96' ' ' PHE . 14.6 t -75.47 -167.25 0.63 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.408 -179.716 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.345 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.43 65.41 8.91 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.941 -1.329 . . . . 0.0 110.733 -179.415 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.478 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.434 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . 0.419 ' N ' HD12 ' A' ' 100' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.446 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER -146.76 135.76 22.44 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.6 p -114.78 132.68 56.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.298 -0.876 . . . . 0.0 109.938 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.52 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.025 -1.047 . . . . 0.0 109.832 -179.858 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.17 17.31 43.22 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.491 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.42 156.29 78.76 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.102 -1.234 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.428 ' HA ' ' CG2' ' A' ' 104' ' ' THR . 38.8 Cg_endo -64.35 167.1 15.44 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.595 1.313 . . . . 0.0 110.465 179.966 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . 0.481 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 -70.79 154.88 41.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.457 -0.777 . . . . 0.0 110.91 -178.83 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . . . . . . . . . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.481 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.417 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . 0.403 ' HB2' ' O ' ' A' ' 114' ' ' SER . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.536 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.458 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.458 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.437 ' CZ ' HG13 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 7.1 t -82.92 -50.6 15.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.468 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.52 162.64 0.42 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.371 -0.831 . . . . 0.0 111.513 -178.888 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.38 -53.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.596 1.314 . . . . 0.0 110.163 179.819 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.89 177.72 17.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.26 -34.39 63.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -1.121 . . . . 0.0 110.203 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.165 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.06 106.37 6.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.257 -1.143 . . . . 0.0 110.064 179.867 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.408 ' O ' HG21 ' A' ' 3' ' ' VAL . 27.5 m -112.99 104.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.285 -0.884 . . . . 0.0 110.024 179.765 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' THR . . . . . 0.486 ' CG2' ' CB ' ' A' ' 112' ' ' ALA . 18.0 p -66.96 141.18 57.7 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 109.894 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.43 HG11 ' CG2' ' A' ' 116' ' ' THR . 0.2 OUTLIER -66.63 147.58 98.95 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.163 -0.961 . . . . 0.0 109.381 179.856 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' PRO . . . . . 0.415 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.86 -168.33 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 124.189 1.626 . . . . 0.0 110.675 179.637 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' HIS . . . . . 0.502 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.81 81.24 0.19 Allowed Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.472 -0.768 . . . . 0.0 109.987 -179.818 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' PRO . . . . . 0.453 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.78 -170.73 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.73 1.384 . . . . 0.0 109.831 179.644 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.84 -14.04 0.87 Allowed 'General case' 0 N--CA 1.508 2.457 0 O-C-N 121.854 -0.529 . . . . 0.0 111.264 -179.497 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . 0.449 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.402 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.435 HG13 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . 0.441 ' CD2' ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' THR . . . . . 0.436 ' O ' ' HD3' ' A' ' 29' ' ' PRO . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' GLU . . . . . 0.414 ' CB ' HD13 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ILE . . . . . 0.461 HG22 ' O ' ' A' ' 28' ' ' ILE . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' PHE . . . . . 0.429 ' N ' ' O ' ' A' ' 26' ' ' LYS . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' LYS . . . . . 0.441 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . 0.42 ' HB2' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' ILE . . . . . 0.461 ' O ' HG22 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' PRO . . . . . 0.453 ' HA ' ' HA3' ' A' ' 19' ' ' GLY . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.446 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.419 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.527 ' HA ' ' CG ' ' A' ' 38' ' ' HIS . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' LYS . . . . . 0.448 ' HB2' ' CD1' ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' HIS . . . . . 0.527 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.401 ' HB3' ' CG1' ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.445 ' CD1' ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.488 ' HD2' ' CE1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' CYS . . . . . 0.441 ' HB3' ' CB ' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.445 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.519 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 55' ' ' LEU . . . . . 0.509 ' CB ' ' CB ' ' A' ' 62' ' ' ALA . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 58' ' ' LEU . . . . . 0.519 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.464 HG22 HG21 ' A' ' 81' ' ' VAL . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 61' ' ' ASN . . . . . 0.403 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . 0.509 ' CB ' ' CB ' ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.463 ' CG2' HG12 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . 0.497 ' HA ' ' O ' ' A' ' 83' ' ' VAL . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 65' ' ' TYR . . . . . 0.461 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.5 ' CZ ' ' CD2' ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 69' ' ' LEU . . . . . 0.5 ' CD2' ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.458 ' O ' ' CD1' ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.436 ' CG2' ' O ' ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.427 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 73' ' ' VAL . . . . . 0.484 ' CG1' ' CG2' ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 74' ' ' ILE . . . . . 0.453 ' O ' ' CD1' ' A' ' 74' ' ' ILE . 1.2 pp -136.93 92.13 14.55 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.0 58.1 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.428 1.225 . . . . 0.0 110.52 179.745 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 p -119.43 -32.0 4.47 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.163 -0.961 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 -150.82 160.65 43.74 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.169 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 65.01 166.65 1.38 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.09 102.97 15.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.1 -1.235 . . . . 0.0 110.171 -179.949 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 37' ' ' ARG . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.484 HG22 ' CB ' ' A' ' 62' ' ' ALA . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . 0.484 ' CG2' ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 83' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 64' ' ' ALA . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 84' ' ' ALA . . . . . 0.461 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.429 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.29 -33.0 72.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.2 mmt 54.06 -89.94 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.585 -0.697 . . . . 0.0 110.144 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 90' ' ' THR . . . . . 0.451 ' CB ' HG21 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.71 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.896 -1.127 . . . . 0.0 110.097 179.843 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.78 -48.65 79.46 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.61 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.56 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.46 -1.024 . . . . 0.0 110.51 -179.893 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 93' ' ' THR . . . . . 0.451 HG21 ' CB ' ' A' ' 90' ' ' THR . 5.6 t -95.1 -152.92 0.37 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.096 -1.003 . . . . 0.0 110.217 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' N ' HG22 ' A' ' 93' ' ' THR . . . 97.35 -10.29 65.18 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.642 179.117 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -124.92 65.0 1.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.748 -1.442 . . . . 0.0 110.893 -179.69 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.445 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 99' ' ' VAL . . . . . 0.531 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 100' ' ' ILE . . . . . . . . . . . . . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p -142.88 133.66 25.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.6 p -113.86 132.42 55.91 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.363 -0.836 . . . . 0.0 109.431 179.246 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.53 -141.95 0.83 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.021 -1.049 . . . . 0.0 109.49 -179.361 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.7 15.37 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.514 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.84 157.21 70.11 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.262 -1.14 . . . . 0.0 109.641 -179.837 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -64.67 166.31 18.24 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.574 1.302 . . . . 0.0 110.212 -179.759 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.07 162.89 28.93 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.213 -0.929 . . . . 0.0 110.8 -179.24 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 111' ' ' ASP . . . . . 0.46 ' O ' ' OG ' ' A' ' 114' ' ' SER . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 112' ' ' ALA . . . . . 0.486 ' CB ' ' CG2' ' A' ' 4' ' ' THR . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 113' ' ' VAL . . . . . 0.422 HG21 ' N ' ' A' ' 114' ' ' SER . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 114' ' ' SER . . . . . 0.46 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.43 ' CG2' HG11 ' A' ' 5' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.41 ' NE2' ' HA ' ' A' ' 117' ' ' GLN . 7.6 tp60 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 119' ' ' ARG . . . . . 0.502 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 121' ' ' ARG . . . . . 0.409 ' O ' ' CD ' ' A' ' 124' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 122' ' ' THR . . . . . 0.459 ' OG1' ' CA ' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 123' ' ' GLY . . . . . 0.454 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 124' ' ' ARG . . . . . 0.426 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 126' ' ' LYS . . . . . 0.481 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.481 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 128' ' ' GLY . . . . . 0.459 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 129' ' ' ILE . . . . . 0.445 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 130' ' ' TYR . . . . . 0.531 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' CZ ' HG11 ' A' ' 32' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -88.96 -38.99 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.18 131.68 28.28 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.201 -0.937 . . . . 0.0 110.212 -179.851 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 135' ' ' PRO . . . . . 0.472 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 49.7 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.529 1.278 . . . . 0.0 110.624 -179.855 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.19 105.37 0.24 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.03 -166.35 1.81 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -1.146 . . . . 0.0 110.205 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.272 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.187 0.518 . . . . 0.0 110.405 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.557 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.733 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.409 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.916 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.549 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.733 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.98 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.641 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.56 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.854 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.911 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.707 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.42 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.811 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.555 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.641 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.0 t-20 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.748 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.929 HG21 ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.911 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.864 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.864 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.841 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.929 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.762 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 122.093 0.949 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.826 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.854 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.507 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.458 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.654 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.006 0.431 . . . . 0.0 110.587 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.518 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.456 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.98 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.301 0.572 . . . . 0.0 110.788 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.542 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.443 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.542 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.443 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.522 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.513 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.513 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.456 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.472 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.498 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 121.263 0.554 . . . . 0.0 109.957 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.753 HG12 HG23 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.405 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.676 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.614 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.414 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.676 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.614 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.757 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.602 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.096 HG23 HG23 ' A' ' 33' ' ' ILE . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.096 HG23 HG23 ' A' ' 32' ' ' VAL . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.629 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.577 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.569 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.82 HD12 HG12 ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.917 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.759 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.41 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.562 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.709 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.602 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.642 HG22 HG22 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.7 t-20 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.93 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.917 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.471 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.939 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.866 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.93 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.921 0.867 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.642 HG22 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.82 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.053 0.454 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.894 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.466 ' O ' HG22 ' A' ' 104' ' ' THR . 0.8 OUTLIER . . . . . 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.526 0.679 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.42 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.517 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.433 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.486 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.753 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' SER . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.404 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.514 HG22 HD23 ' A' ' 15' ' ' LEU . 49.9 t . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.263 0.554 . . . . 0.0 109.765 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.842 HG12 HG23 ' A' ' 122' ' ' THR . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.544 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.751 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.824 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.881 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.441 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.751 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.824 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.881 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.705 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.595 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.431 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 33' ' ' ILE . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.039 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.567 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.659 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.953 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.547 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.464 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.81 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.014 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.563 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.845 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.595 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.554 HG22 HG22 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.774 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.719 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.904 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.81 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.897 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.897 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.829 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.71 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.904 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.774 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.945 0.879 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.554 HG22 HG22 ' A' ' 60' ' ' ILE . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 1.029 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.014 HG11 HD12 ' A' ' 51' ' ' LEU . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.514 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 1.029 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.076 0.465 . . . . 0.0 110.471 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.485 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.881 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.426 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.6 m . . . . . 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.366 0.603 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.494 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.494 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.418 ' O ' ' HB3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.467 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.842 HG23 HG12 ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.482 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.43 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.462 ' HA ' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.544 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.426 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t . . . . . 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.5 m-80 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.136 0.493 . . . . 0.0 109.925 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.819 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.539 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.582 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.944 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.493 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.539 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.944 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.795 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.662 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.487 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.092 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.092 HG23 HG23 ' A' ' 32' ' ' VAL . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.597 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.445 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.951 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.415 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.684 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.883 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.568 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.627 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.95 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.847 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.972 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.972 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.95 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 122.018 0.914 . . . . 0.0 110.053 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.752 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.951 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.501 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.501 ' N ' HG23 ' A' ' 85' ' ' THR . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 120.92 0.391 . . . . 0.0 111.172 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.486 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.908 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.323 0.582 . . . . 0.0 110.963 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.452 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.47 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.47 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.486 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.819 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 26' ' ' LYS . 74.9 t . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.501 2.099 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.74 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.617 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.617 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.891 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.815 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.058 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.058 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.561 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.896 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.464 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.519 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.784 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.85 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.83 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.85 HD23 ' O ' ' A' ' 54' ' ' LYS 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.602 HG22 HG22 ' A' ' 81' ' ' VAL . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.2 t-20 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.559 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.868 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.929 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.929 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.778 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.868 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.884 0.849 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.561 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.816 HG11 ' HB ' ' A' ' 33' ' ' ILE . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.74 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.896 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.529 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.529 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.576 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp . . . . . 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.159 0.505 . . . . 0.0 110.592 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.458 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.563 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.891 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.437 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.454 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.533 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.533 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.454 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.5 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.479 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.448 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.74 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.563 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.47 ' HB2' HG13 ' A' ' 100' ' ' ILE . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.7 t . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.776 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.66 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.504 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.478 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.897 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.471 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.504 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.862 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.877 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.872 HD11 HD12 ' A' ' 58' ' ' LEU . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.478 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.565 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.918 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.918 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.711 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.575 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.897 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.872 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.621 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.486 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.0 OUTLIER -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.664 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.918 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.472 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.868 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.723 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.723 HG23 ' O ' ' A' ' 72' ' ' SER . 1.3 pp . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 122.036 0.922 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.719 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.918 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.547 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.547 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.614 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 120.928 0.394 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.512 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.447 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.815 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.408 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.185 0.517 . . . . 0.0 110.744 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.415 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.469 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.469 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.483 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.498 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.776 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.66 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.751 0 CA-C-O 120.807 0.336 . . . . 0.0 111.155 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.689 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.716 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.82 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.898 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.716 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.82 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.064 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.754 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.732 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.561 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.663 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.94 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.422 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.699 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.077 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.459 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.58 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.778 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.732 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.4 t-20 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.91 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.91 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.566 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.815 0.817 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.52 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.767 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.077 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.002 0.429 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.504 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.707 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.064 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.481 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.387 0.613 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.521 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.472 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.475 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HE ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.663 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.689 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.406 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.445 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.514 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.707 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.404 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.082 0.468 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.664 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.614 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ALA . . . . . 0.458 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.678 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.885 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.451 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.724 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.678 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.885 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.809 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.453 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HD3' ' CG1' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HB2' HG12 ' A' ' 81' ' ' VAL . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.515 HD12 ' O ' ' A' ' 82' ' ' VAL . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.936 HD12 HG12 ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.724 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.742 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.64 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.667 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.734 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.656 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.9 t-20 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.585 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.742 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.885 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.885 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.807 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.688 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.859 0.838 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.695 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.936 HG12 HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.479 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.19 0.519 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.738 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.425 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.526 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.423 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.477 0.656 . . . . 0.0 110.857 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HD3' ' OD2' ' A' ' 101' ' ' ASP . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.448 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.503 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.664 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.46 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.614 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.504 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.623 0.725 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.612 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.672 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.778 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.422 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.672 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.778 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.786 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.677 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.037 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.037 HG23 HG23 ' A' ' 32' ' ' VAL . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.649 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.955 HD12 HG12 ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.469 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.522 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.843 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.753 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.558 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.81 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.677 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.1 t-20 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.657 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.938 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.843 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.966 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.966 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.453 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.938 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.544 ' O ' HG11 ' A' ' 80' ' ' VAL . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 122.009 0.909 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.544 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.955 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.031 0.443 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.409 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.404 0.621 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.527 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.438 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.442 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.612 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.413 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.488 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.504 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.504 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.538 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.445 HG22 HD23 ' A' ' 15' ' ' LEU . 54.3 t . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.566 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.414 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.465 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.925 HD11 HD21 ' A' ' 51' ' ' LEU . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.507 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.507 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.465 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.982 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.77 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.763 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.527 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.614 HD12 ' O ' ' A' ' 82' ' ' VAL . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.753 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.925 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.801 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.74 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.763 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.699 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.511 ' OD1' HD11 ' A' ' 74' ' ' ILE . 2.5 t-20 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.68 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.847 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.847 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.911 0.863 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.659 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.782 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.753 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.463 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.6 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.6 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.42 HD12 ' CD2' ' A' ' 65' ' ' TYR . 14.6 tp . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.091 0.472 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.44 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.982 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.3 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.245 0.545 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.448 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.437 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.541 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.541 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.566 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.409 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.6 t-20 . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 121.104 0.478 . . . . 0.0 110.619 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.531 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.531 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.671 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.436 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.928 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.671 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.928 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.871 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.702 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.457 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.594 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.467 HD12 ' O ' ' A' ' 82' ' ' VAL . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 HG12 ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.413 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.799 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.488 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.544 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.874 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.702 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 11.1 t-20 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.666 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.497 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.961 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.961 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.815 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.703 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.703 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.971 0.891 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.601 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.761 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.836 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.497 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 85' ' ' THR . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.467 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.133 0.492 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.883 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.469 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.427 0.632 . . . . 0.0 110.821 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.522 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.522 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.419 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.431 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.531 ' HG2' HD12 ' A' ' 10' ' ' ILE . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.458 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.498 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.498 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.531 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.411 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.603 HG22 HD23 ' A' ' 15' ' ' LEU . 16.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.2 m120 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.162 0.506 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.482 HD11 ' O ' ' A' ' 122' ' ' THR . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.684 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.615 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.433 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.869 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.459 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.709 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.684 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.869 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.856 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.606 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.511 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.948 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.709 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 44' ' ' SER . . . . . 0.408 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.458 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.849 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.726 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.484 HD13 ' HA ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.606 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.584 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.899 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.52 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.622 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.933 0.873 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.727 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.948 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.472 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.523 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.426 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.757 0.313 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.511 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.442 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.49 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.768 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.474 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 121.614 0.721 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.529 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.529 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.471 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.57 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.57 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.564 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.49 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.6 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.517 HG22 HD23 ' A' ' 15' ' ' LEU . 7.0 t . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.544 0.688 . . . . 0.0 109.261 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.54 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.563 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.512 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.68 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.678 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.439 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.081 HG23 HG23 ' A' ' 33' ' ' ILE . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.081 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.658 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.832 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.458 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.889 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.697 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.52 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.87 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.678 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.689 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.889 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.966 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.966 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.778 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.672 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 122.115 0.96 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.47 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.834 HG11 HD13 ' A' ' 88' ' ' LEU . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.832 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.834 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.242 0.544 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.817 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.422 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.414 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.1 p . . . . . 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.601 0.715 . . . . 0.0 111.198 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.501 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.458 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.54 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.532 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.532 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.426 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.414 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.563 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.512 HG22 HD23 ' A' ' 15' ' ' LEU . 34.4 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 50.7 t30 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.433 0.635 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.515 HD13 HG22 ' A' ' 122' ' ' THR . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.411 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.464 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.485 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.922 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.511 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.539 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.485 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.922 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.801 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.654 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.612 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.564 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 82' ' ' VAL . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.926 HD12 HG12 ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.539 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 10.7 p80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.884 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.705 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.517 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.653 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.538 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.654 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 4.1 t-20 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.653 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.895 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.884 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.499 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.926 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.95 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.95 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.657 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.895 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.633 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.947 0.88 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.651 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.777 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.926 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.499 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.694 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.694 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.124 0.488 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.485 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.499 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.83 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.225 0.536 . . . . 0.0 110.972 . . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.404 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.43 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.481 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.463 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.499 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.44 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.424 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.464 HG22 HD23 ' A' ' 15' ' ' LEU . 32.1 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.495 1.817 0 CA-C-O 120.969 0.414 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 ' O ' ' A' ' 122' ' ' THR . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.781 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.699 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.719 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.917 HD12 HD13 ' A' ' 55' ' ' LEU . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.542 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.699 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.719 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.045 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.748 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.79 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.637 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.574 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.898 HD12 HG12 ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.644 HD12 HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.685 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.917 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.79 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.637 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.2 t-20 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.705 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.745 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.844 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.825 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.799 0.809 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 60' ' ' ILE . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.898 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.515 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.515 ' N ' HG23 ' A' ' 85' ' ' THR . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.034 0.445 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.712 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.045 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.542 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.454 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.406 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 1.3 p . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.354 0.597 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.416 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.416 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.454 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.712 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.431 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' HG21 ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.781 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.15 0.5 . . . . 0.0 110.427 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' O ' ' A' ' 122' ' ' THR . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.537 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.517 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.946 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.517 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.946 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.865 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.757 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.618 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.65 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.902 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.948 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.435 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 1.053 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.619 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.745 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.757 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.8 t-20 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.745 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.511 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.848 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.848 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 122.012 0.91 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.65 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 1.053 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.451 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.451 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.492 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.024 0.44 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.714 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.413 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.399 0.619 . . . . 0.0 111.133 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.472 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.472 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.459 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.53 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.53 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.708 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.537 HG22 HD23 ' A' ' 15' ' ' LEU . 46.2 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 40.9 m-20 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.139 0.495 . . . . 0.0 110.171 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.448 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.9 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.406 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.448 ' CB ' HD23 ' A' ' 15' ' ' LEU . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.9 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.79 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.581 HD11 HD12 ' A' ' 58' ' ' LEU . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.406 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.599 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.939 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.423 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.951 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.809 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.468 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.533 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.734 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.581 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.599 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 7.9 t-20 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.734 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.939 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.951 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.672 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.924 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.644 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.939 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.644 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 122.103 0.954 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' CG1' ' A' ' 73' ' ' VAL . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.939 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.484 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.484 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.462 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.201 0.524 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB2' ' HB ' ' A' ' 129' ' ' ILE . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.867 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.4 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.443 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.546 0.689 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.51 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.45 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.477 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.492 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.492 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 98' ' ' SER . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.42 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.443 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.301 0.572 . . . . 0.0 110.289 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.843 HD13 HG23 ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.743 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.402 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.945 HD12 HD13 ' A' ' 55' ' ' LEU . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.431 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.662 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.743 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 1.037 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.896 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.491 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.054 HG23 HG23 ' A' ' 33' ' ' ILE . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.054 HG23 HG23 ' A' ' 32' ' ' VAL . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.556 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.791 HD12 HG12 ' A' ' 83' ' ' VAL . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.503 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.424 ' HB3' ' O ' ' A' ' 104' ' ' THR . 7.9 p80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.837 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.757 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.537 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.945 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.537 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.5 t-20 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.609 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.86 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.837 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.561 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.85 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.85 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.691 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.86 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.691 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.96 0.886 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.546 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.624 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.803 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.791 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 85' ' ' THR . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.687 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.13 0.491 . . . . 0.0 110.428 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.476 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.738 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 1.037 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.424 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.9 p . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.7 pp0? . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.212 0.529 . . . . 0.0 110.648 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.516 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.466 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.587 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.843 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.477 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.453 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.477 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.738 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.296 0.57 . . . . 0.0 109.908 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.489 HD13 HG22 ' A' ' 122' ' ' THR . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.607 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.451 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.655 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.451 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.915 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.578 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.059 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.059 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.589 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.626 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.486 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.497 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.875 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.578 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t-20 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.911 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.504 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.73 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.911 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 122.029 0.919 . . . . 0.0 110.29 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.623 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.83 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.552 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.552 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.261 0.553 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.492 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.492 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.9 pp0? . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.436 0.636 . . . . 0.0 110.862 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.487 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.515 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.464 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.583 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.607 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.655 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.7 t . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.1 m-80 . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.151 0.501 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 ' O ' ' A' ' 122' ' ' THR . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.714 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.622 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.622 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.916 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.819 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.588 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.584 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.923 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.477 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.412 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.443 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.706 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.442 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.928 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.848 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.819 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.1 t-20 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.578 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.874 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.706 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.611 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.893 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.769 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.442 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.874 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.438 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 122.073 0.939 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.603 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.928 HG11 HD12 ' A' ' 51' ' ' LEU . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.482 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.778 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.504 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.778 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' LEU . . . . . 0.436 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.357 0.599 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.593 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.538 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.538 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.625 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.425 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.538 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 15' ' ' LEU . 54.6 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.8 p30 . . . . . 0 N--CA 1.506 2.373 0 N-CA-C 112.481 0.548 . . . . 0.0 112.481 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.512 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.633 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.431 ' CD2' ' SG ' ' A' ' 102' ' ' CYS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.633 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.987 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.839 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.551 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.046 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.515 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.622 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.926 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.493 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.412 ' HB3' ' O ' ' A' ' 104' ' ' THR . 0.0 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.739 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.993 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.565 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.746 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.589 HG22 HG22 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.629 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.594 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.922 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.476 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.865 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.877 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.877 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.922 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.681 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 122.0 0.905 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.681 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.589 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.771 HG22 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.993 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.476 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.491 ' N ' HG23 ' A' ' 85' ' ' THR . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.04 0.448 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.422 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.987 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.433 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 103' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.412 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.503 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.322 0.582 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.455 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.479 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.503 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.469 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.493 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.469 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.495 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.422 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.437 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.433 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.466 0 CA-C-O 120.63 0.252 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.73 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.902 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 16' ' ' SER . . . . . 0.459 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.683 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.901 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.481 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.902 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.683 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.901 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.767 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.836 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.044 HG23 HG23 ' A' ' 33' ' ' ILE . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.044 HG23 HG23 ' A' ' 32' ' ' VAL . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.617 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.673 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.829 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.481 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.473 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.894 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.714 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.699 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.836 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.617 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.639 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.755 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 79' ' ' ASP . . . . . 0.419 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.864 0.84 . . . . 0.0 109.983 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 80' ' ' VAL . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.599 HG22 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.673 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.829 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.403 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.104 0.478 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.583 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.876 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.473 0.654 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.503 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.462 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.424 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.544 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.544 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.499 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.73 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.7 t . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.667 ' N ' HD21 ' A' ' 9' ' ' ASN . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.045 0.45 . . . . 0.0 110.449 . . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.496 HD13 HG22 ' A' ' 122' ' ' THR . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.79 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.573 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.942 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.502 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.57 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.969 HD11 HG21 ' A' ' 100' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.756 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.478 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.548 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.557 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.535 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.878 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.913 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.665 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 52' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.524 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.2 t-20 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.59 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.913 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.485 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.746 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.746 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.933 0.873 . . . . 0.0 110.216 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.559 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.878 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.601 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.142 0.496 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.576 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.969 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.561 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.322 0.582 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.454 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.524 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.524 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.576 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.79 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.573 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t . . . . . 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.538 HD13 HG22 ' A' ' 122' ' ' THR . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.45 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.699 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.405 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.43 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.936 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.803 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.615 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.473 ' HG2' HG12 ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 104' ' ' THR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 47' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.687 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.741 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.535 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.751 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.615 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 20.3 t-20 -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.691 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.921 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.687 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.994 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.994 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.828 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.92 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.921 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.92 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.595 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.817 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.504 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.158 0.504 . . . . 0.0 110.733 . . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.471 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.936 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.457 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.513 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 39.4 tt0 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.616 0.722 . . . . 0.0 110.91 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 114' ' ' SER . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.424 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.513 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.441 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.424 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.492 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.538 HG22 HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.492 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.492 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.516 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.475 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.438 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 133' ' ' VAL . . . . . 0.662 HG22 HD23 ' A' ' 15' ' ' LEU . 7.1 t . . . . . 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 m120 . . . . . 0 N--CA 1.508 2.457 0 CA-C-O 120.59 0.233 . . . . 0.0 111.264 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.499 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 15' ' ' LEU . . . . . 0.757 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' THR . . . . . 0.808 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 20' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ILE . . . . . 0.978 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.452 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 26' ' ' LYS . . . . . 0.757 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 27' ' ' ALA . . . . . 0.808 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 28' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' PRO . . . . . 0.729 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.581 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' LYS . . . . . 0.627 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.636 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.502 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' CYS . . . . . 0.878 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 50' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 51' ' ' LEU . . . . . 0.803 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 55' ' ' LEU . . . . . 0.978 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 57' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.627 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 61' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.58 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.689 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.878 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.81 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 69' ' ' LEU . . . . . 0.928 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.928 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.692 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.432 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 73' ' ' VAL . . . . . 0.956 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 74' ' ' ILE . . . . . 0.506 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.993 0.902 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.956 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 83' ' ' VAL . . . . . 0.92 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 85' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 86' ' ' ASP . . . . . 0.496 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 120.968 0.413 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 99' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 100' ' ' ILE . . . . . 0.874 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.5 tp60 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.477 0.656 . . . . 0.0 110.8 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 114' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.419 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.8 tp-100 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 119' ' ' ARG . . . . . 0.48 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 122' ' ' THR . . . . . 0.558 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 123' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 124' ' ' ARG . . . . . 0.409 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 126' ' ' LYS . . . . . 0.48 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 128' ' ' GLY . . . . . 0.558 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 129' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 130' ' ' TYR . . . . . 0.615 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 131' ' ' ARG . . . . . 0.499 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 132' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.411 ' HB3' ' CB ' ' A' ' 112' ' ' ALA . 0.5 OUTLIER -106.91 125.5 51.09 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 110.216 179.892 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.4 m -113.29 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.445 HG22 ' OG1' ' A' ' 116' ' ' THR . 13.8 p -78.34 142.98 37.31 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.306 -0.871 . . . . 0.0 110.389 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.67 148.72 85.5 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.28 -0.887 . . . . 0.0 109.5 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -69.12 -169.22 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 124.085 1.571 . . . . 0.0 110.751 179.456 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.458 ' CG ' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 175.68 79.44 0.08 OUTLIER Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.34 -0.85 . . . . 0.0 110.135 -179.537 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.47 -15.36 27.8 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.609 1.32 . . . . 0.0 110.579 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.09 -1.006 . . . . 0.0 110.405 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.557 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.733 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.409 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.916 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.549 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.733 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.98 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.641 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.56 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.854 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.911 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.707 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.42 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.811 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.555 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.641 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.481 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.0 t-20 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.748 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.929 HG21 ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.911 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.864 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.864 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.841 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.929 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.762 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt -136.47 91.29 16.35 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.58 42.22 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.701 1.369 . . . . 0.0 110.421 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -120.3 -24.76 5.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.144 -0.972 . . . . 0.0 110.654 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -163.01 162.22 25.86 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.6 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -61.27 106.77 0.66 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.1 -1.235 . . . . 0.0 109.894 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.826 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.854 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.507 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.458 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.654 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -68.97 -19.9 64.17 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.425 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.71 -150.52 0.37 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.266 -0.896 . . . . 0.0 109.871 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.458 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 109.964 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.32 -29.44 73.16 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.661 -1.375 . . . . 0.0 109.661 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.92 19.16 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.105 -1.232 . . . . 0.0 110.769 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.458 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.5 t -90.55 -154.78 0.35 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.084 -1.01 . . . . 0.0 110.32 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.436 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.26 -32.5 7.51 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.199 -1.161 . . . . 0.0 110.199 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.99 53.94 2.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.946 -1.326 . . . . 0.0 110.587 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.518 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.456 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.98 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.462 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.8 p -146.45 132.52 19.29 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.82 134.32 54.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.936 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.41 29.09 2.65 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.196 -0.94 . . . . 0.0 110.628 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -32.98 5.49 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.29 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.266 -1.138 . . . . 0.0 110.088 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.462 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.0 Cg_endo -65.14 133.75 36.67 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.562 1.296 . . . . 0.0 110.157 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.19 1.8 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 110.788 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.542 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.443 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.542 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.443 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.445 ' OG1' HG22 ' A' ' 4' ' ' THR . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.472 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.425 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.522 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.436 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.513 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.513 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.456 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.472 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.498 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.9 -65.75 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.24 96.75 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.588 -0.695 . . . . 0.0 110.007 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.09 -49.46 0.3 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.688 1.362 . . . . 0.0 110.411 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.22 23.66 4.31 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.59 167.13 10.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -1.096 . . . . 0.0 110.195 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.041 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.76 135.42 34.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.184 . . . . 0.0 110.153 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.671 ' O ' HG13 ' A' ' 3' ' ' VAL . 13.6 p -113.0 104.58 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.179 -0.951 . . . . 0.0 109.899 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.533 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 78.5 p -72.3 144.66 48.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.347 -0.846 . . . . 0.0 110.487 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.44 147.98 98.15 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.306 -0.871 . . . . 0.0 109.672 179.686 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 49.9 Cg_endo -73.35 -173.77 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 O-C-N 124.071 1.564 . . . . 0.0 111.022 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.535 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.71 76.55 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.15 -17.41 45.37 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 O-C-N 123.865 1.455 . . . . 0.0 111.048 -179.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.03 -24.52 54.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.103 -0.998 . . . . 0.0 109.957 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.753 HG12 HG23 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.405 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.676 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.614 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.414 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.676 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.614 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.757 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.602 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.096 HG23 HG23 ' A' ' 33' ' ' ILE . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.096 HG23 HG23 ' A' ' 32' ' ' VAL . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.629 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.577 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.569 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.82 HD12 HG12 ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.917 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.759 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.41 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.562 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.709 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.602 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.642 HG22 HG22 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.7 t-20 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.93 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.917 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.471 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.939 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.866 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.93 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp -137.95 115.72 9.52 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.755 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.2 Cg_endo -87.37 39.16 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.256 1.135 . . . . 0.0 110.97 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.17 46.88 1.42 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.928 -1.107 . . . . 0.0 110.554 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.644 ' OD1' HD13 ' A' ' 74' ' ' ILE . 3.6 m120 -142.26 26.9 1.79 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.191 -0.943 . . . . 0.0 110.177 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.0 -94.92 1.12 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.79 109.06 10.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.169 -1.195 . . . . 0.0 110.164 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.755 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.642 HG22 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.82 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.84 -29.31 69.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.491 ' C ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER 48.64 45.01 21.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.451 -0.781 . . . . 0.0 111.051 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.645 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.5 t 33.92 -118.89 0.09 Allowed 'General case' 0 N--CA 1.505 2.282 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.55 -63.71 4.08 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -119.86 1.86 11.01 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.386 -1.067 . . . . 0.0 110.184 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.645 HG22 ' OG1' ' A' ' 90' ' ' THR . 12.3 t -67.63 -154.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.019 -1.05 . . . . 0.0 110.281 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' N ' HG23 ' A' ' 93' ' ' THR . . . 90.09 -41.53 2.97 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.04 57.49 4.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.178 -1.19 . . . . 0.0 111.114 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.414 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.894 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.541 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.8 OUTLIER -147.35 113.72 5.94 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 59.1 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.17 -0.956 . . . . 0.0 110.615 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.38 28.27 5.65 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.384 -0.823 . . . . 0.0 110.704 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.541 ' C ' HG23 ' A' ' 104' ' ' THR . . . 87.56 -14.83 57.17 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 104' ' ' THR . 8.5 mmtt -96.6 156.68 36.4 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.052 -1.263 . . . . 0.0 109.764 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.67 133.81 41.18 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.625 1.329 . . . . 0.0 110.112 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.66 -177.16 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.378 -0.826 . . . . 0.0 111.128 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.533 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.517 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.433 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.535 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.753 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' SER . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.404 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.514 HG22 HD23 ' A' ' 15' ' ' LEU . 49.9 t -72.33 -61.42 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.97 147.83 33.76 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.388 -0.82 . . . . 0.0 109.953 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.37 -46.97 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.666 1.351 . . . . 0.0 110.484 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.21 -124.37 0.82 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.74 -62.1 1.58 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.232 -1.157 . . . . 0.0 110.213 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.8 ttt85 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.289 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.67 110.0 21.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -1.143 . . . . 0.0 110.325 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.04 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.206 -0.934 . . . . 0.0 110.021 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.505 HG22 ' OG1' ' A' ' 116' ' ' THR . 17.3 p -63.83 145.14 56.35 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.378 -0.826 . . . . 0.0 110.28 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.405 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.45 98.22 Favored Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.228 -0.92 . . . . 0.0 110.147 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.405 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.5 Cg_endo -70.87 -175.86 1.58 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 124.09 1.574 . . . . 0.0 111.041 179.3 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.638 ' CD2' ' HD2' ' A' ' 119' ' ' ARG . 7.5 p-80 -176.55 84.21 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.727 -0.608 . . . . 0.0 109.58 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.98 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.668 1.351 . . . . 0.0 110.554 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 -172.73 -36.99 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.635 -0.666 . . . . 0.0 109.765 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.842 HG12 HG23 ' A' ' 122' ' ' THR . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.544 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.751 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.824 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.881 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.441 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.751 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.824 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.881 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.705 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.595 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.431 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 33' ' ' ILE . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.039 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.567 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.659 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.953 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.547 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.464 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.81 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.014 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.563 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.845 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.595 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.554 HG22 HG22 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.774 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.719 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.904 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.81 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.897 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.897 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.829 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.71 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.904 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.774 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER -136.04 99.08 11.32 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -84.46 48.02 2.33 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.762 1.401 . . . . 0.0 109.988 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.1 40.38 0.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 110.345 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -143.77 -165.45 2.11 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.14 -0.975 . . . . 0.0 110.285 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -50.32 -77.04 0.14 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -147.97 113.41 5.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.163 -1.198 . . . . 0.0 110.407 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.554 HG22 HG22 ' A' ' 60' ' ' ILE . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 1.029 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.014 HG11 HD12 ' A' ' 51' ' ' LEU . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.514 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 1.029 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -69.58 -16.13 63.35 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.425 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 16.8 mmt 53.23 -165.01 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.892 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.493 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.51 30.11 2.92 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 110.038 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.31 -42.09 94.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.24 14.94 11.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.221 -1.164 . . . . 0.0 110.667 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.493 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 6.6 t -80.38 -157.68 0.16 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.056 -1.028 . . . . 0.0 110.182 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 93' ' ' THR . . . 102.8 -32.84 7.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.268 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.81 56.79 3.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.113 -1.227 . . . . 0.0 110.471 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.485 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.881 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.426 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.6 m -143.85 121.68 11.97 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.83 43.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.173 -0.954 . . . . 0.0 110.398 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.13 30.17 5.37 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.308 -0.87 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.98 -28.87 8.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 110.001 -1.239 . . . . 0.0 110.001 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.456 ' O ' HG23 ' A' ' 104' ' ' THR . 0.0 OUTLIER -80.89 155.39 72.97 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.055 -1.262 . . . . 0.0 109.983 179.857 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.09 136.75 45.66 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 O-C-N 123.578 1.304 . . . . 0.0 110.693 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.85 1.02 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.51 -0.744 . . . . 0.0 110.786 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.494 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.494 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.418 ' O ' ' HB3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.505 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.638 ' HD2' ' CD2' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.842 HG23 HG12 ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.482 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.43 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.462 ' HA ' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.544 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.426 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t -77.19 -40.9 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.39 144.02 51.68 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.309 -0.869 . . . . 0.0 110.054 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.45 -55.73 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.585 1.308 . . . . 0.0 110.603 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.71 -91.33 0.41 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.01 68.16 0.89 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.233 -1.157 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.182 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.21 157.16 24.08 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -1.183 . . . . 0.0 110.175 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.95 104.48 17.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.3 -0.875 . . . . 0.0 109.67 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 p -66.68 136.96 56.32 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.415 -0.803 . . . . 0.0 110.517 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.445 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.99 149.03 89.63 Favored Pre-proline 0 C--N 1.303 -1.442 0 O-C-N 121.341 -0.849 . . . . 0.0 109.289 179.228 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD2' HG23 ' A' ' 5' ' ' VAL . 50.6 Cg_endo -80.22 -165.56 0.35 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.027 1.54 . . . . 0.0 111.376 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.502 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.03 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.817 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.16 60.73 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 O-C-N 123.909 1.479 . . . . 0.0 111.953 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 13.2 m120 -131.92 2.6 4.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.481 -0.762 . . . . 0.0 109.925 178.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.819 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.539 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.582 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.944 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.493 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.539 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.944 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.795 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.662 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.487 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.092 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.092 HG23 HG23 ' A' ' 32' ' ' VAL . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.597 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.445 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.951 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.415 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.684 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.883 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.568 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.627 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.95 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.847 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.972 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.972 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.95 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp -136.94 109.54 9.15 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.635 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.2 Cg_endo -86.94 46.82 1.51 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.466 1.245 . . . . 0.0 110.247 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.3 p -129.85 -9.48 4.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.069 -1.02 . . . . 0.0 111.438 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.8 m-20 -88.92 -171.92 3.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.921 -1.112 . . . . 0.0 110.341 -179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.13 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -130.81 114.44 15.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.188 -1.184 . . . . 0.0 110.053 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.635 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.752 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.951 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.501 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.501 ' N ' HG23 ' A' ' 85' ' ' THR . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.86 -29.15 67.4 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.464 ' C ' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER 55.62 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.827 -0.546 . . . . 0.0 110.444 179.866 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.557 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.3 OUTLIER 173.62 43.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.023 -1.048 . . . . 0.0 110.214 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.91 -46.81 90.37 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.22 28.18 2.55 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.423 -1.045 . . . . 0.0 110.138 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.575 ' HG1' ' HE1' ' A' ' 96' ' ' PHE . 3.1 t -86.29 -160.38 0.55 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.204 -0.935 . . . . 0.0 110.413 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' N ' HG23 ' A' ' 93' ' ' THR . . . 100.48 -31.83 8.07 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.48 73.92 0.94 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.859 -1.377 . . . . 0.0 111.172 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.486 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.908 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.1 m-20 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.563 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.9 OUTLIER -147.38 126.25 12.72 Favored 'General case' 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.57 129.26 46.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 110.172 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.36 29.06 16.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.221 -0.924 . . . . 0.0 110.566 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.563 ' C ' HG23 ' A' ' 104' ' ' THR . . . 94.76 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.4 68.81 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.153 -1.204 . . . . 0.0 110.206 -179.863 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.7 137.45 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.555 1.292 . . . . 0.0 110.492 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.3 163.65 0.23 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.443 -0.786 . . . . 0.0 110.963 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.502 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.47 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.47 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.486 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.819 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 26' ' ' LYS . 74.9 t -86.7 -41.3 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.47 111.6 63.99 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.195 -0.941 . . . . 0.0 110.289 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.54 -46.67 0.59 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.508 1.268 . . . . 0.0 110.341 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.32 129.65 6.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.84 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.256 -1.143 . . . . 0.0 110.368 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.306 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.14 102.58 14.39 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -1.174 . . . . 0.0 110.164 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.652 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.4 p -113.34 104.34 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.271 -0.893 . . . . 0.0 109.676 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.447 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.2 p -100.4 140.39 34.72 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 110.451 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.858 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -67.15 147.37 99.02 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.829 . . . . 0.0 109.108 179.596 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.6 Cg_endo -73.92 -19.56 20.55 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 124.066 1.561 . . . . 0.0 113.101 -178.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CD2' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p-80 42.78 75.77 0.6 Allowed Pre-proline 0 N--CA 1.502 2.175 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -177.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.412 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.9 Cg_endo -71.01 -175.13 1.34 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.753 1.397 . . . . 0.0 110.133 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 65.78 7.15 4.35 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.637 -0.664 . . . . 0.0 111.226 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.74 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.617 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.617 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.891 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.815 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.058 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.058 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.561 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.896 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.464 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.519 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.784 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.85 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.83 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.85 HD23 ' O ' ' A' ' 54' ' ' LYS 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.602 HG22 HG22 ' A' ' 81' ' ' VAL . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.466 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.2 t-20 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.559 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.868 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.929 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.929 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.778 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.868 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -133.78 89.94 28.96 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -90.63 53.5 1.1 Allowed 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.972 1.512 . . . . 0.0 110.582 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.1 t -125.66 -25.97 3.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.113 -0.992 . . . . 0.0 111.043 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 18.8 m120 -155.25 167.68 29.55 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.991 -1.068 . . . . 0.0 110.599 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.57 174.73 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -94.74 110.21 22.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.265 . . . . 0.0 110.194 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.561 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.816 HG11 ' HB ' ' A' ' 33' ' ' ILE . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.74 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.896 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.529 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.529 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.576 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp -67.44 -42.27 83.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.51 ' HA ' ' HE2' ' A' ' 89' ' ' MET . 0.5 OUTLIER 49.71 23.45 0.99 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.531 -0.731 . . . . 0.0 110.447 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.93 HG23 ' HB ' ' A' ' 93' ' ' THR . 89.5 m 53.93 -85.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.708 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.13 -83.38 0.07 OUTLIER Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.422 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.5 p90 -97.89 37.83 1.37 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.384 -1.068 . . . . 0.0 108.557 178.159 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.93 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -137.76 -168.75 2.39 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.307 0.575 . . . . 0.0 110.328 -179.282 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.02 -17.87 4.55 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.39 75.92 3.89 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.175 -1.191 . . . . 0.0 110.592 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.405 ' HZ ' HG21 ' A' ' 93' ' ' THR . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.458 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.563 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.891 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.437 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.496 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.45 130.53 16.36 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.3 p -107.58 134.92 49.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.105 -0.997 . . . . 0.0 110.545 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t0 55.98 32.86 20.66 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.31 -0.868 . . . . 0.0 110.94 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.39 12.46 83.81 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 179.52 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 104' ' ' THR . 0.1 OUTLIER -123.44 156.05 64.59 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.075 -1.25 . . . . 0.0 109.607 179.698 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.91 127.76 21.29 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.549 1.289 . . . . 0.0 110.716 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.454 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.09 160.95 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 -179.19 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.533 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.447 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.533 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.454 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.858 HG23 HG13 ' A' ' 5' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.448 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.74 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.563 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.47 ' HB2' HG13 ' A' ' 100' ' ' ILE . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.7 t -84.77 -67.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.424 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 52.77 95.22 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.55 -0.719 . . . . 0.0 110.397 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.28 -34.98 7.19 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.671 1.353 . . . . 0.0 110.382 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.37 -170.06 17.14 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.09 122.06 14.6 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.323 -1.104 . . . . 0.0 110.25 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.285 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 133.04 43.28 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.211 -1.17 . . . . 0.0 110.329 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.1 m -113.4 104.43 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.239 -0.913 . . . . 0.0 110.187 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.4 p -65.96 145.04 56.37 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.328 -0.858 . . . . 0.0 110.232 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.479 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.22 147.22 99.0 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.891 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.479 ' HD2' HG23 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.0 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 124.13 1.595 . . . . 0.0 111.076 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.516 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 13.3 p-80 -178.9 83.02 0.21 Allowed Pre-proline 0 N--CA 1.489 1.484 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.83 89.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.732 1.385 . . . . 0.0 110.844 -179.127 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 0.3 OUTLIER -179.98 -35.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.776 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.66 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.504 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.478 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.897 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.471 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.504 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.862 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.877 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.872 HD11 HD12 ' A' ' 58' ' ' LEU . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.478 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.565 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.918 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.918 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.711 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.575 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.897 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.872 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.621 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.486 ' OD1' HD11 ' A' ' 74' ' ' ILE . 1.0 OUTLIER -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.664 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.918 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.472 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.868 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.723 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.723 HG23 ' O ' ' A' ' 72' ' ' SER . 1.3 pp -137.71 91.6 13.61 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.473 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.9 Cg_endo -89.37 44.89 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.633 1.333 . . . . 0.0 109.919 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.34 -21.99 4.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.252 -0.905 . . . . 0.0 111.257 -179.101 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.885 -1.135 . . . . 0.0 110.861 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.74 -177.78 0.07 OUTLIER Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.52 112.29 24.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.329 -1.101 . . . . 0.0 109.977 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.719 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.918 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.547 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.547 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.614 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.62 -40.33 95.3 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.485 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.06 26.77 0.24 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.833 -0.542 . . . . 0.0 111.267 179.419 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.596 HG21 ' NE ' ' A' ' 121' ' ' ARG . 64.8 p 43.46 -133.45 0.57 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.561 -0.712 . . . . 0.0 110.973 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.86 -78.06 0.79 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -95.52 18.3 13.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -1.097 . . . . 0.0 109.814 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.49 HG23 ' N ' ' A' ' 94' ' ' GLY . 13.3 t -98.89 -148.54 0.34 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.37 -0.831 . . . . 0.0 110.206 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' N ' HG23 ' A' ' 93' ' ' THR . . . 115.11 18.54 6.27 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.179 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.29 59.58 1.25 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.925 -1.338 . . . . 0.0 110.348 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.512 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.447 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.815 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.427 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.63 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.21 137.96 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.6 p -111.14 121.95 46.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.356 -0.84 . . . . 0.0 109.491 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.07 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.01 . . . . 0.0 109.405 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.24 9.62 57.06 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.794 -1.193 . . . . 0.0 110.242 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.401 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.17 155.5 73.6 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.92 -1.341 . . . . 0.0 109.865 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.63 ' HA ' HG22 ' A' ' 104' ' ' THR . 41.0 Cg_endo -67.47 160.7 46.69 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.531 1.28 . . . . 0.0 110.573 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.13 147.61 52.07 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.349 -0.844 . . . . 0.0 110.744 -179.48 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.415 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.469 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.469 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.483 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.516 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.596 ' NE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.498 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.449 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.776 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.66 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t -94.27 -45.99 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.46 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 110.261 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.37 -21.38 23.02 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 O-C-N 123.564 1.297 . . . . 0.0 110.72 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.43 140.54 15.82 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.58 -29.35 66.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.233 -1.157 . . . . 0.0 110.272 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.237 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.83 108.06 4.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.282 -1.128 . . . . 0.0 110.235 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -113.36 105.19 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.337 -0.852 . . . . 0.0 109.996 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.16 144.84 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.374 -0.829 . . . . 0.0 110.358 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.464 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.4 147.23 94.96 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 110.276 -179.884 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 5' ' ' VAL . 52.5 Cg_endo -76.36 -173.63 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 124.237 1.651 . . . . 0.0 110.985 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.496 ' CE1' ' HG3' ' A' ' 119' ' ' ARG . 3.9 p80 -177.94 83.69 0.23 Allowed Pre-proline 0 N--CA 1.489 1.51 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.83 58.51 1.6 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.487 1.256 . . . . 0.0 111.566 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.57 7.94 0.77 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.123 -0.986 . . . . 0.0 111.155 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.689 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.716 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.82 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.898 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.716 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.82 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.064 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.754 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.732 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.561 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.663 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.94 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.422 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.699 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.077 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.459 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.58 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.778 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.732 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 2.4 t-20 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.91 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.91 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.566 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.65 93.6 12.31 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -79.59 60.93 8.02 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 123.757 1.398 . . . . 0.0 110.216 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.76 40.21 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.041 -1.037 . . . . 0.0 110.535 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.49 -163.51 1.58 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.199 -0.938 . . . . 0.0 109.812 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.34 -73.95 0.31 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.25 111.77 3.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -1.188 . . . . 0.0 110.315 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.52 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.767 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.077 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp -63.51 -29.91 71.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.501 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.18 27.32 0.2 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.804 -0.56 . . . . 0.0 111.459 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.549 HG21 ' HD3' ' A' ' 121' ' ' ARG . 61.2 p 42.06 52.58 4.35 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.779 -0.575 . . . . 0.0 111.422 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.52 -66.49 2.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -110.12 23.0 14.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.268 -1.136 . . . . 0.0 110.241 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.529 HG21 ' CB ' ' A' ' 90' ' ' THR . 14.6 t -78.84 -148.44 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 110.15 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.436 ' N ' HG23 ' A' ' 93' ' ' THR . . . 103.54 -43.11 1.74 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.74 66.62 9.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 110.842 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.504 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.707 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.064 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.481 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -143.11 140.53 30.9 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.433 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.4 p -114.31 127.69 55.99 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.356 -0.84 . . . . 0.0 109.985 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.1 t0 51.45 30.15 5.99 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.558 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.06 -32.96 5.51 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.4 mtmt -76.66 156.5 82.89 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.274 -1.133 . . . . 0.0 110.023 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.5 Cg_endo -65.64 133.27 33.65 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.658 1.346 . . . . 0.0 110.381 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -47.93 167.0 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.412 -0.805 . . . . 0.0 110.91 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.521 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.472 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.475 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.663 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.689 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.445 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.514 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.707 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.404 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t -85.91 -42.44 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.7 155.14 54.95 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.515 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.11 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.719 1.378 . . . . 0.0 110.518 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.69 74.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.62 81.42 4.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.201 -1.176 . . . . 0.0 110.245 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.282 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.9 m -87.97 150.67 23.31 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.299 -1.118 . . . . 0.0 110.368 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 3' ' ' VAL . 17.4 m -113.18 104.45 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.28 -0.888 . . . . 0.0 109.833 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.448 HG23 ' HB1' ' A' ' 112' ' ' ALA . 16.8 p -68.9 138.54 54.74 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.371 -0.83 . . . . 0.0 110.343 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.436 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.18 147.83 98.91 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 109.509 179.701 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.436 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.0 Cg_endo -71.5 -169.33 0.41 Allowed 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 124.142 1.601 . . . . 0.0 111.108 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.68 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.595 -0.691 . . . . 0.0 109.64 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.52 -10.58 28.25 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.68 1.358 . . . . 0.0 111.181 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -74.96 -11.24 60.07 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.973 -1.079 . . . . 0.0 110.437 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.664 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.614 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.458 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.678 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.885 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.451 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.724 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.678 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.885 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.809 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.453 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HD3' ' CG1' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HB2' HG12 ' A' ' 81' ' ' VAL . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.515 HD12 ' O ' ' A' ' 82' ' ' VAL . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.936 HD12 HG12 ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.724 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.742 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.64 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.667 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.734 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.656 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.485 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.9 t-20 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.585 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.742 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.885 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.885 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.807 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.688 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp -136.34 98.3 11.39 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.689 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.0 Cg_endo -78.95 53.35 4.65 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 O-C-N 123.32 1.168 . . . . 0.0 110.192 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.626 HG23 ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.25 40.0 0.31 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.68 1.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.193 -0.942 . . . . 0.0 110.323 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.21 4.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.84 109.5 17.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.156 . . . . 0.0 110.136 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.689 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.695 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.936 HG12 HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.479 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.37 -26.98 68.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.542 ' C ' HG22 ' A' ' 90' ' ' THR . 27.4 mmt 47.26 30.83 1.56 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.396 -0.815 . . . . 0.0 110.74 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.761 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.04 -134.95 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -178.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.29 21.03 8.03 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.679 -0.895 . . . . 0.0 109.391 178.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.761 HG22 ' OG1' ' A' ' 90' ' ' THR . 4.9 t -102.81 -155.5 0.53 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.88 . . . . 0.0 110.356 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.529 ' N ' HG23 ' A' ' 93' ' ' THR . . . 92.39 -33.98 4.68 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.2 59.01 5.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.973 -1.31 . . . . 0.0 110.423 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.403 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.738 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.425 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.526 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.517 ' ND2' ' HB2' ' A' ' 132' ' ' PHE . 1.0 OUTLIER 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.01 136.42 22.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.417 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.1 p -113.12 126.66 55.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 110.124 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.74 35.61 19.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.773 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.24 -6.01 77.86 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.417 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.37 156.33 35.37 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.308 . . . . 0.0 110.078 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.5 129.18 21.86 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.732 1.385 . . . . 0.0 110.514 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -51.08 152.87 2.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.484 -0.76 . . . . 0.0 110.857 -179.483 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.448 ' HB1' HG23 ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HD3' ' OD2' ' A' ' 101' ' ' ASP . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.503 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.664 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.46 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.614 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.517 ' HB2' ' ND2' ' A' ' 103' ' ' ASN . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.5 -46.86 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.35 31.08 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.365 -0.834 . . . . 0.0 110.736 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.25 -23.75 15.23 Favored 'Trans proline' 0 C--N 1.315 -1.195 0 O-C-N 123.551 1.29 . . . . 0.0 110.726 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.61 147.05 29.2 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.49 -51.52 19.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.168 -1.195 . . . . 0.0 110.151 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.294 179.981 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.07 153.66 22.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.308 -1.113 . . . . 0.0 110.289 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 3' ' ' VAL . 33.7 m -113.42 104.52 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.235 -0.916 . . . . 0.0 110.026 179.679 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.685 HG22 ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.03 143.73 57.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.312 -0.868 . . . . 0.0 110.026 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.506 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.24 149.01 86.73 Favored Pre-proline 0 C--N 1.301 -1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.579 179.656 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.8 Cg_endo -80.82 -57.94 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 124.229 1.647 . . . . 0.0 111.678 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.645 ' CD2' ' O ' ' A' ' 7' ' ' HIS . 49.8 p-80 38.34 83.07 0.21 Allowed Pre-proline 0 N--CA 1.492 1.627 0 CA-C-O 121.129 0.49 . . . . 0.0 111.787 -178.751 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.21 58.14 2.88 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.329 1.173 . . . . 0.0 110.849 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.504 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.3 -28.0 7.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.396 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.612 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.672 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.778 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.422 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.672 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.778 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.786 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.677 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.037 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.037 HG23 HG23 ' A' ' 32' ' ' VAL . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.649 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.955 HD12 HG12 ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.469 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.522 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.843 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.753 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.558 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.81 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.677 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.468 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.1 t-20 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.657 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.938 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.843 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.966 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.966 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.453 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.938 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.544 ' O ' HG11 ' A' ' 80' ' ' VAL . 0.9 OUTLIER -137.8 91.77 13.34 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -86.64 55.46 3.33 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.638 1.336 . . . . 0.0 109.797 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.71 -24.69 2.69 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.176 -0.953 . . . . 0.0 111.542 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.37 158.56 40.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.847 -1.158 . . . . 0.0 110.901 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.13 162.35 0.07 OUTLIER Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.48 102.97 10.03 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.103 -1.234 . . . . 0.0 109.756 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.544 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.955 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.29 -30.11 57.65 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.406 ' O ' ' HB ' ' A' ' 90' ' ' THR . 5.7 mmt 50.87 -115.47 0.87 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.382 -0.824 . . . . 0.0 109.764 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.646 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.07 42.87 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.528 -1.358 . . . . 0.0 110.012 179.823 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.84 74.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.432 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 36.3 p90 -137.81 21.18 2.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.351 -1.087 . . . . 0.0 110.636 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.646 HG22 ' OG1' ' A' ' 90' ' ' THR . 0.6 OUTLIER -100.89 -162.36 0.93 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.093 -1.004 . . . . 0.0 110.282 -179.859 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.615 ' N ' HG23 ' A' ' 93' ' ' THR . . . 118.98 11.87 7.37 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.928 -1.13 . . . . 0.0 110.325 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.82 65.58 1.11 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.749 -1.442 . . . . 0.0 110.487 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.409 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.13 15.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.4 p -107.67 130.91 54.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.286 -0.883 . . . . 0.0 110.144 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.1 t70 53.84 26.67 6.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.199 -0.938 . . . . 0.0 110.109 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.77 -33.09 5.39 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.16 157.25 78.58 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.279 -1.13 . . . . 0.0 110.066 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.64 128.68 24.08 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.652 1.343 . . . . 0.0 110.358 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -46.57 146.7 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.613 -0.68 . . . . 0.0 111.241 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.527 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.685 ' OG1' HG22 ' A' ' 4' ' ' THR . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.442 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.625 ' HD2' ' HE1' ' A' ' 7' ' ' HIS . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.428 ' CB ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.488 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.504 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.504 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.538 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.445 HG22 HD23 ' A' ' 15' ' ' LEU . 54.3 t -73.24 -37.7 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.21 143.62 49.7 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.217 -0.927 . . . . 0.0 110.315 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -73.62 -50.2 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.695 1.366 . . . . 0.0 110.265 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.44 -54.42 0.65 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.99 -55.74 3.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.298 -1.119 . . . . 0.0 110.279 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.167 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 112' ' ' ALA . 1.9 p -81.35 106.73 13.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.296 -1.12 . . . . 0.0 110.101 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.674 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.05 16.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.208 -0.933 . . . . 0.0 110.01 179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.7 p -73.16 145.3 46.45 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 110.17 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.4 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.06 147.01 60.17 Favored Pre-proline 0 C--N 1.302 -1.495 0 O-C-N 121.336 -0.852 . . . . 0.0 109.752 179.686 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.4 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.5 Cg_endo -73.16 -165.09 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 124.066 1.561 . . . . 0.0 110.931 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.538 ' CD2' ' HB ' ' A' ' 10' ' ' ILE . 6.9 p-80 -177.59 82.17 0.24 Allowed Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.9 81.4 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.851 1.448 . . . . 0.0 110.708 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.18 -37.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.538 ' HB ' ' CD2' ' A' ' 7' ' ' HIS . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.566 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.414 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.465 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.925 HD11 HD21 ' A' ' 51' ' ' LEU . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.507 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.507 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.465 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.982 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.77 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.763 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.527 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.614 HD12 ' O ' ' A' ' 82' ' ' VAL . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.753 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.925 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.801 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.74 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.763 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.699 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.511 ' OD1' HD11 ' A' ' 74' ' ' ILE . 2.5 t-20 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.68 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.847 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.847 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -136.21 92.99 15.3 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -82.82 53.4 4.4 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.705 1.371 . . . . 0.0 109.601 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.09 19.38 1.24 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.305 -0.872 . . . . 0.0 110.394 -179.271 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.35 -164.48 1.22 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.949 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.76 -77.86 0.11 Allowed Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -146.83 113.39 5.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.15 -1.206 . . . . 0.0 110.344 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.659 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.782 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.753 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.463 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.6 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.6 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.453 HD11 ' HZ ' ' A' ' 92' ' ' PHE . 14.6 tp -61.99 -34.45 76.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.503 ' C ' HG22 ' A' ' 90' ' ' THR . 14.8 mmt 48.17 47.02 19.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 110.906 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.569 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 34.73 -128.05 0.09 Allowed 'General case' 0 N--CA 1.506 2.33 0 O-C-N 122.065 -0.397 . . . . 0.0 112.019 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.431 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.64 -61.49 2.04 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.453 ' HZ ' HD11 ' A' ' 88' ' ' LEU . 33.2 p90 -121.93 3.4 9.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.459 -1.024 . . . . 0.0 109.946 178.827 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.569 HG22 ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.36 -160.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.091 -1.006 . . . . 0.0 109.819 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.34 -39.37 3.07 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.23 57.02 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.104 -1.233 . . . . 0.0 110.73 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.543 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.44 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.982 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.656 ' HB3' ' HB3' ' A' ' 134' ' ' ALA . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.15 129.62 15.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.8 p -103.38 134.04 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.364 -0.835 . . . . 0.0 109.332 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.23 1.66 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.192 -0.942 . . . . 0.0 110.474 -179.488 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.16 -32.73 5.71 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.7 157.36 82.15 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.354 -1.086 . . . . 0.0 110.148 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.45 130.14 25.87 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.578 1.304 . . . . 0.0 110.153 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.3 pt20 -51.73 153.99 2.2 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.455 -0.778 . . . . 0.0 110.984 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' SER . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.448 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.437 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.541 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.541 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.566 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.409 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t -98.0 -30.79 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.656 ' HB3' ' HB3' ' A' ' 103' ' ' ASN . . . -95.72 117.74 66.32 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.555 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.15 47.3 2.01 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.514 1.27 . . . . 0.0 110.377 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.03 -136.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.57 34.76 23.81 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -1.112 . . . . 0.0 110.235 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.055 179.821 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.25 143.44 38.94 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.235 -1.156 . . . . 0.0 110.077 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.1 m -112.92 103.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.193 -0.942 . . . . 0.0 110.029 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.48 HG21 ' HD2' ' A' ' 115' ' ' ARG . 61.1 p -103.39 143.14 33.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.34 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.23 149.45 98.43 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 179.468 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.8 Cg_endo -68.49 -165.3 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 124.001 1.527 . . . . 0.0 110.585 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.562 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.38 82.46 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.495 -0.753 . . . . 0.0 109.966 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.39 66.5 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 O-C-N 123.675 1.355 . . . . 0.0 109.849 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.6 t-20 -153.64 -34.86 0.11 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.552 -0.717 . . . . 0.0 110.619 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.531 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.531 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.671 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.436 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.928 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.671 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.928 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.871 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.702 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.457 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.594 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.467 HD12 ' O ' ' A' ' 82' ' ' VAL . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 HG12 ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.413 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.799 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.488 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.544 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.874 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.702 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 11.1 t-20 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.666 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.497 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.961 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.961 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.815 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.703 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.703 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 92.51 14.09 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -83.16 51.43 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.625 1.329 . . . . 0.0 109.714 178.731 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.24 13.89 1.27 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 111.037 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 8.8 m120 -135.86 -149.9 0.35 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.044 -1.035 . . . . 0.0 109.815 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.27 174.64 0.11 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.46 114.98 2.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -1.183 . . . . 0.0 110.37 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.601 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.761 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.836 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.497 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 85' ' ' THR . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.467 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.73 -46.46 65.85 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.419 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.0 2.13 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.341 -0.85 . . . . 0.0 110.211 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.484 HG21 ' HG3' ' A' ' 121' ' ' ARG . 0.3 OUTLIER 45.46 36.26 2.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.456 -0.777 . . . . 0.0 110.83 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.84 -70.87 0.79 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.63 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 108.932 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.418 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.67 0.7 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.588 -0.695 . . . . 0.0 110.044 -179.35 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' N ' HG22 ' A' ' 90' ' ' THR . . . 126.73 -25.99 5.21 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.48 80.32 6.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -1.209 . . . . 0.0 110.694 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.418 ' CZ ' HG21 ' A' ' 93' ' ' THR . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.883 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.469 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.7 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.436 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.6 p -113.97 133.66 55.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.15 -0.969 . . . . 0.0 110.175 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.2 28.78 7.46 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 110.461 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.07 4.24 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.436 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.46 75.81 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.188 -1.184 . . . . 0.0 110.056 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -66.16 135.5 40.55 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.6 1.316 . . . . 0.0 110.203 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.54 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 110.821 -179.105 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.522 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.522 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.419 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.48 ' HD2' HG21 ' A' ' 4' ' ' THR . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.562 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.484 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.458 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.406 ' HD2' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.498 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.498 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.531 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.411 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.603 HG22 HD23 ' A' ' 15' ' ' LEU . 16.5 t -84.06 -68.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.1 83.04 0.23 Allowed Pre-proline 0 C--N 1.304 -1.373 0 O-C-N 121.746 -0.596 . . . . 0.0 110.254 -179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.81 -53.27 0.14 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.729 1.384 . . . . 0.0 110.515 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.34 135.77 7.11 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.95 -68.21 0.83 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.206 -1.173 . . . . 0.0 110.259 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.245 -179.928 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -91.93 137.98 31.92 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -1.162 . . . . 0.0 110.233 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 3' ' ' VAL . 14.6 m -113.06 104.46 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.865 . . . . 0.0 109.904 179.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.648 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 34.8 p -92.62 144.9 24.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.485 -0.759 . . . . 0.0 110.062 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.35 147.08 98.93 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.205 -0.935 . . . . 0.0 109.73 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.9 Cg_endo -70.98 -167.65 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.092 1.575 . . . . 0.0 110.465 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.537 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.7 83.12 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.49 -0.757 . . . . 0.0 109.583 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.23 -13.62 28.33 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.95 1.5 . . . . 0.0 111.095 -179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.2 m120 -64.95 -31.25 72.39 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.082 -1.011 . . . . 0.0 110.382 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.482 HD11 ' O ' ' A' ' 122' ' ' THR . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.684 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.615 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.433 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.869 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.459 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.709 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.684 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.869 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.856 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.606 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.511 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.948 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.709 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 44' ' ' SER . . . . . 0.408 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.458 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.849 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.726 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.484 HD13 ' HA ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.606 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.584 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.899 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.52 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.622 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.1 92.12 14.26 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.408 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.1 Cg_endo -87.73 50.94 1.99 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.617 1.325 . . . . 0.0 109.715 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.44 -25.64 4.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.136 -0.977 . . . . 0.0 111.283 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.1 160.34 37.22 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.884 -1.135 . . . . 0.0 110.699 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.99 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.28 111.08 13.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.238 . . . . 0.0 110.072 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.727 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.948 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.472 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.523 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.426 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.62 -36.56 83.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.477 ' C ' HG22 ' A' ' 90' ' ' THR . 0.6 OUTLIER 46.05 43.93 11.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.549 -0.719 . . . . 0.0 110.667 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.668 ' OG1' HG22 ' A' ' 93' ' ' THR . 1.8 t 35.34 -119.06 0.11 Allowed 'General case' 0 N--CA 1.504 2.227 0 O-C-N 122.171 -0.331 . . . . 0.0 111.691 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.413 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.92 -58.42 4.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -122.13 20.16 10.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -1.131 . . . . 0.0 110.139 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.668 HG22 ' OG1' ' A' ' 90' ' ' THR . 8.3 t -94.35 -171.46 2.52 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.214 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 119.62 5.63 10.99 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.788 -1.196 . . . . 0.0 110.512 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.82 58.56 1.32 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.684 -1.48 . . . . 0.0 110.464 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.511 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.442 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.49 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.768 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.474 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -144.68 120.81 10.79 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.2 p -102.39 141.57 35.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 110.3 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.29 28.32 5.57 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.276 -0.89 . . . . 0.0 110.566 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.19 -13.27 57.94 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 104' ' ' THR . 14.6 mttt -96.6 156.65 36.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 120.999 -1.294 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.45 130.03 27.11 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.594 1.313 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.26 168.08 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 111.176 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.529 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.648 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.529 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.537 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.534 ' NE ' HG21 ' A' ' 93' ' ' THR . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.57 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.432 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.57 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.564 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.49 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.6 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.517 HG22 HD23 ' A' ' 15' ' ' LEU . 7.0 t -78.1 -69.29 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.431 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.47 83.3 0.23 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.653 -0.654 . . . . 0.0 110.85 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -83.39 7.84 4.97 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.688 1.362 . . . . 0.0 110.581 179.335 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.02 -124.62 4.02 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.07 155.19 22.73 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 179.559 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.35 141.74 41.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.358 -1.084 . . . . 0.0 110.342 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.666 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.6 p -113.43 104.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.305 -0.872 . . . . 0.0 109.745 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.0 p -66.52 145.54 55.53 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.287 -0.883 . . . . 0.0 110.749 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.515 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.71 149.93 90.72 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.294 -0.879 . . . . 0.0 109.751 179.606 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.517 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.4 Cg_endo -79.62 -64.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 124.159 1.61 . . . . 0.0 112.533 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.539 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.88 88.78 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 CA-C-O 121.564 0.697 . . . . 0.0 110.405 -177.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.39 2.4 5.13 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 O-C-N 123.526 1.277 . . . . 0.0 112.319 -178.446 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 -51.56 -25.09 6.15 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.653 -1.279 . . . . 0.0 109.261 179.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.54 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.563 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.512 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.68 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.678 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.439 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.081 HG23 HG23 ' A' ' 33' ' ' ILE . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.081 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.658 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.832 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.458 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.889 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.697 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.52 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.87 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.678 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.689 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.889 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.966 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.966 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.778 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.672 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -138.36 94.72 10.66 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.59 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.7 Cg_endo -78.73 58.01 6.63 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.691 1.364 . . . . 0.0 110.012 179.192 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.29 41.91 0.07 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.322 -0.861 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.451 ' HB2' HD12 ' A' ' 74' ' ' ILE . 5.4 m120 -141.03 29.36 1.85 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.154 -0.966 . . . . 0.0 110.424 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.76 -89.03 0.57 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -140.51 102.86 4.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.153 -1.204 . . . . 0.0 110.262 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.59 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.834 HG11 HD13 ' A' ' 88' ' ' LEU . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.832 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.834 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -70.22 -33.43 71.67 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.403 ' O ' HD23 ' A' ' 88' ' ' LEU . 2.3 tpt 53.43 -144.14 0.68 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.085 -1.01 . . . . 0.0 109.356 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.487 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.5 OUTLIER -155.55 24.86 0.4 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.923 -1.111 . . . . 0.0 110.416 179.468 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.02 -62.46 5.92 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.19 36.21 2.05 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.365 -1.079 . . . . 0.0 108.633 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.646 HG22 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.75 -167.54 1.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.712 -0.617 . . . . 0.0 110.073 -179.439 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.434 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 120.64 -24.18 7.67 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.42 73.21 10.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.003 -1.292 . . . . 0.0 110.213 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.646 ' CE2' HG22 ' A' ' 93' ' ' THR . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.817 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.45 ' CB ' ' HB3' ' A' ' 134' ' ' ALA . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.582 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.31 133.42 22.87 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.9 p -113.42 128.6 56.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.311 -0.868 . . . . 0.0 109.392 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.73 -141.58 0.83 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.048 -1.032 . . . . 0.0 109.533 -179.305 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.34 18.43 41.66 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.77 156.99 78.13 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.099 -1.236 . . . . 0.0 109.597 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.582 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.0 Cg_endo -63.25 158.33 45.1 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.514 1.271 . . . . 0.0 110.436 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.83 164.79 11.71 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.296 -0.877 . . . . 0.0 111.198 -178.786 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.501 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.458 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.54 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' HE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.532 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.434 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.532 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.426 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.414 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.563 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.512 HG22 HD23 ' A' ' 15' ' ' LEU . 34.4 t -86.98 -41.09 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.45 ' HB3' ' CB ' ' A' ' 103' ' ' ASN . . . -91.14 113.07 57.06 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.301 -0.875 . . . . 0.0 109.962 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.442 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.5 -22.98 23.98 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.481 1.253 . . . . 0.0 110.751 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.33 148.16 5.02 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -90.67 -32.41 16.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.257 -1.143 . . . . 0.0 110.181 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.146 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -89.9 105.96 18.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.233 -1.157 . . . . 0.0 110.178 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -112.84 104.46 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.346 -0.846 . . . . 0.0 109.619 179.624 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.474 HG21 ' HD3' ' A' ' 115' ' ' ARG . 43.8 p -90.03 143.36 26.85 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.194 -0.941 . . . . 0.0 110.82 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.71 148.46 98.03 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.392 -0.817 . . . . 0.0 109.476 179.448 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' VAL . 39.5 Cg_endo -67.57 -167.02 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 124.013 1.533 . . . . 0.0 111.104 179.33 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.557 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.31 83.2 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.712 -0.618 . . . . 0.0 109.341 -179.714 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.71 -9.6 26.01 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.91 1.479 . . . . 0.0 111.094 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 50.7 t30 -77.94 -29.45 49.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.923 -1.111 . . . . 0.0 109.633 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.515 HD13 HG22 ' A' ' 122' ' ' THR . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.411 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.464 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.485 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.922 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.511 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.539 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.485 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.922 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.801 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.654 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.612 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.564 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 82' ' ' VAL . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.926 HD12 HG12 ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.539 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 10.7 p80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.884 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.705 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.517 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.653 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.538 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.654 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 4.1 t-20 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.653 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.895 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.884 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.499 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.926 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.95 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.95 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.657 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.895 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.633 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -126.27 96.94 35.41 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.55 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.5 Cg_endo -82.29 54.04 4.78 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.681 1.359 . . . . 0.0 109.913 179.196 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.4 HG23 ' OD1' ' A' ' 77' ' ' ASN . 9.4 t -157.0 42.45 0.34 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.245 -0.91 . . . . 0.0 110.476 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.421 ' CG ' HD13 ' A' ' 74' ' ' ILE . 3.9 m120 -141.48 -164.95 1.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.166 -0.959 . . . . 0.0 110.175 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.44 -73.4 0.36 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -149.86 111.66 4.55 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.291 -1.123 . . . . 0.0 110.123 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.651 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.777 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.926 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.499 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.694 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.694 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.63 -26.83 68.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.499 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 5.6 tpt 45.17 32.47 0.94 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.729 -0.607 . . . . 0.0 111.171 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.451 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.2 p 44.12 36.73 1.57 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.718 -0.614 . . . . 0.0 111.221 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.0 -63.99 4.65 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.2 p90 -122.28 41.1 3.49 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.383 -1.069 . . . . 0.0 109.884 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.541 ' HG1' ' HE2' ' A' ' 96' ' ' PHE . 15.4 t -91.19 -159.39 0.63 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.369 -0.832 . . . . 0.0 110.765 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.48 -36.88 3.64 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.686 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.44 55.03 3.21 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.97 -1.312 . . . . 0.0 110.511 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.541 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.485 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.499 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.83 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.25 130.83 16.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.415 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.0 p -112.86 127.84 56.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.868 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.45 26.95 9.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.312 -0.867 . . . . 0.0 110.526 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.79 3.32 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.54 82.09 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -1.137 . . . . 0.0 110.069 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.92 132.63 30.87 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 O-C-N 123.647 1.341 . . . . 0.0 109.902 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.68 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.256 -0.902 . . . . 0.0 110.972 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.474 ' HD3' HG21 ' A' ' 4' ' ' THR . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.43 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.557 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.51 ' HD2' HG21 ' A' ' 93' ' ' THR . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.463 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.499 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.44 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.424 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.619 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 32.1 t -94.68 -56.99 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.619 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 69.07 145.17 0.1 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.732 -0.605 . . . . 0.0 110.353 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.34 -55.97 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.386 0 O-C-N 123.783 1.412 . . . . 0.0 110.49 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.81 -32.47 2.44 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.29 -161.15 1.27 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -1.153 . . . . 0.0 110.262 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.7 ttt-85 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.135 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.33 10.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -1.149 . . . . 0.0 110.287 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.1 m -113.39 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.1 p -63.57 139.91 58.82 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.329 -0.857 . . . . 0.0 110.508 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.457 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.839 . . . . 0.0 109.702 179.681 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.4 Cg_endo -71.97 -165.71 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 124.094 1.576 . . . . 0.0 110.914 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.52 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.61 80.6 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.513 -0.742 . . . . 0.0 109.507 -179.602 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.14 55.21 3.95 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.747 1.393 . . . . 0.0 111.434 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.72 2.28 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.027 -1.045 . . . . 0.0 110.947 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 ' O ' ' A' ' 122' ' ' THR . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.781 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.699 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.719 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.917 HD12 HD13 ' A' ' 55' ' ' LEU . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.542 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.699 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.719 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.045 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.748 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.79 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.637 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.574 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.898 HD12 HG12 ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 5.4 p80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.644 HD12 HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.685 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.917 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.79 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.637 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 15.2 t-20 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.705 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.745 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.844 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.825 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -137.48 110.03 8.84 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.644 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.2 Cg_endo -87.33 40.12 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.307 1.162 . . . . 0.0 110.644 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.4 26.25 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 110.201 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.6 m-20 -135.47 27.33 3.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.237 -0.914 . . . . 0.0 110.163 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.37 -156.46 15.54 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.68 112.58 15.94 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.107 -1.231 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 60' ' ' ILE . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.898 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.515 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.515 ' N ' HG23 ' A' ' 85' ' ' THR . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.18 -33.43 61.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.404 ' O ' ' HB ' ' A' ' 90' ' ' THR . 1.6 mmt 51.03 -106.77 0.26 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.283 -0.886 . . . . 0.0 109.988 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.741 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.76 41.59 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.637 -1.29 . . . . 0.0 110.424 179.74 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.43 51.12 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 179.208 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.494 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 14.2 p90 -145.48 38.32 1.13 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.66 -0.906 . . . . 0.0 109.798 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.741 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -126.91 -162.41 1.15 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.324 -0.86 . . . . 0.0 110.197 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.679 ' N ' HG23 ' A' ' 93' ' ' THR . . . 123.48 -40.44 1.98 Allowed Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.343 179.142 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -84.45 81.09 8.99 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.135 -1.214 . . . . 0.0 110.82 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.49 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.712 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.045 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.542 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.454 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.656 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -147.76 129.38 15.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.5 p -113.35 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.61 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.47 -141.9 0.83 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.095 -1.003 . . . . 0.0 109.637 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 18.09 41.22 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.79 156.3 79.54 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.242 . . . . 0.0 109.713 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.656 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.4 Cg_endo -64.67 159.79 43.43 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.625 1.329 . . . . 0.0 110.164 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.17 153.32 12.01 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.219 -0.926 . . . . 0.0 110.706 -179.28 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.416 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.416 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.52 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.494 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.712 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.431 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' HG21 ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.781 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.86 -46.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.19 160.97 39.15 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 110.247 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 -27.36 16.02 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.791 1.416 . . . . 0.0 110.545 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.44 79.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.92 143.37 0.56 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.278 -1.131 . . . . 0.0 110.187 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.184 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.06 150.92 20.19 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.205 -1.174 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 3' ' ' VAL . 21.2 m -113.32 104.69 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.366 -0.834 . . . . 0.0 110.039 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.809 HG22 ' OG1' ' A' ' 116' ' ' THR . 6.2 p -66.08 145.04 56.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.336 -0.853 . . . . 0.0 110.346 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.673 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -70.19 147.85 95.62 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.257 -0.902 . . . . 0.0 109.828 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.533 ' HD2' HG23 ' A' ' 5' ' ' VAL . 38.6 Cg_endo -73.14 -64.64 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 124.13 1.594 . . . . 0.0 112.47 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.673 ' HD1' HG22 ' A' ' 5' ' ' VAL . 47.8 p-80 41.25 87.29 0.12 Allowed Pre-proline 0 N--CA 1.492 1.674 0 CA-C-O 121.262 0.553 . . . . 0.0 111.226 -178.474 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -74.91 0.74 8.49 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.454 1.239 . . . . 0.0 111.567 -179.255 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.17 4.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.805 -1.184 . . . . 0.0 110.427 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' O ' ' A' ' 122' ' ' THR . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.537 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.517 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.946 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.517 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.946 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.865 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.757 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.618 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.65 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.902 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.948 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.435 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 1.053 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.619 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.745 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.757 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 14.8 t-20 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.745 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.511 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.848 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.848 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.1 100.49 9.61 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.6 Cg_endo -88.16 36.87 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.636 1.335 . . . . 0.0 110.53 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.43 16.41 6.54 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.045 -1.035 . . . . 0.0 110.67 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HB2' HD12 ' A' ' 74' ' ' ILE . 2.7 m120 -116.14 -165.39 1.04 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.057 -1.027 . . . . 0.0 110.09 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.78 -87.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.83 114.97 15.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -1.186 . . . . 0.0 110.391 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.646 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.65 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 1.053 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.451 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.451 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.492 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp -62.44 -23.53 66.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.548 ' C ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER 46.3 28.36 0.69 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.466 -0.771 . . . . 0.0 110.731 179.721 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.772 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.1 -126.34 0.11 Allowed 'General case' 0 N--CA 1.5 2.049 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 178.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.44 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.72 -51.22 3.25 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.918 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.17 23.67 4.15 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.572 -0.958 . . . . 0.0 109.428 179.066 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.772 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.7 t -98.92 -156.28 0.54 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.696 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.538 ' N ' HG23 ' A' ' 93' ' ' THR . . . 94.08 -25.01 24.13 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.277 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.17 60.94 6.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.025 -1.279 . . . . 0.0 110.814 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.714 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 4.0 m-20 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 107' ' ' GLY . 1.1 m -143.42 120.14 11.17 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.485 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.91 121.72 39.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.311 -0.868 . . . . 0.0 110.334 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.79 32.88 20.19 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.271 -0.893 . . . . 0.0 110.727 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 104' ' ' THR . . . 92.26 -28.2 9.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.42 155.77 51.21 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.064 -1.256 . . . . 0.0 110.137 -179.768 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.85 128.44 22.02 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.512 1.269 . . . . 0.0 110.779 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.413 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -46.35 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.569 -0.707 . . . . 0.0 111.133 -179.451 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.472 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.809 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.477 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.53 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.53 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.708 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.537 HG22 HD23 ' A' ' 15' ' ' LEU . 46.2 t -74.6 -31.74 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -127.67 134.01 25.72 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.177 -0.952 . . . . 0.0 110.061 179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.51 -18.77 19.77 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.549 1.289 . . . . 0.0 110.692 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.09 -42.62 1.89 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.23 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.486 -1.008 . . . . 0.0 110.546 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.628 0 O-C-N 120.975 -1.078 . . . . 0.0 110.277 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.06 140.15 49.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -1.153 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.1 p -112.83 104.8 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.303 -0.873 . . . . 0.0 109.769 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 72.2 p -62.85 141.75 58.53 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.34 -0.85 . . . . 0.0 110.376 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.86 148.88 98.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.792 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.3 Cg_endo -69.1 -171.98 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.03 1.542 . . . . 0.0 110.93 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.504 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.6 OUTLIER 175.66 75.15 0.07 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.535 -0.728 . . . . 0.0 109.51 -179.721 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.71 -13.49 32.33 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.861 1.453 . . . . 0.0 110.691 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 40.9 m-20 -59.85 -18.11 41.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.049 -1.032 . . . . 0.0 110.171 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.448 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.9 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.406 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.448 ' CB ' HD23 ' A' ' 15' ' ' LEU . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.9 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.79 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.581 HD11 HD12 ' A' ' 58' ' ' LEU . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.406 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.599 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.939 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.423 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 7.1 p80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.951 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.809 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.468 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.533 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.734 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.581 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.599 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 7.9 t-20 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.734 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.939 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.951 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.672 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.924 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.644 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.939 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.644 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp -137.76 100.99 8.87 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -82.05 53.4 4.55 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.487 1.257 . . . . 0.0 110.12 178.985 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 p -149.62 22.39 0.91 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 110.925 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.19 -165.85 1.38 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.038 -1.038 . . . . 0.0 110.145 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.64 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.03 16.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.16 -1.2 . . . . 0.0 110.168 179.537 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' CG1' ' A' ' 73' ' ' VAL . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.939 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.484 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.484 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.462 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.58 -24.51 53.5 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.415 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.365 -179.209 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.609 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.14 0.93 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.991 -1.068 . . . . 0.0 110.066 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.6 -39.55 60.89 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.15 5.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.427 -1.043 . . . . 0.0 110.436 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.609 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -108.31 -171.06 1.79 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.186 -0.946 . . . . 0.0 109.843 179.666 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.556 ' N ' HG23 ' A' ' 93' ' ' THR . . . 121.76 -26.9 6.39 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -83.95 65.81 8.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.909 -1.348 . . . . 0.0 110.24 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB2' ' HB ' ' A' ' 129' ' ' ILE . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.867 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.4 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.443 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.405 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.3 m -141.6 127.91 19.88 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.46 50.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.299 -0.876 . . . . 0.0 110.618 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.19 34.78 24.47 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.328 -0.857 . . . . 0.0 111.257 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.8 -33.9 4.8 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.308 179.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.22 155.31 57.56 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.161 -1.199 . . . . 0.0 110.05 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.9 138.49 57.85 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.415 1.218 . . . . 0.0 110.76 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.3 156.67 0.8 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.528 -0.733 . . . . 0.0 110.948 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.51 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.45 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.504 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.492 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.441 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.492 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 98' ' ' SER . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.42 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.443 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t -79.86 -54.16 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.49 134.98 31.53 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.233 -0.917 . . . . 0.0 110.132 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.85 0.13 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 O-C-N 123.527 1.278 . . . . 0.0 110.4 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.29 -69.29 0.42 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.49 96.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.214 -1.168 . . . . 0.0 110.114 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.191 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.06 128.35 56.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.2 t -113.18 104.2 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.248 -0.907 . . . . 0.0 110.201 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.516 HG22 ' OG1' ' A' ' 116' ' ' THR . 69.1 p -72.18 146.15 47.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.495 -0.753 . . . . 0.0 110.109 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.614 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -66.46 148.45 98.6 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.542 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.8 Cg_endo -80.33 -59.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 124.244 1.655 . . . . 0.0 112.413 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.862 ' HE1' ' HD2' ' A' ' 119' ' ' ARG . 50.3 p-80 39.31 89.25 0.08 OUTLIER Pre-proline 0 N--CA 1.493 1.683 0 CA-C-O 121.025 0.44 . . . . 0.0 111.459 -178.379 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.68 57.29 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.317 1.167 . . . . 0.0 110.9 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 -119.99 -18.78 8.07 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.242 -0.911 . . . . 0.0 110.289 179.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.843 HD13 HG23 ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.743 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.402 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.945 HD12 HD13 ' A' ' 55' ' ' LEU . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.431 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.662 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.743 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 1.037 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.896 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.491 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.054 HG23 HG23 ' A' ' 33' ' ' ILE . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.054 HG23 HG23 ' A' ' 32' ' ' VAL . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.556 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.791 HD12 HG12 ' A' ' 83' ' ' VAL . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.503 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.424 ' HB3' ' O ' ' A' ' 104' ' ' THR . 7.9 p80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.837 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.757 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.537 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.945 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.537 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 1.5 t-20 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.609 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.86 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.837 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.561 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.85 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.85 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.691 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.86 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.691 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 91.79 14.69 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.515 ' HA ' HG11 ' A' ' 80' ' ' VAL . 53.0 Cg_endo -79.86 55.73 5.76 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.716 1.377 . . . . 0.0 110.345 179.816 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.89 0.34 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.175 -0.953 . . . . 0.0 110.457 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.97 -164.77 1.43 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.15 -0.969 . . . . 0.0 110.034 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.64 -73.58 0.35 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.179 -1.189 . . . . 0.0 110.036 179.375 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.546 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.624 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.803 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.791 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 85' ' ' THR . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.687 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.69 -47.0 64.77 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.456 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.11 21.89 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 110.075 -179.743 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER 62.36 -72.78 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.589 -0.694 . . . . 0.0 110.708 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.66 -98.7 0.05 OUTLIER Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.515 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 46.6 p90 -88.89 48.42 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.26 -1.141 . . . . 0.0 109.602 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.424 ' CG2' ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.64 -146.15 0.19 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.336 -0.853 . . . . 0.0 109.941 -179.64 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.408 ' N ' HG22 ' A' ' 90' ' ' THR . . . 111.47 -30.61 7.74 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.582 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.11 80.97 9.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -1.181 . . . . 0.0 110.428 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.476 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.738 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 1.037 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.513 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.9 p -146.91 128.91 15.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.3 p -114.37 134.6 54.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.099 -1.001 . . . . 0.0 110.406 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.03 27.02 6.97 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.245 -0.91 . . . . 0.0 110.416 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.4 -31.51 6.35 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 155.91 78.0 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.164 -1.198 . . . . 0.0 110.132 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.513 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.3 Cg_endo -66.59 133.5 32.23 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.659 1.347 . . . . 0.0 110.336 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.7 pp0? -47.94 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.351 -0.843 . . . . 0.0 110.648 -179.453 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.516 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.516 ' OG1' HG22 ' A' ' 4' ' ' THR . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.862 ' HD2' ' HE1' ' A' ' 7' ' ' HIS . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.843 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.477 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.453 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.477 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.738 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.09 -34.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.06 159.78 65.06 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.22 -0.925 . . . . 0.0 110.329 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.67 -40.98 1.24 Allowed 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.74 1.389 . . . . 0.0 110.441 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.06 88.78 0.06 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -78.47 130.77 36.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.234 -1.156 . . . . 0.0 110.335 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.316 179.941 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.5 m -111.58 155.31 23.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 110.219 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.5 m -113.29 104.0 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.264 -0.897 . . . . 0.0 109.889 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.22 138.09 58.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.436 -0.79 . . . . 0.0 110.607 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.446 HG12 ' H ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -67.58 147.8 98.67 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.606 179.601 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.6 Cg_endo -69.88 -169.28 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 124.1 1.579 . . . . 0.0 111.096 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.547 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.43 82.48 0.24 Allowed Pre-proline 0 C--N 1.302 -1.476 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.595 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.83 89.24 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.658 1.346 . . . . 0.0 110.496 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.22 -33.97 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.76 -0.587 . . . . 0.0 109.908 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.489 HD13 HG22 ' A' ' 122' ' ' THR . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.607 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.451 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.655 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.451 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.915 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.578 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.059 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.059 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.589 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.626 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.486 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.497 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.875 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.578 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.7 t-20 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.911 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.504 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.73 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.911 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -134.04 103.78 11.72 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -87.07 43.66 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.523 1.275 . . . . 0.0 110.304 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.66 4.59 2.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.998 -1.063 . . . . 0.0 111.091 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' HD12 ' A' ' 74' ' ' ILE . 2.5 m120 -100.77 -169.15 1.67 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.282 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.42 -70.45 0.95 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -144.91 113.64 6.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.164 -1.198 . . . . 0.0 110.29 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.623 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.83 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.552 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.552 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp -64.48 -32.21 73.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.477 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.83 34.84 0.95 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.58 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.5 p 47.26 -130.32 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.675 -0.641 . . . . 0.0 110.459 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.96 -85.11 1.13 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -94.43 16.98 13.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -1.142 . . . . 0.0 109.785 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.51 ' HG1' ' HE1' ' A' ' 96' ' ' PHE . 14.9 t -92.53 -151.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.316 -0.865 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 94.05 -31.89 6.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.6 57.26 3.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.99 -1.3 . . . . 0.0 110.285 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.51 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.492 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.492 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.43 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.745 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -144.1 126.02 15.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.2 p -112.67 139.21 48.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.145 -0.972 . . . . 0.0 109.582 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.8 -143.55 0.73 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.051 -1.031 . . . . 0.0 109.581 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.74 26.44 12.52 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.12 156.78 67.87 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.21 -1.171 . . . . 0.0 109.821 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.745 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -65.85 162.11 36.35 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.644 1.339 . . . . 0.0 110.494 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.9 pp0? -64.91 168.12 6.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.302 -0.874 . . . . 0.0 110.862 -179.307 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.487 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.544 ' OG1' HG22 ' A' ' 4' ' ' THR . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.547 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.58 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.515 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.443 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.464 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.583 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.607 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.655 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.7 t -76.08 -60.41 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.43 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.15 146.83 35.34 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.316 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -73.97 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.312 -1.387 0 O-C-N 123.795 1.418 . . . . 0.0 110.426 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.69 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.9 82.02 3.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -1.165 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.286 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.31 50.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -1.163 . . . . 0.0 110.217 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.5 t -112.85 104.32 16.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.616 HG22 ' OG1' ' A' ' 116' ' ' THR . 18.1 p -69.13 138.25 54.06 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.435 -0.79 . . . . 0.0 110.181 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -67.79 146.25 98.32 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 0.0 109.529 179.702 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -72.71 -174.3 1.45 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.997 1.525 . . . . 0.0 110.53 179.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.515 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.87 76.78 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.452 -0.78 . . . . 0.0 109.859 -179.626 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.23 53.96 3.6 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 O-C-N 123.763 1.402 . . . . 0.0 111.096 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 11.3 m120 -138.41 8.31 2.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.999 -1.063 . . . . 0.0 110.358 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 ' O ' ' A' ' 122' ' ' THR . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.714 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.622 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.577 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.622 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.916 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.819 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.588 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.584 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.923 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.477 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.412 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.443 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.706 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.442 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.928 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.848 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.819 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 17.1 t-20 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.578 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.874 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.706 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.611 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.893 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.769 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.442 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.874 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.438 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER -131.29 100.34 16.9 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.68 59.8 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.609 1.321 . . . . 0.0 109.902 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 76' ' ' THR . 4.7 t -135.86 61.85 1.64 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.443 -0.785 . . . . 0.0 109.288 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.425 ' HB2' ' O ' ' A' ' 76' ' ' THR . 3.2 m-20 62.7 -154.14 0.34 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.812 -0.555 . . . . 0.0 110.03 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.69 151.34 0.05 OUTLIER Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.531 -1.828 . . . . 0.0 108.531 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.4 94.04 6.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.941 -1.329 . . . . 0.0 110.238 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.603 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.928 HG11 HD12 ' A' ' 51' ' ' LEU . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.482 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.778 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.504 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.778 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.436 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp -64.06 -47.87 78.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.441 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.2 20.61 2.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 109.943 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 93' ' ' THR . 0.1 OUTLIER 46.85 54.65 8.81 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.393 -0.817 . . . . 0.0 110.805 179.837 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.55 -67.94 1.83 Allowed Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.12 21.74 5.63 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.308 -1.113 . . . . 0.0 109.617 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -127.99 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.433 -0.792 . . . . 0.0 109.806 -179.922 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' HA3' ' NH1' ' A' ' 124' ' ' ARG . . . 150.76 -51.02 0.53 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.408 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.31 97.41 10.78 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 110.589 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.543 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.593 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.2 m -144.01 109.93 5.32 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.81 128.73 35.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.319 -0.863 . . . . 0.0 111.071 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.38 34.29 20.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.413 -0.805 . . . . 0.0 111.288 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.65 -14.96 54.3 Favored Glycine 0 N--CA 1.494 2.535 0 C-N-CA 119.856 -1.164 . . . . 0.0 110.301 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 104' ' ' THR . 10.6 mttt -98.02 156.57 35.77 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 120.986 -1.302 . . . . 0.0 109.788 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -62.51 127.29 20.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.512 1.27 . . . . 0.0 110.508 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.49 157.43 0.06 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.538 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.538 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 4' ' ' THR . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.515 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.506 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.625 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.426 ' NH1' ' HA3' ' A' ' 94' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.538 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 15' ' ' LEU . 54.6 t -69.18 -55.61 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.87 159.29 45.13 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.184 -0.947 . . . . 0.0 110.299 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.446 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.9 Cg_endo -72.16 -23.12 21.62 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.697 1.367 . . . . 0.0 110.395 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.5 -64.61 0.31 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.64 -48.96 9.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.215 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ARG . . . . . 0.446 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.128 179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 p -104.04 106.87 17.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -1.167 . . . . 0.0 110.268 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.558 ' O ' HG13 ' A' ' 3' ' ' VAL . 4.8 p -113.3 103.95 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.311 -0.868 . . . . 0.0 109.88 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 112' ' ' ALA . 18.1 p -75.24 142.67 43.35 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.243 -0.911 . . . . 0.0 110.309 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.461 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.76 146.89 97.82 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.623 179.601 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.3 Cg_endo -71.98 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.116 1.588 . . . . 0.0 110.447 179.169 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.555 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.66 81.9 0.38 Allowed Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.543 179.546 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 40.1 Cg_endo -67.06 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.38 1.2 . . . . 0.0 111.021 -179.161 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.8 p30 171.79 -5.82 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 O-C-N 121.523 -0.736 . . . . 0.0 112.481 179.3 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.522 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.512 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.633 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.431 ' CD2' ' SG ' ' A' ' 102' ' ' CYS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.633 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.987 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.839 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.551 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.046 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.515 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.622 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.926 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.493 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.412 ' HB3' ' O ' ' A' ' 104' ' ' THR . 0.0 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.739 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.993 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.565 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.746 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.589 HG22 HG22 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.629 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.594 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.922 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.476 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.865 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.877 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.877 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.922 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.871 HD13 ' OD1' ' A' ' 77' ' ' ASN . 1.3 pp -137.19 104.11 8.75 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -89.33 35.6 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.655 1.345 . . . . 0.0 110.589 179.341 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 76' ' ' THR . . . . . 0.698 HG23 ' ND2' ' A' ' 77' ' ' ASN . 6.9 t -127.81 -11.14 5.48 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.855 -1.153 . . . . 0.0 111.533 -179.167 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.871 ' OD1' HD13 ' A' ' 74' ' ' ILE . 8.1 m120 -104.85 -150.36 0.43 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.86 -1.15 . . . . 0.0 110.358 -179.776 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.04 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -54.88 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.139 -1.212 . . . . 0.0 110.1 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.681 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.589 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.771 HG22 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.993 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.476 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.491 ' N ' HG23 ' A' ' 85' ' ' THR . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.58 -34.28 47.01 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.42 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.4 -96.15 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.713 -0.617 . . . . 0.0 110.526 179.73 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.677 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.1 57.1 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 120.779 -1.201 . . . . 0.0 110.713 179.924 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.03 -50.2 67.79 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 108.458 -1.857 . . . . 0.0 108.458 179.175 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.423 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 51.8 p90 -137.49 38.72 2.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.688 HG23 ' N ' ' A' ' 94' ' ' GLY . 1.3 t -98.37 -153.74 0.44 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.93 . . . . 0.0 110.659 -179.449 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.688 ' N ' HG23 ' A' ' 93' ' ' THR . . . 109.74 7.54 27.44 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.61 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.89 1.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.771 -1.429 . . . . 0.0 110.795 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.502 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.422 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.987 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.433 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 103' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.412 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p -145.15 128.7 17.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.408 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.11 134.52 54.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 -179.716 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.14 41.53 31.97 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.163 -0.961 . . . . 0.0 110.329 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.77 66.31 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' O ' ' A' ' 105' ' ' SER . 1.0 OUTLIER -126.55 157.56 70.41 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.206 -1.173 . . . . 0.0 109.719 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.61 123.65 12.75 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.629 1.331 . . . . 0.0 110.213 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.503 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.61 147.37 2.55 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.535 -0.728 . . . . 0.0 111.095 -179.191 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.455 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.479 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.503 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.469 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.493 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.555 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.495 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.422 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.437 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.433 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.558 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 18.2 t -94.98 -56.03 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 63.29 146.87 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.662 -0.649 . . . . 0.0 110.227 -179.611 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.29 -52.05 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.711 1.374 . . . . 0.0 110.433 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.19 -151.69 22.35 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.917 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.44 159.19 19.41 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.27 -1.135 . . . . 0.0 110.161 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.142 -179.916 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.84 146.42 28.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -1.145 . . . . 0.0 110.408 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.685 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.8 p -113.12 104.67 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.589 179.321 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -80.13 145.63 32.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.31 -0.869 . . . . 0.0 110.732 -179.565 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.547 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -74.98 148.98 85.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.348 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -71.16 -43.59 1.5 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.144 1.602 . . . . 0.0 112.843 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.4 p-80 41.26 85.35 0.16 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 122.13 -0.356 . . . . 0.0 110.786 -177.207 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.7 Cg_endo -68.29 -161.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.842 1.443 . . . . 0.0 110.132 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.483 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.09 -35.89 0.2 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.66 -0.65 . . . . 0.0 111.047 -179.159 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.73 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.902 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 16' ' ' SER . . . . . 0.459 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.683 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.901 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.481 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.902 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.683 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.901 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.767 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.836 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.044 HG23 HG23 ' A' ' 33' ' ' ILE . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.044 HG23 HG23 ' A' ' 32' ' ' VAL . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.617 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.673 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.829 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.481 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.473 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.894 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.714 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.699 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.836 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.617 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.639 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.755 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp -137.35 98.8 9.96 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.657 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.8 Cg_endo -81.59 51.6 3.93 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.578 1.304 . . . . 0.0 110.421 179.261 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.91 8.94 1.92 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.976 -1.078 . . . . 0.0 111.072 -179.694 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -108.61 -165.48 1.03 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.897 -1.127 . . . . 0.0 109.923 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.1 -91.84 0.01 OUTLIER Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 79' ' ' ASP . . . . . 0.419 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 -124.26 113.72 18.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.151 -1.206 . . . . 0.0 109.983 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.657 HG11 ' HA ' ' A' ' 75' ' ' PRO . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.599 HG22 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.673 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.829 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.403 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.53 -23.49 66.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.514 ' C ' HG22 ' A' ' 90' ' ' THR . 32.3 mmt 49.81 37.26 12.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.406 -0.809 . . . . 0.0 110.941 179.567 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 89' ' ' MET . 3.2 t 32.7 42.66 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.13 -38.52 88.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 179.567 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -136.21 12.43 3.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.455 -1.026 . . . . 0.0 110.76 -179.753 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.495 ' HA ' ' CE2' ' A' ' 96' ' ' PHE . 14.9 t -67.43 -158.99 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.96 -1.087 . . . . 0.0 110.468 -179.834 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.93 3.34 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.07 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.22 60.23 5.82 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.261 . . . . 0.0 110.938 -179.248 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.583 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.876 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.49 130.37 16.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.7 p -113.97 127.67 56.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.304 -0.872 . . . . 0.0 109.916 179.309 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.98 28.96 11.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.229 -0.92 . . . . 0.0 110.488 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.13 3.93 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.772 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.87 156.6 82.44 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.321 -1.105 . . . . 0.0 109.918 179.873 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -64.8 138.97 60.57 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.52 1.274 . . . . 0.0 109.968 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.76 150.63 2.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.274 -0.892 . . . . 0.0 110.843 -178.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.503 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.462 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.547 HG23 HG13 ' A' ' 5' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.5 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.424 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.544 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.453 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.544 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.499 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.73 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.7 t -78.45 -61.12 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.624 ' HB1' ' HD2' ' A' ' 135' ' ' PRO . . . -115.97 170.75 5.35 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.258 -0.901 . . . . 0.0 110.437 -179.713 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 134' ' ' ALA . 49.0 Cg_endo -74.69 -50.35 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.735 1.387 . . . . 0.0 110.327 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.03 87.07 1.67 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.08 -164.75 1.04 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.234 -1.157 . . . . 0.0 110.315 -179.943 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.264 179.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.23 138.02 31.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -1.169 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.9 m -113.2 104.1 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.18 -0.95 . . . . 0.0 109.959 179.712 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.46 135.8 44.14 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.309 -0.869 . . . . 0.0 110.23 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.411 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.12 147.56 99.0 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.248 -0.908 . . . . 0.0 109.175 179.604 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.43 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.6 Cg_endo -73.66 -168.91 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.021 1.537 . . . . 0.0 110.635 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.71 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 121.633 -0.667 . . . . 0.0 109.22 -179.764 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.49 -5.86 17.94 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.805 1.424 . . . . 0.0 111.236 -179.296 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.47 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.58 -14.24 62.74 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.132 . . . . 0.0 110.449 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.496 HD13 HG22 ' A' ' 122' ' ' THR . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.79 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.573 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.942 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.502 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.57 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.969 HD11 HG21 ' A' ' 100' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.756 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.478 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.548 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.557 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.535 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.878 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.913 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.665 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.524 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 22.2 t-20 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.59 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.913 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.485 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.746 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.746 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp -136.15 95.02 13.66 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.694 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.7 Cg_endo -81.39 52.81 4.43 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.622 1.328 . . . . 0.0 110.887 179.889 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.982 -1.073 . . . . 0.0 110.652 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.4 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 3.0 m120 -112.54 -165.83 1.03 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.121 -0.987 . . . . 0.0 110.173 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -66.35 2.66 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.904 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -151.79 110.91 3.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.218 -1.166 . . . . 0.0 110.216 179.748 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.694 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.878 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.601 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.25 -45.47 32.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.22 20.74 1.96 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.615 -0.678 . . . . 0.0 110.713 179.642 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.513 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.09 32.7 3.08 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.207 -0.933 . . . . 0.0 110.527 179.559 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.91 -67.84 1.91 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.441 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 53.2 p90 -96.68 33.96 1.75 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -1.097 . . . . 0.0 109.155 179.087 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.513 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -131.22 -151.64 0.47 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.553 -0.717 . . . . 0.0 110.303 -179.37 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 124.42 -35.76 3.11 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.577 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.61 80.1 9.36 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.956 -1.32 . . . . 0.0 110.872 -179.463 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.512 ' CZ ' HG21 ' A' ' 93' ' ' THR . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.576 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.969 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.429 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -147.44 122.14 9.88 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 33.0 p -102.6 131.53 49.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.299 -0.876 . . . . 0.0 110.219 179.848 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 55.97 30.73 16.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.334 -0.854 . . . . 0.0 111.032 179.611 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 -29.7 8.01 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.349 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.27 154.43 59.97 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.057 -1.261 . . . . 0.0 110.14 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.85 139.21 56.18 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.535 1.281 . . . . 0.0 110.292 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.561 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -48.04 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.297 -0.877 . . . . 0.0 110.872 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.454 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.524 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.43 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.524 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.576 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.79 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.573 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t -95.34 -24.09 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.04 124.65 5.47 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.266 -0.896 . . . . 0.0 110.186 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.511 1.269 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.75 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.77 83.89 2.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.4 ttt180 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.196 -179.948 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 2' ' ' SER . . . . . 0.555 ' OG ' ' HB2' ' A' ' 112' ' ' ALA . 2.5 t -84.16 106.28 15.67 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -1.179 . . . . 0.0 110.319 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.4 m -113.13 104.41 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.324 -0.86 . . . . 0.0 110.076 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.77 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 50.5 p -88.57 136.33 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.304 -0.872 . . . . 0.0 110.221 179.696 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.409 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.62 147.28 98.71 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.654 179.654 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.409 ' HD2' HG23 ' A' ' 5' ' ' VAL . 55.7 Cg_endo -82.01 -169.33 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 124.106 1.582 . . . . 0.0 110.862 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.74 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.158 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.7 108.82 1.32 Allowed 'Trans proline' 0 C--N 1.312 -1.367 0 O-C-N 123.844 1.444 . . . . 0.0 110.884 -179.51 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 179.69 -32.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.538 HD13 HG22 ' A' ' 122' ' ' THR . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.45 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.699 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.405 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.43 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.936 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.803 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.615 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.473 ' HG2' HG12 ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 104' ' ' THR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 47' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.687 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.741 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.535 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.751 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.615 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 20.3 t-20 -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.691 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.921 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.687 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.994 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.994 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.828 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.92 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.921 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.92 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -136.68 113.33 10.02 Favored Pre-proline 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.456 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.3 Cg_endo -89.31 40.97 0.51 Allowed 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.566 1.298 . . . . 0.0 110.357 178.722 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.57 47.67 1.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.068 -1.02 . . . . 0.0 110.652 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 77' ' ' ASN . . . . . 0.402 ' HB2' HD12 ' A' ' 74' ' ' ILE . 3.8 m120 -148.45 27.38 0.92 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.139 -0.976 . . . . 0.0 110.275 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.71 -94.6 1.39 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.27 111.68 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.189 -1.183 . . . . 0.0 110.097 179.675 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.595 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.817 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.504 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.44 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -67.04 -33.86 76.45 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 89' ' ' MET . . . . . 0.538 ' C ' HG22 ' A' ' 90' ' ' THR . 4.5 mmt 55.09 -87.48 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.606 -0.684 . . . . 0.0 110.505 179.801 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.538 HG22 ' C ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -179.5 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.944 -1.097 . . . . 0.0 110.46 -179.833 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 91' ' ' GLY . . . . . 0.418 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 70.09 -65.38 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 92' ' ' PHE . . . . . 0.41 ' N ' ' O ' ' A' ' 90' ' ' THR . 38.3 p90 -128.22 13.93 6.68 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -1.213 . . . . 0.0 110.858 -179.637 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.534 HG22 ' OG1' ' A' ' 90' ' ' THR . 14.6 t -75.47 -167.25 0.63 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.408 -179.716 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.345 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.43 65.41 8.91 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.941 -1.329 . . . . 0.0 110.733 -179.415 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.471 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.936 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.901 HG22 ' HA ' ' A' ' 109' ' ' PRO . 0.8 OUTLIER -146.76 135.76 22.44 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.6 p -114.78 132.68 56.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.298 -0.876 . . . . 0.0 109.938 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.52 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.025 -1.047 . . . . 0.0 109.832 -179.858 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.17 17.31 43.22 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.491 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.42 156.29 78.76 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.102 -1.234 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.901 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.8 Cg_endo -64.35 167.1 15.44 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.595 1.313 . . . . 0.0 110.465 179.966 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.513 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 39.4 tt0 -70.79 154.88 41.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.457 -0.777 . . . . 0.0 110.91 -178.83 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 114' ' ' SER . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.77 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.424 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.513 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.441 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.424 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.536 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.538 HG22 HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.492 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.492 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.516 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.475 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 133' ' ' VAL . . . . . 0.662 HG22 HD23 ' A' ' 15' ' ' LEU . 7.1 t -82.92 -50.6 15.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.468 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.52 162.64 0.42 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.371 -0.831 . . . . 0.0 111.513 -178.888 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.38 -53.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.596 1.314 . . . . 0.0 110.163 179.819 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.89 177.72 17.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.26 -34.39 63.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -1.121 . . . . 0.0 110.203 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.165 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.06 106.37 6.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.257 -1.143 . . . . 0.0 110.064 179.867 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.597 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.5 m -112.99 104.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.285 -0.884 . . . . 0.0 110.024 179.765 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' THR . . . . . 0.867 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.0 p -66.96 141.18 57.7 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 109.894 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.456 HG13 ' CG2' ' A' ' 116' ' ' THR . 0.2 OUTLIER -66.63 147.58 98.95 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.163 -0.961 . . . . 0.0 109.381 179.856 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 6' ' ' PRO . . . . . 0.424 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.86 -168.33 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 124.189 1.626 . . . . 0.0 110.675 179.637 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.81 81.24 0.19 Allowed Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.472 -0.768 . . . . 0.0 109.987 -179.818 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 8' ' ' PRO . . . . . 0.453 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.78 -170.73 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.73 1.384 . . . . 0.0 109.831 179.644 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.84 -14.04 0.87 Allowed 'General case' 0 N--CA 1.508 2.457 0 O-C-N 121.854 -0.529 . . . . 0.0 111.264 -179.497 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 10' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.499 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 15' ' ' LEU . . . . . 0.757 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' THR . . . . . 0.808 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 20' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ILE . . . . . 0.978 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.452 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 26' ' ' LYS . . . . . 0.757 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 27' ' ' ALA . . . . . 0.808 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 28' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' PRO . . . . . 0.729 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.581 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' LYS . . . . . 0.627 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.636 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.502 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' CYS . . . . . 0.878 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 50' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.803 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 55' ' ' LEU . . . . . 0.978 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 57' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.627 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 61' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.58 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.689 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.878 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.81 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 69' ' ' LEU . . . . . 0.928 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.928 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.692 ' O ' HG23 ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.432 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 73' ' ' VAL . . . . . 0.956 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 74' ' ' ILE . . . . . 0.506 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -136.93 92.13 14.55 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.439 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.4 Cg_endo -77.0 58.1 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.428 1.225 . . . . 0.0 110.52 179.745 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 p -119.43 -32.0 4.47 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.163 -0.961 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 -150.82 160.65 43.74 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.169 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 65.01 166.65 1.38 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.09 102.97 15.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.1 -1.235 . . . . 0.0 110.171 -179.949 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.956 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 83' ' ' VAL . . . . . 0.92 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 85' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 86' ' ' ASP . . . . . 0.496 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.429 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.29 -33.0 72.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.2 mmt 54.06 -89.94 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.585 -0.697 . . . . 0.0 110.144 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 90' ' ' THR . . . . . 0.519 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.71 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.896 -1.127 . . . . 0.0 110.097 179.843 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.78 -48.65 79.46 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.61 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.56 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.46 -1.024 . . . . 0.0 110.51 -179.893 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 93' ' ' THR . . . . . 0.559 HG23 ' N ' ' A' ' 94' ' ' GLY . 5.6 t -95.1 -152.92 0.37 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.096 -1.003 . . . . 0.0 110.217 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.559 ' N ' HG23 ' A' ' 93' ' ' THR . . . 97.35 -10.29 65.18 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.642 179.117 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -124.92 65.0 1.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.748 -1.442 . . . . 0.0 110.893 -179.69 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.425 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 99' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 100' ' ' ILE . . . . . 0.874 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.654 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -142.88 133.66 25.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.6 p -113.86 132.42 55.91 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.363 -0.836 . . . . 0.0 109.431 179.246 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.53 -141.95 0.83 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.021 -1.049 . . . . 0.0 109.49 -179.361 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.7 15.37 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.514 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.84 157.21 70.11 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.262 -1.14 . . . . 0.0 109.641 -179.837 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.654 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.9 Cg_endo -64.67 166.31 18.24 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.574 1.302 . . . . 0.0 110.212 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.07 162.89 28.93 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.213 -0.929 . . . . 0.0 110.8 -179.24 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 112' ' ' ALA . . . . . 0.867 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 114' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.456 ' CG2' HG13 ' A' ' 5' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.8 tp-100 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 122' ' ' THR . . . . . 0.558 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 123' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 124' ' ' ARG . . . . . 0.429 ' HD3' ' HA2' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 126' ' ' LYS . . . . . 0.48 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 128' ' ' GLY . . . . . 0.558 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 129' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 130' ' ' TYR . . . . . 0.615 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 131' ' ' ARG . . . . . 0.499 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 132' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -88.96 -38.99 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.18 131.68 28.28 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.201 -0.937 . . . . 0.0 110.212 -179.851 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 135' ' ' PRO . . . . . 0.443 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 49.7 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.529 1.278 . . . . 0.0 110.624 -179.855 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.19 105.37 0.24 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.03 -166.35 1.81 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -1.146 . . . . 0.0 110.205 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.272 179.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 121.187 0.518 . . . . 0.0 110.405 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.557 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.733 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.409 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.916 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.549 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.733 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.98 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.641 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.56 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.854 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.911 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.707 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.42 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.811 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.555 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.641 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.659 HD22 HG23 ' A' ' 80' ' ' VAL . 1.4 t30 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.748 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.929 HG21 ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.911 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.864 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.864 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.841 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.929 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.762 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt . . . . . 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 122.093 0.949 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.826 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.854 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.507 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.458 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.654 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 121.006 0.431 . . . . 0.0 110.587 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.518 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.456 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.98 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 121.301 0.572 . . . . 0.0 110.788 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.542 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.443 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.542 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.443 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.522 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.513 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.513 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.456 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.472 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.498 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t . . . . . 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 . . . . . 0 N--CA 1.491 1.606 0 CA-C-O 121.263 0.554 . . . . 0.0 109.957 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.753 HG12 HG23 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.405 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.676 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.614 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.414 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.676 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.614 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.757 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.602 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.096 HG23 HG23 ' A' ' 33' ' ' ILE . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.096 HG23 HG23 ' A' ' 32' ' ' VAL . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.629 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.577 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.569 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.82 HD12 HG12 ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.917 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.759 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.41 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.562 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.709 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.602 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.642 HG22 HG22 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.93 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.917 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.471 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.939 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.866 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.93 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.893 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp . . . . . 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.921 0.867 . . . . 0.0 110.164 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.642 HG22 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.82 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.053 0.454 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.894 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.466 ' O ' HG22 ' A' ' 104' ' ' THR . 0.8 OUTLIER . . . . . 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 121.526 0.679 . . . . 0.0 111.128 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.42 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.517 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.433 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.486 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.753 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' SER . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.404 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.514 HG22 HD23 ' A' ' 15' ' ' LEU . 49.9 t . . . . . 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 . . . . . 0 N--CA 1.493 1.699 0 CA-C-O 121.263 0.554 . . . . 0.0 109.765 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.842 HG12 HG23 ' A' ' 122' ' ' THR . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.544 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.751 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.824 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.881 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.441 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.751 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.824 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.881 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.705 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.595 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.431 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 33' ' ' ILE . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.039 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.567 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.659 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.953 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.547 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.464 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.81 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.014 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.563 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.845 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.595 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.554 HG22 HG22 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.774 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.719 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.904 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.81 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.897 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.897 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.829 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.71 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.904 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.774 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.945 0.879 . . . . 0.0 110.407 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.554 HG22 HG22 ' A' ' 60' ' ' ILE . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 1.029 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.014 HG11 HD12 ' A' ' 51' ' ' LEU . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.514 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 1.029 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.076 0.465 . . . . 0.0 110.471 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.485 ' CE2' ' HB2' ' A' ' 39' ' ' LEU . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.881 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.426 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.6 m . . . . . 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 121.366 0.603 . . . . 0.0 110.786 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.494 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.494 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.418 ' O ' ' HB3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.431 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.467 ' HG2' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.842 HG23 HG12 ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.482 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.43 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.462 ' HA ' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.544 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.426 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t . . . . . 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.5 m-80 . . . . . 0 N--CA 1.49 1.549 0 CA-C-O 121.136 0.493 . . . . 0.0 109.925 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.819 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.539 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.582 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.944 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.493 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.539 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.944 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.795 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.662 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.487 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.092 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.092 HG23 HG23 ' A' ' 32' ' ' VAL . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.597 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.445 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.951 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.415 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.684 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.883 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.568 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.627 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.95 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.847 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.972 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.972 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.95 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp . . . . . 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 . . . . . 0 N--CA 1.49 1.536 0 CA-C-O 122.018 0.914 . . . . 0.0 110.053 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.752 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.951 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.501 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.501 ' N ' HG23 ' A' ' 85' ' ' THR . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 . . . . . 0 N--CA 1.492 1.626 0 CA-C-O 120.92 0.391 . . . . 0.0 111.172 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.486 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.908 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 121.323 0.582 . . . . 0.0 110.963 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.452 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.47 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.47 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.486 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.819 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 26' ' ' LYS . 74.9 t . . . . . 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.501 2.099 0 CA-C-O 120.816 0.341 . . . . 0.0 111.226 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.74 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.617 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.617 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.891 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.815 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.058 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.058 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.561 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.896 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.464 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.519 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.784 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.85 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.83 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.85 HD23 ' O ' ' A' ' 54' ' ' LYS 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.602 HG22 HG22 ' A' ' 81' ' ' VAL . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HD11 ' A' ' 74' ' ' ILE . 35.1 t30 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.559 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.868 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.929 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.929 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.778 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.868 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.884 0.849 . . . . 0.0 110.194 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.561 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.816 HG11 ' HB ' ' A' ' 33' ' ' ILE . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.74 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.896 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.529 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.529 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.576 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp . . . . . 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 CA-C-O 121.159 0.505 . . . . 0.0 110.592 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.458 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.563 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.891 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.437 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.454 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 . . . . . 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.533 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.533 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.454 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.5 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.479 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.448 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.74 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.563 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.47 ' HB2' HG13 ' A' ' 100' ' ' ILE . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.7 t . . . . . 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.488 HD13 HG22 ' A' ' 122' ' ' THR . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.776 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.66 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.504 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.478 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.897 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.471 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.504 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.862 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.877 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.872 HD11 HD12 ' A' ' 58' ' ' LEU . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.478 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.565 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.918 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.918 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.711 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.575 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.897 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.872 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.621 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.636 ' ND2' HD11 ' A' ' 74' ' ' ILE . 16.8 t30 -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.664 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.918 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.472 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.868 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.723 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.723 HG23 ' O ' ' A' ' 72' ' ' SER . 1.3 pp . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 . . . . . 0 N--CA 1.49 1.528 0 CA-C-O 122.036 0.922 . . . . 0.0 109.977 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.719 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.918 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.547 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.547 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.614 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 . . . . . 0 N--CA 1.491 1.616 0 CA-C-O 120.928 0.394 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.512 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.447 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.815 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.408 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.713 0 CA-C-O 121.185 0.517 . . . . 0.0 110.744 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.415 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.469 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.469 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.483 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.457 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.498 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.776 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.66 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 . . . . . 0 N--CA 1.494 1.751 0 CA-C-O 120.807 0.336 . . . . 0.0 111.155 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.689 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.716 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.82 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.898 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.716 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.82 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.064 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.754 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.732 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.561 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.663 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.94 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.422 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.699 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.077 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.459 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.58 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.778 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.732 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 21.0 t30 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.91 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.91 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.566 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.815 0.817 . . . . 0.0 110.315 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.52 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.767 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.077 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp . . . . . 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 . . . . . 0 N--CA 1.491 1.612 0 CA-C-O 121.002 0.429 . . . . 0.0 110.842 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.504 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.707 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.064 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.481 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 p . . . . . 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 . . . . . 0 N--CA 1.494 1.746 0 CA-C-O 121.387 0.613 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.521 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.472 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.475 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.485 ' HE ' HD12 ' A' ' 10' ' ' ILE . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.663 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.689 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.406 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.445 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.445 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.514 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.707 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.404 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.082 0.468 . . . . 0.0 110.437 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.664 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.614 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . 0.458 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.678 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.885 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.451 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.678 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.885 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.809 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.453 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HD3' ' CG1' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HB2' HG12 ' A' ' 81' ' ' VAL . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.515 HD12 ' O ' ' A' ' 82' ' ' VAL . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.936 HD12 HG12 ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.742 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.64 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.667 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.734 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.656 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HG23 ' A' ' 80' ' ' VAL . 1.9 t30 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.585 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.742 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.885 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.885 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.807 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.688 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp . . . . . 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 . . . . . 0 N--CA 1.49 1.564 0 CA-C-O 121.859 0.838 . . . . 0.0 110.136 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.555 HG23 HD22 ' A' ' 61' ' ' ASN . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.695 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.936 HG12 HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.479 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.19 0.519 . . . . 0.0 110.423 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.738 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.425 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.526 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.423 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 . . . . . 0 N--CA 1.49 1.567 0 CA-C-O 121.477 0.656 . . . . 0.0 110.857 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HD3' ' OD2' ' A' ' 101' ' ' ASP . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.448 ' HG2' ' CD1' ' A' ' 10' ' ' ILE . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.503 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.664 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.46 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.614 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t . . . . . 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.504 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.623 0.725 . . . . 0.0 109.396 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.612 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.672 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.778 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.422 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.672 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.778 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.786 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.677 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.037 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.037 HG23 HG23 ' A' ' 32' ' ' VAL . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.649 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.955 HD12 HG12 ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.469 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.522 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.843 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.753 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.558 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.81 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.677 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.577 ' ND2' HD11 ' A' ' 74' ' ' ILE . 17.0 t30 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.657 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.938 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.843 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.966 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.966 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.453 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.938 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.577 HD11 ' ND2' ' A' ' 61' ' ' ASN . 0.9 OUTLIER . . . . . 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 . . . . . 0 N--CA 1.488 1.465 0 CA-C-O 122.009 0.909 . . . . 0.0 109.756 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.544 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.955 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.031 0.443 . . . . 0.0 110.487 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.409 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p . . . . . 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 . . . . . 0 N--CA 1.494 1.728 0 CA-C-O 121.404 0.621 . . . . 0.0 111.241 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.527 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.438 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.442 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.612 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.413 ' HD3' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.488 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.504 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.504 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.538 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.445 HG22 HD23 ' A' ' 15' ' ' LEU . 54.3 t . . . . . 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.491 HD13 HG22 ' A' ' 122' ' ' THR . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.418 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.566 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.414 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.465 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.925 HD11 HD21 ' A' ' 51' ' ' LEU . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.507 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.507 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.465 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.982 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.77 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.763 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.527 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.614 HD12 ' O ' ' A' ' 82' ' ' VAL . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.753 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.925 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.801 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.74 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.763 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.699 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.661 ' ND2' HD11 ' A' ' 74' ' ' ILE . 28.7 t30 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.68 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.847 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.847 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 . . . . . 0 N--CA 1.492 1.647 0 CA-C-O 121.911 0.863 . . . . 0.0 110.344 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.659 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.782 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.753 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.463 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.6 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.6 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.42 HD12 ' CD2' ' A' ' 65' ' ' TYR . 14.6 tp . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.091 0.472 . . . . 0.0 110.73 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.44 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.982 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.409 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.3 pt20 . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.245 0.545 . . . . 0.0 110.984 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.448 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.489 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.437 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.541 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.541 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.566 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.409 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t . . . . . 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.6 t-20 . . . . . 0 N--CA 1.494 1.727 0 CA-C-O 121.104 0.478 . . . . 0.0 110.619 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.531 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.531 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.671 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.436 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.928 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.671 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.928 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.871 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.702 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.457 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.594 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.467 HD12 ' O ' ' A' ' 82' ' ' VAL . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 HG12 ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.413 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.799 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.488 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.544 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.874 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.702 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.5 t30 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.666 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.497 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.961 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.961 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.815 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.703 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.703 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.971 0.891 . . . . 0.0 110.37 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.601 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.761 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.836 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.497 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 85' ' ' THR . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.467 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp . . . . . 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.133 0.492 . . . . 0.0 110.694 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.883 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.469 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.7 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.61 0 CA-C-O 121.427 0.632 . . . . 0.0 110.821 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.522 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.522 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.419 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.431 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.531 ' HG2' HD12 ' A' ' 10' ' ' ILE . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.423 ' HB2' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.458 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.498 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.498 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.531 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.411 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.603 HG22 HD23 ' A' ' 15' ' ' LEU . 16.5 t . . . . . 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.2 m120 . . . . . 0 N--CA 1.493 1.72 0 CA-C-O 121.162 0.506 . . . . 0.0 110.382 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.482 HD11 ' O ' ' A' ' 122' ' ' THR . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.684 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.615 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.433 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.869 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.459 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.684 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.869 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.856 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.606 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.511 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.948 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.408 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.458 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.849 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.726 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.484 HD13 ' HA ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.606 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.584 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.899 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.52 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.622 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 121.933 0.873 . . . . 0.0 110.072 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.727 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.948 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.472 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.523 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.426 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.527 0 CA-C-O 120.757 0.313 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.511 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.442 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.49 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.768 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.474 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? . . . . . 0 N--CA 1.493 1.677 0 CA-C-O 121.614 0.721 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.529 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.442 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.529 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.471 ' O ' ' N ' ' A' ' 121' ' ' ARG . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.471 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.57 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.57 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.564 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.49 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.6 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.517 HG22 HD23 ' A' ' 15' ' ' LEU . 7.0 t . . . . . 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 . . . . . 0 N--CA 1.496 1.84 0 CA-C-O 121.544 0.688 . . . . 0.0 109.261 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.54 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.563 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.512 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.68 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.678 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.439 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.081 HG23 HG23 ' A' ' 33' ' ' ILE . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.081 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.658 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.832 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.458 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.889 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.697 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.52 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.87 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.678 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.689 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.889 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.966 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.966 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.778 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.672 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 122.115 0.96 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.47 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.834 HG11 HD13 ' A' ' 88' ' ' LEU . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.832 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.834 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 121.242 0.544 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.817 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.422 ' O ' ' HG2' ' A' ' 110' ' ' GLN . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.414 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.1 p . . . . . 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.601 0.715 . . . . 0.0 111.198 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.501 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.458 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.54 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.442 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.532 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.532 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.426 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.414 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.563 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.512 HG22 HD23 ' A' ' 15' ' ' LEU . 34.4 t . . . . . 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.433 0.635 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.515 HD13 HG22 ' A' ' 122' ' ' THR . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.411 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.464 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.485 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.922 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.511 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.47 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.485 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.922 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.801 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.654 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.612 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.564 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 82' ' ' VAL . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.926 HD12 HG12 ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.47 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . 0.421 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.884 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.705 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.517 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.653 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.538 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.654 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.3 t30 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.653 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.895 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.884 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.499 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.926 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.95 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.95 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.657 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.895 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.633 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 . . . . . 0 N--CA 1.491 1.62 0 CA-C-O 121.947 0.88 . . . . 0.0 110.123 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.524 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.651 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.777 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.926 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.499 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.694 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.694 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp . . . . . 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 . . . . . 0 N--CA 1.491 1.595 0 CA-C-O 121.124 0.488 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.485 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.499 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.83 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p . . . . . 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.225 0.536 . . . . 0.0 110.972 . . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.404 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.43 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.481 ' NH1' HD12 ' A' ' 10' ' ' ILE . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.401 ' CG ' ' O ' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.463 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.499 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.44 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.424 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.464 HG22 HD23 ' A' ' 15' ' ' LEU . 32.1 t . . . . . 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 . . . . . 0 N--CA 1.495 1.817 0 CA-C-O 120.969 0.414 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 ' O ' ' A' ' 122' ' ' THR . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.781 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.699 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.719 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.917 HD12 HD13 ' A' ' 55' ' ' LEU . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.699 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.719 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.045 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.748 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.79 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.637 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.574 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.898 HD12 HG12 ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.644 HD12 HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.685 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.917 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.79 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.637 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.705 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.745 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.844 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.825 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp . . . . . 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.799 0.809 . . . . 0.0 110.184 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.457 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 60' ' ' ILE . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.898 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.515 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.515 ' N ' HG23 ' A' ' 85' ' ' THR . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.034 0.445 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.712 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.045 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.542 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.454 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.406 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 1.3 p . . . . . 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.354 0.597 . . . . 0.0 110.706 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.416 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.416 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.454 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.712 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.431 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' HG21 ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.781 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 . . . . . 0 N--CA 1.494 1.77 0 CA-C-O 121.15 0.5 . . . . 0.0 110.427 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' O ' ' A' ' 122' ' ' THR . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.537 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.517 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.946 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.517 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.946 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.865 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.757 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.618 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.65 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.902 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.948 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.435 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 1.053 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.619 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.745 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.757 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.506 ' ND2' HD11 ' A' ' 74' ' ' ILE . 45.8 t30 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.745 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.511 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.848 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.848 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.506 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp . . . . . 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 . . . . . 0 N--CA 1.49 1.571 0 CA-C-O 122.012 0.91 . . . . 0.0 110.391 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.65 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.713 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 1.053 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.451 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.451 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.492 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 . . . . . 0 N--CA 1.493 1.685 0 CA-C-O 121.024 0.44 . . . . 0.0 110.814 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.714 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.413 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.845 0 CA-C-O 121.399 0.619 . . . . 0.0 111.133 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.472 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.472 ' N ' ' HG2' ' A' ' 115' ' ' ARG . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.459 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.53 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.53 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.708 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.537 HG22 HD23 ' A' ' 15' ' ' LEU . 46.2 t . . . . . 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.139 0.495 . . . . 0.0 110.171 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.448 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.9 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.434 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.448 ' CB ' HD23 ' A' ' 15' ' ' LEU . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.9 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.79 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.581 HD11 HD12 ' A' ' 58' ' ' LEU . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.406 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.599 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.939 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.423 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.434 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.951 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.809 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.468 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.533 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.734 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.581 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.599 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.734 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.939 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.951 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.672 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.924 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.644 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.939 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.644 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp . . . . . 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 122.103 0.954 . . . . 0.0 110.168 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' CG1' ' A' ' 73' ' ' VAL . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.939 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.484 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.484 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.462 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.201 0.524 . . . . 0.0 110.24 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB2' ' HB ' ' A' ' 129' ' ' ILE . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.867 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.4 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.443 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m . . . . . 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 CA-C-O 121.546 0.689 . . . . 0.0 110.948 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.51 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.51 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.45 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.477 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.492 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.465 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.492 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 98' ' ' SER . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.42 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.443 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t . . . . . 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 121.301 0.572 . . . . 0.0 110.289 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.843 HD13 HG23 ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.743 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.402 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.945 HD12 HD13 ' A' ' 55' ' ' LEU . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.431 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.662 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.743 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 1.037 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.896 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.491 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.054 HG23 HG23 ' A' ' 33' ' ' ILE . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.054 HG23 HG23 ' A' ' 32' ' ' VAL . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.556 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.791 HD12 HG12 ' A' ' 83' ' ' VAL . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.503 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.537 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.837 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.757 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.537 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.945 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.537 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.614 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.3 t30 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.609 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.86 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.837 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.561 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.85 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.85 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.691 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.86 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.691 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.96 0.886 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.546 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.624 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.803 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.791 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 85' ' ' THR . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.687 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.13 0.491 . . . . 0.0 110.428 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.476 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.738 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 1.037 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.424 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.9 p . . . . . 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.697 0 CA-C-O 121.212 0.529 . . . . 0.0 110.648 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.516 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.466 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.587 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.843 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.477 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.453 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.477 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.738 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.296 0.57 . . . . 0.0 109.908 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.489 HD13 HG22 ' A' ' 122' ' ' THR . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.607 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.451 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.655 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.451 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.915 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.578 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.059 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.059 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.589 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.626 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.486 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.497 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.875 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.578 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 49.9 t30 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.911 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.504 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.73 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.911 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 122.029 0.919 . . . . 0.0 110.29 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.623 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.83 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.552 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.552 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.261 0.553 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.492 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.492 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.414 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 p . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.412 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.436 0.636 . . . . 0.0 110.862 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.487 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.472 ' O ' ' CD1' ' A' ' 10' ' ' ILE . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.438 ' N ' ' O ' ' A' ' 119' ' ' ARG . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.515 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.464 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.583 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.607 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.655 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.7 t . . . . . 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.1 m-80 . . . . . 0 N--CA 1.492 1.642 0 CA-C-O 121.151 0.501 . . . . 0.0 110.358 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 ' O ' ' A' ' 122' ' ' THR . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.714 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.622 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.622 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.916 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.819 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.588 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.584 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.923 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.477 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.443 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.706 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.442 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.928 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.848 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.819 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.578 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.874 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.706 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.611 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.893 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.769 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.442 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.874 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.438 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER . . . . . 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.489 1.501 0 CA-C-O 122.073 0.939 . . . . 0.0 110.238 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.603 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.928 HG11 HD12 ' A' ' 51' ' ' LEU . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.482 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.778 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.504 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.778 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . 0.436 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp . . . . . 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 . . . . . 0 N--CA 1.49 1.566 0 CA-C-O 121.357 0.599 . . . . 0.0 110.589 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.593 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.2 m . . . . . 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.538 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.538 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.482 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.625 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.425 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.538 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 15' ' ' LEU . 54.6 t . . . . . 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.46 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER . . . . . 0 N--CA 1.506 2.373 0 N-CA-C 112.481 0.548 . . . . 0.0 112.481 . . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.512 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.633 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.476 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.633 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.987 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.839 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.551 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.046 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.515 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.622 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.926 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.493 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.476 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.739 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.993 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.565 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.746 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.589 HG22 HG22 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.629 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.594 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.922 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.476 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.865 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.877 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.877 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.922 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.681 ' O ' HG11 ' A' ' 80' ' ' VAL . 1.3 pp . . . . . 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 122.0 0.905 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.681 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.589 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.771 HG22 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.993 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.476 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.491 ' N ' HG23 ' A' ' 85' ' ' THR . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.492 1.644 0 CA-C-O 121.04 0.448 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.422 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.987 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.433 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.412 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.503 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 121.322 0.582 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.455 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.479 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.503 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.469 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.493 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.469 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.495 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.422 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.437 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.433 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 18.2 t . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.508 2.466 0 CA-C-O 120.63 0.252 . . . . 0.0 111.047 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.73 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.902 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . 0.459 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.683 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.435 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.901 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.481 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.902 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.683 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.901 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.767 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.836 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.044 HG23 HG23 ' A' ' 33' ' ' ILE . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.044 HG23 HG23 ' A' ' 32' ' ' VAL . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.617 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.673 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.829 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.481 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.473 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.894 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.714 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.699 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.836 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.617 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.639 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.755 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp . . . . . 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . 0.419 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 . . . . . 0 N--CA 1.491 1.613 0 CA-C-O 121.864 0.84 . . . . 0.0 109.983 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.494 HG13 ' O ' ' A' ' 80' ' ' VAL . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.599 HG22 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.673 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.829 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.403 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp . . . . . 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 . . . . . 0 N--CA 1.491 1.597 0 CA-C-O 121.104 0.478 . . . . 0.0 110.938 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.583 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.876 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p . . . . . 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 121.473 0.654 . . . . 0.0 110.843 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.503 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.462 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 115' ' ' ARG . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.424 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.544 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.544 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.499 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.73 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.7 t . . . . . 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.47 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.045 0.45 . . . . 0.0 110.449 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.496 HD13 HG22 ' A' ' 122' ' ' THR . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.79 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.573 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.942 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.502 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.57 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.969 HD11 HG21 ' A' ' 100' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.756 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.478 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.548 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.557 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.535 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.878 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.913 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.665 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.524 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.793 HD22 HG23 ' A' ' 80' ' ' VAL . 1.3 t30 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.59 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.913 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.485 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.746 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.746 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 . . . . . 0 N--CA 1.49 1.54 0 CA-C-O 121.933 0.873 . . . . 0.0 110.216 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.793 HG23 HD22 ' A' ' 61' ' ' ASN . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.878 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.601 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp . . . . . 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.142 0.496 . . . . 0.0 110.872 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.576 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.969 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . 0.422 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.422 ' NE2' ' O ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.322 0.582 . . . . 0.0 110.872 . . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.454 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.483 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.524 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.524 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.576 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.79 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.573 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t . . . . . 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 . . . . . 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.538 HD13 HG22 ' A' ' 122' ' ' THR . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.45 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.699 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.405 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.43 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.936 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.803 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.615 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.473 ' HG2' HG12 ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 104' ' ' THR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.687 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.741 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.535 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.751 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.615 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.655 HD22 HG23 ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.691 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.921 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.687 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.994 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.994 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.828 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.92 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.921 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.92 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp . . . . . 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 . . . . . 0 N--CA 1.489 1.509 0 CA-C-O 121.965 0.888 . . . . 0.0 110.097 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.655 HG23 HD22 ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.595 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.817 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.504 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.7 tp . . . . . 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 121.158 0.504 . . . . 0.0 110.733 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.471 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.936 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.457 ' HA ' ' N ' ' A' ' 110' ' ' GLN . 0.8 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.513 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.616 0.722 . . . . 0.0 110.91 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 114' ' ' SER . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.424 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.513 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.441 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.424 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.492 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.538 HG22 HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.492 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.492 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.516 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.475 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.438 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . 0.662 HG22 HD23 ' A' ' 15' ' ' LEU . 7.1 t . . . . . 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' ASN . . . . . 0.427 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.5 m120 . . . . . 0 N--CA 1.508 2.457 0 CA-C-O 120.59 0.233 . . . . 0.0 111.264 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.446 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.499 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' LEU . . . . . 0.757 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' THR . . . . . 0.808 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ILE . . . . . 0.978 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.452 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' LYS . . . . . 0.757 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . 0.808 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' PRO . . . . . 0.729 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.581 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.426 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' LYS . . . . . 0.627 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.636 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.502 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' CYS . . . . . 0.878 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 51' ' ' LEU . . . . . 0.803 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 55' ' ' LEU . . . . . 0.978 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 57' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.627 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 61' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.58 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.689 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.878 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.81 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 69' ' ' LEU . . . . . 0.928 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.928 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.692 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.432 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 73' ' ' VAL . . . . . 0.956 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 74' ' ' ILE . . . . . 0.506 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp . . . . . 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 . . . . . 0 N--CA 1.491 1.588 0 CA-C-O 121.993 0.902 . . . . 0.0 110.171 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.956 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 83' ' ' VAL . . . . . 0.92 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 84' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 85' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 86' ' ' ASP . . . . . 0.496 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.3 tp . . . . . 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 . . . . . 0 N--CA 1.492 1.641 0 CA-C-O 120.968 0.413 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 97' ' ' ASP . . . . . 0.45 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 99' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 100' ' ' ILE . . . . . 0.874 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.404 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p . . . . . 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.477 0.656 . . . . 0.0 110.8 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 112' ' ' ALA . . . . . 0.433 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 114' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.419 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 117' ' ' GLN . . . . . 0.4 ' HA ' ' NE2' ' A' ' 117' ' ' GLN . 7.6 tp60 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 119' ' ' ARG . . . . . 0.48 ' HA ' ' CD2' ' A' ' 130' ' ' TYR . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 122' ' ' THR . . . . . 0.558 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 123' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 124' ' ' ARG . . . . . 0.409 ' CD ' ' O ' ' A' ' 121' ' ' ARG . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 126' ' ' LYS . . . . . 0.48 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.48 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 128' ' ' GLY . . . . . 0.558 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 129' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 130' ' ' TYR . . . . . 0.615 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 131' ' ' ARG . . . . . 0.499 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 132' ' ' PHE . . . . . 0.442 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.411 ' HB3' ' CB ' ' A' ' 112' ' ' ALA . 0.5 OUTLIER -106.91 125.5 51.09 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.298 -1.119 . . . . 0.0 110.216 179.892 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.4 m -113.29 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.365 -0.834 . . . . 0.0 109.981 179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.445 HG22 ' OG1' ' A' ' 116' ' ' THR . 13.8 p -78.34 142.98 37.31 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.306 -0.871 . . . . 0.0 110.389 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -74.67 148.72 85.5 Favored Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.28 -0.887 . . . . 0.0 109.5 179.43 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.6 Cg_endo -69.12 -169.22 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 124.085 1.571 . . . . 0.0 110.751 179.456 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.544 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.68 79.44 0.08 OUTLIER Pre-proline 0 N--CA 1.498 1.965 0 O-C-N 121.34 -0.85 . . . . 0.0 110.135 -179.537 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.47 -15.36 27.8 Favored 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.609 1.32 . . . . 0.0 110.579 179.744 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.9 m120 -65.24 -25.8 67.83 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.09 -1.006 . . . . 0.0 110.405 -179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.493 HD11 ' O ' ' A' ' 122' ' ' THR . 20.0 mt -107.77 135.34 46.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.923 -1.111 . . . . 0.0 110.376 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 35.2 tt0 -84.93 128.71 34.74 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.459 -0.776 . . . . 0.0 109.518 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 9.8 mt-10 -89.1 131.84 35.06 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.083 -1.011 . . . . 0.0 110.097 -179.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 10.8 t -126.68 158.15 37.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 O-C-N 121.366 -0.834 . . . . 0.0 110.235 -179.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.68 108.54 20.1 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.218 -0.926 . . . . 0.0 109.7 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.557 HD11 HG12 ' A' ' 28' ' ' ILE . 9.7 tp -55.22 138.69 44.42 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.333 -0.854 . . . . 0.0 109.89 -179.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 18.2 p -136.41 -179.67 5.82 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.286 -0.884 . . . . 0.0 110.498 -179.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -78.94 74.49 5.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 109.906 179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.733 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 2.6 m -147.67 113.11 5.61 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.291 -0.88 . . . . 0.0 110.384 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.438 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -162.24 27.94 Favored Glycine 0 N--CA 1.488 2.117 0 C-N-CA 118.929 -1.605 . . . . 0.0 110.663 179.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.409 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.0 OUTLIER -118.16 -22.67 7.66 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.824 -0.809 . . . . 0.0 110.454 -179.972 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.916 HG23 ' HB ' ' A' ' 28' ' ' ILE . 10.1 tt -97.2 100.42 7.75 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.674 -1.21 . . . . 0.0 110.291 -179.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.1 Cg_endo -62.29 147.28 95.23 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.42 1.221 . . . . 0.0 109.672 179.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.585 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 68.7 t80 -160.83 96.26 1.12 Allowed 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.189 -0.944 . . . . 0.0 111.482 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.585 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 26.0 m-85 59.15 67.3 0.93 Allowed 'General case' 0 N--CA 1.501 2.076 0 O-C-N 121.43 -0.794 . . . . 0.0 111.64 178.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.49 14.36 13.64 Favored Glycine 0 N--CA 1.494 2.516 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.533 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.549 ' CB ' HD23 ' A' ' 15' ' ' LEU . 41.3 mmtm -130.64 156.42 44.92 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.03 -1.276 . . . . 0.0 109.146 179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.733 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.17 107.13 13.58 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.875 -1.141 . . . . 0.0 109.501 179.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.98 HD11 HG21 ' A' ' 100' ' ' ILE . 4.2 mt -71.25 113.8 22.37 Favored Pre-proline 0 C--N 1.3 -1.585 0 O-C-N 121.284 -0.885 . . . . 0.0 110.137 -179.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.7 Cg_endo -68.7 129.58 19.02 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 N-CA-C 106.871 -2.011 . . . . 0.0 106.871 176.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.641 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.7 mt -55.6 -19.33 9.95 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.848 -1.157 . . . . 0.0 110.747 -177.341 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.45 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.3 OUTLIER -59.71 -16.09 24.52 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.779 -1.201 . . . . 0.0 110.411 179.685 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 12.4 m -91.95 -25.09 5.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 120.986 -1.071 . . . . 0.0 111.038 -179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 6.2 pt -117.58 -21.03 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.901 -1.125 . . . . 0.0 110.75 -179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.56 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.0 tptt -94.34 148.41 22.24 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.063 -1.023 . . . . 0.0 110.15 179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.64 -6.36 33.39 Favored Glycine 0 N--CA 1.485 1.937 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 -179.558 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.25 -140.49 4.88 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.282 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.443 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -111.74 131.57 55.22 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.316 -1.108 . . . . 0.0 110.427 -179.642 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 86.4 m-70 -139.28 151.92 46.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.241 -0.912 . . . . 0.0 110.676 -179.892 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.48 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 17.2 tp -114.38 122.08 45.56 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.336 -0.853 . . . . 0.0 110.198 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.854 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.2 mt -104.24 129.49 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.472 0 O-C-N 121.267 -0.895 . . . . 0.0 109.484 179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -94.45 123.91 38.15 Favored 'General case' 0 C--N 1.294 -1.832 0 O-C-N 121.459 -0.776 . . . . 0.0 109.951 -179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.79 159.17 22.72 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.191 -0.943 . . . . 0.0 110.715 -179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.525 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 17.8 p80 -108.26 0.42 21.35 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.422 -0.799 . . . . 0.0 110.139 179.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 29.9 p -136.38 141.39 43.68 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.067 -1.021 . . . . 0.0 110.513 -179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.86 -40.16 69.16 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.556 -0.715 . . . . 0.0 110.583 -179.809 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.86 -34.11 71.23 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.38 -0.825 . . . . 0.0 110.725 -179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 10.0 tppt? -72.21 -35.05 68.81 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.237 -0.914 . . . . 0.0 109.532 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.911 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -61.34 -33.86 74.32 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.441 -0.787 . . . . 0.0 109.464 179.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.5 m-20 -69.21 -50.56 46.31 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.274 -0.891 . . . . 0.0 110.859 -179.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -72.69 -47.14 49.72 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.137 -0.977 . . . . 0.0 110.534 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.707 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.6 tm? -56.73 -37.64 71.27 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.583 -0.698 . . . . 0.0 111.256 -178.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.42 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -76.24 -51.31 12.32 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.853 -1.154 . . . . 0.0 110.412 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.09 -39.53 92.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.132 -0.98 . . . . 0.0 109.979 179.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.3 OUTLIER -57.27 -44.57 84.1 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.355 -0.841 . . . . 0.0 109.387 179.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.811 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.35 -42.98 74.59 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.685 -0.634 . . . . 0.0 110.075 179.932 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 44.8 t -56.21 -33.12 36.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.091 -1.005 . . . . 0.0 108.951 179.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.74 -31.49 59.61 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.023 179.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.555 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -71.65 -26.35 62.51 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.362 -0.836 . . . . 0.0 109.349 179.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.72 5.52 9.1 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 -179.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.641 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.6 mt -108.24 143.27 18.94 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.252 -1.146 . . . . 0.0 110.3 -179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.659 HD22 HG23 ' A' ' 80' ' ' VAL . 1.4 t30 -88.09 107.14 18.6 Favored 'General case' 0 C--N 1.308 -1.223 0 N-CA-C 106.674 -1.602 . . . . 0.0 106.674 177.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.748 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.07 143.93 45.22 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.866 -1.134 . . . . 0.0 111.882 -177.013 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.929 HG21 ' HA ' ' A' ' 73' ' ' VAL . 95.3 t -125.06 147.48 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.706 -0.621 . . . . 0.0 109.76 179.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.911 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.5 123.01 48.99 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 119.449 -0.9 . . . . 0.0 109.468 178.567 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.3 t80 -117.66 136.35 53.38 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.119 -0.988 . . . . 0.0 110.771 -179.345 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.864 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -169.15 176.26 5.34 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.457 -0.777 . . . . 0.0 109.806 179.667 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -51.02 122.92 8.25 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.184 -0.947 . . . . 0.0 110.853 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.46 38.77 16.52 Favored Glycine 0 N--CA 1.492 2.426 0 N-CA-C 110.078 -1.209 . . . . 0.0 110.078 179.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.864 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.03 154.84 30.25 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.05 -1.264 . . . . 0.0 109.884 179.681 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.841 ' N ' HD13 ' A' ' 69' ' ' LEU . 10.2 m-20 -94.14 149.12 21.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.297 -0.877 . . . . 0.0 110.503 -179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.666 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.59 110.41 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.201 -1.0 . . . . 0.0 109.525 179.526 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 75.8 m -132.55 -17.55 2.56 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.567 -0.708 . . . . 0.0 110.896 -179.549 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.929 ' HA ' HG21 ' A' ' 63' ' ' VAL . 61.0 t -65.39 141.93 17.53 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.104 -0.998 . . . . 0.0 109.743 -179.581 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.762 ' O ' HG11 ' A' ' 80' ' ' VAL . 6.0 pt -136.47 91.29 16.35 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.242 -0.911 . . . . 0.0 110.397 -179.531 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -92.58 42.22 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.701 1.369 . . . . 0.0 110.421 179.631 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -120.3 -24.76 5.83 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.144 -0.972 . . . . 0.0 110.654 -179.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -163.01 162.22 25.86 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 64.6 134.83 0.01 OUTLIER Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.38 -1.488 . . . . 0.0 109.38 179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -61.27 106.77 0.66 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.1 -1.235 . . . . 0.0 109.894 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.762 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -116.96 134.26 61.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.843 0 CA-C-O 122.072 0.939 . . . . 0.0 110.358 -179.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.576 HG22 HG22 ' A' ' 60' ' ' ILE . 14.0 m -113.41 124.67 70.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.261 0 N-CA-C 108.72 -0.844 . . . . 0.0 108.72 178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.826 HG22 HG13 ' A' ' 73' ' ' VAL . 11.3 t -97.46 119.21 45.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 120.88 -1.138 . . . . 0.0 110.563 -177.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.854 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -112.67 100.59 11.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.846 -1.159 . . . . 0.0 108.302 179.263 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.93 162.67 34.84 Favored 'General case' 0 C--N 1.299 -1.62 0 O-C-N 120.835 -1.166 . . . . 0.0 111.561 -177.522 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.507 HG23 ' N ' ' A' ' 86' ' ' ASP . 6.3 t -84.15 -126.09 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.888 -0.782 . . . . 0.0 108.888 179.136 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.507 ' N ' HG23 ' A' ' 85' ' ' THR . 1.0 OUTLIER -101.41 40.3 1.32 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 120.492 -1.38 . . . . 0.0 110.209 179.679 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.458 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -106.73 -34.7 7.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.28 -0.887 . . . . 0.0 109.853 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.654 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -68.97 -19.9 64.17 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.258 -0.901 . . . . 0.0 109.866 179.509 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.425 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.2 OUTLIER 53.71 -150.52 0.37 Allowed 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.266 -0.896 . . . . 0.0 109.871 -179.791 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.458 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.1 OUTLIER -150.62 31.51 0.64 Allowed 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.251 -0.906 . . . . 0.0 109.964 -179.961 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.32 -29.44 73.16 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.661 -1.375 . . . . 0.0 109.661 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 53.9 p90 -131.92 19.16 4.58 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.105 -1.232 . . . . 0.0 110.769 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.458 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 14.5 t -90.55 -154.78 0.35 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.084 -1.01 . . . . 0.0 110.32 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.436 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 103.26 -32.5 7.51 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 110.199 -1.161 . . . . 0.0 110.199 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -83.99 53.94 2.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.946 -1.326 . . . . 0.0 110.587 -179.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 17.5 m-85 -120.16 145.69 46.71 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.049 -1.032 . . . . 0.0 110.169 179.588 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.518 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -79.52 -31.54 42.18 Favored 'General case' 0 C--N 1.299 -1.603 0 C-N-CA 119.694 -0.803 . . . . 0.0 109.725 179.528 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.456 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 4.1 p -161.56 163.94 29.81 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.173 -0.954 . . . . 0.0 111.316 179.879 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.86 115.5 39.45 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.483 -0.761 . . . . 0.0 110.007 179.311 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.98 HG21 HD11 ' A' ' 28' ' ' ILE . 3.6 mp -93.38 112.53 26.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.171 -0.956 . . . . 0.0 108.895 179.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.7 t0 -116.79 161.1 19.81 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.113 -0.992 . . . . 0.0 111.759 -178.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.459 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 14.9 t -103.0 8.28 38.97 Favored 'General case' 0 C--N 1.304 -1.396 0 O-C-N 121.711 -0.618 . . . . 0.0 109.48 178.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 5.4 m-20 47.08 26.13 0.59 Allowed 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.2 -0.937 . . . . 0.0 111.113 -179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.462 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.8 p -146.45 132.52 19.29 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.053 -1.029 . . . . 0.0 110.56 179.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 80.6 p -112.82 134.32 54.39 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.345 -0.847 . . . . 0.0 109.936 179.545 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.4 t0 49.41 29.09 2.65 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.196 -0.94 . . . . 0.0 110.628 -179.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.03 -32.98 5.49 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 109.717 -1.353 . . . . 0.0 109.717 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.438 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.66 157.3 82.29 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.266 -1.138 . . . . 0.0 110.088 179.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.462 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.0 Cg_endo -65.14 133.75 36.67 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 O-C-N 123.562 1.296 . . . . 0.0 110.157 179.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.447 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 16.2 pt20 -49.21 150.19 1.8 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.257 -0.902 . . . . 0.0 110.788 -179.439 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.542 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -89.07 161.57 16.47 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.355 -0.841 . . . . 0.0 110.415 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.443 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -41.69 -53.9 3.46 Favored 'General case' 0 N--CA 1.499 1.98 0 O-C-N 121.511 -0.743 . . . . 0.0 112.366 -178.652 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.542 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.0 m -68.65 -29.48 43.94 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.629 -1.294 . . . . 0.0 111.275 -178.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.447 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.66 -56.46 7.21 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.082 -1.011 . . . . 0.0 110.553 -179.268 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.443 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -67.68 -34.81 77.66 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.122 -0.986 . . . . 0.0 108.579 178.776 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.445 ' OG1' HG22 ' A' ' 4' ' ' THR . 13.3 m -59.62 -49.79 76.4 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.354 -0.98 . . . . 0.0 108.354 178.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.7 tt0 -73.97 -35.86 64.52 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.588 -0.695 . . . . 0.0 109.906 178.809 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 3.3 mtt85 -71.17 -44.79 64.78 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.066 -1.021 . . . . 0.0 110.722 -179.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.544 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 2.7 ttm105 -60.38 -42.61 96.21 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.95 -1.094 . . . . 0.0 110.472 -179.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.57 86.15 0.09 OUTLIER Glycine 0 N--CA 1.492 2.412 0 N-CA-C 109.777 -1.329 . . . . 0.0 109.777 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.425 ' NH1' ' O ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -164.7 -45.39 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.57 -0.959 . . . . 0.0 108.623 179.493 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.522 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.0 t -98.62 142.56 30.03 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 108.447 -0.945 . . . . 0.0 108.447 178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.475 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 115.13 10.46 12.0 Favored Glycine 0 N--CA 1.486 1.998 0 C-N-CA 119.07 -1.538 . . . . 0.0 110.576 179.81 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.436 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 5.8 mtt180 -84.87 83.96 7.87 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.018 -1.284 . . . . 0.0 109.84 -179.907 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.75 -23.5 9.46 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 108.942 -1.663 . . . . 0.0 108.942 -179.283 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.513 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -147.72 -169.67 0.22 Allowed Pre-proline 0 N--CA 1.49 1.544 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.902 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.513 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 46.9 Cg_endo -88.0 111.09 0.7 Allowed 'Trans proline' 0 C--N 1.31 -1.472 0 O-C-N 122.858 0.925 . . . . 0.0 109.984 179.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.522 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.68 150.94 38.76 Favored Glycine 0 N--CA 1.494 2.541 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 -179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.456 ' HB ' ' CB ' ' A' ' 98' ' ' SER . 5.7 mt -107.4 141.46 22.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.149 -1.206 . . . . 0.0 109.152 179.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.472 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 8.0 t80 -131.86 116.48 17.26 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 120.913 -1.117 . . . . 0.0 110.719 -179.909 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.498 ' NH1' HG11 ' A' ' 32' ' ' VAL . 9.6 mtt-85 -105.84 125.76 51.37 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.405 -0.809 . . . . 0.0 109.609 179.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.417 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 28.6 p90 -114.56 157.87 22.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 120.975 -1.078 . . . . 0.0 110.251 179.91 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.459 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 15.1 t -89.9 -65.75 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.186 -0.947 . . . . 0.0 109.991 179.674 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 54.24 96.75 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.588 -0.695 . . . . 0.0 110.007 -179.099 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.09 -49.46 0.3 Allowed 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.688 1.362 . . . . 0.0 110.411 -179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -131.22 23.66 4.31 Favored Glycine 0 N--CA 1.489 2.223 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -110.59 167.13 10.45 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.337 -1.096 . . . . 0.0 110.195 -179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.611 0 CA-C-O 118.021 -0.99 . . . . 0.0 110.041 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -92.76 135.42 34.12 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.188 -1.184 . . . . 0.0 110.153 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.671 ' O ' HG13 ' A' ' 3' ' ' VAL . 13.6 p -113.0 104.58 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.179 -0.951 . . . . 0.0 109.899 179.671 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.533 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 78.5 p -72.3 144.66 48.27 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.347 -0.846 . . . . 0.0 110.487 -179.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.458 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.44 147.98 98.15 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.306 -0.871 . . . . 0.0 109.672 179.686 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.458 ' HD2' HG23 ' A' ' 5' ' ' VAL . 49.9 Cg_endo -73.35 -173.77 1.4 Allowed 'Trans proline' 0 C--N 1.308 -1.559 0 O-C-N 124.071 1.564 . . . . 0.0 111.022 179.596 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.535 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 1.0 OUTLIER 170.71 76.55 0.03 OUTLIER Pre-proline 0 N--CA 1.495 1.821 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 179.571 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_endo -68.15 -17.41 45.37 Favored 'Trans proline' 0 C--N 1.311 -1.444 0 O-C-N 123.865 1.455 . . . . 0.0 111.048 -179.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.6 t-20 -57.03 -24.52 54.34 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.103 -0.998 . . . . 0.0 109.957 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.753 HG12 HG23 ' A' ' 122' ' ' THR . 9.1 mt -105.97 133.26 50.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.059 -1.025 . . . . 0.0 109.907 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.405 ' HB3' HG12 ' A' ' 129' ' ' ILE . 6.4 tp10 -85.69 128.41 34.77 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.347 -0.845 . . . . 0.0 108.991 178.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 20.3 mt-10 -89.19 139.25 30.67 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.048 -1.033 . . . . 0.0 110.309 -179.19 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.7 155.59 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.508 -0.745 . . . . 0.0 110.23 -179.505 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.07 113.29 26.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.321 -0.862 . . . . 0.0 110.098 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.676 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.6 tp -54.32 139.95 34.87 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.297 -0.877 . . . . 0.0 109.916 179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 25.5 p -136.42 172.52 12.89 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.239 -0.913 . . . . 0.0 110.252 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.6 p -71.67 71.57 0.73 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.289 -0.882 . . . . 0.0 110.047 179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.614 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 31.4 m -146.14 109.34 4.67 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.304 -0.873 . . . . 0.0 110.542 -179.714 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.42 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.88 -173.92 28.66 Favored Glycine 0 N--CA 1.488 2.156 0 C-N-CA 118.793 -1.67 . . . . 0.0 111.293 179.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.414 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -107.85 -22.77 12.32 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.822 -0.811 . . . . 0.0 110.45 179.976 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.895 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -95.07 102.42 9.31 Favored Pre-proline 0 N--CA 1.486 1.339 0 C-N-CA 118.678 -1.209 . . . . 0.0 109.714 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 20' ' ' GLU . 37.3 Cg_endo -61.96 139.91 81.87 Favored 'Trans proline' 0 C--N 1.311 -1.397 0 O-C-N 123.536 1.282 . . . . 0.0 110.601 -179.321 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.441 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -133.8 -164.07 1.45 Allowed 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.407 -0.808 . . . . 0.0 111.047 -178.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 34.3 m-85 -58.16 81.66 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.554 -0.716 . . . . 0.0 111.193 -179.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 68.03 5.06 38.35 Favored Glycine 0 N--CA 1.493 2.474 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 -179.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.676 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.5 mmtm -131.05 155.87 46.15 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 120.983 -1.304 . . . . 0.0 109.441 179.949 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.614 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.86 107.31 16.3 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.058 -1.026 . . . . 0.0 108.956 179.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.895 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -68.03 114.55 21.36 Favored Pre-proline 0 C--N 1.3 -1.566 0 O-C-N 121.263 -0.898 . . . . 0.0 110.896 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.757 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -70.2 128.28 15.4 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.657 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.602 HD11 HD12 ' A' ' 58' ' ' LEU . 9.8 mt -56.2 -18.54 10.54 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.814 -1.179 . . . . 0.0 110.827 -177.594 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 -59.52 -16.13 22.64 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.605 -1.31 . . . . 0.0 110.44 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.096 HG23 HG23 ' A' ' 33' ' ' ILE . 9.2 m -91.81 -25.12 5.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.036 -1.04 . . . . 0.0 110.903 -179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.096 HG23 HG23 ' A' ' 32' ' ' VAL . 38.1 pt -118.32 -17.11 7.4 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.036 -1.04 . . . . 0.0 110.608 -179.563 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.629 ' HB2' HD11 ' A' ' 60' ' ' ILE . 6.1 tptm -98.68 148.4 23.87 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 120.945 -1.097 . . . . 0.0 109.845 179.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 108.57 -6.12 33.44 Favored Glycine 0 N--CA 1.483 1.831 0 N-CA-C 109.292 -1.523 . . . . 0.0 109.292 -179.453 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.96 -136.82 2.98 Favored Glycine 0 N--CA 1.492 2.373 0 C-N-CA 119.306 -1.426 . . . . 0.0 110.301 179.945 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.429 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -117.6 132.55 56.49 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.311 -1.111 . . . . 0.0 110.432 -179.549 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.577 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 73.5 m80 -139.84 150.23 44.42 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.232 -0.917 . . . . 0.0 110.828 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.569 HD12 ' HB ' ' A' ' 82' ' ' VAL . 24.3 tp -112.13 114.74 27.74 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.464 -0.773 . . . . 0.0 110.008 179.678 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.82 HD12 HG12 ' A' ' 83' ' ' VAL . 43.9 mt -97.64 127.95 49.46 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.342 -0.849 . . . . 0.0 109.974 179.826 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.407 ' CB ' ' OD2' ' A' ' 101' ' ' ASP . 3.6 m-85 -95.33 123.0 38.62 Favored 'General case' 0 C--N 1.291 -1.949 0 O-C-N 121.218 -0.926 . . . . 0.0 109.94 179.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.41 160.16 21.61 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.262 -0.899 . . . . 0.0 110.689 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.8 p80 -107.17 0.52 23.41 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.442 -0.786 . . . . 0.0 110.365 179.233 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -134.25 137.49 44.37 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.971 -1.081 . . . . 0.0 110.808 -179.902 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.6 OUTLIER -71.59 -39.68 70.37 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.764 -0.585 . . . . 0.0 110.754 -179.766 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.4 mttp -58.54 -36.73 74.34 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.189 -0.945 . . . . 0.0 110.385 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.408 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.4 OUTLIER -73.83 -34.35 64.51 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.453 -0.779 . . . . 0.0 109.617 -179.951 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.917 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.8 m -60.55 -33.97 73.46 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.454 -0.779 . . . . 0.0 109.46 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 51.4 m-20 -69.51 -49.59 53.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.24 -0.912 . . . . 0.0 110.287 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.428 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.2 mt-10 -71.86 -44.43 63.82 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.313 -0.867 . . . . 0.0 110.354 -179.842 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.759 HD12 HG11 ' A' ' 83' ' ' VAL . 2.0 tm? -56.85 -43.04 80.75 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.48 -0.763 . . . . 0.0 110.776 -179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.41 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -74.19 -51.84 14.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.878 -1.139 . . . . 0.0 110.661 -179.696 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.7 -38.76 86.1 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 120.866 -1.146 . . . . 0.0 109.374 179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.562 ' HE3' HD22 ' A' ' 51' ' ' LEU . 2.5 ttmm -59.37 -45.91 90.13 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.384 -0.822 . . . . 0.0 109.555 179.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.709 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.41 -40.24 71.22 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.452 -0.78 . . . . 0.0 109.776 179.823 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 70.1 t -56.42 -34.5 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.067 -1.021 . . . . 0.0 108.778 178.805 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.46 -31.25 60.21 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.557 -0.714 . . . . 0.0 110.049 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.602 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.23 -26.08 62.77 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.333 -0.854 . . . . 0.0 109.536 179.867 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.66 4.73 9.55 Favored Glycine 0 N--CA 1.492 2.399 0 N-CA-C 109.473 -1.451 . . . . 0.0 109.473 -179.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.642 HG22 HG22 ' A' ' 81' ' ' VAL . 58.3 mt -108.05 143.35 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.383 0 O-C-N 121.319 -1.106 . . . . 0.0 110.052 -179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 52.4 t30 -86.27 107.62 18.03 Favored 'General case' 0 N--CA 1.486 1.328 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.534 ' HB2' ' HB3' ' A' ' 55' ' ' LEU . . . -120.97 149.8 42.1 Favored 'General case' 0 C--N 1.296 -1.718 0 C-N-CA 118.914 -1.114 . . . . 0.0 112.076 -176.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.93 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -138.26 152.38 25.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 C-N-CA 119.927 -0.709 . . . . 0.0 109.46 179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.917 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.47 130.81 56.76 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.308 -0.957 . . . . 0.0 110.099 179.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.471 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.6 OUTLIER -120.54 122.27 40.24 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.304 -0.873 . . . . 0.0 110.374 -179.891 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -156.27 176.76 12.25 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.539 -0.726 . . . . 0.0 109.637 179.81 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -53.25 125.08 16.4 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.025 -1.047 . . . . 0.0 110.483 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.99 38.54 15.31 Favored Glycine 0 N--CA 1.493 2.465 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.819 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.939 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.6 tm? -117.46 156.07 28.6 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.175 -1.191 . . . . 0.0 110.137 -179.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.866 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.3 m-20 -96.7 148.91 22.39 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 110.577 -179.379 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.22 110.96 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 C-N-CA 119.145 -1.022 . . . . 0.0 109.032 179.17 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 12.4 m -132.63 -35.2 1.13 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.438 -0.789 . . . . 0.0 110.555 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.93 HG22 ' HB ' ' A' ' 63' ' ' VAL . 58.8 t -52.26 128.98 11.76 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.261 -0.9 . . . . 0.0 110.067 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.893 ' O ' HD12 ' A' ' 74' ' ' ILE . 2.0 pp -137.95 115.72 9.52 Favored Pre-proline 0 N--CA 1.495 1.792 0 O-C-N 121.275 -0.891 . . . . 0.0 110.488 179.712 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.755 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.2 Cg_endo -87.37 39.16 0.56 Allowed 'Trans proline' 0 C--N 1.314 -1.262 0 O-C-N 123.256 1.135 . . . . 0.0 110.97 179.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.5 p -144.17 46.88 1.42 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.928 -1.107 . . . . 0.0 110.554 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.803 ' ND2' HD13 ' A' ' 74' ' ' ILE . 3.8 m-80 -142.26 26.9 1.79 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.191 -0.943 . . . . 0.0 110.177 179.834 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 104.0 -94.92 1.12 Allowed Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 73.4 m-20 -128.79 109.06 10.96 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.169 -1.195 . . . . 0.0 110.164 179.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.755 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.1 p -117.0 134.5 60.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 122.045 0.926 . . . . 0.0 110.637 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.642 HG22 HG22 ' A' ' 60' ' ' ILE . 13.5 m -112.92 122.35 66.9 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 178.576 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.725 HG22 HG13 ' A' ' 73' ' ' VAL . 4.3 t -97.01 119.66 45.34 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.697 0 O-C-N 120.963 -1.085 . . . . 0.0 110.31 -177.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.82 HG12 HD12 ' A' ' 40' ' ' ILE . 4.5 m -111.39 100.41 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 120.995 -1.065 . . . . 0.0 108.595 179.475 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.471 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.44 162.81 34.59 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 120.698 -1.252 . . . . 0.0 111.59 -177.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -93.3 -136.02 0.18 Allowed 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.631 -0.668 . . . . 0.0 109.517 179.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 12.3 p-10 -86.38 46.66 1.37 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.732 -1.23 . . . . 0.0 110.648 -179.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.09 -23.09 8.09 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.949 -1.095 . . . . 0.0 110.427 179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -65.84 -29.31 69.75 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.113 -0.992 . . . . 0.0 109.686 179.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.491 ' C ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER 48.64 45.01 21.56 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.451 -0.781 . . . . 0.0 111.051 179.771 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.645 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.5 t 33.92 -118.89 0.09 Allowed 'General case' 0 N--CA 1.505 2.282 0 N-CA-C 112.021 0.378 . . . . 0.0 112.021 179.155 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 86.55 -63.71 4.08 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -119.86 1.86 11.01 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.386 -1.067 . . . . 0.0 110.184 179.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.645 HG22 ' OG1' ' A' ' 90' ' ' THR . 12.3 t -67.63 -154.41 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.019 -1.05 . . . . 0.0 110.281 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.414 ' N ' HG23 ' A' ' 93' ' ' THR . . . 90.09 -41.53 2.97 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 110.145 -1.182 . . . . 0.0 110.145 179.399 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -84.04 57.49 4.21 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.178 -1.19 . . . . 0.0 111.114 -179.326 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.414 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 29.8 m-85 -119.65 146.66 45.37 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.053 -1.029 . . . . 0.0 109.891 178.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -72.05 -33.39 67.94 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.395 -0.816 . . . . 0.0 109.829 179.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.408 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.72 163.73 26.72 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.268 -0.895 . . . . 0.0 111.072 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.526 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 114.59 38.4 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.915 0 O-C-N 121.345 -0.847 . . . . 0.0 109.994 178.8 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.894 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.8 mp -93.23 114.76 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.218 -0.926 . . . . 0.0 108.575 179.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' OD2' ' CB ' ' A' ' 41' ' ' PHE . 2.8 t0 -122.16 160.18 25.67 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.09 -1.006 . . . . 0.0 111.79 -178.167 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.4 p -90.97 -7.38 52.18 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 50.89 18.78 0.55 Allowed 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.287 -0.883 . . . . 0.0 112.204 179.213 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.541 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.8 OUTLIER -147.35 113.72 5.94 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.759 -1.213 . . . . 0.0 109.424 179.535 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.438 ' N ' ' O ' ' A' ' 108' ' ' LYS . 59.1 p -88.01 140.17 29.76 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.17 -0.956 . . . . 0.0 110.615 -179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER 52.38 28.27 5.65 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.384 -0.823 . . . . 0.0 110.704 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.541 ' C ' HG23 ' A' ' 104' ' ' THR . . . 87.56 -14.83 57.17 Favored Glycine 0 N--CA 1.492 2.424 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 179.891 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 104' ' ' THR . 8.5 mmtt -96.6 156.68 36.4 Favored Pre-proline 0 N--CA 1.492 1.662 0 O-C-N 121.052 -1.263 . . . . 0.0 109.764 -179.982 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.67 133.81 41.18 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.625 1.329 . . . . 0.0 110.112 179.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 4.5 pt20 -57.66 -177.16 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.378 -0.826 . . . . 0.0 111.128 -178.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.517 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -108.01 161.59 14.81 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.588 -0.695 . . . . 0.0 110.566 -179.836 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.533 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -41.52 -55.11 2.96 Favored 'General case' 0 N--CA 1.497 1.908 0 O-C-N 121.625 -0.672 . . . . 0.0 112.632 -178.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.517 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.33 -29.79 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 120.676 -1.265 . . . . 0.0 111.527 -178.482 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.433 ' O ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -47.75 -57.64 5.32 Favored 'General case' 0 N--CA 1.497 1.894 0 O-C-N 121.014 -1.054 . . . . 0.0 110.519 -179.029 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.42 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -65.56 -33.87 76.92 Favored 'General case' 0 N--CA 1.487 1.414 0 C-N-CA 119.308 -0.957 . . . . 0.0 108.8 178.684 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 26.2 m -60.26 -49.26 78.3 Favored 'General case' 0 C--N 1.307 -1.28 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 178.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 34.7 tt0 -73.42 -40.98 63.83 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.478 -0.764 . . . . 0.0 110.29 179.101 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' O ' ' A' ' 114' ' ' SER . 4.3 mpt_? -70.03 -44.03 70.1 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.044 -1.035 . . . . 0.0 110.762 -179.593 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.535 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.9 OUTLIER -54.24 -38.49 65.81 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.04 -1.038 . . . . 0.0 110.215 -179.883 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.23 76.9 0.06 OUTLIER Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.454 ' N ' ' O ' ' A' ' 119' ' ' ARG . 73.8 mmt-85 -151.39 -43.52 0.11 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.563 -0.963 . . . . 0.0 108.883 179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.753 HG23 HG12 ' A' ' 10' ' ' ILE . 15.0 t -104.35 139.48 39.27 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.543 -0.723 . . . . 0.0 109.365 179.019 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.41 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 121.81 19.8 3.28 Favored Glycine 0 N--CA 1.491 2.339 0 C-N-CA 119.229 -1.463 . . . . 0.0 110.575 179.509 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.472 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.9 OUTLIER -93.39 81.82 4.43 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.011 -1.288 . . . . 0.0 110.071 179.814 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.32 -30.44 5.4 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.811 -1.715 . . . . 0.0 108.811 -179.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 2.5 ptmm? -144.79 -168.83 0.2 Allowed Pre-proline 0 C--N 1.302 -1.467 0 O-C-N 121.661 -0.905 . . . . 0.0 108.571 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.465 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 46.2 Cg_endo -84.08 111.75 1.66 Allowed 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.094 1.05 . . . . 0.0 109.916 179.768 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.462 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.63 168.99 54.82 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.881 -1.288 . . . . 0.0 109.881 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.408 ' O ' ' HA ' ' A' ' 98' ' ' SER . 41.7 mt -127.16 142.13 44.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.379 -1.071 . . . . 0.0 109.244 179.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.526 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.4 t80 -128.03 115.06 17.9 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.165 -1.014 . . . . 0.0 110.596 179.651 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.404 ' NH2' HG21 ' A' ' 129' ' ' ILE . 6.8 mtt85 -106.43 123.25 47.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.547 -0.721 . . . . 0.0 109.386 179.47 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 7.0 p90 -118.92 155.45 31.27 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.166 -0.959 . . . . 0.0 110.589 -179.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.514 HG22 HD23 ' A' ' 15' ' ' LEU . 49.9 t -72.33 -61.42 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.197 -0.939 . . . . 0.0 109.315 179.131 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -98.97 147.83 33.76 Favored Pre-proline 0 N--CA 1.49 1.53 0 O-C-N 121.388 -0.82 . . . . 0.0 109.953 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.37 -46.97 0.43 Allowed 'Trans proline' 0 C--N 1.31 -1.464 0 O-C-N 123.666 1.351 . . . . 0.0 110.484 -179.806 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -176.21 -124.37 0.82 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.468 -1.453 . . . . 0.0 109.468 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -110.74 -62.1 1.58 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.232 -1.157 . . . . 0.0 110.213 179.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 32.8 ttt85 . . . . . 0 N--CA 1.492 1.65 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.289 -179.997 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 52.2 p -94.67 110.0 21.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.257 -1.143 . . . . 0.0 110.325 -179.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.613 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.6 p -113.29 104.04 16.37 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.206 -0.934 . . . . 0.0 110.021 179.625 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.505 HG22 ' OG1' ' A' ' 116' ' ' THR . 17.3 p -63.83 145.14 56.35 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.378 -0.826 . . . . 0.0 110.28 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.405 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.99 146.45 98.22 Favored Pre-proline 0 N--CA 1.493 1.697 0 O-C-N 121.228 -0.92 . . . . 0.0 110.147 -179.848 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.405 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.5 Cg_endo -70.87 -175.86 1.58 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 124.09 1.574 . . . . 0.0 111.041 179.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.523 ' CE1' ' HB ' ' A' ' 10' ' ' ILE . 1.7 p80 -176.55 84.21 0.27 Allowed Pre-proline 0 N--CA 1.487 1.417 0 O-C-N 121.727 -0.608 . . . . 0.0 109.58 179.073 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -66.98 83.21 0.33 Allowed 'Trans proline' 0 C--N 1.309 -1.542 0 O-C-N 123.668 1.351 . . . . 0.0 110.554 -179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.43 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 4.3 m-80 -172.73 -36.99 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.635 -0.666 . . . . 0.0 109.765 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.842 HG12 HG23 ' A' ' 122' ' ' THR . 20.7 mt -95.16 128.19 46.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.209 -0.932 . . . . 0.0 109.527 179.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 -84.16 128.13 34.36 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.194 -0.941 . . . . 0.0 108.963 178.84 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -89.29 134.72 33.94 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.111 -0.993 . . . . 0.0 110.091 -179.258 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.544 HG11 ' HE ' ' A' ' 131' ' ' ARG . 5.6 t -128.69 157.69 41.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.385 -0.822 . . . . 0.0 110.195 -179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 113.76 27.34 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.291 -0.88 . . . . 0.0 110.079 179.698 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.751 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.2 tp -53.75 143.96 19.36 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.292 -0.88 . . . . 0.0 110.06 179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.8 p -139.41 170.18 16.39 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.162 -0.961 . . . . 0.0 110.373 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 20.7 p -72.89 81.6 1.18 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.246 -0.909 . . . . 0.0 109.783 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.824 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.5 m -158.31 111.46 2.39 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.217 -0.927 . . . . 0.0 110.815 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.25 -170.4 30.23 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 118.865 -1.636 . . . . 0.0 111.104 179.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -111.71 -19.14 12.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.775 -0.838 . . . . 0.0 110.032 179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.881 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -99.9 104.01 25.84 Favored Pre-proline 0 N--CA 1.49 1.528 0 C-N-CA 118.955 -1.098 . . . . 0.0 109.829 179.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.441 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.7 Cg_endo -63.1 125.92 16.83 Favored 'Trans proline' 0 C--N 1.312 -1.375 0 O-C-N 123.236 1.124 . . . . 0.0 111.027 -179.204 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 5.1 t80 -112.96 -169.57 1.51 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.733 -0.604 . . . . 0.0 110.325 -179.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.499 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 40.1 m-85 -59.44 82.28 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.295 -0.878 . . . . 0.0 111.423 -179.481 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.41 0.21 61.72 Favored Glycine 0 N--CA 1.494 2.515 0 C-N-CA 120.155 -1.021 . . . . 0.0 110.619 179.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.751 ' CB ' HD23 ' A' ' 15' ' ' LEU . 26.6 mmtt -129.9 156.56 44.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 120.864 -1.374 . . . . 0.0 109.636 179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.824 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -107.36 107.12 17.88 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 120.974 -1.079 . . . . 0.0 108.974 179.598 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.881 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.4 mt -70.3 113.24 16.49 Favored Pre-proline 0 C--N 1.299 -1.588 0 C-N-CA 119.646 -0.821 . . . . 0.0 110.716 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.705 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -69.66 130.81 20.11 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 N-CA-C 106.779 -2.047 . . . . 0.0 106.779 175.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.595 HD11 HD12 ' A' ' 58' ' ' LEU . 9.7 mt -56.06 -18.63 10.18 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.8 -1.187 . . . . 0.0 110.488 -177.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.431 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 1.2 pp20? -58.99 -16.04 16.12 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.85 -1.156 . . . . 0.0 110.572 179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.039 HG23 HG23 ' A' ' 33' ' ' ILE . 9.5 m -93.92 -25.32 4.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.853 0 O-C-N 120.92 -1.112 . . . . 0.0 110.965 -179.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.039 HG23 HG23 ' A' ' 32' ' ' VAL . 27.1 pt -117.92 -14.94 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 120.944 -1.098 . . . . 0.0 110.98 -179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.55 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -98.55 148.05 24.16 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.836 -1.165 . . . . 0.0 110.411 179.689 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.68 -4.38 50.23 Favored Glycine 0 N--CA 1.483 1.826 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 -179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.99 -149.02 7.23 Favored Glycine 0 N--CA 1.492 2.41 0 C-N-CA 118.994 -1.574 . . . . 0.0 110.581 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 5.2 mtt85 -110.03 132.55 54.06 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.446 -1.032 . . . . 0.0 110.216 -179.614 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.567 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.7 m80 -139.91 150.47 44.62 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.161 -0.962 . . . . 0.0 110.895 -179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.659 HD12 ' O ' ' A' ' 82' ' ' VAL . 51.4 tp -110.93 115.23 29.14 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.408 -0.808 . . . . 0.0 110.021 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.953 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.7 mm -96.11 125.41 48.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.226 -0.922 . . . . 0.0 109.067 179.46 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.547 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 33.8 m-85 -95.0 122.77 37.99 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 121.105 -0.997 . . . . 0.0 109.871 179.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.65 159.36 23.07 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.344 -0.847 . . . . 0.0 110.397 -179.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.499 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.7 p80 -107.47 -2.58 20.31 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.35 -0.844 . . . . 0.0 110.038 179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 10.3 p -132.83 139.17 47.35 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.101 -0.999 . . . . 0.0 110.465 179.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.411 ' HE3' ' CE1' ' A' ' 66' ' ' TYR . 3.4 tttm -70.58 -34.11 71.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.469 -0.769 . . . . 0.0 110.418 -179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.2 mtpt -62.47 -34.12 76.19 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.288 -0.882 . . . . 0.0 110.34 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.464 ' HD2' ' CZ ' ' A' ' 24' ' ' TYR . 0.3 OUTLIER -74.04 -36.37 64.4 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.236 -0.915 . . . . 0.0 109.65 179.789 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.81 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 65.0 m -61.0 -39.19 88.74 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.537 -0.727 . . . . 0.0 109.489 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.5 -46.63 87.55 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.295 -0.878 . . . . 0.0 110.029 179.663 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.44 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 2.4 mt-10 -71.37 -45.52 62.66 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.397 -0.815 . . . . 0.0 110.452 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.014 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.39 -45.02 80.78 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.348 -0.845 . . . . 0.0 111.163 -178.979 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.475 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -71.74 -51.59 22.02 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.987 -1.071 . . . . 0.0 110.387 -179.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.46 -42.27 99.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.156 -0.965 . . . . 0.0 109.75 179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.563 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.47 -46.79 85.9 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.268 -0.895 . . . . 0.0 109.671 179.602 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.845 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.21 -43.49 78.59 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.661 -0.649 . . . . 0.0 110.17 179.842 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 50.4 t -55.51 -32.63 30.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.453 0 O-C-N 121.161 -0.962 . . . . 0.0 109.04 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.54 -31.09 59.94 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.311 -0.868 . . . . 0.0 109.84 179.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.595 HD12 HD11 ' A' ' 30' ' ' LEU . 3.9 mm? -72.09 -26.46 62.16 Favored 'General case' 0 N--CA 1.49 1.536 0 CA-C-O 121.875 0.845 . . . . 0.0 109.808 179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.92 4.59 10.27 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.195 -1.562 . . . . 0.0 109.195 -179.043 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.554 HG22 HG22 ' A' ' 81' ' ' VAL . 28.2 mt -105.5 143.35 16.8 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.381 0 O-C-N 121.348 -1.089 . . . . 0.0 110.071 -179.735 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.774 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.7 t-20 -88.03 106.06 17.89 Favored 'General case' 0 C--N 1.307 -1.278 0 N-CA-C 106.6 -1.63 . . . . 0.0 106.6 178.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.719 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.25 143.08 46.28 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 119.053 -1.059 . . . . 0.0 111.258 -177.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.904 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.2 t -129.36 139.61 51.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.688 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.79 179.651 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.81 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -101.31 122.74 44.25 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.099 -1.04 . . . . 0.0 109.18 178.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' CB ' ' HB2' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -115.05 134.9 54.78 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.276 -0.89 . . . . 0.0 111.136 -178.931 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.897 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -168.9 170.67 8.93 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.562 -0.711 . . . . 0.0 109.677 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -51.72 118.33 3.31 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.205 -0.935 . . . . 0.0 110.789 -179.428 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 90.86 37.32 6.43 Favored Glycine 0 N--CA 1.493 2.462 0 N-CA-C 109.606 -1.397 . . . . 0.0 109.606 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.897 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.74 155.41 30.04 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.287 -1.125 . . . . 0.0 110.201 -179.715 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.829 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.3 m-20 -91.81 149.56 21.52 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.319 -0.863 . . . . 0.0 110.583 -179.494 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.7 m -62.14 110.9 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.044 -1.035 . . . . 0.0 109.4 179.313 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.71 ' O ' HG23 ' A' ' 74' ' ' ILE . 19.5 m -133.23 -39.28 0.93 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.466 -0.772 . . . . 0.0 110.204 -179.686 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.904 ' HA ' HG21 ' A' ' 63' ' ' VAL . 79.2 t -47.61 133.06 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.446 -0.784 . . . . 0.0 110.034 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.774 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.0 OUTLIER -136.04 99.08 11.32 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 121.131 -0.98 . . . . 0.0 110.843 -179.484 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -84.46 48.02 2.33 Favored 'Trans proline' 0 C--N 1.31 -1.488 0 O-C-N 123.762 1.401 . . . . 0.0 109.988 179.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.6 p -148.1 40.38 0.96 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.202 -0.936 . . . . 0.0 110.345 -179.217 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.0 m120 -143.77 -165.45 2.11 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.14 -0.975 . . . . 0.0 110.285 -179.829 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -50.32 -77.04 0.14 Allowed Glycine 0 N--CA 1.494 2.544 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.1 m-20 -147.97 113.41 5.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.163 -1.198 . . . . 0.0 110.407 179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -117.69 134.04 62.56 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 CA-C-O 122.084 0.945 . . . . 0.0 110.076 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.554 HG22 HG22 ' A' ' 60' ' ' ILE . 16.9 m -113.26 122.67 67.82 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.317 0 O-C-N 121.45 -0.781 . . . . 0.0 108.991 179.343 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 1.029 HG11 HD13 ' A' ' 88' ' ' LEU . 12.2 t -96.92 118.54 43.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 120.708 -1.245 . . . . 0.0 111.098 -177.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.014 HG11 HD12 ' A' ' 51' ' ' LEU . 4.4 m -108.7 99.71 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.046 -1.034 . . . . 0.0 108.855 178.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -135.78 155.96 49.54 Favored 'General case' 0 C--N 1.299 -1.628 0 O-C-N 120.485 -1.384 . . . . 0.0 110.855 -178.471 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.514 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.9 t -84.19 -42.44 15.95 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.372 -0.83 . . . . 0.0 110.386 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.514 ' N ' HG23 ' A' ' 85' ' ' THR . 0.6 OUTLIER -179.2 32.5 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.222 -0.924 . . . . 0.0 110.317 179.972 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.674 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -103.15 -31.0 10.35 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.156 -0.965 . . . . 0.0 110.042 -179.906 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 1.029 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -69.58 -16.13 63.35 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.205 -0.934 . . . . 0.0 110.072 179.414 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.425 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 16.8 mmt 53.23 -165.01 0.08 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.272 -0.893 . . . . 0.0 109.892 -179.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.493 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 0.7 OUTLIER -136.51 30.11 2.92 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.192 -0.942 . . . . 0.0 110.038 179.935 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.31 -42.09 94.25 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.541 -1.424 . . . . 0.0 109.541 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.2 p90 -121.24 14.94 11.37 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.221 -1.164 . . . . 0.0 110.667 -179.837 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.493 ' CG2' ' HA ' ' A' ' 90' ' ' THR . 6.6 t -80.38 -157.68 0.16 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.056 -1.028 . . . . 0.0 110.182 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.422 ' N ' HG23 ' A' ' 93' ' ' THR . . . 102.8 -32.84 7.11 Favored Glycine 0 N--CA 1.49 2.236 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.268 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -83.81 56.79 3.81 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.113 -1.227 . . . . 0.0 110.471 -179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.485 ' CE1' ' OG1' ' A' ' 93' ' ' THR . 16.8 m-85 -119.91 149.77 41.57 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.144 -0.973 . . . . 0.0 110.056 179.422 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.433 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 3.8 m-20 -83.95 -31.46 25.56 Favored 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.408 -0.807 . . . . 0.0 109.599 179.536 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.42 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.5 p -162.27 163.42 28.15 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.239 -0.913 . . . . 0.0 111.488 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.462 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -126.69 117.75 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.971 0 O-C-N 121.491 -0.756 . . . . 0.0 109.632 178.755 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.881 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -97.57 117.18 41.84 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.855 0 O-C-N 121.2 -0.937 . . . . 0.0 109.453 179.896 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.426 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 4.8 t0 -129.82 161.31 31.05 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.08 -1.013 . . . . 0.0 111.641 -178.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 52.8 t -92.03 -7.41 48.89 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.62 -0.675 . . . . 0.0 109.554 177.975 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.24 13.42 1.67 Allowed 'General case' 0 N--CA 1.497 1.879 0 O-C-N 121.227 -0.92 . . . . 0.0 111.893 179.692 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.456 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.6 m -143.85 121.68 11.97 Favored 'General case' 0 C--N 1.306 -1.316 0 O-C-N 120.754 -1.216 . . . . 0.0 109.395 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.441 ' N ' ' O ' ' A' ' 108' ' ' LYS . 12.5 p -98.85 132.83 43.89 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.173 -0.954 . . . . 0.0 110.398 -179.863 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 4.8 t0 51.13 30.17 5.37 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.308 -0.87 . . . . 0.0 110.608 179.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.98 -28.87 8.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 110.001 -1.239 . . . . 0.0 110.001 179.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.456 ' O ' HG23 ' A' ' 104' ' ' THR . 0.0 OUTLIER -80.89 155.39 72.97 Favored Pre-proline 0 N--CA 1.492 1.63 0 O-C-N 121.055 -1.262 . . . . 0.0 109.983 179.857 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -66.09 136.75 45.66 Favored 'Trans proline' 0 C--N 1.308 -1.556 0 O-C-N 123.578 1.304 . . . . 0.0 110.693 -179.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.8 pt20 -49.99 154.85 1.02 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.51 -0.744 . . . . 0.0 110.786 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.494 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -80.83 159.04 25.19 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.315 -0.866 . . . . 0.0 109.876 179.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.416 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.67 -50.89 17.07 Favored 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.313 -0.867 . . . . 0.0 111.863 -178.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.494 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.1 m -69.72 -28.43 37.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.672 0 O-C-N 120.827 -1.171 . . . . 0.0 111.427 -178.732 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.439 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.24 -56.59 6.45 Favored 'General case' 0 N--CA 1.498 1.966 0 O-C-N 121.0 -1.063 . . . . 0.0 110.446 -179.16 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.418 ' O ' ' HB3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.75 -35.01 76.55 Favored 'General case' 0 N--CA 1.487 1.383 0 O-C-N 121.233 -0.917 . . . . 0.0 108.872 178.738 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.505 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -59.92 -46.7 88.52 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 48.3 tt0 -73.58 -40.41 63.91 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.639 -0.663 . . . . 0.0 109.809 178.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 16.1 mtt180 -69.68 -44.18 71.0 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.29 -0.882 . . . . 0.0 110.338 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.522 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -56.55 -43.76 80.24 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.357 -0.839 . . . . 0.0 109.997 179.654 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.66 73.0 0.11 Allowed Glycine 0 N--CA 1.493 2.436 0 N-CA-C 109.912 -1.275 . . . . 0.0 109.912 -179.668 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 12.1 mmt-85 -149.75 -46.45 0.13 Allowed 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.542 -0.975 . . . . 0.0 108.766 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.842 HG23 HG12 ' A' ' 10' ' ' ILE . 15.2 t -97.16 141.87 29.76 Favored 'General case' 0 N--CA 1.488 1.439 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 123.25 17.13 3.35 Favored Glycine 0 N--CA 1.489 2.208 0 C-N-CA 119.155 -1.498 . . . . 0.0 110.597 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.492 ' CD ' ' N ' ' A' ' 124' ' ' ARG . 0.1 OUTLIER -90.12 81.71 6.14 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.863 -1.375 . . . . 0.0 110.033 -179.769 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.51 -52.1 0.7 Allowed Glycine 0 N--CA 1.492 2.396 0 N-CA-C 108.296 -1.922 . . . . 0.0 108.296 -179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.482 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -116.93 176.58 1.5 Allowed Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 121.75 -0.853 . . . . 0.0 109.143 179.289 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.43 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.4 Cg_endo -73.15 112.87 3.63 Favored 'Trans proline' 0 C--N 1.308 -1.554 0 N-CA-C 108.84 -1.254 . . . . 0.0 108.84 178.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.474 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -73.03 177.88 41.48 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.78 -1.328 . . . . 0.0 109.78 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.42 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.2 mt -135.21 142.76 38.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.204 -1.174 . . . . 0.0 109.693 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.462 ' HA ' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -124.82 114.52 19.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 119.111 -1.036 . . . . 0.0 110.035 178.736 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.544 ' HE ' HG11 ' A' ' 13' ' ' VAL . 3.8 mtt85 -105.97 122.76 46.8 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.516 -0.74 . . . . 0.0 109.319 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.426 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 11.0 p90 -122.96 157.84 31.75 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.08 -1.012 . . . . 0.0 110.471 -179.56 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.442 HG22 HD23 ' A' ' 15' ' ' LEU . 37.8 t -77.19 -40.9 30.29 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.189 -0.945 . . . . 0.0 109.729 179.588 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -131.39 144.02 51.68 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.309 -0.869 . . . . 0.0 110.054 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -75.45 -55.73 0.07 OUTLIER 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.585 1.308 . . . . 0.0 110.603 -179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 124.71 -91.33 0.41 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 -179.958 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 54.01 68.16 0.89 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.233 -1.157 . . . . 0.0 110.147 179.974 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.182 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 11.3 p -115.21 157.16 24.08 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -1.183 . . . . 0.0 110.175 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 45.9 t -112.95 104.48 17.1 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.3 -0.875 . . . . 0.0 109.67 179.503 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.6 p -66.68 136.96 56.32 Favored 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.415 -0.803 . . . . 0.0 110.517 -179.703 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.445 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.99 149.03 89.63 Favored Pre-proline 0 C--N 1.303 -1.442 0 O-C-N 121.341 -0.849 . . . . 0.0 109.289 179.228 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.445 ' HD2' HG23 ' A' ' 5' ' ' VAL . 50.6 Cg_endo -80.22 -165.56 0.35 Allowed 'Trans proline' 0 C--N 1.307 -1.617 0 O-C-N 124.027 1.54 . . . . 0.0 111.376 179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.502 ' NE2' ' NE ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.03 83.35 0.04 OUTLIER Pre-proline 0 N--CA 1.495 1.8 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 179.817 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.16 60.73 0.47 Allowed 'Trans proline' 0 C--N 1.311 -1.43 0 O-C-N 123.909 1.479 . . . . 0.0 111.953 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 19.5 m-80 -131.92 2.6 4.02 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.481 -0.762 . . . . 0.0 109.925 178.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.469 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 11.7 mt -128.47 137.67 56.73 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 120.964 -1.085 . . . . 0.0 109.351 179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 43.3 tt0 -82.66 128.18 34.1 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.122 -0.986 . . . . 0.0 109.405 179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -89.52 127.98 35.93 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.134 -0.979 . . . . 0.0 110.202 -179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.819 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 15.8 t -122.98 155.38 28.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.287 -0.883 . . . . 0.0 110.191 -179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.06 110.5 22.64 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.315 -0.865 . . . . 0.0 109.88 179.683 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.539 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.8 tp -56.65 134.72 54.81 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.256 -0.902 . . . . 0.0 110.004 -179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.7 p -135.37 171.53 14.31 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.217 -0.927 . . . . 0.0 110.19 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.55 69.99 0.17 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.216 -0.927 . . . . 0.0 110.119 -179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.582 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.5 m -140.55 112.29 7.52 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.313 -0.867 . . . . 0.0 110.41 -179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.72 -163.26 26.94 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.101 -1.523 . . . . 0.0 110.552 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 -119.17 -22.4 7.19 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.62 -0.93 . . . . 0.0 110.479 179.884 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.944 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.0 tt -97.38 107.11 36.82 Favored Pre-proline 0 N--CA 1.49 1.552 0 O-C-N 120.856 -1.153 . . . . 0.0 110.295 -179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.493 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.6 Cg_endo -63.92 157.62 51.63 Favored 'Trans proline' 0 C--N 1.312 -1.384 0 O-C-N 123.334 1.176 . . . . 0.0 110.118 179.939 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.578 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 80.5 t80 -170.54 93.7 0.2 Allowed 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.188 -0.945 . . . . 0.0 110.947 -178.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.578 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 23.4 m-85 60.27 68.55 0.76 Allowed 'General case' 0 N--CA 1.5 2.061 0 O-C-N 121.541 -0.724 . . . . 0.0 111.259 179.564 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 55.79 15.33 9.14 Favored Glycine 0 N--CA 1.493 2.494 0 N-CA-C 110.369 -1.093 . . . . 0.0 110.369 179.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.539 ' CB ' HD23 ' A' ' 15' ' ' LEU . 5.2 mmpt? -130.67 156.2 45.31 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.017 -1.284 . . . . 0.0 109.241 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.582 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.53 15.17 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 120.983 -1.073 . . . . 0.0 109.352 179.608 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.944 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.84 113.84 20.48 Favored Pre-proline 0 C--N 1.298 -1.656 0 O-C-N 121.421 -0.799 . . . . 0.0 110.684 -179.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.795 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.9 Cg_endo -70.14 130.81 19.5 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 N-CA-C 106.455 -2.171 . . . . 0.0 106.455 175.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.662 HD22 ' CD1' ' A' ' 60' ' ' ILE . 8.1 mt -55.87 -18.45 8.86 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 120.762 -1.211 . . . . 0.0 110.522 -177.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.487 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -59.75 -16.1 24.97 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.788 -1.195 . . . . 0.0 110.511 179.666 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.092 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.06 -25.06 5.25 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.856 0 O-C-N 120.958 -1.089 . . . . 0.0 110.918 -179.692 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.092 HG23 HG23 ' A' ' 32' ' ' VAL . 42.1 pt -117.11 -17.44 7.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 121.07 -1.018 . . . . 0.0 110.606 -179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 22.2 tptt -96.75 148.45 22.88 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 120.958 -1.089 . . . . 0.0 110.29 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.06 -7.53 27.21 Favored Glycine 0 N--CA 1.485 1.902 0 N-CA-C 109.371 -1.492 . . . . 0.0 109.371 -179.565 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 175.54 -136.01 3.21 Favored Glycine 0 N--CA 1.492 2.369 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.343 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.436 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.9 mtt180 -112.02 129.97 56.02 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.336 -1.096 . . . . 0.0 110.239 -179.73 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.597 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.0 m-70 -136.66 146.9 46.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.037 -1.039 . . . . 0.0 110.99 -179.834 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.445 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 36.6 tp -109.56 115.63 30.27 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.506 -0.746 . . . . 0.0 110.255 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.951 HD12 ' CG1' ' A' ' 83' ' ' VAL . 35.9 mt -98.97 127.65 51.38 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 O-C-N 121.219 -0.926 . . . . 0.0 109.465 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.2 m-85 -94.91 122.65 37.76 Favored 'General case' 0 C--N 1.297 -1.714 0 O-C-N 121.533 -0.729 . . . . 0.0 110.503 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.5 155.16 31.32 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.305 -0.872 . . . . 0.0 110.594 179.681 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.528 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 31.4 p80 -109.26 8.15 25.59 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.301 -0.874 . . . . 0.0 109.5 178.354 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -134.92 135.93 41.92 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.194 -0.941 . . . . 0.0 110.324 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.532 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.9 -42.39 66.79 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.558 -0.714 . . . . 0.0 110.835 -179.72 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -58.64 -36.49 74.18 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.318 -0.864 . . . . 0.0 110.43 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.415 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -72.27 -36.32 68.97 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.415 -0.803 . . . . 0.0 109.828 -179.781 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 2.2 m -60.88 -34.0 73.97 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.353 -0.842 . . . . 0.0 109.803 179.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -69.37 -49.35 56.3 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.266 -0.896 . . . . 0.0 110.647 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.406 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 10.2 mt-10 -71.53 -43.8 65.78 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.209 -0.932 . . . . 0.0 110.419 -179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.684 HD12 HG11 ' A' ' 83' ' ' VAL . 1.5 tm? -56.37 -41.11 75.64 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.422 -0.798 . . . . 0.0 110.913 -179.175 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.23 -51.45 13.28 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.957 -1.089 . . . . 0.0 110.342 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.69 -43.91 97.95 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.026 -1.046 . . . . 0.0 109.587 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.516 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -56.83 -43.81 81.43 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.31 -0.869 . . . . 0.0 109.561 179.517 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.883 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.48 -42.91 75.04 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.436 -0.79 . . . . 0.0 109.672 179.61 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.7 t -55.79 -30.83 28.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.153 -0.967 . . . . 0.0 108.696 179.124 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.481 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -76.15 -33.34 59.39 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.602 -0.686 . . . . 0.0 110.103 179.16 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.568 ' HB3' HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.75 -26.34 62.41 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.324 -0.86 . . . . 0.0 109.615 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.94 5.65 8.07 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 -179.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.662 ' CD1' HD22 ' A' ' 30' ' ' LEU . 19.8 mt -108.26 143.57 18.42 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.248 -1.148 . . . . 0.0 110.291 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 19.5 t30 -86.1 107.36 17.8 Favored 'General case' 0 N--CA 1.486 1.327 0 N-CA-C 106.865 -1.532 . . . . 0.0 106.865 178.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.627 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.0 146.89 46.72 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.003 -1.079 . . . . 0.0 112.073 -177.146 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.95 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.2 t -135.89 150.29 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 178.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.67 131.89 55.44 Favored 'General case' 0 C--N 1.301 -1.54 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.2 179.474 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.483 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.8 t80 -120.88 123.44 42.53 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.179 -0.95 . . . . 0.0 110.716 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.847 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.1 p90 -155.22 178.37 10.29 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.487 -0.758 . . . . 0.0 109.619 179.58 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 56.1 ttt180 -52.34 128.1 24.31 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.035 -1.041 . . . . 0.0 110.669 -179.386 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 76.32 39.23 31.75 Favored Glycine 0 N--CA 1.492 2.432 0 N-CA-C 110.083 -1.207 . . . . 0.0 110.083 179.483 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.972 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -116.99 155.68 28.76 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.132 -1.216 . . . . 0.0 109.774 179.785 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.972 ' N ' HD13 ' A' ' 69' ' ' LEU . 27.0 m-20 -95.44 149.11 21.76 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 121.273 -0.892 . . . . 0.0 110.882 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.8 m -62.18 111.36 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.073 -1.017 . . . . 0.0 108.861 178.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.771 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.2 m -134.28 -36.01 0.91 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.262 -0.899 . . . . 0.0 110.909 -179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.95 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.5 t -50.96 134.71 11.64 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.211 -0.931 . . . . 0.0 109.876 -179.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.771 HG23 ' O ' ' A' ' 72' ' ' SER . 1.8 pp -136.94 109.54 9.15 Favored Pre-proline 0 N--CA 1.495 1.78 0 O-C-N 121.247 -0.908 . . . . 0.0 110.893 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.635 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.2 Cg_endo -86.94 46.82 1.51 Allowed 'Trans proline' 0 C--N 1.312 -1.379 0 O-C-N 123.466 1.245 . . . . 0.0 110.247 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 63.3 p -129.85 -9.48 4.43 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.069 -1.02 . . . . 0.0 111.438 -179.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -88.92 -171.92 3.49 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.921 -1.112 . . . . 0.0 110.341 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.13 -80.19 0.07 OUTLIER Glycine 0 N--CA 1.493 2.445 0 N-CA-C 109.472 -1.451 . . . . 0.0 109.472 179.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 48.5 m-20 -130.81 114.44 15.32 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.188 -1.184 . . . . 0.0 110.053 179.596 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.635 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -116.85 134.99 58.66 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 122.009 0.909 . . . . 0.0 109.88 -179.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 16.0 m -113.37 124.49 70.05 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.316 0 O-C-N 121.377 -0.827 . . . . 0.0 109.479 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.752 HG22 ' CG1' ' A' ' 73' ' ' VAL . 5.7 t -97.42 117.3 41.86 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 O-C-N 121.124 -0.985 . . . . 0.0 109.948 -178.621 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.951 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -112.14 100.07 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 120.995 -1.065 . . . . 0.0 108.587 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.483 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.92 162.23 35.68 Favored 'General case' 0 C--N 1.297 -1.713 0 O-C-N 120.706 -1.246 . . . . 0.0 110.957 -178.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.501 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.6 t -91.34 -133.14 0.12 Allowed 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.619 -0.675 . . . . 0.0 109.263 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.501 ' N ' HG23 ' A' ' 85' ' ' THR . 46.6 p-10 -88.4 43.3 1.12 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 120.663 -1.273 . . . . 0.0 110.369 179.674 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.473 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -115.76 -30.3 6.16 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.103 -0.998 . . . . 0.0 110.174 179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.446 ' O ' ' N ' ' A' ' 90' ' ' THR . 2.2 tp -68.86 -29.15 67.4 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.027 -1.045 . . . . 0.0 109.288 179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.464 ' C ' HG22 ' A' ' 90' ' ' THR . 0.8 OUTLIER 55.62 -85.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.827 -0.546 . . . . 0.0 110.444 179.866 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.557 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.3 OUTLIER 173.62 43.16 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.968 0 O-C-N 121.023 -1.048 . . . . 0.0 110.214 -179.966 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -56.91 -46.81 90.37 Favored Glycine 0 N--CA 1.49 2.3 0 N-CA-C 108.776 -1.73 . . . . 0.0 108.776 179.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -138.22 28.18 2.55 Favored 'General case' 0 N--CA 1.486 1.373 0 O-C-N 121.423 -1.045 . . . . 0.0 110.138 179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.575 ' HG1' ' HE1' ' A' ' 96' ' ' PHE . 3.1 t -86.29 -160.38 0.55 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.204 -0.935 . . . . 0.0 110.413 -179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.482 ' N ' HG23 ' A' ' 93' ' ' THR . . . 100.48 -31.83 8.07 Favored Glycine 0 N--CA 1.488 2.142 0 N-CA-C 110.206 -1.158 . . . . 0.0 110.206 179.237 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 32.1 t0 -107.48 73.92 0.94 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 120.859 -1.377 . . . . 0.0 111.172 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.575 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 25.6 m-85 -119.72 153.2 36.0 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.005 -1.06 . . . . 0.0 110.147 178.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.9 -27.06 25.24 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.438 -0.789 . . . . 0.0 109.537 179.402 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.432 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.8 p -162.48 163.65 27.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.252 -0.905 . . . . 0.0 111.468 -179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.486 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -134.0 126.26 49.91 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.978 0 O-C-N 121.436 -0.79 . . . . 0.0 109.712 179.095 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.908 HG21 HD11 ' A' ' 28' ' ' ILE . 2.8 mp -105.58 111.54 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 121.094 -1.004 . . . . 0.0 109.125 179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.41 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -121.54 161.02 23.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.235 -0.916 . . . . 0.0 111.562 -178.863 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.442 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 48.4 t -96.27 -6.9 36.86 Favored 'General case' 0 C--N 1.302 -1.496 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 177.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER 57.8 11.01 1.22 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.369 -0.832 . . . . 0.0 112.225 179.691 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.563 HG23 ' C ' ' A' ' 107' ' ' GLY . 0.9 OUTLIER -147.38 126.25 12.72 Favored 'General case' 0 C--N 1.309 -1.157 0 O-C-N 120.58 -1.325 . . . . 0.0 109.514 179.84 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.461 ' N ' ' O ' ' A' ' 108' ' ' LYS . 24.6 p -100.57 129.26 46.48 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.206 -0.934 . . . . 0.0 110.172 179.724 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 57.36 29.06 16.26 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.221 -0.924 . . . . 0.0 110.566 -179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.563 ' C ' HG23 ' A' ' 104' ' ' THR . . . 94.76 -30.56 7.78 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 179.515 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.461 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -82.51 155.4 68.81 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.153 -1.204 . . . . 0.0 110.206 -179.863 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_endo -64.7 137.45 54.17 Favored 'Trans proline' 0 C--N 1.307 -1.651 0 O-C-N 123.555 1.292 . . . . 0.0 110.492 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.43 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 5.5 pt20 -51.3 163.65 0.23 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.443 -0.786 . . . . 0.0 110.963 -179.294 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.54 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.2 p30 -83.54 161.36 21.23 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.308 -0.87 . . . . 0.0 110.07 179.69 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.44 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -61.89 1.24 Allowed 'General case' 0 N--CA 1.498 1.937 0 O-C-N 121.416 -0.803 . . . . 0.0 112.152 -178.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.54 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.1 m -60.43 -29.31 44.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.849 0 O-C-N 120.742 -1.223 . . . . 0.0 111.684 -178.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.17 -56.52 6.48 Favored 'General case' 0 N--CA 1.498 1.967 0 O-C-N 121.027 -1.045 . . . . 0.0 110.754 -178.808 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.44 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.94 -34.02 76.86 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.088 -1.008 . . . . 0.0 108.673 178.928 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 14.1 m -60.47 -50.02 75.24 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 178.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.6 tt0 -74.31 -38.27 63.38 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.462 -0.774 . . . . 0.0 110.146 179.032 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 10.8 mtt85 -71.21 -44.32 65.61 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.155 -0.966 . . . . 0.0 111.103 -179.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.502 ' NE ' ' NE2' ' A' ' 7' ' ' HIS . 11.8 ttp180 -70.41 -40.02 74.12 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 120.967 -1.083 . . . . 0.0 110.006 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -69.95 63.35 0.71 Allowed Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 -179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -137.15 -45.94 0.57 Allowed 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.195 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.47 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.2 t -95.18 142.27 27.81 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.106 -0.702 . . . . 0.0 109.106 178.33 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.468 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 91.26 17.23 51.2 Favored Glycine 0 N--CA 1.484 1.869 0 C-N-CA 119.524 -1.322 . . . . 0.0 110.361 178.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -52.0 -37.86 54.74 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.019 -1.283 . . . . 0.0 109.73 179.678 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -136.01 28.55 2.93 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 108.461 -1.856 . . . . 0.0 108.461 179.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.476 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 14.4 ptmt -173.58 -168.31 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.681 -0.893 . . . . 0.0 109.121 -179.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.478 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.2 Cg_endo -86.63 96.39 0.51 Allowed 'Trans proline' 0 C--N 1.311 -1.424 0 O-C-N 123.172 1.091 . . . . 0.0 110.58 179.576 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.47 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.14 157.67 41.25 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.028 -1.229 . . . . 0.0 110.028 179.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.432 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -106.79 141.58 21.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.054 -1.263 . . . . 0.0 109.133 178.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.486 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.9 t80 -130.09 114.81 16.21 Favored 'General case' 0 C--N 1.301 -1.531 0 C-N-CA 119.095 -1.042 . . . . 0.0 110.223 179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.819 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -101.48 122.16 43.28 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.407 -0.808 . . . . 0.0 109.666 179.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.415 ' C ' ' CD1' ' A' ' 132' ' ' PHE . 14.2 p90 -120.26 154.59 34.72 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.343 -0.848 . . . . 0.0 109.908 -179.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.435 HG13 ' HG3' ' A' ' 26' ' ' LYS . 74.9 t -86.7 -41.3 14.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.157 -0.964 . . . . 0.0 110.192 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -101.47 111.6 63.99 Favored Pre-proline 0 N--CA 1.491 1.608 0 O-C-N 121.195 -0.941 . . . . 0.0 110.289 -179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -71.54 -46.67 0.59 Allowed 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.508 1.268 . . . . 0.0 110.341 179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 97.32 129.65 6.35 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 179.926 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 51.84 82.23 0.07 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.256 -1.143 . . . . 0.0 110.368 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.701 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.306 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.546 -1.422 . . . . 0.0 109.546 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -95.14 102.58 14.39 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.205 -1.174 . . . . 0.0 110.164 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.652 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.4 p -113.34 104.34 16.84 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.271 -0.893 . . . . 0.0 109.676 179.479 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.447 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.2 p -100.4 140.39 34.72 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.318 -0.864 . . . . 0.0 110.451 -179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.858 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -67.15 147.37 99.02 Favored Pre-proline 0 N--CA 1.492 1.644 0 O-C-N 121.374 -0.829 . . . . 0.0 109.108 179.596 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.6 Cg_endo -73.92 -19.56 20.55 Favored 'Trans proline' 0 C--N 1.31 -1.452 0 O-C-N 124.066 1.561 . . . . 0.0 113.101 -178.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.527 ' CD2' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p-80 42.78 75.77 0.6 Allowed Pre-proline 0 N--CA 1.502 2.175 0 O-C-N 121.384 -0.823 . . . . 0.0 110.713 -177.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.412 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 43.9 Cg_endo -71.01 -175.13 1.34 Allowed 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 123.753 1.397 . . . . 0.0 110.133 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 65.78 7.15 4.35 Favored 'General case' 0 N--CA 1.501 2.099 0 O-C-N 121.637 -0.664 . . . . 0.0 111.226 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.74 HG12 HG23 ' A' ' 122' ' ' THR . 0.7 OUTLIER -118.54 126.27 75.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.648 -1.282 . . . . 0.0 109.341 179.112 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -85.79 127.59 34.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.5 mt-10 -90.44 136.15 33.24 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.186 -0.946 . . . . 0.0 110.123 -179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.457 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 22.1 t -129.71 154.93 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.35 -0.844 . . . . 0.0 109.968 -179.602 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.47 112.88 25.98 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.155 -0.966 . . . . 0.0 110.392 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.617 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.9 tp -59.33 140.53 55.98 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.35 -0.844 . . . . 0.0 109.149 179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 53.4 p -140.32 -178.21 5.38 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.169 -0.957 . . . . 0.0 110.498 -179.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 71.4 p -77.0 59.89 1.73 Allowed 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.301 -0.874 . . . . 0.0 110.045 179.781 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.625 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 10.0 m -132.47 109.32 9.72 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.336 -0.852 . . . . 0.0 110.752 -179.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.21 -167.12 29.0 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.899 -1.619 . . . . 0.0 110.694 179.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 6.4 mm-40 -115.58 -18.84 10.81 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.701 -0.882 . . . . 0.0 110.328 -179.989 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.886 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -99.39 104.49 27.26 Favored Pre-proline 0 N--CA 1.49 1.567 0 C-N-CA 118.761 -1.175 . . . . 0.0 109.859 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.448 ' HD2' ' HE3' ' A' ' 54' ' ' LYS . 38.1 Cg_endo -63.57 128.53 22.55 Favored 'Trans proline' 0 C--N 1.313 -1.292 0 O-C-N 123.345 1.181 . . . . 0.0 111.014 -179.116 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.444 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.5 t80 -118.47 -165.97 1.18 Allowed 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.768 -0.582 . . . . 0.0 109.886 -179.47 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.519 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 71.0 m-85 -58.03 82.18 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.25 -0.906 . . . . 0.0 111.596 -179.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 73.13 0.45 52.32 Favored Glycine 0 N--CA 1.495 2.573 0 O-C-N 121.148 -0.97 . . . . 0.0 110.919 179.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.617 ' HB2' HD23 ' A' ' 15' ' ' LEU . 27.3 mmtp -130.49 157.02 43.78 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.868 -1.372 . . . . 0.0 109.565 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.625 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -108.27 107.71 18.42 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.979 -1.076 . . . . 0.0 109.456 -179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.891 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -67.13 113.48 13.78 Favored Pre-proline 0 C--N 1.3 -1.582 0 O-C-N 121.365 -0.835 . . . . 0.0 110.731 -179.327 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.815 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.6 Cg_endo -68.56 130.98 21.92 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 N-CA-C 106.867 -2.013 . . . . 0.0 106.867 176.016 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 10.6 mt -56.25 -17.61 8.05 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.804 -1.185 . . . . 0.0 110.706 -177.785 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -59.91 -16.36 29.01 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.669 -1.269 . . . . 0.0 110.527 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.058 HG23 HG23 ' A' ' 33' ' ' ILE . 13.6 m -93.11 -23.49 5.47 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 121.029 -1.044 . . . . 0.0 111.224 -179.562 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.058 HG23 HG23 ' A' ' 32' ' ' VAL . 18.9 pt -119.48 -21.45 4.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.952 -1.093 . . . . 0.0 110.625 -179.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.556 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -94.81 148.25 22.5 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.878 -1.139 . . . . 0.0 110.284 179.482 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.17 -3.91 60.32 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.583 -1.407 . . . . 0.0 109.583 -179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -178.33 -158.68 21.53 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.479 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.467 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.4 mpt_? -103.68 132.37 50.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.373 -1.075 . . . . 0.0 110.668 -179.59 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.561 ' CD2' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -139.81 147.04 40.19 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.225 -0.922 . . . . 0.0 110.52 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 11.8 tp -109.09 122.22 46.81 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.328 -0.857 . . . . 0.0 110.065 179.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.896 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.3 mm -100.53 126.04 54.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.292 -0.88 . . . . 0.0 109.191 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.464 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.2 m-85 -96.49 121.38 38.25 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.073 -1.017 . . . . 0.0 110.075 179.897 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -119.09 157.34 28.04 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.251 -0.905 . . . . 0.0 110.509 179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.519 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 34.1 p80 -102.85 4.13 37.4 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.274 -0.891 . . . . 0.0 110.074 178.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.5 p -131.98 135.37 46.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.035 -1.04 . . . . 0.0 110.473 179.887 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HD3' ' CD1' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -72.43 -31.42 65.46 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.663 -0.648 . . . . 0.0 110.934 -179.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -68.28 -32.77 73.16 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.33 -0.856 . . . . 0.0 110.859 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -73.51 -36.35 65.72 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.351 -0.843 . . . . 0.0 109.879 -179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.876 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.7 m -61.13 -38.55 86.8 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.373 -0.829 . . . . 0.0 109.538 179.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -65.36 -49.21 70.19 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.132 -0.98 . . . . 0.0 110.526 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.8 mm-40 -71.98 -46.31 57.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.213 -0.929 . . . . 0.0 110.619 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.784 HD21 HD11 ' A' ' 21' ' ' ILE . 3.0 tm? -56.76 -41.03 76.9 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.494 -0.754 . . . . 0.0 111.435 -178.732 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -66.38 -51.05 61.1 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.827 -1.17 . . . . 0.0 109.789 179.993 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.86 -32.45 69.46 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.237 -0.914 . . . . 0.0 109.345 179.253 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.85 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -61.72 -33.67 74.44 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.59 -0.694 . . . . 0.0 109.364 179.574 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.83 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -74.92 -42.42 57.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.405 -0.81 . . . . 0.0 110.407 -179.895 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 75.2 t -56.05 -33.06 35.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.043 -1.036 . . . . 0.0 109.185 179.575 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.39 -32.98 60.95 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.507 -0.746 . . . . 0.0 109.893 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.85 HD23 ' O ' ' A' ' 54' ' ' LYS 0.25 3.5 mm? -71.99 -26.32 62.19 Favored 'General case' 0 N--CA 1.488 1.43 0 CA-C-O 121.879 0.847 . . . . 0.0 109.959 -179.945 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.79 3.03 10.24 Favored Glycine 0 N--CA 1.492 2.405 0 N-CA-C 109.283 -1.527 . . . . 0.0 109.283 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.602 HG22 HG22 ' A' ' 81' ' ' VAL . 31.3 mt -103.85 143.96 14.92 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.409 0 O-C-N 121.373 -1.074 . . . . 0.0 109.96 -179.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HD11 ' A' ' 74' ' ' ILE . 35.1 t30 -88.61 106.86 18.6 Favored 'General case' 0 C--N 1.306 -1.317 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.559 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.91 145.27 44.78 Favored 'General case' 0 C--N 1.296 -1.719 0 C-N-CA 118.857 -1.137 . . . . 0.0 111.779 -177.242 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.868 HG21 ' HA ' ' A' ' 73' ' ' VAL . 70.7 t -129.23 152.7 37.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.062 -179.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.876 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -118.61 117.3 28.6 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.282 177.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.46 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -105.75 127.49 53.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.173 -0.954 . . . . 0.0 110.825 -179.253 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.929 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 10.0 p90 -155.57 -178.64 7.42 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.512 -0.743 . . . . 0.0 110.117 179.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.0 ttm180 -52.41 127.43 22.37 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.965 . . . . 0.0 110.843 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 68.21 53.11 23.64 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 110.216 -1.154 . . . . 0.0 110.216 179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.929 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.43 154.43 31.4 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.187 -1.184 . . . . 0.0 109.768 179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.834 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.7 m-20 -91.18 149.35 21.82 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.251 -0.905 . . . . 0.0 110.42 -179.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.2 m -61.65 110.67 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.046 179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.778 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.4 m -132.21 -38.76 1.07 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.493 -0.754 . . . . 0.0 109.965 -179.678 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.868 ' HA ' HG21 ' A' ' 63' ' ' VAL . 95.4 t -49.46 133.32 8.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.387 -0.821 . . . . 0.0 109.518 179.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -133.78 89.94 28.96 Favored Pre-proline 0 N--CA 1.493 1.722 0 O-C-N 120.97 -1.081 . . . . 0.0 110.423 179.999 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_endo -90.63 53.5 1.1 Allowed 'Trans proline' 0 C--N 1.312 -1.368 0 O-C-N 123.972 1.512 . . . . 0.0 110.582 179.634 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.1 t -125.66 -25.97 3.6 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.113 -0.992 . . . . 0.0 111.043 -179.735 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 56.4 m-80 -155.25 167.68 29.55 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.991 -1.068 . . . . 0.0 110.599 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 54.57 174.73 0.09 OUTLIER Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.8 m-20 -94.74 110.21 22.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.049 -1.265 . . . . 0.0 110.194 179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.561 HG11 ' O ' ' A' ' 74' ' ' ILE . 6.4 p -116.7 135.11 58.07 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.718 0 CA-C-O 122.005 0.907 . . . . 0.0 110.318 -179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.816 HG11 ' HB ' ' A' ' 33' ' ' ILE . 10.0 m -112.98 121.21 64.77 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.173 0 O-C-N 121.224 -0.922 . . . . 0.0 108.879 179.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.74 HG22 HG13 ' A' ' 73' ' ' VAL . 15.1 t -97.77 120.0 46.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.842 -1.162 . . . . 0.0 111.288 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.896 HG12 ' CG1' ' A' ' 40' ' ' ILE . 2.8 m -111.25 98.98 7.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 CA-C-O 122.324 1.059 . . . . 0.0 108.883 179.261 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.46 155.03 46.38 Favored 'General case' 0 C--N 1.298 -1.662 0 O-C-N 120.516 -1.365 . . . . 0.0 110.528 -178.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.529 HG23 ' N ' ' A' ' 86' ' ' ASP . 14.8 t -86.86 -43.68 12.27 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.221 -0.924 . . . . 0.0 110.639 -179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.529 ' N ' HG23 ' A' ' 85' ' ' THR . 0.2 OUTLIER -179.02 30.76 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.081 -1.012 . . . . 0.0 110.633 179.906 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.576 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -101.02 -33.96 9.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.149 -0.969 . . . . 0.0 109.023 179.349 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 5.3 tp -67.44 -42.27 83.39 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.566 -0.709 . . . . 0.0 109.339 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.51 ' HA ' ' HE2' ' A' ' 89' ' ' MET . 0.5 OUTLIER 49.71 23.45 0.99 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.531 -0.731 . . . . 0.0 110.447 179.957 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.93 HG23 ' HB ' ' A' ' 93' ' ' THR . 89.5 m 53.93 -85.53 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.505 -0.747 . . . . 0.0 110.708 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 65.13 -83.38 0.07 OUTLIER Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.422 ' N ' ' O ' ' A' ' 90' ' ' THR . 29.5 p90 -97.89 37.83 1.37 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.384 -1.068 . . . . 0.0 108.557 178.159 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.93 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -137.76 -168.75 2.39 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.307 0.575 . . . . 0.0 110.328 -179.282 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 133.02 -17.87 4.55 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -94.39 75.92 3.89 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.175 -1.191 . . . . 0.0 110.592 -179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.405 ' HZ ' HG21 ' A' ' 93' ' ' THR . 27.3 m-85 -113.45 150.86 32.19 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.195 -0.941 . . . . 0.0 109.812 179.46 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 7.3 m-20 -77.16 -32.6 56.37 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.376 179.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.458 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.2 p -161.42 163.08 30.76 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.299 -0.876 . . . . 0.0 111.16 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.563 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.21 113.27 21.25 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.889 0 O-C-N 121.356 -0.84 . . . . 0.0 110.051 179.235 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.891 HG21 HD11 ' A' ' 28' ' ' ILE . 3.3 mp -93.41 112.84 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.719 0 O-C-N 121.248 -0.908 . . . . 0.0 108.592 179.068 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.429 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 8.3 t0 -118.91 161.39 20.27 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.206 -0.933 . . . . 0.0 111.541 -178.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.437 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 58.5 m -88.88 -13.29 39.52 Favored 'General case' 0 C--N 1.299 -1.595 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 58.2 10.53 1.28 Allowed 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.331 -0.856 . . . . 0.0 112.074 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.496 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 0.9 OUTLIER -147.45 130.53 16.36 Favored 'General case' 0 C--N 1.306 -1.29 0 O-C-N 120.716 -1.24 . . . . 0.0 109.166 179.636 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.448 ' N ' ' O ' ' A' ' 108' ' ' LYS . 86.3 p -107.58 134.92 49.89 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.105 -0.997 . . . . 0.0 110.545 -179.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 35.5 t0 55.98 32.86 20.66 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.31 -0.868 . . . . 0.0 110.94 179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 79.39 12.46 83.81 Favored Glycine 0 N--CA 1.492 2.417 0 N-CA-C 110.214 -1.155 . . . . 0.0 110.214 179.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.496 ' O ' ' HA ' ' A' ' 104' ' ' THR . 0.1 OUTLIER -123.44 156.05 64.59 Favored Pre-proline 0 N--CA 1.49 1.551 0 O-C-N 121.075 -1.25 . . . . 0.0 109.607 179.698 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -62.91 127.76 21.29 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.549 1.289 . . . . 0.0 110.716 -179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.454 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 7.1 pt20 -44.09 160.95 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.763 0 CA-C-O 121.431 0.634 . . . . 0.0 111.539 -179.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.533 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -87.47 160.83 18.13 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.434 -0.791 . . . . 0.0 110.352 179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.447 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.08 -55.29 3.26 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.641 -0.662 . . . . 0.0 112.551 -178.663 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.533 HG22 ' OD1' ' A' ' 111' ' ' ASP . 9.3 m -70.65 -29.66 39.05 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 120.73 -1.231 . . . . 0.0 111.8 -178.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.454 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.45 -56.34 7.2 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.13 -0.981 . . . . 0.0 110.525 -179.239 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.428 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -68.17 -35.13 77.54 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.262 -0.899 . . . . 0.0 108.754 178.95 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.858 HG23 HG13 ' A' ' 5' ' ' VAL . 99.4 m -59.09 -49.85 76.31 Favored 'General case' 0 N--CA 1.486 1.332 0 O-C-N 121.178 -0.951 . . . . 0.0 108.547 178.833 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 7.7 tt0 -73.26 -36.07 66.31 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.495 -0.753 . . . . 0.0 109.955 179.023 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.406 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 8.8 mtt85 -71.9 -44.94 62.88 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.237 -0.914 . . . . 0.0 111.138 -179.499 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.527 ' CD ' ' CD2' ' A' ' 7' ' ' HIS . 0.8 OUTLIER -64.38 -36.62 84.72 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.979 -1.076 . . . . 0.0 110.294 -179.867 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -70.16 63.41 0.76 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.448 ' HB3' HG11 ' A' ' 99' ' ' VAL . 0.0 OUTLIER -135.52 -43.02 0.69 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.43 -1.041 . . . . 0.0 109.162 179.503 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.74 HG23 HG12 ' A' ' 10' ' ' ILE . 14.8 t -102.31 141.73 34.68 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.557 -0.715 . . . . 0.0 109.65 179.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.448 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 113.17 10.81 14.78 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 119.581 -1.295 . . . . 0.0 110.165 179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -74.08 84.74 1.81 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.029 -1.277 . . . . 0.0 109.889 -179.988 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 96.33 16.1 38.77 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 6.9 pttt -174.82 -173.92 0.22 Allowed Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.266 -1.138 . . . . 0.0 109.377 -179.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.466 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.1 Cg_endo -88.07 101.34 0.45 Allowed 'Trans proline' 0 C--N 1.31 -1.467 0 O-C-N 123.4 1.21 . . . . 0.0 110.385 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.455 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -79.26 160.05 45.62 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.45 ' O ' ' HA ' ' A' ' 98' ' ' SER . 22.9 mt -117.51 142.77 30.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.43 -1.041 . . . . 0.0 108.775 178.872 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.563 ' CD2' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -129.93 117.33 19.95 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.93 -1.106 . . . . 0.0 110.987 -179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.47 ' HB2' HG13 ' A' ' 100' ' ' ILE . 22.2 mtt180 -101.49 123.49 45.62 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.578 -0.701 . . . . 0.0 109.334 179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.408 ' CD1' ' C ' ' A' ' 132' ' ' PHE . 29.8 p90 -116.15 156.23 26.83 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.05 -1.031 . . . . 0.0 110.525 -179.682 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.437 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 4.7 t -84.77 -67.46 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.216 -0.928 . . . . 0.0 109.412 179.408 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.424 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 52.77 95.22 0.04 OUTLIER Pre-proline 0 N--CA 1.489 1.493 0 O-C-N 121.55 -0.719 . . . . 0.0 110.397 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -72.28 -34.98 7.19 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.671 1.353 . . . . 0.0 110.382 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 63.37 -170.06 17.14 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 179.897 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -62.09 122.06 14.6 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.323 -1.104 . . . . 0.0 110.25 -179.908 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.285 179.911 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.407 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -98.31 133.04 43.28 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.211 -1.17 . . . . 0.0 110.329 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.613 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.1 m -113.4 104.43 16.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.239 -0.913 . . . . 0.0 110.187 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 34.4 p -65.96 145.04 56.37 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.328 -0.858 . . . . 0.0 110.232 179.827 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.479 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.22 147.22 99.0 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.224 -0.923 . . . . 0.0 109.891 179.92 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.479 ' HD2' HG23 ' A' ' 5' ' ' VAL . 44.8 Cg_endo -71.73 -169.0 0.39 Allowed 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 124.13 1.595 . . . . 0.0 111.076 179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.537 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 3.3 p80 -178.9 83.02 0.21 Allowed Pre-proline 0 N--CA 1.489 1.484 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.447 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -65.83 89.68 0.24 Allowed 'Trans proline' 0 C--N 1.31 -1.449 0 O-C-N 123.732 1.385 . . . . 0.0 110.844 -179.127 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -179.98 -35.64 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.625 0 CA-C-O 121.582 0.706 . . . . 0.0 109.376 179.848 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.508 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 14.6 mt -96.73 133.74 37.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 120.929 -1.107 . . . . 0.0 110.225 179.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 15.8 tp10 -84.19 128.13 34.37 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.352 -0.842 . . . . 0.0 109.548 179.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 43.8 mt-10 -89.38 121.47 31.67 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.11 -0.994 . . . . 0.0 109.915 -179.584 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.776 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 4.8 t -115.72 156.6 16.76 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.4 -0.813 . . . . 0.0 110.189 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -103.74 105.06 15.17 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.246 -0.909 . . . . 0.0 109.631 179.097 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.66 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -54.14 132.47 43.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.87 . . . . 0.0 109.654 -179.955 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.3 p -137.53 -174.69 3.83 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.287 -0.883 . . . . 0.0 110.265 -179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.0 p -78.97 63.43 3.65 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.225 -0.922 . . . . 0.0 110.048 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.504 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.0 m -132.07 112.05 12.02 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.322 -0.861 . . . . 0.0 110.247 -179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.478 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 141.25 -163.39 26.74 Favored Glycine 0 N--CA 1.487 2.05 0 C-N-CA 119.096 -1.525 . . . . 0.0 110.424 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 -121.41 -22.46 5.96 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.568 -0.96 . . . . 0.0 110.718 179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.897 HD12 HD13 ' A' ' 55' ' ' LEU . 6.6 tt -93.94 113.22 59.99 Favored Pre-proline 0 N--CA 1.487 1.418 0 C-N-CA 118.691 -1.204 . . . . 0.0 110.068 -179.499 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -64.23 150.73 87.73 Favored 'Trans proline' 0 C--N 1.313 -1.324 0 O-C-N 123.553 1.291 . . . . 0.0 110.031 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.471 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 81.6 t80 -162.93 88.87 0.62 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.127 -0.983 . . . . 0.0 111.367 -178.454 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.515 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 20.3 m-85 60.08 67.21 0.88 Allowed 'General case' 0 N--CA 1.5 2.03 0 O-C-N 121.328 -0.857 . . . . 0.0 111.245 179.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.07 13.68 21.21 Favored Glycine 0 N--CA 1.493 2.448 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 15.7 mmtt -130.29 156.18 45.09 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.024 -1.28 . . . . 0.0 109.376 179.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.504 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.48 106.97 15.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.984 -1.072 . . . . 0.0 109.252 179.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.862 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.2 mt -69.44 114.11 21.74 Favored Pre-proline 0 C--N 1.301 -1.543 0 O-C-N 121.325 -0.859 . . . . 0.0 110.409 -179.351 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.877 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.7 Cg_endo -70.7 129.99 17.47 Favored 'Trans proline' 0 C--N 1.305 -1.757 0 N-CA-C 107.02 -1.954 . . . . 0.0 107.02 176.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.872 HD11 HD12 ' A' ' 58' ' ' LEU . 15.8 mt -56.63 -17.49 8.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.885 -1.134 . . . . 0.0 110.74 -177.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.478 ' OE1' HG12 ' A' ' 32' ' ' VAL . 0.0 OUTLIER -60.82 -16.25 38.92 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.783 -1.198 . . . . 0.0 110.321 179.5 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -93.72 -25.37 4.85 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.836 0 O-C-N 120.998 -1.064 . . . . 0.0 111.191 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 45.9 pt -118.34 -28.36 2.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.024 -1.047 . . . . 0.0 110.456 -179.192 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.01 147.88 24.79 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.243 -0.911 . . . . 0.0 110.432 179.888 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 106.35 -5.68 38.55 Favored Glycine 0 N--CA 1.484 1.844 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 -179.521 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.96 -145.57 7.09 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 119.188 -1.482 . . . . 0.0 110.433 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.441 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 39.0 mtt85 -108.54 132.66 53.61 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.362 -1.081 . . . . 0.0 110.262 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.565 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 87.9 m-70 -140.7 150.61 43.68 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.011 -1.056 . . . . 0.0 111.004 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 62.2 tp -111.0 114.3 27.51 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.453 -0.779 . . . . 0.0 109.912 179.567 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.918 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -98.7 127.14 51.58 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.134 -0.979 . . . . 0.0 109.528 179.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.41 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 6.8 m-85 -95.43 124.03 39.25 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 121.199 -0.938 . . . . 0.0 110.152 -179.783 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -115.95 159.77 21.15 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.246 -0.909 . . . . 0.0 110.485 -179.696 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.515 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 25.1 p80 -107.02 -1.4 22.19 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.386 -0.821 . . . . 0.0 110.054 179.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -134.95 136.81 42.54 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.088 -1.007 . . . . 0.0 110.446 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.472 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 2.2 ttpt -71.76 -38.26 70.4 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.432 -0.793 . . . . 0.0 110.646 -179.823 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 15.4 mttt -58.84 -35.61 73.2 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 -179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.428 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.4 OUTLIER -73.69 -35.83 65.22 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.347 -0.846 . . . . 0.0 109.788 -179.983 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.918 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 76.1 m -61.17 -34.07 74.44 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.422 -0.799 . . . . 0.0 109.764 179.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.64 -50.22 53.06 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.152 -0.967 . . . . 0.0 110.273 -179.878 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.5 mt-10 -72.31 -43.46 64.13 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.293 -0.88 . . . . 0.0 110.116 179.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.711 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -57.14 -42.44 80.99 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.633 -0.667 . . . . 0.0 111.297 -179.057 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.1 -51.03 42.77 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.811 -1.181 . . . . 0.0 110.032 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.29 -34.61 68.86 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.221 179.448 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.575 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.84 -46.34 84.9 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.892 -0.781 . . . . 0.0 108.892 179.299 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.897 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -59.81 -43.37 94.52 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 121.411 -0.805 . . . . 0.0 110.974 -179.594 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 61.5 t -56.11 -34.07 37.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.957 -1.09 . . . . 0.0 109.386 179.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.58 -34.46 60.66 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.872 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.33 -25.82 62.57 Favored 'General case' 0 N--CA 1.486 1.337 0 O-C-N 121.295 -0.878 . . . . 0.0 109.705 179.918 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.22 7.88 8.15 Favored Glycine 0 N--CA 1.492 2.415 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.621 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.9 mt -108.51 143.5 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.255 -1.144 . . . . 0.0 110.087 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.636 ' ND2' HD11 ' A' ' 74' ' ' ILE . 16.8 t30 -89.23 106.44 18.44 Favored 'General case' 0 C--N 1.307 -1.275 0 N-CA-C 106.551 -1.648 . . . . 0.0 106.551 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.664 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.43 145.2 45.39 Favored 'General case' 0 C--N 1.297 -1.699 0 C-N-CA 118.962 -1.095 . . . . 0.0 111.612 -177.21 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.877 HG21 ' HA ' ' A' ' 73' ' ' VAL . 3.6 t -130.84 143.97 39.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 C-N-CA 120.014 -0.674 . . . . 0.0 109.45 179.692 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.918 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.18 122.5 47.05 Favored 'General case' 0 C--N 1.3 -1.55 0 C-N-CA 119.052 -1.059 . . . . 0.0 109.587 178.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.472 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.4 OUTLIER -109.5 131.34 55.16 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.305 -0.872 . . . . 0.0 110.807 -179.544 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.0 p90 -167.23 178.35 5.66 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.508 -0.745 . . . . 0.0 109.924 179.588 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.2 tpt85 -54.54 125.51 19.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.087 -1.008 . . . . 0.0 110.793 -179.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 79.85 40.94 13.37 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.797 -1.321 . . . . 0.0 109.797 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.4 tm? -117.42 157.03 26.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.19 -1.182 . . . . 0.0 110.3 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.868 ' N ' HD13 ' A' ' 69' ' ' LEU . 21.8 m-20 -98.49 149.39 22.76 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.542 -179.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.612 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.5 m -62.43 111.4 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.08 -1.013 . . . . 0.0 109.254 179.158 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.723 ' O ' HG23 ' A' ' 74' ' ' ILE . 43.9 m -134.33 -38.15 0.85 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.544 -0.722 . . . . 0.0 110.371 -179.42 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.895 HG13 HG22 ' A' ' 82' ' ' VAL . 76.9 t -46.49 131.88 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.492 -0.755 . . . . 0.0 110.687 -179.879 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.723 HG23 ' O ' ' A' ' 72' ' ' SER . 1.3 pp -137.71 91.6 13.61 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.204 -0.935 . . . . 0.0 110.658 179.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.473 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.9 Cg_endo -89.37 44.89 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.495 0 O-C-N 123.633 1.333 . . . . 0.0 109.919 178.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -124.34 -21.99 4.82 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.252 -0.905 . . . . 0.0 111.257 -179.101 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-20 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.885 -1.135 . . . . 0.0 110.861 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 51.74 -177.78 0.07 OUTLIER Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.926 -1.27 . . . . 0.0 109.926 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 26.5 m-20 -94.52 112.29 24.05 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.329 -1.101 . . . . 0.0 109.977 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.719 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.6 p -116.4 135.85 55.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.909 0.861 . . . . 0.0 110.23 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.616 HG22 HG22 ' A' ' 60' ' ' ILE . 10.1 m -111.87 123.35 67.58 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 O-C-N 121.415 -0.803 . . . . 0.0 109.025 179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.895 HG22 HG13 ' A' ' 73' ' ' VAL . 33.7 t -96.66 118.16 42.5 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.674 0 O-C-N 121.05 -1.031 . . . . 0.0 110.555 -178.045 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.918 ' CG1' HD12 ' A' ' 40' ' ' ILE . 4.2 m -111.78 98.42 7.02 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.364 0 C-N-CA 118.96 -1.096 . . . . 0.0 108.735 179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -131.45 156.47 45.56 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 120.713 -1.242 . . . . 0.0 110.329 -178.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.547 HG23 ' OD2' ' A' ' 86' ' ' ASP . 9.1 t -94.08 -30.43 14.67 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.361 -0.837 . . . . 0.0 111.479 -178.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.547 ' OD2' HG23 ' A' ' 85' ' ' THR . 2.7 p30 -175.9 -28.61 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.874 0 O-C-N 120.87 -1.144 . . . . 0.0 111.519 -179.964 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.614 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.75 -39.93 12.59 Favored 'General case' 0 N--CA 1.499 2.018 0 O-C-N 120.942 -1.099 . . . . 0.0 110.165 -179.8 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.8 tp -64.62 -40.33 95.3 Favored 'General case' 0 N--CA 1.488 1.442 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 178.207 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.485 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 45.06 26.77 0.24 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.833 -0.542 . . . . 0.0 111.267 179.419 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.596 HG21 ' NE ' ' A' ' 121' ' ' ARG . 64.8 p 43.46 -133.45 0.57 Allowed 'General case' 0 N--CA 1.497 1.878 0 O-C-N 121.561 -0.712 . . . . 0.0 110.973 179.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 95.86 -78.06 0.79 Allowed Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.0 p90 -95.52 18.3 13.02 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.334 -1.097 . . . . 0.0 109.814 179.302 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.49 HG23 ' N ' ' A' ' 94' ' ' GLY . 13.3 t -98.89 -148.54 0.34 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.37 -0.831 . . . . 0.0 110.206 -179.969 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.49 ' N ' HG23 ' A' ' 93' ' ' THR . . . 115.11 18.54 6.27 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.179 179.515 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.4 t70 -125.29 59.58 1.25 Allowed 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.925 -1.338 . . . . 0.0 110.348 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 25.2 m-85 -120.19 135.51 54.95 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.022 -1.049 . . . . 0.0 110.433 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.512 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 4.5 m-20 -76.1 -27.76 57.25 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.261 -0.899 . . . . 0.0 109.566 179.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.447 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 6.0 p -160.36 163.02 33.54 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.33 -0.856 . . . . 0.0 110.526 179.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.43 HG23 ' HA ' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.84 115.9 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.002 0 O-C-N 121.181 -0.949 . . . . 0.0 110.329 179.659 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.815 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -93.48 114.63 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.037 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.0 t0 -122.62 161.3 24.03 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.108 -0.995 . . . . 0.0 111.842 -178.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 49.5 t -103.25 9.13 38.28 Favored 'General case' 0 C--N 1.304 -1.411 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 177.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.427 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 52.33 23.14 2.29 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.186 -0.946 . . . . 0.0 111.001 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.63 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.21 137.96 27.72 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.127 -0.983 . . . . 0.0 110.652 179.597 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.401 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.6 p -111.14 121.95 46.63 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.356 -0.84 . . . . 0.0 109.491 179.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 55.07 -141.61 0.85 Allowed 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.085 -1.01 . . . . 0.0 109.405 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -82.24 9.62 57.06 Favored Glycine 0 N--CA 1.491 2.317 0 C-N-CA 119.794 -1.193 . . . . 0.0 110.242 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.401 ' O ' ' N ' ' A' ' 105' ' ' SER . 11.3 mmtt -126.17 155.5 73.6 Favored Pre-proline 0 N--CA 1.493 1.7 0 O-C-N 120.92 -1.341 . . . . 0.0 109.865 -179.94 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.63 ' HA ' HG22 ' A' ' 104' ' ' THR . 41.0 Cg_endo -67.47 160.7 46.69 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.531 1.28 . . . . 0.0 110.573 179.883 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.468 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -68.13 147.61 52.07 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.349 -0.844 . . . . 0.0 110.744 -179.48 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.415 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -84.97 161.0 19.95 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.157 -0.964 . . . . 0.0 110.077 179.61 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.414 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.31 -57.42 3.02 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.555 -0.716 . . . . 0.0 112.443 -178.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.469 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 11.1 m -68.52 -29.41 43.86 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.822 0 O-C-N 120.653 -1.279 . . . . 0.0 111.898 -178.216 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.468 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.2 OUTLIER -47.23 -56.24 7.09 Favored 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.026 -1.046 . . . . 0.0 110.535 -179.222 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.483 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 5.8 ptm180 -70.43 -35.17 73.23 Favored 'General case' 0 C--N 1.304 -1.384 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.858 179.074 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.469 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 35.4 m -58.95 -49.58 77.3 Favored 'General case' 0 N--CA 1.486 1.331 0 O-C-N 121.029 -1.044 . . . . 0.0 108.383 178.626 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tp60 -73.77 -35.82 65.02 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.429 -0.794 . . . . 0.0 109.864 178.685 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.483 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 19.4 mtt-85 -71.65 -44.55 64.11 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.113 -0.992 . . . . 0.0 110.921 -179.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.537 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 17.2 ttm180 -53.2 -41.75 65.61 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.893 -1.129 . . . . 0.0 109.685 179.645 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.4 63.23 0.26 Allowed Glycine 0 N--CA 1.494 2.554 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.71 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.596 ' NE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -132.49 -42.78 0.94 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.497 -1.002 . . . . 0.0 108.678 179.126 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.498 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.8 t -98.12 144.05 28.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.668 -0.645 . . . . 0.0 109.597 179.145 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.453 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 104.3 9.17 36.89 Favored Glycine 0 N--CA 1.488 2.135 0 C-N-CA 119.652 -1.261 . . . . 0.0 110.325 179.342 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.449 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.9 mmt180 -66.28 87.54 0.11 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.001 -1.294 . . . . 0.0 109.539 179.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.71 23.29 28.66 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 108.559 -1.816 . . . . 0.0 108.559 -178.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.466 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -178.45 -179.84 0.3 Allowed Pre-proline 0 N--CA 1.491 1.614 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 -179.471 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.507 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 48.6 Cg_endo -88.89 105.91 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.129 1.068 . . . . 0.0 110.864 -179.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.498 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -80.57 179.46 53.45 Favored Glycine 0 N--CA 1.495 2.62 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 179.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.441 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -134.64 142.52 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.431 -1.04 . . . . 0.0 108.942 179.02 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 11.8 t80 -129.75 115.84 17.89 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 118.904 -1.118 . . . . 0.0 111.024 179.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.776 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 1.7 mtt180 -100.55 134.33 43.67 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 109.04 -0.726 . . . . 0.0 109.04 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.447 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 29.5 p90 -126.29 156.7 39.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.932 -1.105 . . . . 0.0 110.557 -179.467 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.66 HG22 HD23 ' A' ' 15' ' ' LEU . 55.9 t -94.27 -45.99 13.58 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.257 -0.902 . . . . 0.0 109.917 179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.427 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -119.79 103.77 45.46 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 110.261 -179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.37 -21.38 23.02 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 O-C-N 123.564 1.297 . . . . 0.0 110.72 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -117.43 140.54 15.82 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -69.58 -29.35 66.88 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.233 -1.157 . . . . 0.0 110.272 179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.631 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.237 179.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -70.83 108.06 4.3 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.282 -1.128 . . . . 0.0 110.235 -179.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -113.36 105.19 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 O-C-N 121.337 -0.852 . . . . 0.0 109.996 179.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 36.7 p -63.16 144.84 56.57 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.374 -0.829 . . . . 0.0 110.358 -179.861 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.464 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -70.4 147.23 94.96 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 110.276 -179.884 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.464 ' HD2' HG23 ' A' ' 5' ' ' VAL . 52.5 Cg_endo -76.36 -173.63 1.78 Allowed 'Trans proline' 0 C--N 1.311 -1.421 0 O-C-N 124.237 1.651 . . . . 0.0 110.985 179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.496 ' CE1' ' HG3' ' A' ' 119' ' ' ARG . 3.9 p80 -177.94 83.69 0.23 Allowed Pre-proline 0 N--CA 1.489 1.51 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 179.298 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -69.83 58.51 1.6 Allowed 'Trans proline' 0 C--N 1.31 -1.492 0 O-C-N 123.487 1.256 . . . . 0.0 111.566 -178.97 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 14.8 m120 -148.57 7.94 0.77 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.123 -0.986 . . . . 0.0 111.155 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.689 HD11 ' O ' ' A' ' 122' ' ' THR . 27.1 mt -129.01 137.41 57.28 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.707 0 O-C-N 120.856 -1.153 . . . . 0.0 110.65 179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.3 tp10 -83.62 128.42 34.51 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.324 -0.86 . . . . 0.0 108.886 178.292 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 46.1 mt-10 -89.51 142.63 27.49 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.007 -1.058 . . . . 0.0 110.638 -178.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' HB ' ' CG ' ' A' ' 131' ' ' ARG . 13.3 t -137.71 158.02 33.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 110.406 -179.652 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -115.91 109.39 17.53 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.436 -0.79 . . . . 0.0 109.577 179.082 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.716 HD23 ' HB2' ' A' ' 26' ' ' LYS . 10.2 tp -53.48 136.86 37.42 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.268 -0.895 . . . . 0.0 109.93 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 8.2 p -137.37 174.5 10.54 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.273 -0.892 . . . . 0.0 110.246 -179.594 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 25.8 p -71.66 80.09 0.83 Allowed 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.2 -0.938 . . . . 0.0 110.079 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.82 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -155.51 109.11 2.8 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.194 -0.941 . . . . 0.0 110.776 -179.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.411 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 149.31 -170.25 29.59 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 118.855 -1.641 . . . . 0.0 110.962 179.139 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 14.2 mm-40 -111.19 -20.39 12.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.788 -0.831 . . . . 0.0 110.416 -179.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.898 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.2 tt -98.86 103.87 21.86 Favored Pre-proline 0 N--CA 1.491 1.624 0 C-N-CA 118.915 -1.114 . . . . 0.0 109.81 179.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.5 Cg_endo -62.66 124.97 15.1 Favored 'Trans proline' 0 C--N 1.312 -1.353 0 O-C-N 123.337 1.177 . . . . 0.0 110.851 -179.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.436 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.3 t80 -113.44 -166.83 1.12 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.69 -0.631 . . . . 0.0 110.43 -179.237 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.523 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 37.4 m-85 -58.27 81.83 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.441 -0.787 . . . . 0.0 111.482 -179.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 72.04 2.29 52.07 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.597 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.716 ' HB2' HD23 ' A' ' 15' ' ' LEU . 15.1 mmtp -130.2 156.31 44.8 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.001 -1.294 . . . . 0.0 109.375 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.82 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.68 107.42 18.43 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 120.921 -1.112 . . . . 0.0 109.079 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.064 HD11 HG21 ' A' ' 100' ' ' ILE . 5.2 mt -69.36 112.95 13.53 Favored Pre-proline 0 C--N 1.3 -1.557 0 O-C-N 121.325 -0.859 . . . . 0.0 110.504 -179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.754 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.2 Cg_endo -68.52 129.64 19.35 Favored 'Trans proline' 0 C--N 1.306 -1.688 0 N-CA-C 107.151 -1.904 . . . . 0.0 107.151 176.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.732 HD22 ' CD1' ' A' ' 60' ' ' ILE . 10.8 mt -56.32 -17.73 8.63 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.847 -1.158 . . . . 0.0 110.691 -177.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -59.87 -16.11 26.48 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.688 -1.258 . . . . 0.0 110.57 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 10.7 m -94.0 -25.19 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.977 -1.077 . . . . 0.0 110.756 -179.666 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 12.3 pt -114.66 -23.28 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.06 -1.025 . . . . 0.0 110.549 -179.514 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.561 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptm -93.75 147.95 22.57 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 120.849 -1.157 . . . . 0.0 110.224 179.348 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 101.75 -3.36 52.9 Favored Glycine 0 N--CA 1.484 1.892 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.829 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.66 -150.61 8.63 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 118.976 -1.583 . . . . 0.0 110.635 179.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.454 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.9 OUTLIER -109.44 129.4 55.55 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.45 -1.029 . . . . 0.0 109.941 -179.766 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.2 m-70 -137.81 149.38 46.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.976 -1.078 . . . . 0.0 110.945 -179.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.663 HD23 ' HG2' ' A' ' 121' ' ' ARG . 34.2 tp -110.76 117.28 33.03 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.416 -0.802 . . . . 0.0 110.243 179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.94 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.1 mm -97.94 125.38 51.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.262 -0.899 . . . . 0.0 109.505 179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.422 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 3.0 m-85 -98.62 123.38 42.77 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.08 -1.012 . . . . 0.0 109.892 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.22 159.39 22.72 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.186 -0.947 . . . . 0.0 110.532 -179.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 22.8 p80 -98.7 -10.59 22.97 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.336 -0.852 . . . . 0.0 110.161 179.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.4 p -128.32 141.12 51.53 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.145 -0.972 . . . . 0.0 110.365 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.452 ' HG3' ' CB ' ' A' ' 66' ' ' TYR . 3.9 ttpt -71.6 -31.83 67.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.522 -0.737 . . . . 0.0 110.57 -179.788 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 32.8 mttt -59.32 -36.54 75.84 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.173 -0.954 . . . . 0.0 110.471 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.44 ' HE2' ' CE1' ' A' ' 24' ' ' TYR . 0.2 OUTLIER -73.77 -34.34 64.65 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.314 -0.866 . . . . 0.0 109.618 179.844 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.699 ' O ' ' HB2' ' A' ' 64' ' ' ALA . 62.6 m -60.46 -35.09 75.05 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.393 -0.817 . . . . 0.0 109.182 179.502 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -67.51 -49.07 65.08 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.173 -0.955 . . . . 0.0 110.351 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.4 mm-40 -71.53 -43.23 66.82 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.155 -0.966 . . . . 0.0 110.79 -179.659 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.077 HD12 HG11 ' A' ' 83' ' ' VAL . 0.7 OUTLIER -56.16 -40.42 73.86 Favored 'General case' 0 N--CA 1.496 1.832 0 O-C-N 121.275 -0.891 . . . . 0.0 110.931 -179.056 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.459 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.77 -51.31 12.92 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.989 -1.07 . . . . 0.0 110.301 -179.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.52 -42.4 99.49 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.019 -1.051 . . . . 0.0 109.657 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.58 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.44 -47.37 81.96 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.381 -0.824 . . . . 0.0 109.488 179.64 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.778 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.92 -43.01 76.96 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.656 -0.653 . . . . 0.0 110.354 179.987 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 54.6 t -55.43 -34.58 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.077 -1.015 . . . . 0.0 109.186 179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.41 -30.02 59.94 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.305 -0.872 . . . . 0.0 109.752 179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.58 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.7 mm? -71.54 -26.3 62.59 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.905 0.86 . . . . 0.0 109.583 179.461 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.13 6.24 10.09 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.22 -1.552 . . . . 0.0 109.22 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.732 ' CD1' HD22 ' A' ' 30' ' ' LEU . 37.8 mt -108.05 143.69 18.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.327 -1.102 . . . . 0.0 110.148 -179.803 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.458 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 21.0 t30 -87.91 106.55 18.18 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 177.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.644 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.34 144.29 45.98 Favored 'General case' 0 C--N 1.297 -1.698 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.368 -177.268 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 2.5 t -131.05 142.58 43.2 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 C-N-CA 119.677 -0.809 . . . . 0.0 109.773 179.594 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.699 ' HB2' ' O ' ' A' ' 48' ' ' CYS . . . -105.81 118.3 36.25 Favored 'General case' 0 C--N 1.3 -1.545 0 C-N-CA 119.153 -1.019 . . . . 0.0 109.824 178.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.456 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 0.8 OUTLIER -105.27 118.43 36.54 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.373 -0.829 . . . . 0.0 110.732 -179.442 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.91 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -149.67 -179.86 7.44 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.498 -0.751 . . . . 0.0 109.685 179.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -56.75 129.4 41.05 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.064 -1.023 . . . . 0.0 110.678 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.76 44.99 23.6 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.91 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.27 154.73 30.7 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.305 -1.115 . . . . 0.0 109.985 -179.744 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 23.7 m-20 -94.92 149.76 20.9 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.335 -0.853 . . . . 0.0 110.398 -179.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.654 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -60.68 110.85 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 C-N-CA 118.903 -1.119 . . . . 0.0 108.992 179.38 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.501 ' O ' HG23 ' A' ' 74' ' ' ILE . 36.8 m -133.05 -33.48 1.15 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.489 -0.757 . . . . 0.0 110.732 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 89.5 t -56.55 134.71 20.6 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 O-C-N 121.153 -0.967 . . . . 0.0 109.756 -179.782 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.566 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.65 93.6 12.31 Favored Pre-proline 0 N--CA 1.495 1.814 0 O-C-N 121.199 -0.938 . . . . 0.0 110.654 179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -79.59 60.93 8.02 Favored 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 123.757 1.398 . . . . 0.0 110.216 179.432 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.0 t -162.76 40.21 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.041 -1.037 . . . . 0.0 110.535 -179.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -141.49 -163.51 1.58 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.199 -0.938 . . . . 0.0 109.812 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.34 -73.95 0.31 Allowed Glycine 0 N--CA 1.494 2.534 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 29.2 m-20 -152.25 111.77 3.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.181 -1.188 . . . . 0.0 110.315 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.52 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.58 134.26 61.74 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.667 0 CA-C-O 122.035 0.921 . . . . 0.0 110.344 -179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.61 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -113.2 124.57 69.97 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 178.99 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.767 HG22 HG13 ' A' ' 73' ' ' VAL . 8.8 t -97.69 118.79 44.79 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.698 0 O-C-N 121.055 -1.028 . . . . 0.0 110.769 -177.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.077 HG11 HD12 ' A' ' 51' ' ' LEU . 4.1 m -111.87 98.54 7.17 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 120.824 -1.172 . . . . 0.0 108.825 179.112 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.456 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -129.42 161.89 29.33 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 120.597 -1.314 . . . . 0.0 110.116 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 9.6 t -103.34 -24.75 13.48 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.155 -0.966 . . . . 0.0 111.317 -178.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.438 ' O ' ' N ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 179.93 -29.4 0.01 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 O-C-N 120.951 -1.093 . . . . 0.0 111.038 -179.927 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -48.93 -39.04 24.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.026 -1.046 . . . . 0.0 110.265 -179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 4.8 tp -63.51 -29.91 71.11 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.133 -0.979 . . . . 0.0 108.715 178.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.501 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 44.18 27.32 0.2 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.804 -0.56 . . . . 0.0 111.459 179.605 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.549 HG21 ' HD3' ' A' ' 121' ' ' ARG . 61.2 p 42.06 52.58 4.35 Favored 'General case' 0 N--CA 1.496 1.871 0 O-C-N 121.779 -0.575 . . . . 0.0 111.422 179.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.52 -66.49 2.28 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.799 -1.32 . . . . 0.0 109.799 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -110.12 23.0 14.89 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.268 -1.136 . . . . 0.0 110.241 -179.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.529 HG21 ' CB ' ' A' ' 90' ' ' THR . 14.6 t -78.84 -148.44 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.337 -0.852 . . . . 0.0 110.15 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.436 ' N ' HG23 ' A' ' 93' ' ' THR . . . 103.54 -43.11 1.74 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.194 -1.162 . . . . 0.0 110.194 179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 24.0 t0 -86.74 66.62 9.54 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.925 -1.338 . . . . 0.0 110.842 -179.363 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.504 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 15.3 m-85 -119.71 150.66 40.0 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 120.964 -1.085 . . . . 0.0 110.236 179.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.459 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 64.7 m-20 -76.83 -31.98 57.27 Favored 'General case' 0 C--N 1.298 -1.665 0 O-C-N 121.497 -0.752 . . . . 0.0 109.903 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.426 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.9 p -162.6 164.0 26.91 Favored 'General case' 0 N--CA 1.494 1.736 0 C-N-CA 119.208 -0.997 . . . . 0.0 111.74 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.707 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.99 113.75 30.0 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.011 0 O-C-N 121.506 -0.746 . . . . 0.0 110.052 179.111 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.064 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -92.72 116.16 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.065 -1.022 . . . . 0.0 108.365 178.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.3 t0 -129.23 161.06 31.05 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.069 -1.019 . . . . 0.0 112.036 -177.931 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.481 ' HB2' ' CD2' ' A' ' 24' ' ' TYR . 12.4 t -95.74 -1.09 50.57 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 177.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.404 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 54.89 20.87 3.32 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.163 -0.96 . . . . 0.0 111.196 179.786 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.435 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -143.11 140.53 30.9 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.033 -1.042 . . . . 0.0 110.642 179.669 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.433 ' N ' ' O ' ' A' ' 108' ' ' LYS . 15.4 p -114.31 127.69 55.99 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.356 -0.84 . . . . 0.0 109.985 179.504 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 34.1 t0 51.45 30.15 5.99 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.558 179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.06 -32.96 5.51 Favored Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.692 -1.363 . . . . 0.0 109.692 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.433 ' O ' ' N ' ' A' ' 105' ' ' SER . 7.4 mtmt -76.66 156.5 82.89 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.274 -1.133 . . . . 0.0 110.023 179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.435 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.5 Cg_endo -65.64 133.27 33.65 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.658 1.346 . . . . 0.0 110.381 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 5.7 pt20 -47.93 167.0 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.412 -0.805 . . . . 0.0 110.91 -179.307 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.521 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -98.11 160.79 14.07 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.355 -0.84 . . . . 0.0 110.156 179.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.402 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.49 -50.66 7.02 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.546 -0.721 . . . . 0.0 112.326 -178.667 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.521 HG22 ' OD1' ' A' ' 111' ' ' ASP . 16.1 m -71.24 -29.22 35.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.805 0 O-C-N 120.75 -1.219 . . . . 0.0 111.438 -178.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.415 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.36 -56.02 7.71 Favored 'General case' 0 N--CA 1.498 1.954 0 O-C-N 121.084 -1.01 . . . . 0.0 110.408 -179.332 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.475 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.0 OUTLIER -69.03 -35.05 76.18 Favored 'General case' 0 C--N 1.303 -1.414 0 C-N-CA 119.379 -0.928 . . . . 0.0 108.877 178.713 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.472 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 47.6 m -59.86 -49.94 75.72 Favored 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 119.527 -0.869 . . . . 0.0 108.694 179.099 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.41 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 0.7 OUTLIER -73.24 -37.25 66.42 Favored 'General case' 0 N--CA 1.486 1.346 0 O-C-N 121.6 -0.687 . . . . 0.0 109.559 178.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.475 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 21.3 mtt85 -68.47 -44.92 73.75 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.146 -0.971 . . . . 0.0 110.497 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.496 ' HG3' ' CE1' ' A' ' 7' ' ' HIS . 0.0 OUTLIER -59.93 -46.48 89.23 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.22 -0.925 . . . . 0.0 110.363 179.98 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.406 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -45.02 -26.36 1.22 Allowed Glycine 0 N--CA 1.498 2.818 0 O-C-N 121.461 -0.774 . . . . 0.0 111.423 -178.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.663 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -48.79 -55.44 11.55 Favored 'General case' 0 N--CA 1.496 1.869 0 O-C-N 120.898 -1.354 . . . . 0.0 110.868 -179.445 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.689 ' O ' HD11 ' A' ' 10' ' ' ILE . 1.3 t -91.58 142.59 27.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.141 -0.975 . . . . 0.0 109.504 179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.426 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 110.67 12.52 16.46 Favored Glycine 0 N--CA 1.491 2.323 0 C-N-CA 119.373 -1.394 . . . . 0.0 110.285 -179.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.411 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 6.2 mtt180 -102.48 76.6 1.55 Allowed 'General case' 0 N--CA 1.493 1.72 0 O-C-N 120.926 -1.338 . . . . 0.0 109.913 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.99 4.76 Favored Glycine 0 N--CA 1.493 2.481 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.445 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -145.13 167.09 15.43 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 121.592 -0.946 . . . . 0.0 108.773 179.797 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.445 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.0 Cg_endo -63.9 111.97 1.7 Allowed 'Trans proline' 0 C--N 1.308 -1.58 0 O-C-N 123.244 1.128 . . . . 0.0 109.629 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.514 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -87.22 166.2 36.5 Favored Glycine 0 N--CA 1.488 2.108 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 -178.899 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' A' ' 98' ' ' SER . 2.7 mt -124.34 141.79 43.32 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.491 -1.005 . . . . 0.0 108.544 178.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.707 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.0 OUTLIER -126.58 115.47 19.55 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 118.708 -1.197 . . . . 0.0 110.949 179.822 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.454 ' CG ' ' HB ' ' A' ' 13' ' ' VAL . 0.7 OUTLIER -107.38 121.9 45.51 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.534 -0.729 . . . . 0.0 109.143 179.302 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.404 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 24.4 p90 -119.56 157.73 27.78 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.12 -0.987 . . . . 0.0 110.002 -179.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 50.6 t -85.91 -42.44 15.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.194 -0.941 . . . . 0.0 110.007 179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.7 155.14 54.95 Favored Pre-proline 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.515 -179.742 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -77.11 -57.32 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.348 0 O-C-N 123.719 1.378 . . . . 0.0 110.518 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 162.69 74.42 0.02 OUTLIER Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.552 -1.419 . . . . 0.0 109.552 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.4 tt0 -78.62 81.42 4.94 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.201 -1.176 . . . . 0.0 110.245 -179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 51.8 ttt180 . . . . . 0 N--CA 1.491 1.602 0 CA-C-O 118.001 -1.0 . . . . 0.0 110.282 -179.998 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.303 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.9 m -87.97 150.67 23.31 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.299 -1.118 . . . . 0.0 110.368 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 3' ' ' VAL . 17.4 m -113.18 104.45 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.28 -0.888 . . . . 0.0 109.833 179.587 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.448 HG23 ' HB1' ' A' ' 112' ' ' ALA . 16.8 p -68.9 138.54 54.74 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.371 -0.83 . . . . 0.0 110.343 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.436 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.18 147.83 98.91 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.221 -0.925 . . . . 0.0 109.509 179.701 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.436 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.0 Cg_endo -71.5 -169.33 0.41 Allowed 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 124.142 1.601 . . . . 0.0 111.108 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.518 ' CG ' ' HD2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER 172.43 77.68 0.04 OUTLIER Pre-proline 0 N--CA 1.498 1.952 0 O-C-N 121.595 -0.691 . . . . 0.0 109.64 -179.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -70.52 -10.58 28.25 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.68 1.358 . . . . 0.0 111.181 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.5 m-80 -74.96 -11.24 60.07 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 120.973 -1.079 . . . . 0.0 110.437 179.801 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.664 HG12 HG23 ' A' ' 122' ' ' THR . 1.9 mt -112.82 135.48 52.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 109.793 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 26.3 tt0 -85.93 125.1 33.09 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.222 -0.924 . . . . 0.0 108.749 178.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 53.0 mt-10 -89.35 129.56 35.87 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.01 -1.056 . . . . 0.0 110.246 -179.228 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.614 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 12.1 t -125.35 157.9 34.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.41 -0.806 . . . . 0.0 110.395 -179.199 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.458 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . . . -111.48 114.13 27.03 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.299 -0.875 . . . . 0.0 109.617 179.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.678 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -52.17 143.89 13.52 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.206 -0.934 . . . . 0.0 109.902 179.982 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 32.7 p -142.09 -178.19 5.59 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.255 -0.903 . . . . 0.0 110.209 -179.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 35.3 p -80.34 59.13 3.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.258 -0.901 . . . . 0.0 110.093 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.456 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 23.8 m -132.69 109.19 9.53 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.398 -0.814 . . . . 0.0 110.618 -179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.424 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 148.36 -171.65 28.74 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 118.838 -1.649 . . . . 0.0 111.134 179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.4 mm-40 -113.66 -22.82 10.06 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.737 -0.861 . . . . 0.0 110.524 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.885 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.8 tt -93.45 109.5 40.96 Favored Pre-proline 0 N--CA 1.489 1.5 0 C-N-CA 118.742 -1.183 . . . . 0.0 109.251 -179.954 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.451 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.8 Cg_endo -63.12 145.56 93.84 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.356 1.187 . . . . 0.0 111.49 -178.302 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.447 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.2 t80 -136.84 -165.12 1.69 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.655 -0.653 . . . . 0.0 110.376 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.526 ' CD2' ' HB3' ' A' ' 102' ' ' CYS . 38.3 m-85 -60.61 79.72 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.852 0 O-C-N 121.466 -0.771 . . . . 0.0 110.669 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.447 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.65 6.98 57.49 Favored Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.498 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.678 ' HB2' HD23 ' A' ' 15' ' ' LEU . 1.3 mmtp -130.17 156.09 45.15 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.049 -1.265 . . . . 0.0 109.551 179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.456 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.09 106.9 16.09 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.968 -1.083 . . . . 0.0 109.08 179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.885 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -66.49 113.78 14.33 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.328 -0.858 . . . . 0.0 110.837 -179.17 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.809 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.5 Cg_endo -70.33 130.55 18.82 Favored 'Trans proline' 0 C--N 1.306 -1.705 0 N-CA-C 106.691 -2.08 . . . . 0.0 106.691 175.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.734 HD11 HD12 ' A' ' 58' ' ' LEU . 14.3 mt -55.96 -17.97 8.01 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 120.848 -1.158 . . . . 0.0 110.593 -177.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -59.36 -16.44 22.66 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 120.555 -1.341 . . . . 0.0 110.545 179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 13.4 m -92.75 -24.31 5.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.736 0 O-C-N 121.029 -1.044 . . . . 0.0 111.04 -179.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 37.9 pt -117.45 -26.33 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.003 -1.06 . . . . 0.0 110.357 -179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.635 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -90.28 148.78 22.67 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.105 -0.997 . . . . 0.0 110.036 179.085 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.453 ' N ' ' HG3' ' A' ' 34' ' ' LYS . . . 112.78 -4.83 25.97 Favored Glycine 0 N--CA 1.484 1.857 0 N-CA-C 109.167 -1.573 . . . . 0.0 109.167 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 168.51 -130.99 2.19 Favored Glycine 0 N--CA 1.493 2.447 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.235 179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.421 ' HD3' ' CG1' ' A' ' 80' ' ' VAL . 3.2 mtt-85 -115.6 131.07 57.05 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.349 -1.089 . . . . 0.0 110.22 -179.689 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.567 ' HB2' HG12 ' A' ' 81' ' ' VAL . 74.4 m-70 -140.9 146.39 37.38 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.106 -0.996 . . . . 0.0 110.878 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.515 HD12 ' O ' ' A' ' 82' ' ' VAL . 20.4 tp -106.81 127.58 53.52 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.498 -0.751 . . . . 0.0 109.95 179.617 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.936 HD12 HG12 ' A' ' 83' ' ' VAL . 35.2 mt -109.78 128.24 66.02 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.307 -0.871 . . . . 0.0 109.478 179.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -95.07 124.11 38.93 Favored 'General case' 0 C--N 1.294 -1.836 0 O-C-N 121.26 -0.9 . . . . 0.0 109.989 -179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.58 159.88 21.49 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 121.273 -0.892 . . . . 0.0 110.747 -179.639 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.523 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.5 OUTLIER -106.78 3.09 26.15 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.429 -0.795 . . . . 0.0 110.213 179.272 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 5.1 p -136.69 136.75 39.31 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.985 -1.072 . . . . 0.0 110.833 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.9 ttpt -71.96 -36.93 69.99 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.525 -0.734 . . . . 0.0 110.622 179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -33.64 76.44 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.28 -0.888 . . . . 0.0 110.385 -179.751 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.58 -35.51 65.45 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.51 -0.744 . . . . 0.0 109.708 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.742 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 93.3 m -61.08 -36.03 78.55 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.407 -0.808 . . . . 0.0 109.478 179.437 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 17.0 m-20 -67.57 -49.92 60.89 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.188 -0.945 . . . . 0.0 110.52 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.412 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 1.4 mm-40 -72.26 -44.8 62.29 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.181 -0.949 . . . . 0.0 110.24 179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.64 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -56.8 -43.6 81.09 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.628 -0.67 . . . . 0.0 111.119 -179.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -67.69 -51.17 52.77 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.853 -1.155 . . . . 0.0 109.829 179.899 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.9 -35.56 69.12 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.2 -0.937 . . . . 0.0 109.249 179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.667 ' HD3' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.53 -46.97 83.23 Favored 'General case' 0 N--CA 1.491 1.587 0 N-CA-C 108.947 -0.76 . . . . 0.0 108.947 179.267 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.847 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -58.2 -41.88 84.94 Favored 'General case' 0 C--N 1.297 -1.676 0 O-C-N 121.336 -0.853 . . . . 0.0 110.84 -179.773 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 79.7 t -56.12 -32.91 35.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.064 -1.022 . . . . 0.0 109.194 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.75 -33.4 60.22 Favored 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.381 -0.824 . . . . 0.0 110.503 179.661 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.734 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.33 -25.41 62.39 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 121.189 -0.944 . . . . 0.0 109.939 -179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.8 4.62 9.49 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.267 -1.533 . . . . 0.0 109.267 -179.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.656 ' CD1' HD22 ' A' ' 30' ' ' LEU . 44.6 mt -105.71 143.35 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.345 -1.091 . . . . 0.0 109.882 -179.762 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.555 HD22 HG23 ' A' ' 80' ' ' VAL . 1.9 t30 -88.57 106.99 18.66 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 178.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.585 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.54 146.36 44.63 Favored 'General case' 0 C--N 1.295 -1.783 0 C-N-CA 118.672 -1.211 . . . . 0.0 111.722 -177.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 89.7 t -128.23 149.7 33.32 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.442 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.742 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.23 117.7 30.74 Favored 'General case' 0 C--N 1.3 -1.559 0 C-N-CA 119.1 -1.04 . . . . 0.0 109.589 178.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 3.2 t80 -112.45 142.34 45.11 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.368 -0.832 . . . . 0.0 110.389 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.885 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.9 p90 -175.3 -177.26 1.01 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.387 -0.821 . . . . 0.0 110.024 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttm180 -54.49 119.75 5.67 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.184 -0.948 . . . . 0.0 111.232 -179.243 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.55 41.01 11.73 Favored Glycine 0 N--CA 1.492 2.43 0 N-CA-C 110.261 -1.136 . . . . 0.0 110.261 179.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.885 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -117.63 155.41 29.93 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.049 -1.265 . . . . 0.0 110.183 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.807 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -93.63 149.46 21.21 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.281 -0.887 . . . . 0.0 110.396 -179.539 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.655 HG23 ' O ' ' A' ' 71' ' ' VAL . 28.0 m -62.53 110.62 0.73 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 C-N-CA 119.183 -1.007 . . . . 0.0 109.375 179.398 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 67.1 m -132.57 -20.96 2.28 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.517 -0.739 . . . . 0.0 111.052 -179.452 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 54.9 t -64.03 128.16 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.009 -1.057 . . . . 0.0 109.515 -179.771 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.688 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.4 pp -136.34 98.3 11.39 Favored Pre-proline 0 N--CA 1.495 1.791 0 O-C-N 121.073 -1.017 . . . . 0.0 110.902 -179.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.689 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.0 Cg_endo -78.95 53.35 4.65 Favored 'Trans proline' 0 C--N 1.311 -1.425 0 O-C-N 123.32 1.168 . . . . 0.0 110.192 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.626 HG23 ' O ' ' A' ' 75' ' ' PRO . 5.6 p -157.25 40.0 0.31 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.227 -0.921 . . . . 0.0 110.412 -179.481 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 10.2 m120 -145.21 31.68 1.11 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.193 -0.942 . . . . 0.0 110.323 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 108.52 -116.21 4.65 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.394 -1.482 . . . . 0.0 109.394 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -115.84 109.5 17.73 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.236 -1.156 . . . . 0.0 110.136 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.689 HG11 ' HA ' ' A' ' 75' ' ' PRO . 6.8 p -116.66 135.36 57.22 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.688 0 CA-C-O 122.022 0.915 . . . . 0.0 110.738 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 9.5 m -113.2 122.88 68.19 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.14 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 178.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.695 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -97.32 118.79 44.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.818 -1.176 . . . . 0.0 110.454 -178.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.936 HG12 HD12 ' A' ' 40' ' ' ILE . 3.5 m -109.78 100.67 11.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.079 -1.013 . . . . 0.0 108.937 179.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.22 163.84 31.87 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 120.636 -1.29 . . . . 0.0 111.395 -177.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.488 HG23 ' N ' ' A' ' 86' ' ' ASP . 11.2 t -91.34 -140.77 0.17 Allowed 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.445 -0.785 . . . . 0.0 109.345 179.767 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.488 ' N ' HG23 ' A' ' 85' ' ' THR . 3.8 p30 -84.46 52.15 2.29 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.818 -1.176 . . . . 0.0 110.197 179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.479 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -122.42 -19.66 6.34 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.215 -0.928 . . . . 0.0 110.95 -179.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -62.37 -26.98 68.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.961 -1.087 . . . . 0.0 109.602 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.542 ' C ' HG22 ' A' ' 90' ' ' THR . 27.4 mmt 47.26 30.83 1.56 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.396 -0.815 . . . . 0.0 110.74 179.59 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.761 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.5 t 35.04 -134.95 0.04 OUTLIER 'General case' 0 N--CA 1.499 1.985 0 N-CA-C 112.321 0.489 . . . . 0.0 112.321 178.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 93.1 -49.61 2.46 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 108.018 -2.033 . . . . 0.0 108.018 -178.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 50.8 p90 -125.29 21.03 8.03 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.679 -0.895 . . . . 0.0 109.391 178.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.761 HG22 ' OG1' ' A' ' 90' ' ' THR . 4.9 t -102.81 -155.5 0.53 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.293 -0.88 . . . . 0.0 110.356 -179.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.529 ' N ' HG23 ' A' ' 93' ' ' THR . . . 92.39 -33.98 4.68 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 179.424 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -84.2 59.01 5.09 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.973 -1.31 . . . . 0.0 110.423 -179.611 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.403 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 48.7 m-85 -119.47 153.08 35.85 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.18 -0.95 . . . . 0.0 110.159 179.458 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -84.83 -29.24 25.51 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 121.396 -0.815 . . . . 0.0 109.524 179.394 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.3 p -161.87 163.71 29.1 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.257 -0.902 . . . . 0.0 111.165 -179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.489 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.54 125.8 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.998 0 O-C-N 121.415 -0.803 . . . . 0.0 110.106 179.236 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.738 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -102.81 112.2 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.247 -0.908 . . . . 0.0 109.036 179.204 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.425 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.0 t0 -118.16 162.0 18.95 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.157 -0.964 . . . . 0.0 111.843 -178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.526 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 30.0 p -103.25 9.43 38.14 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.731 -0.606 . . . . 0.0 109.773 178.571 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.423 ' ND2' ' NE2' ' A' ' 110' ' ' GLN . 2.8 m-20 46.55 25.19 0.38 Allowed 'General case' 0 N--CA 1.497 1.898 0 O-C-N 121.118 -0.989 . . . . 0.0 111.424 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -147.01 136.42 22.76 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 120.967 -1.083 . . . . 0.0 110.514 179.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.417 ' N ' ' O ' ' A' ' 108' ' ' LYS . 60.1 p -113.12 126.66 55.7 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.372 -0.83 . . . . 0.0 110.124 179.845 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 52.74 35.61 19.01 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.306 -0.871 . . . . 0.0 110.773 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 84.24 -6.01 77.86 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.417 ' O ' ' N ' ' A' ' 105' ' ' SER . 72.1 mmtt -100.37 156.33 35.37 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 120.977 -1.308 . . . . 0.0 110.078 -179.788 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -65.5 129.18 21.86 Favored 'Trans proline' 0 C--N 1.309 -1.515 0 O-C-N 123.732 1.385 . . . . 0.0 110.514 -179.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.423 ' NE2' ' ND2' ' A' ' 103' ' ' ASN . 13.9 pt20 -51.08 152.87 2.1 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.484 -0.76 . . . . 0.0 110.857 -179.483 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.5 p30 -93.27 161.08 14.55 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.413 -0.804 . . . . 0.0 109.69 179.234 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.448 ' HB1' HG23 ' A' ' 4' ' ' THR . . . -43.13 -51.75 5.79 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.417 -0.802 . . . . 0.0 112.321 -178.618 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 12.7 m -69.71 -29.14 39.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.755 -1.216 . . . . 0.0 111.381 -178.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.417 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.5 -56.09 7.77 Favored 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.16 -0.962 . . . . 0.0 110.538 -179.075 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.412 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -68.04 -34.91 77.36 Favored 'General case' 0 C--N 1.305 -1.341 0 O-C-N 121.122 -0.986 . . . . 0.0 108.694 178.887 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.471 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 98.9 m -59.9 -49.92 75.8 Favored 'General case' 0 N--CA 1.486 1.342 0 O-C-N 121.122 -0.986 . . . . 0.0 108.464 178.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -73.75 -36.92 65.19 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.588 -0.695 . . . . 0.0 109.886 179.039 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HD3' ' OD2' ' A' ' 101' ' ' ASP . 13.6 mtt180 -71.16 -44.66 65.08 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.152 -0.967 . . . . 0.0 110.527 -179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.518 ' HD2' ' CG ' ' A' ' 7' ' ' HIS . 0.5 OUTLIER -58.55 -42.25 87.45 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.12 -0.987 . . . . 0.0 109.907 179.714 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -57.95 89.44 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 -179.932 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.503 ' HG2' HD22 ' A' ' 39' ' ' LEU . 6.0 tpp180 -169.68 -44.07 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.551 -0.97 . . . . 0.0 108.562 179.69 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.664 HG23 HG12 ' A' ' 10' ' ' ILE . 14.6 t -102.06 132.6 47.82 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.46 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 129.37 8.22 3.68 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 119.051 -1.547 . . . . 0.0 110.905 179.607 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.421 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 18.0 mmt180 -85.43 82.55 8.26 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.867 -1.372 . . . . 0.0 110.263 -179.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 117.66 -52.11 0.71 Allowed Glycine 0 N--CA 1.491 2.315 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 -179.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.46 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.7 OUTLIER -115.87 178.72 0.91 Allowed Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 121.599 -0.942 . . . . 0.0 109.34 179.371 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.8 Cg_endo -77.54 109.5 2.78 Favored 'Trans proline' 0 C--N 1.307 -1.608 0 O-C-N 123.536 1.282 . . . . 0.0 109.402 179.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.478 ' CA ' ' OG1' ' A' ' 122' ' ' THR . . . -75.53 161.78 52.9 Favored Glycine 0 N--CA 1.49 2.252 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.286 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 41.4 mt -119.64 142.65 34.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.415 -1.05 . . . . 0.0 109.378 179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' HD1' HG23 ' A' ' 99' ' ' VAL . 5.5 t80 -130.31 115.43 16.92 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.189 -0.944 . . . . 0.0 110.411 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.614 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 2.0 mtt180 -103.25 133.94 47.49 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.474 -0.766 . . . . 0.0 109.929 -179.925 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.458 ' CE1' ' HA ' ' A' ' 14' ' ' ALA . 8.2 p90 -127.11 152.44 47.31 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.178 -0.951 . . . . 0.0 110.233 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.407 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 24.9 t -77.5 -46.86 27.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 121.165 -0.96 . . . . 0.0 109.816 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.42 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -65.69 116.35 31.08 Favored Pre-proline 0 N--CA 1.492 1.672 0 O-C-N 121.365 -0.834 . . . . 0.0 110.736 -179.339 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.25 -23.75 15.23 Favored 'Trans proline' 0 C--N 1.315 -1.195 0 O-C-N 123.551 1.29 . . . . 0.0 110.726 179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -79.61 147.05 29.2 Favored Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.974 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -72.49 -51.52 19.74 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.168 -1.195 . . . . 0.0 110.151 179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.1 mtt-85 . . . . . 0 N--CA 1.491 1.624 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.294 179.981 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.07 153.66 22.29 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.308 -1.113 . . . . 0.0 110.289 -179.954 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 3' ' ' VAL . 33.7 m -113.42 104.52 17.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.435 0 O-C-N 121.235 -0.916 . . . . 0.0 110.026 179.679 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.685 HG22 ' OG1' ' A' ' 116' ' ' THR . 40.6 p -66.03 143.73 57.17 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.312 -0.868 . . . . 0.0 110.026 179.769 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.592 HG22 ' HD2' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -74.24 149.01 86.73 Favored Pre-proline 0 C--N 1.301 -1.52 0 O-C-N 121.236 -0.915 . . . . 0.0 109.579 179.656 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.521 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 41.8 Cg_endo -80.82 -57.94 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 124.229 1.647 . . . . 0.0 111.678 179.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.592 ' HD2' HG22 ' A' ' 5' ' ' VAL . 17.3 p80 38.34 83.07 0.21 Allowed Pre-proline 0 N--CA 1.492 1.627 0 CA-C-O 121.129 0.49 . . . . 0.0 111.787 -178.751 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_endo -72.21 58.14 2.88 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 O-C-N 123.329 1.173 . . . . 0.0 110.849 -179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.504 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.2 t-20 -114.3 -28.0 7.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.218 -0.926 . . . . 0.0 109.396 179.337 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.612 HD12 ' HG2' ' A' ' 119' ' ' ARG . 28.3 mt -102.11 136.68 33.09 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.109 -0.994 . . . . 0.0 109.774 179.45 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 7.1 tt0 -83.2 129.1 34.99 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.21 -0.932 . . . . 0.0 109.565 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 7.9 mt-10 -88.95 121.57 31.44 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.205 -0.935 . . . . 0.0 110.178 -179.28 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 10.8 t -116.47 157.15 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.447 -0.783 . . . . 0.0 110.101 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.84 111.33 23.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.179 -0.951 . . . . 0.0 109.906 179.456 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.672 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.0 tp -55.73 139.65 44.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.323 -0.86 . . . . 0.0 109.928 -179.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -136.45 -172.73 3.22 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.243 -0.911 . . . . 0.0 110.331 -179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -84.57 84.29 7.71 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.206 -0.934 . . . . 0.0 109.867 179.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.778 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 25.2 m -158.94 109.79 2.06 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.204 -0.935 . . . . 0.0 110.906 -179.484 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.422 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 150.34 -174.42 29.73 Favored Glycine 0 N--CA 1.488 2.162 0 C-N-CA 118.824 -1.655 . . . . 0.0 111.215 178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -108.03 -19.61 13.44 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.804 -0.821 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.3 tt -98.21 106.32 34.48 Favored Pre-proline 0 N--CA 1.49 1.569 0 C-N-CA 118.826 -1.15 . . . . 0.0 109.975 -179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.439 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.6 Cg_endo -62.94 123.42 12.22 Favored 'Trans proline' 0 C--N 1.313 -1.322 0 O-C-N 123.328 1.173 . . . . 0.0 110.768 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.428 ' O ' ' N ' ' A' ' 25' ' ' GLY . 4.0 t80 -111.49 -167.8 1.23 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.654 -0.654 . . . . 0.0 110.378 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.498 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 38.7 m-85 -58.92 81.37 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.461 -0.774 . . . . 0.0 111.148 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.72 3.85 56.16 Favored Glycine 0 N--CA 1.494 2.504 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 179.845 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.672 ' CB ' HD23 ' A' ' 15' ' ' LEU . 4.9 mmpt? -129.68 156.42 44.28 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.004 -1.292 . . . . 0.0 109.222 179.73 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.778 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.17 106.45 16.97 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.971 -1.081 . . . . 0.0 108.583 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.0 mt -69.76 113.43 17.29 Favored Pre-proline 0 C--N 1.301 -1.531 0 O-C-N 121.341 -0.849 . . . . 0.0 110.505 -178.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.786 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.8 Cg_endo -69.73 130.75 19.91 Favored 'Trans proline' 0 C--N 1.305 -1.722 0 N-CA-C 107.199 -1.885 . . . . 0.0 107.199 176.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.677 HD11 HD12 ' A' ' 58' ' ' LEU . 10.5 mt -56.76 -16.41 6.43 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.821 -1.174 . . . . 0.0 110.503 -178.26 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.43 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.08 -16.1 49.76 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.592 -1.318 . . . . 0.0 110.501 179.54 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.037 HG23 HG23 ' A' ' 33' ' ' ILE . 12.8 m -93.44 -25.79 4.81 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.939 0 O-C-N 120.958 -1.088 . . . . 0.0 111.088 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.037 HG23 HG23 ' A' ' 32' ' ' VAL . 24.8 pt -115.98 -26.0 2.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 121.038 -1.039 . . . . 0.0 109.977 -179.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.62 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -91.23 148.03 22.64 Favored 'General case' 0 C--N 1.298 -1.655 0 O-C-N 121.204 -0.935 . . . . 0.0 110.449 179.919 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 105.18 -4.74 41.3 Favored Glycine 0 N--CA 1.484 1.836 0 N-CA-C 109.369 -1.493 . . . . 0.0 109.369 -179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.6 -149.49 9.37 Favored Glycine 0 N--CA 1.493 2.436 0 C-N-CA 119.24 -1.457 . . . . 0.0 110.396 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.6 OUTLIER -106.61 129.95 54.45 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.353 -1.086 . . . . 0.0 110.344 -179.641 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.553 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 70.2 m80 -138.41 153.62 48.9 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.046 -1.034 . . . . 0.0 111.068 -179.518 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.649 HD12 ' O ' ' A' ' 82' ' ' VAL . 24.9 tp -113.21 114.0 26.13 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.346 -0.846 . . . . 0.0 109.818 179.6 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.955 HD12 HG12 ' A' ' 83' ' ' VAL . 38.4 mt -97.09 126.74 49.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.235 -0.916 . . . . 0.0 109.582 179.384 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.469 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 10.5 m-85 -95.01 123.74 38.66 Favored 'General case' 0 C--N 1.294 -1.825 0 O-C-N 121.345 -0.847 . . . . 0.0 110.16 -179.758 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.14 159.99 21.72 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.21 -0.931 . . . . 0.0 110.87 -179.724 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.498 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 27.8 p80 -104.4 -5.51 21.63 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.392 -0.818 . . . . 0.0 110.127 179.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.0 p -126.64 137.36 53.29 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.118 -0.989 . . . . 0.0 110.641 -179.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.522 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 22.0 ttpt -71.69 -43.3 66.21 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.656 -0.653 . . . . 0.0 110.737 -179.781 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.9 mptt -61.25 -36.94 81.35 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.253 -0.905 . . . . 0.0 110.655 -179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -67.67 -35.36 78.71 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.332 -0.855 . . . . 0.0 109.479 -179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.843 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 94.3 m -61.41 -34.87 76.1 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.454 -0.779 . . . . 0.0 109.398 179.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -63.59 -49.03 74.98 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.17 -0.956 . . . . 0.0 110.461 179.864 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -71.75 -40.4 69.37 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.176 -0.952 . . . . 0.0 110.467 -179.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.753 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -57.12 -39.98 76.2 Favored 'General case' 0 N--CA 1.496 1.828 0 O-C-N 121.488 -0.758 . . . . 0.0 110.931 -179.31 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.41 -51.35 13.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.037 -1.04 . . . . 0.0 110.391 -179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.35 -41.21 93.18 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.09 -1.006 . . . . 0.0 109.499 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.558 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.66 -46.87 83.66 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.429 -0.794 . . . . 0.0 109.654 179.452 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.81 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.18 -43.35 78.33 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.558 -0.714 . . . . 0.0 110.301 179.927 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 64.4 t -55.71 -33.17 33.16 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.028 -1.045 . . . . 0.0 109.173 179.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.17 -30.87 60.82 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.289 -0.882 . . . . 0.0 109.811 179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.677 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -72.01 -26.25 62.15 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.349 -0.844 . . . . 0.0 109.702 179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.59 6.44 9.52 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.282 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.63 HG22 HG22 ' A' ' 81' ' ' VAL . 48.4 mt -108.32 143.11 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.297 -1.119 . . . . 0.0 110.182 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.577 ' ND2' HD11 ' A' ' 74' ' ' ILE . 17.0 t30 -86.72 106.63 17.78 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.902 -1.518 . . . . 0.0 106.902 178.234 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.657 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.81 144.56 48.27 Favored 'General case' 0 C--N 1.296 -1.733 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.543 -177.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.938 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.7 t -134.52 145.1 33.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 179.186 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.843 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -108.84 128.79 55.21 Favored 'General case' 0 C--N 1.299 -1.602 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.987 179.274 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.465 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 2.7 t80 -118.14 137.12 53.18 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.336 -0.853 . . . . 0.0 110.381 -179.838 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.939 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.4 p90 -170.53 174.65 5.01 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.477 -0.764 . . . . 0.0 109.659 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.81 120.84 5.69 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.209 -0.932 . . . . 0.0 110.739 -179.194 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 85.28 34.36 14.61 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.949 -1.26 . . . . 0.0 109.949 179.531 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.966 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.6 tm? -117.02 156.24 27.84 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.132 -1.216 . . . . 0.0 109.971 179.949 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.966 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.0 m-20 -93.97 148.36 22.23 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.21 -0.931 . . . . 0.0 110.902 -179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.644 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.7 m -63.26 111.44 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.148 -0.97 . . . . 0.0 109.364 178.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.453 ' O ' HG23 ' A' ' 74' ' ' ILE . 5.4 m -134.76 -33.16 0.96 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.391 -0.818 . . . . 0.0 110.922 -179.551 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.938 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.9 t -53.93 140.09 11.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.136 -0.978 . . . . 0.0 110.305 -179.429 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.577 HD11 ' ND2' ' A' ' 61' ' ' ASN . 0.9 OUTLIER -137.8 91.77 13.34 Favored Pre-proline 0 N--CA 1.495 1.821 0 O-C-N 121.289 -0.882 . . . . 0.0 110.867 179.776 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -86.64 55.46 3.33 Favored 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.638 1.336 . . . . 0.0 109.797 179.013 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.4 p -129.71 -24.69 2.69 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.176 -0.953 . . . . 0.0 111.542 -179.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.5 m-80 -154.37 158.56 40.24 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.847 -1.158 . . . . 0.0 110.901 -179.516 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.13 162.35 0.07 OUTLIER Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.395 -1.482 . . . . 0.0 109.395 179.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -80.48 102.97 10.03 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.103 -1.234 . . . . 0.0 109.756 179.694 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.544 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.4 p -111.02 134.54 52.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.844 0 CA-C-O 121.922 0.867 . . . . 0.0 110.008 -179.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.63 HG22 HG22 ' A' ' 60' ' ' ILE . 6.3 m -112.09 125.92 69.43 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 O-C-N 121.433 -0.792 . . . . 0.0 109.215 179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.736 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.9 t -97.58 116.15 39.31 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.723 0 O-C-N 121.153 -0.967 . . . . 0.0 110.097 -178.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.955 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -110.65 100.2 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.085 -1.01 . . . . 0.0 108.75 179.714 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.465 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.24 163.19 33.52 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 120.557 -1.339 . . . . 0.0 111.541 -177.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.533 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -86.93 -135.2 0.08 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.609 -0.682 . . . . 0.0 109.378 179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.533 ' N ' HG23 ' A' ' 85' ' ' THR . 9.9 p-10 -90.09 42.94 1.12 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.723 -1.236 . . . . 0.0 110.477 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.447 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -113.99 -26.08 8.28 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.127 -0.983 . . . . 0.0 110.332 -179.996 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -76.29 -30.11 57.65 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.107 -0.996 . . . . 0.0 109.939 179.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.406 ' O ' ' HB ' ' A' ' 90' ' ' THR . 5.7 mmt 50.87 -115.47 0.87 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.382 -0.824 . . . . 0.0 109.764 -179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.646 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.07 42.87 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.949 0 O-C-N 120.528 -1.358 . . . . 0.0 110.012 179.823 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -67.27 -29.84 74.78 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.162 -1.575 . . . . 0.0 109.162 179.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.432 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 36.3 p90 -137.81 21.18 2.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.351 -1.087 . . . . 0.0 110.636 -179.78 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.646 HG22 ' OG1' ' A' ' 90' ' ' THR . 0.6 OUTLIER -100.89 -162.36 0.93 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.093 -1.004 . . . . 0.0 110.282 -179.859 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.615 ' N ' HG23 ' A' ' 93' ' ' THR . . . 118.98 11.87 7.37 Favored Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.928 -1.13 . . . . 0.0 110.325 179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 38.3 t0 -124.82 65.58 1.11 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 120.749 -1.442 . . . . 0.0 110.487 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.474 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 50.9 m-85 -119.81 152.83 36.67 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.048 -1.032 . . . . 0.0 110.476 179.677 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -90.38 -30.16 17.58 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.483 -0.761 . . . . 0.0 109.344 179.206 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.44 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.8 p -160.85 163.04 32.34 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.438 -0.789 . . . . 0.0 110.298 179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.454 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.41 122.67 53.79 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.955 0 O-C-N 121.118 -0.989 . . . . 0.0 110.391 179.511 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.827 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.7 mp -97.98 112.66 30.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.402 -0.811 . . . . 0.0 109.135 179.269 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.409 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 5.2 t0 -120.99 160.74 22.9 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.11 -0.994 . . . . 0.0 111.572 -178.723 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.447 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 14.0 t -100.64 5.55 43.85 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.68 -0.637 . . . . 0.0 109.459 178.102 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.414 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 49.2 24.43 0.97 Allowed 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.155 -0.966 . . . . 0.0 111.042 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 p -145.41 127.13 15.26 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.105 -0.997 . . . . 0.0 110.311 179.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 108' ' ' LYS . 96.4 p -107.67 130.91 54.88 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.286 -0.883 . . . . 0.0 110.144 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 25.1 t70 53.84 26.67 6.33 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.199 -0.938 . . . . 0.0 110.109 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.77 -33.09 5.39 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.423 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.2 OUTLIER -78.16 157.25 78.58 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.279 -1.13 . . . . 0.0 110.066 179.997 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -62.64 128.68 24.08 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 O-C-N 123.652 1.343 . . . . 0.0 110.358 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 16.1 pt20 -46.57 146.7 1.42 Allowed 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.613 -0.68 . . . . 0.0 111.241 -179.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.527 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.4 p30 -77.39 160.59 28.64 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.427 -0.796 . . . . 0.0 110.205 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.418 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.56 -52.87 12.54 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.364 -0.835 . . . . 0.0 112.065 -178.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.527 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.3 m -68.55 -28.93 42.16 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.801 0 O-C-N 120.82 -1.175 . . . . 0.0 111.423 -178.544 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.437 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.47 6.49 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.111 -0.993 . . . . 0.0 110.549 -179.258 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.7 OUTLIER -68.9 -34.64 75.75 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.203 -0.936 . . . . 0.0 108.738 178.934 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.685 ' OG1' HG22 ' A' ' 4' ' ' THR . 40.7 m -59.58 -49.96 75.74 Favored 'General case' 0 N--CA 1.486 1.328 0 C-N-CA 119.317 -0.953 . . . . 0.0 108.516 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.2 tt0 -73.75 -36.17 65.09 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.499 -0.75 . . . . 0.0 109.916 178.923 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.442 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 18.0 mtt180 -71.26 -44.58 64.99 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.167 -0.958 . . . . 0.0 110.736 -179.614 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.612 ' HG2' HD12 ' A' ' 10' ' ' ILE . 14.0 ttm180 -56.17 -43.35 78.29 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 120.957 -1.089 . . . . 0.0 110.402 -179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -64.72 79.56 0.06 OUTLIER Glycine 0 N--CA 1.493 2.47 0 N-CA-C 109.965 -1.254 . . . . 0.0 109.965 -179.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.487 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -152.08 -43.98 0.11 Allowed 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.286 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 8.8 t -100.24 144.05 29.71 Favored 'General case' 0 C--N 1.304 -1.41 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 178.299 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 95.7 14.65 46.03 Favored Glycine 0 N--CA 1.484 1.899 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.392 179.383 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.428 ' CB ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -58.68 -31.81 68.56 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.098 -1.237 . . . . 0.0 110.023 -179.921 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -133.86 20.73 4.04 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.284 -1.527 . . . . 0.0 109.284 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.488 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 0.0 OUTLIER -174.25 -165.42 0.05 OUTLIER Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.43 -1.041 . . . . 0.0 108.559 -179.539 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.504 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 50.1 Cg_endo -85.35 102.07 0.74 Allowed 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 122.89 0.942 . . . . 0.0 110.62 179.362 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.504 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.54 176.59 50.29 Favored Glycine 0 N--CA 1.497 2.767 0 N-CA-C 110.092 -1.203 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.44 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mt -131.35 142.85 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.486 -1.008 . . . . 0.0 109.05 179.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 18.7 t80 -131.27 116.0 17.05 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.071 -1.018 . . . . 0.0 110.962 -179.991 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.538 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 4.9 mtt180 -101.81 134.84 44.36 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.504 -0.747 . . . . 0.0 109.458 179.42 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.459 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 33.0 p90 -128.87 148.94 50.94 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.059 -1.026 . . . . 0.0 110.073 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.445 HG22 HD23 ' A' ' 15' ' ' LEU . 54.3 t -73.24 -37.7 52.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.177 -0.952 . . . . 0.0 109.886 179.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.414 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -132.21 143.62 49.7 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.217 -0.927 . . . . 0.0 110.315 -179.798 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.2 Cg_endo -73.62 -50.2 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.695 1.366 . . . . 0.0 110.265 179.967 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 140.44 -54.42 0.65 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 179.972 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.3 mt-10 -90.99 -55.74 3.44 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.298 -1.119 . . . . 0.0 110.279 -179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 23.7 mtt180 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.167 179.98 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.461 -1.456 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 112' ' ' ALA . 1.9 p -81.35 106.73 13.56 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.296 -1.12 . . . . 0.0 110.101 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.674 ' O ' HG13 ' A' ' 3' ' ' VAL . 9.2 p -113.01 104.05 16.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 O-C-N 121.208 -0.933 . . . . 0.0 110.01 179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 7.7 p -73.16 145.3 46.45 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 121.329 -0.857 . . . . 0.0 110.17 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.4 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -81.06 147.01 60.17 Favored Pre-proline 0 C--N 1.302 -1.495 0 O-C-N 121.336 -0.852 . . . . 0.0 109.752 179.686 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.4 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.5 Cg_endo -73.16 -165.09 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 124.066 1.561 . . . . 0.0 110.931 179.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.543 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 1.7 p80 -177.59 82.17 0.24 Allowed Pre-proline 0 C--N 1.302 -1.477 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.585 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -64.9 81.4 0.18 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.851 1.448 . . . . 0.0 110.708 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 1.6 m120 -172.18 -37.42 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.568 0 CA-C-O 121.365 0.602 . . . . 0.0 109.544 179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.516 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 13.7 mt -96.22 130.23 45.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.47 0 O-C-N 121.066 -1.021 . . . . 0.0 110.156 179.764 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.418 ' HB3' HG12 ' A' ' 129' ' ' ILE . 18.4 tt0 -84.95 129.43 34.8 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.408 -0.808 . . . . 0.0 109.684 179.414 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -88.44 133.03 34.23 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.084 -1.01 . . . . 0.0 109.928 -179.465 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.566 HG11 ' NE ' ' A' ' 131' ' ' ARG . 12.0 t -126.68 157.97 37.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.428 -0.795 . . . . 0.0 110.517 -179.044 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.66 110.74 23.01 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.259 -0.901 . . . . 0.0 109.902 179.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.414 HD23 ' CB ' ' A' ' 26' ' ' LYS . 10.7 tp -56.5 140.09 47.27 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.253 -0.905 . . . . 0.0 109.75 179.948 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 51.8 p -135.32 170.51 15.82 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.182 -0.949 . . . . 0.0 110.256 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -70.7 63.61 0.29 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.286 -0.884 . . . . 0.0 110.086 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.465 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.4 m -133.94 111.69 10.65 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.371 -0.831 . . . . 0.0 110.389 -179.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.26 -165.34 27.83 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.88 -1.629 . . . . 0.0 110.813 179.422 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -118.47 -19.14 8.95 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.736 -0.861 . . . . 0.0 110.304 179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.925 HD11 HD21 ' A' ' 51' ' ' LEU . 8.1 tt -96.54 113.24 62.26 Favored Pre-proline 0 N--CA 1.485 1.32 0 C-N-CA 118.318 -1.353 . . . . 0.0 110.428 -179.482 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.5 Cg_endo -65.46 144.2 78.69 Favored 'Trans proline' 0 C--N 1.312 -1.385 0 O-C-N 123.611 1.321 . . . . 0.0 109.626 179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.507 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 33.6 t80 -162.05 98.71 1.07 Allowed 'General case' 0 N--CA 1.489 1.479 0 C-N-CA 119.091 -1.043 . . . . 0.0 111.657 -178.639 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.487 ' N ' ' CD1' ' A' ' 24' ' ' TYR . 22.6 m-85 55.41 65.23 1.53 Allowed 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.335 -0.853 . . . . 0.0 111.599 178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.89 14.61 10.46 Favored Glycine 0 N--CA 1.494 2.509 0 N-CA-C 110.183 -1.167 . . . . 0.0 110.183 179.703 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.507 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 48.7 mmtt -130.89 156.21 45.44 Favored 'General case' 0 N--CA 1.487 1.409 0 O-C-N 121.069 -1.253 . . . . 0.0 108.938 179.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.465 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.43 106.48 14.03 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 120.901 -1.125 . . . . 0.0 109.466 179.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.982 HD11 HG21 ' A' ' 100' ' ' ILE . 3.9 mt -68.63 114.84 24.93 Favored Pre-proline 0 C--N 1.298 -1.643 0 C-N-CA 119.707 -0.797 . . . . 0.0 110.072 -179.721 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.77 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -69.51 128.66 16.59 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 N-CA-C 106.582 -2.122 . . . . 0.0 106.582 176.267 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.763 HD11 HD12 ' A' ' 58' ' ' LEU . 14.0 mt -55.53 -18.86 8.22 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.923 -1.111 . . . . 0.0 110.49 -177.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -59.06 -16.55 19.47 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.727 -1.233 . . . . 0.0 110.554 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 11.0 m -92.51 -24.13 5.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.94 -1.1 . . . . 0.0 110.951 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 6.9 pt -119.44 -20.31 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.965 -1.084 . . . . 0.0 110.979 -179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.527 ' HB2' HD11 ' A' ' 60' ' ' ILE . 4.6 tptm -93.48 148.47 22.05 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.93 -1.106 . . . . 0.0 110.415 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.85 -2.89 67.03 Favored Glycine 0 N--CA 1.485 1.956 0 N-CA-C 109.803 -1.319 . . . . 0.0 109.803 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -173.09 -158.69 18.09 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.993 -1.575 . . . . 0.0 110.658 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.5 OUTLIER -107.54 132.8 52.86 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.448 -1.031 . . . . 0.0 110.185 -179.618 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.512 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.8 m80 -141.1 153.16 45.3 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.216 -0.927 . . . . 0.0 110.918 -179.431 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.614 HD12 ' O ' ' A' ' 82' ' ' VAL . 49.9 tp -113.3 114.39 26.62 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.838 . . . . 0.0 110.257 179.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.753 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.0 mt -97.28 128.77 48.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.099 -1.001 . . . . 0.0 109.572 179.363 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.408 ' HA ' ' O ' ' A' ' 84' ' ' ALA . 7.9 m-85 -97.59 123.29 41.43 Favored 'General case' 0 C--N 1.293 -1.88 0 O-C-N 121.136 -0.977 . . . . 0.0 110.406 -179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.37 159.89 22.03 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.35 -0.843 . . . . 0.0 110.369 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 18.6 p-80 -104.73 -5.57 21.16 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.367 -0.833 . . . . 0.0 110.089 179.151 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 24.8 p -128.14 139.84 52.26 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.003 -1.06 . . . . 0.0 110.856 -179.552 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 8.6 tttm -71.88 -39.56 69.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.636 -0.665 . . . . 0.0 110.45 179.867 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -59.03 -33.43 70.73 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.378 -0.826 . . . . 0.0 110.698 -179.659 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' CB ' ' A' ' 51' ' ' LEU . 4.3 tppt? -72.72 -37.05 67.89 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.331 -0.856 . . . . 0.0 109.914 -179.574 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 69.7 m -62.17 -36.4 81.75 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.659 179.519 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -66.31 -50.23 64.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.06 -1.025 . . . . 0.0 110.301 179.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.8 mm-40 -72.67 -44.82 61.32 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.288 -0.883 . . . . 0.0 110.379 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.925 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -61.27 -36.88 81.24 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.542 -0.723 . . . . 0.0 111.56 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.426 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.75 -51.7 12.08 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 120.853 -1.154 . . . . 0.0 110.793 -179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -58.81 -38.17 78.01 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.028 -1.045 . . . . 0.0 109.567 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.801 ' HE2' HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.1 -46.53 82.51 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.626 -0.671 . . . . 0.0 109.42 179.293 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.74 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.68 -40.18 71.97 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.401 -0.812 . . . . 0.0 110.174 179.911 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 90.1 t -59.13 -30.91 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.092 -1.005 . . . . 0.0 109.135 179.264 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.78 -33.73 60.19 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.475 -0.766 . . . . 0.0 110.027 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.763 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.3 -25.53 62.47 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.389 -0.82 . . . . 0.0 109.714 179.958 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.77 7.07 8.97 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.261 -1.536 . . . . 0.0 109.261 -179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.699 ' CD1' HD22 ' A' ' 30' ' ' LEU . 39.4 mt -107.76 142.72 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.379 0 O-C-N 121.262 -1.14 . . . . 0.0 109.836 -179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.661 ' ND2' HD11 ' A' ' 74' ' ' ILE . 28.7 t30 -88.82 106.49 18.41 Favored 'General case' 0 C--N 1.306 -1.301 0 N-CA-C 106.664 -1.606 . . . . 0.0 106.664 177.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.68 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -115.92 141.75 47.69 Favored 'General case' 0 C--N 1.297 -1.717 0 C-N-CA 118.785 -1.166 . . . . 0.0 111.504 -177.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 58.7 t -122.98 143.2 36.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.729 -0.607 . . . . 0.0 109.972 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.32 117.86 34.29 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.33 -0.948 . . . . 0.0 109.351 178.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.463 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 0.3 OUTLIER -108.33 127.12 53.59 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.194 -0.941 . . . . 0.0 111.067 -179.28 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.869 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 7.3 p90 -157.56 -179.19 7.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.705 -0.622 . . . . 0.0 109.631 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 6.3 ttt180 -54.2 127.02 25.19 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.09 -1.006 . . . . 0.0 110.993 -179.334 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.48 44.35 21.72 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 110.002 -1.239 . . . . 0.0 110.002 179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.869 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.3 tm? -116.61 154.92 29.66 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.1 -1.235 . . . . 0.0 109.879 179.713 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.838 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.7 m-20 -94.79 149.57 21.11 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.384 -0.823 . . . . 0.0 110.515 -179.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.664 HG23 ' O ' ' A' ' 71' ' ' VAL . 31.0 m -61.78 110.62 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 C-N-CA 118.978 -1.089 . . . . 0.0 108.774 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.847 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.5 m -130.69 -34.7 1.52 Allowed 'General case' 0 C--N 1.298 -1.637 0 O-C-N 121.439 -0.788 . . . . 0.0 110.244 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 91.2 t -46.89 129.88 3.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.455 -0.778 . . . . 0.0 109.916 179.437 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.847 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -136.21 92.99 15.3 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.017 -1.052 . . . . 0.0 111.147 -179.145 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -82.82 53.4 4.4 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.705 1.371 . . . . 0.0 109.601 178.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.9 p -147.09 19.38 1.24 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.305 -0.872 . . . . 0.0 110.394 -179.271 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -123.35 -164.48 1.22 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.213 -0.929 . . . . 0.0 109.949 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.76 -77.86 0.11 Allowed Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 47.7 m-20 -146.83 113.39 5.99 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.15 -1.206 . . . . 0.0 110.344 179.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.62 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.5 p -117.27 133.92 62.49 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.724 0 CA-C-O 121.992 0.901 . . . . 0.0 110.456 -179.952 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.659 HG11 ' HB ' ' A' ' 33' ' ' ILE . 12.6 m -112.6 122.02 66.02 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.102 0 O-C-N 121.331 -0.856 . . . . 0.0 108.993 179.147 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.782 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -96.93 119.55 45.13 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.679 0 O-C-N 120.843 -1.161 . . . . 0.0 110.721 -177.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.753 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.4 m -110.17 99.54 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.313 0 C-N-CA 118.889 -1.124 . . . . 0.0 109.011 179.392 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.463 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -132.39 162.12 31.91 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.686 -1.258 . . . . 0.0 110.31 -178.799 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.6 HG23 ' OD2' ' A' ' 86' ' ' ASP . 7.1 t -99.12 -27.93 13.6 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.21 -0.931 . . . . 0.0 110.655 -179.286 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.6 ' OD2' HG23 ' A' ' 85' ' ' THR . 1.3 p30 177.96 -30.13 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.928 0 O-C-N 121.387 -0.821 . . . . 0.0 110.247 -179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.493 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.34 -25.59 0.67 Allowed 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.225 -0.922 . . . . 0.0 110.928 -179.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.453 HD11 ' HZ ' ' A' ' 92' ' ' PHE . 14.6 tp -61.99 -34.45 76.19 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.169 -0.957 . . . . 0.0 109.769 179.753 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.503 ' C ' HG22 ' A' ' 90' ' ' THR . 14.8 mmt 48.17 47.02 19.65 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.441 -0.787 . . . . 0.0 110.906 179.761 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.569 ' OG1' HG22 ' A' ' 93' ' ' THR . 2.6 t 34.73 -128.05 0.09 Allowed 'General case' 0 N--CA 1.506 2.33 0 O-C-N 122.065 -0.397 . . . . 0.0 112.019 179.362 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.431 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 93.64 -61.49 2.04 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 108.384 -1.886 . . . . 0.0 108.384 -179.122 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.453 ' HZ ' HD11 ' A' ' 88' ' ' LEU . 33.2 p90 -121.93 3.4 9.97 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.459 -1.024 . . . . 0.0 109.946 178.827 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.569 HG22 ' OG1' ' A' ' 90' ' ' THR . 13.1 t -67.36 -160.84 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.091 -1.006 . . . . 0.0 109.819 179.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 91.34 -39.37 3.07 Favored Glycine 0 N--CA 1.489 2.175 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 12.9 p-10 -84.23 57.02 4.01 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.104 -1.233 . . . . 0.0 110.73 -179.49 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.543 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 28.4 m-85 -119.23 149.49 41.68 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.127 -0.983 . . . . 0.0 110.047 179.235 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.44 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 9.6 m-20 -78.59 -30.76 46.86 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.354 -0.842 . . . . 0.0 109.623 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.6 p -161.67 163.21 29.96 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.216 -0.927 . . . . 0.0 110.914 179.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -129.17 114.35 31.73 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.976 0 O-C-N 121.35 -0.844 . . . . 0.0 110.175 179.207 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.982 HG21 HD11 ' A' ' 28' ' ' ILE . 3.8 mp -93.09 112.44 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.012 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.42 ' CB ' ' OH ' ' A' ' 130' ' ' TYR . 2.8 t0 -118.81 160.87 21.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.122 -0.986 . . . . 0.0 111.742 -177.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.452 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 57.0 m -98.49 2.3 47.5 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.649 -0.657 . . . . 0.0 109.316 177.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.656 ' HB3' ' HB3' ' A' ' 134' ' ' ALA . 2.4 m120 53.85 24.88 4.79 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.147 -0.971 . . . . 0.0 111.117 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.0 p -147.15 129.62 15.86 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.048 -1.032 . . . . 0.0 110.961 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.8 p -103.38 134.04 47.43 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.364 -0.835 . . . . 0.0 109.332 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER 49.09 27.23 1.66 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.192 -0.942 . . . . 0.0 110.474 -179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.16 -32.73 5.71 Favored Glycine 0 N--CA 1.494 2.529 0 N-CA-C 109.625 -1.39 . . . . 0.0 109.625 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.435 ' O ' ' N ' ' A' ' 105' ' ' SER . 9.8 mmpt? -76.7 157.36 82.15 Favored Pre-proline 0 N--CA 1.489 1.519 0 O-C-N 121.354 -1.086 . . . . 0.0 110.148 -179.984 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -64.45 130.14 25.87 Favored 'Trans proline' 0 C--N 1.309 -1.521 0 O-C-N 123.578 1.304 . . . . 0.0 110.153 -179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.427 ' HB2' ' HB3' ' A' ' 114' ' ' SER . 4.3 pt20 -51.73 153.99 2.2 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.455 -0.778 . . . . 0.0 110.984 -179.08 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.532 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.1 p30 -85.28 161.5 19.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.256 -0.902 . . . . 0.0 110.287 179.724 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 2' ' ' SER . . . -41.71 -57.93 2.15 Favored 'General case' 0 N--CA 1.499 1.981 0 O-C-N 121.553 -0.717 . . . . 0.0 112.486 -178.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.532 HG22 ' OD1' ' A' ' 111' ' ' ASP . 8.1 m -67.36 -29.64 46.4 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.85 0 O-C-N 120.694 -1.254 . . . . 0.0 111.498 -178.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.427 ' HB3' ' HB2' ' A' ' 110' ' ' GLN . 0.1 OUTLIER -47.51 -56.08 7.8 Favored 'General case' 0 N--CA 1.498 1.964 0 O-C-N 121.122 -0.986 . . . . 0.0 110.487 -179.29 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.464 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 2.5 ptm180 -67.09 -34.11 76.92 Favored 'General case' 0 C--N 1.306 -1.283 0 C-N-CA 119.122 -1.031 . . . . 0.0 108.572 178.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 31.7 m -59.29 -48.88 79.97 Favored 'General case' 0 N--CA 1.485 1.28 0 O-C-N 121.066 -1.021 . . . . 0.0 108.398 178.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -73.07 -35.77 66.73 Favored 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 119.767 -0.773 . . . . 0.0 109.797 178.792 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.448 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 0.8 OUTLIER -70.54 -45.09 66.15 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.106 -0.996 . . . . 0.0 110.48 -179.845 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.543 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.1 ttm180 -59.39 -40.79 87.71 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.984 -1.073 . . . . 0.0 110.013 179.78 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -65.32 75.8 0.09 OUTLIER Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.437 ' HG2' ' CD2' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -149.06 -45.16 0.14 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.501 -1.0 . . . . 0.0 108.606 179.367 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.541 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -98.15 143.34 28.78 Favored 'General case' 0 C--N 1.302 -1.487 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 178.493 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.56 12.5 10.49 Favored Glycine 0 N--CA 1.489 2.229 0 C-N-CA 119.408 -1.377 . . . . 0.0 110.536 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -79.54 85.14 5.32 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.01 -1.288 . . . . 0.0 109.828 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.401 ' O ' ' HB3' ' A' ' 126' ' ' LYS . . . 98.7 17.19 29.06 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.287 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 4.5 pttt -177.01 -177.05 0.25 Allowed Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.549 -0.971 . . . . 0.0 108.395 -179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.479 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 45.8 Cg_endo -88.98 106.96 0.44 Allowed 'Trans proline' 0 C--N 1.308 -1.587 0 O-C-N 123.168 1.088 . . . . 0.0 109.49 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.541 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.02 174.02 49.73 Favored Glycine 0 N--CA 1.492 2.428 0 C-N-CA 119.646 -1.264 . . . . 0.0 110.311 -179.126 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' O ' ' HA ' ' A' ' 98' ' ' SER . 20.3 mt -130.24 141.85 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.532 -0.981 . . . . 0.0 108.863 179.124 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.489 ' CD2' ' HA ' ' A' ' 119' ' ' ARG . 12.8 t80 -132.17 115.91 16.31 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.13 -1.028 . . . . 0.0 110.867 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.566 ' NE ' HG11 ' A' ' 13' ' ' VAL . 0.3 OUTLIER -102.63 122.14 43.81 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.876 -0.786 . . . . 0.0 108.876 179.213 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.409 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 39.1 p90 -115.16 158.09 22.72 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.989 -1.069 . . . . 0.0 110.247 -179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 44.5 t -98.0 -30.79 3.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.149 -0.969 . . . . 0.0 110.382 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.656 ' HB3' ' HB3' ' A' ' 103' ' ' ASN . . . -95.72 117.74 66.32 Favored Pre-proline 0 N--CA 1.492 1.631 0 O-C-N 121.18 -0.95 . . . . 0.0 110.555 -179.358 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -85.15 47.3 2.01 Favored 'Trans proline' 0 C--N 1.314 -1.239 0 O-C-N 123.514 1.27 . . . . 0.0 110.377 179.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -66.03 -136.5 0.03 OUTLIER Glycine 0 N--CA 1.491 2.323 0 N-CA-C 109.774 -1.33 . . . . 0.0 109.774 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.5 tp10 55.57 34.76 23.81 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.309 -1.112 . . . . 0.0 110.235 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 29.5 ttt85 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.055 179.821 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 4.3 p -77.25 143.44 38.94 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.235 -1.156 . . . . 0.0 110.077 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.622 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.1 m -112.92 103.93 16.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.193 -0.942 . . . . 0.0 110.029 179.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.48 HG21 ' HD2' ' A' ' 115' ' ' ARG . 61.1 p -103.39 143.14 33.08 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.37 -0.831 . . . . 0.0 110.34 179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.455 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.23 149.45 98.43 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.278 -0.889 . . . . 0.0 109.452 179.468 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.455 ' HD2' HG23 ' A' ' 5' ' ' VAL . 40.8 Cg_endo -68.49 -165.3 0.12 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 124.001 1.527 . . . . 0.0 110.585 179.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.562 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.4 OUTLIER 173.38 82.46 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.837 0 O-C-N 121.495 -0.753 . . . . 0.0 109.966 -179.96 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_endo -69.39 66.5 1.55 Allowed 'Trans proline' 0 C--N 1.309 -1.549 0 O-C-N 123.675 1.355 . . . . 0.0 109.849 179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.417 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 6.6 t-20 -153.64 -34.86 0.11 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.552 -0.717 . . . . 0.0 110.619 -179.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.531 HD12 ' HG2' ' A' ' 119' ' ' ARG . 45.2 mt -103.44 128.26 56.7 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 120.876 -1.14 . . . . 0.0 110.201 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -84.35 127.95 34.29 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.225 -0.922 . . . . 0.0 109.117 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 18.1 mt-10 -89.61 142.02 28.06 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.031 -1.043 . . . . 0.0 110.403 -179.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.531 HG11 ' NE ' ' A' ' 131' ' ' ARG . 4.8 t -128.98 157.7 41.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.496 -0.752 . . . . 0.0 109.881 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.62 112.3 25.32 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.214 -0.929 . . . . 0.0 110.349 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 13.5 tp -62.89 135.63 57.42 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.219 -0.925 . . . . 0.0 109.317 179.356 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.4 p -137.2 -178.2 5.11 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.006 -1.059 . . . . 0.0 110.621 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.0 p -77.86 81.28 4.28 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.396 -0.815 . . . . 0.0 109.773 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.671 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 3.5 m -156.64 113.56 3.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.227 -0.921 . . . . 0.0 110.607 -179.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.436 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 146.99 -168.2 28.22 Favored Glycine 0 N--CA 1.487 2.074 0 C-N-CA 118.835 -1.65 . . . . 0.0 111.093 179.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.7 mm-40 -115.44 -20.85 10.08 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.805 -0.821 . . . . 0.0 110.28 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.928 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -96.84 107.74 38.96 Favored Pre-proline 0 N--CA 1.489 1.49 0 C-N-CA 118.821 -1.152 . . . . 0.0 109.758 -179.832 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.414 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.58 126.99 17.87 Favored 'Trans proline' 0 C--N 1.312 -1.382 0 O-C-N 123.347 1.182 . . . . 0.0 110.841 -178.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -116.28 -169.77 1.68 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.557 -0.715 . . . . 0.0 110.355 -179.417 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.521 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 39.2 m-85 -57.47 81.21 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.472 -0.768 . . . . 0.0 111.564 -179.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.82 -1.21 59.43 Favored Glycine 0 N--CA 1.495 2.57 0 O-C-N 121.089 -1.007 . . . . 0.0 110.738 179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.405 ' HD2' ' O ' ' A' ' 15' ' ' LEU . 0.5 OUTLIER -129.64 156.9 43.48 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.876 -1.367 . . . . 0.0 110.007 -179.882 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.671 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -104.81 106.87 17.55 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.101 -0.999 . . . . 0.0 108.872 179.42 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.928 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.9 mt -68.35 113.09 13.23 Favored Pre-proline 0 C--N 1.301 -1.509 0 O-C-N 121.233 -0.917 . . . . 0.0 110.705 -179.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.871 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.5 Cg_endo -68.94 130.63 20.7 Favored 'Trans proline' 0 C--N 1.306 -1.671 0 N-CA-C 107.174 -1.895 . . . . 0.0 107.174 175.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.702 HD11 HD12 ' A' ' 58' ' ' LEU . 13.0 mt -56.27 -19.02 12.32 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.858 -1.151 . . . . 0.0 110.158 -178.108 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.457 ' OE2' HG12 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -59.7 -16.12 24.62 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.64 -1.287 . . . . 0.0 110.425 179.699 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.001 HG23 HG23 ' A' ' 33' ' ' ILE . 16.9 m -91.79 -25.05 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.915 -1.116 . . . . 0.0 110.857 179.916 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.001 HG23 HG23 ' A' ' 32' ' ' VAL . 38.7 pt -119.4 -20.7 4.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.042 -1.036 . . . . 0.0 111.154 -178.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.594 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.2 tptm -92.92 148.28 22.14 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 120.946 -1.096 . . . . 0.0 110.082 179.536 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.99 -5.35 46.24 Favored Glycine 0 N--CA 1.484 1.896 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 -179.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.65 -157.93 21.97 Favored Glycine 0 N--CA 1.492 2.387 0 C-N-CA 119.175 -1.488 . . . . 0.0 110.282 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 1.0 OUTLIER -97.8 133.0 42.9 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.452 -1.028 . . . . 0.0 110.316 -179.789 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 81.4 m-70 -140.3 149.2 42.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.19 -0.944 . . . . 0.0 110.787 179.981 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.467 HD12 ' O ' ' A' ' 82' ' ' VAL . 26.7 tp -111.39 114.09 27.0 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.431 -0.793 . . . . 0.0 110.098 179.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.836 HD12 HG12 ' A' ' 83' ' ' VAL . 35.0 mt -96.65 127.7 48.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.177 -0.952 . . . . 0.0 109.785 179.522 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 14.0 m-85 -95.33 123.42 38.84 Favored 'General case' 0 C--N 1.296 -1.741 0 O-C-N 121.612 -0.68 . . . . 0.0 109.915 -179.952 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -117.76 157.05 27.22 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.718 -179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.521 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 18.1 p80 -104.46 0.91 29.42 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.338 -0.851 . . . . 0.0 109.983 178.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.8 p -131.47 138.07 48.85 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.125 -0.985 . . . . 0.0 110.283 179.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.413 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.8 ttpt -71.66 -41.89 68.19 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.513 -0.742 . . . . 0.0 110.875 -179.635 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 27.8 mttt -59.9 -33.77 72.3 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.292 -0.88 . . . . 0.0 110.806 -179.542 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.512 ' HD3' ' CE1' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -68.23 -39.6 82.29 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.285 -0.884 . . . . 0.0 109.919 -179.5 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.874 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.8 m -61.21 -34.67 75.47 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.321 -0.862 . . . . 0.0 109.743 179.576 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -65.59 -50.38 65.33 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.044 -1.035 . . . . 0.0 110.284 -179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 -72.98 -46.14 54.0 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.173 -0.955 . . . . 0.0 110.401 179.715 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.799 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.02 -36.51 70.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.667 -0.646 . . . . 0.0 111.41 -178.831 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.488 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.84 -51.12 13.25 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.851 -1.156 . . . . 0.0 110.704 -179.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.11 -39.4 89.84 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.032 -1.042 . . . . 0.0 109.86 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.544 ' HE3' HD21 ' A' ' 58' ' ' LEU . 1.8 tmtp? -57.2 -45.83 83.41 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.305 -0.872 . . . . 0.0 109.562 179.505 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.874 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.33 -39.92 70.58 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 121.527 -0.733 . . . . 0.0 110.086 179.864 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 68.0 t -57.91 -34.86 49.61 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.064 -1.022 . . . . 0.0 108.971 179.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.2 -30.83 60.75 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.412 -0.805 . . . . 0.0 110.238 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.702 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.55 -25.91 62.41 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.317 -0.864 . . . . 0.0 109.835 179.89 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.1 4.69 10.05 Favored Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.155 -1.578 . . . . 0.0 109.155 -179.165 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.666 ' CD1' HD22 ' A' ' 30' ' ' LEU . 46.0 mt -107.58 143.4 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.405 0 O-C-N 121.354 -1.086 . . . . 0.0 109.921 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.465 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 55.5 t30 -89.45 106.87 18.73 Favored 'General case' 0 C--N 1.305 -1.345 0 N-CA-C 106.509 -1.663 . . . . 0.0 106.509 178.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.666 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.22 143.48 45.83 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.71 -1.196 . . . . 0.0 112.267 -176.655 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.924 HG21 ' HA ' ' A' ' 73' ' ' VAL . 85.2 t -124.29 151.89 29.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 N-CA-C 109.286 -0.635 . . . . 0.0 109.286 179.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.874 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -121.24 118.29 29.22 Favored 'General case' 0 C--N 1.3 -1.552 0 C-N-CA 119.178 -1.009 . . . . 0.0 109.736 178.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.497 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 1.9 t80 -108.82 133.82 52.35 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.297 -0.877 . . . . 0.0 110.562 -179.605 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.961 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.5 p90 -165.83 -173.32 2.64 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.435 -0.79 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 3.3 ttp180 -58.81 125.41 23.37 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.04 42.54 29.22 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.961 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.11 155.45 29.29 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.197 -1.178 . . . . 0.0 109.954 179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.815 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.5 m-20 -97.27 149.17 22.35 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.277 -0.889 . . . . 0.0 110.69 -179.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.677 HG23 ' O ' ' A' ' 71' ' ' VAL . 32.4 m -62.96 110.98 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.2 -0.938 . . . . 0.0 109.187 179.174 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.703 ' O ' HG23 ' A' ' 74' ' ' ILE . 72.8 m -131.38 -32.47 1.54 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.403 -0.811 . . . . 0.0 110.737 -179.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.924 ' HA ' HG21 ' A' ' 63' ' ' VAL . 99.7 t -47.89 134.56 4.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.409 -0.807 . . . . 0.0 110.176 -179.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.703 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 92.51 14.09 Favored Pre-proline 0 N--CA 1.494 1.772 0 O-C-N 121.126 -0.984 . . . . 0.0 111.109 -179.763 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_endo -83.16 51.43 3.63 Favored 'Trans proline' 0 C--N 1.31 -1.482 0 O-C-N 123.625 1.329 . . . . 0.0 109.714 178.731 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -146.24 13.89 1.27 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.189 -0.945 . . . . 0.0 111.037 -178.939 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -135.86 -149.9 0.35 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.044 -1.035 . . . . 0.0 109.815 179.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.27 174.64 0.11 Allowed Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.531 -1.428 . . . . 0.0 109.531 179.798 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 67.9 m-20 -56.46 114.98 2.24 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.19 -1.183 . . . . 0.0 110.37 -179.806 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.3 p -116.49 134.72 59.03 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.63 0 CA-C-O 121.99 0.9 . . . . 0.0 109.865 179.771 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.601 HG22 HG22 ' A' ' 60' ' ' ILE . 16.5 m -112.89 123.5 68.61 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.225 0 O-C-N 121.331 -0.855 . . . . 0.0 109.558 179.894 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.761 HG22 HG13 ' A' ' 73' ' ' VAL . 10.8 t -97.9 116.39 40.39 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 O-C-N 120.909 -1.119 . . . . 0.0 110.622 -178.139 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.836 HG12 HD12 ' A' ' 40' ' ' ILE . 2.8 m -107.83 100.42 10.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.967 -1.083 . . . . 0.0 108.564 179.529 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.497 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -135.65 162.21 33.36 Favored 'General case' 0 C--N 1.299 -1.597 0 O-C-N 120.723 -1.235 . . . . 0.0 111.337 -177.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.423 ' H ' HG22 ' A' ' 85' ' ' THR . 5.4 t -91.61 -132.88 0.12 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.689 -0.632 . . . . 0.0 109.619 179.785 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -90.12 21.38 3.76 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.682 -1.261 . . . . 0.0 110.625 -179.964 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.467 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -90.29 -34.87 15.58 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.187 -0.945 . . . . 0.0 109.651 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tp -69.73 -46.46 65.85 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 109.603 179.457 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.419 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 1.2 mmt 53.32 21.0 2.13 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.341 -0.85 . . . . 0.0 110.211 -179.88 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.484 HG21 ' HG3' ' A' ' 121' ' ' ARG . 0.3 OUTLIER 45.46 36.26 2.36 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.456 -0.777 . . . . 0.0 110.83 179.802 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.84 -70.87 0.79 Allowed Glycine 0 N--CA 1.494 2.536 0 N-CA-C 109.428 -1.469 . . . . 0.0 109.428 179.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 37.9 p90 -99.54 41.63 1.14 Allowed 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.235 -1.156 . . . . 0.0 108.932 178.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.418 HG21 ' CZ ' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -139.23 -156.67 0.7 Allowed 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.588 -0.695 . . . . 0.0 110.044 -179.35 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.461 ' N ' HG22 ' A' ' 90' ' ' THR . . . 126.73 -25.99 5.21 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.974 -1.25 . . . . 0.0 109.974 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -89.48 80.32 6.75 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -1.209 . . . . 0.0 110.694 -179.572 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.418 ' CZ ' HG21 ' A' ' 93' ' ' THR . 46.4 m-85 -119.21 148.47 43.08 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.123 -0.986 . . . . 0.0 109.971 179.237 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -75.79 -32.2 59.78 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.294 -0.879 . . . . 0.0 109.254 179.111 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.2 p -161.17 163.6 31.1 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.345 -0.847 . . . . 0.0 110.964 179.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.574 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -130.02 117.51 41.06 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.367 -0.833 . . . . 0.0 110.689 179.772 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.883 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -93.4 112.13 25.96 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 N-CA-C 108.222 -1.029 . . . . 0.0 108.222 178.572 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.9 t0 -120.8 160.69 22.86 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.138 -0.976 . . . . 0.0 111.52 -178.142 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.469 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 13.6 t -99.98 8.23 44.18 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.65 -0.656 . . . . 0.0 109.595 178.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.411 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 2.4 m120 46.95 25.94 0.53 Allowed 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.269 -0.894 . . . . 0.0 110.703 -179.627 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.7 p -147.31 129.73 15.8 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.242 -0.911 . . . . 0.0 110.094 179.492 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.436 ' N ' ' O ' ' A' ' 108' ' ' LYS . 5.6 p -113.97 133.66 55.34 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.15 -0.969 . . . . 0.0 110.175 179.877 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER 53.2 28.78 7.46 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.193 -0.942 . . . . 0.0 110.461 179.927 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.06 -35.07 4.24 Favored Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.816 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.436 ' O ' ' N ' ' A' ' 105' ' ' SER . 1.9 mttm -79.47 156.46 75.81 Favored Pre-proline 0 N--CA 1.492 1.638 0 O-C-N 121.188 -1.184 . . . . 0.0 110.056 179.985 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -66.16 135.5 40.55 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 O-C-N 123.6 1.316 . . . . 0.0 110.203 -179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -49.54 165.74 0.06 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.289 -0.882 . . . . 0.0 110.821 -179.105 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.522 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -97.22 161.32 13.86 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.248 -0.908 . . . . 0.0 110.278 179.792 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.14 -53.18 5.13 Favored 'General case' 0 N--CA 1.497 1.895 0 O-C-N 121.513 -0.742 . . . . 0.0 112.256 -178.856 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.522 HG22 ' OD1' ' A' ' 111' ' ' ASP . 15.1 m -70.49 -29.07 37.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 120.719 -1.238 . . . . 0.0 111.41 -178.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.419 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.39 -56.45 6.88 Favored 'General case' 0 N--CA 1.497 1.882 0 O-C-N 121.168 -0.957 . . . . 0.0 110.453 -179.064 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.48 ' HD2' HG21 ' A' ' 4' ' ' THR . 16.3 ptp180 -68.9 -35.18 76.55 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.236 -0.915 . . . . 0.0 108.666 178.721 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.432 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 26.9 m -59.31 -49.89 76.08 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.13 -0.981 . . . . 0.0 108.566 178.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 49.5 tt0 -73.74 -38.56 64.71 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.448 -0.782 . . . . 0.0 110.053 178.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.423 ' O ' ' HB2' ' A' ' 121' ' ' ARG . 19.1 mtt180 -70.47 -44.66 67.26 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.245 -0.909 . . . . 0.0 110.84 -179.609 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.562 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 1.3 ttp180 -55.32 -48.7 73.76 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.297 -0.877 . . . . 0.0 110.491 -179.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -49.23 -18.85 1.45 Allowed Glycine 0 N--CA 1.498 2.825 0 O-C-N 121.529 -0.732 . . . . 0.0 112.327 -178.537 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.484 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -56.65 -35.5 68.46 Favored 'General case' 0 N--CA 1.499 1.995 0 O-C-N 120.529 -1.571 . . . . 0.0 112.007 -178.678 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.458 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.3 t -100.11 144.67 28.87 Favored 'General case' 0 N--CA 1.497 1.914 0 O-C-N 120.696 -1.253 . . . . 0.0 111.503 -179.0 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.439 ' CA ' ' O ' ' A' ' 126' ' ' LYS . . . 92.61 8.08 62.63 Favored Glycine 0 N--CA 1.486 2.007 0 C-N-CA 119.753 -1.213 . . . . 0.0 110.593 178.679 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.406 ' HD2' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.09 86.82 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.085 -1.244 . . . . 0.0 109.017 179.46 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.436 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 105.82 -21.4 34.25 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 108.959 -1.657 . . . . 0.0 108.959 -178.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.498 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.5 OUTLIER -139.05 -168.9 0.2 Allowed Pre-proline 0 N--CA 1.491 1.586 0 O-C-N 121.397 -1.06 . . . . 0.0 109.059 179.922 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.498 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.4 Cg_endo -87.85 108.0 0.61 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.14 1.074 . . . . 0.0 110.584 179.675 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.458 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -84.56 168.38 43.85 Favored Glycine 0 N--CA 1.498 2.796 0 C-N-CA 120.119 -1.039 . . . . 0.0 110.954 -179.566 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.451 ' O ' ' HA ' ' A' ' 98' ' ' SER . 27.1 mt -124.9 143.26 39.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.654 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.574 ' CD2' HG23 ' A' ' 99' ' ' VAL . 9.9 t80 -130.24 121.95 27.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.661 -1.274 . . . . 0.0 111.762 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.531 ' NE ' HG11 ' A' ' 13' ' ' VAL . 12.5 mmt180 -107.22 124.36 49.63 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.883 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.411 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 45.8 p90 -123.28 155.98 36.16 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 120.917 -1.114 . . . . 0.0 110.888 -179.357 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.603 HG22 HD23 ' A' ' 15' ' ' LEU . 16.5 t -84.06 -68.76 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.353 -0.842 . . . . 0.0 109.131 178.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . 52.1 83.04 0.23 Allowed Pre-proline 0 C--N 1.304 -1.373 0 O-C-N 121.746 -0.596 . . . . 0.0 110.254 -179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.81 -53.27 0.14 Allowed 'Trans proline' 0 C--N 1.313 -1.342 0 O-C-N 123.729 1.384 . . . . 0.0 110.515 -179.827 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 110.34 135.77 7.11 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.478 -1.449 . . . . 0.0 109.478 -179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.95 -68.21 0.83 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.206 -1.173 . . . . 0.0 110.259 -179.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.6 ttt-85 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.245 -179.928 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.295 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 51.8 p -91.93 137.98 31.92 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.224 -1.162 . . . . 0.0 110.233 179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.472 HG23 ' O ' ' A' ' 3' ' ' VAL . 14.6 m -113.06 104.46 17.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.315 -0.865 . . . . 0.0 109.904 179.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.648 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 34.8 p -92.62 144.9 24.86 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.485 -0.759 . . . . 0.0 110.062 179.871 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.442 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.35 147.08 98.93 Favored Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.205 -0.935 . . . . 0.0 109.73 -179.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.442 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.9 Cg_endo -70.98 -167.65 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 124.092 1.575 . . . . 0.0 110.465 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.537 ' CE1' ' HD3' ' A' ' 119' ' ' ARG . 0.5 OUTLIER 173.7 83.12 0.05 OUTLIER Pre-proline 0 N--CA 1.496 1.851 0 O-C-N 121.49 -0.757 . . . . 0.0 109.583 179.599 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.23 -13.62 28.33 Favored 'Trans proline' 0 C--N 1.312 -1.388 0 O-C-N 123.95 1.5 . . . . 0.0 111.095 -179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 18.2 m120 -64.95 -31.25 72.39 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.082 -1.011 . . . . 0.0 110.382 -179.867 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.482 HD11 ' O ' ' A' ' 122' ' ' THR . 25.0 mt -106.19 135.83 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.068 -1.02 . . . . 0.0 110.23 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -84.5 128.53 34.64 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.362 -0.836 . . . . 0.0 109.374 179.244 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 13.7 mt-10 -89.35 125.52 35.16 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.067 -1.021 . . . . 0.0 110.078 -179.568 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.454 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 15.2 t -118.04 155.02 20.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.368 -0.833 . . . . 0.0 110.297 -179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.57 110.44 22.74 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.326 -0.859 . . . . 0.0 109.599 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.684 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -56.54 135.37 54.56 Favored 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.974 -179.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 60.4 p -134.54 167.47 20.73 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.247 -0.908 . . . . 0.0 110.4 -179.696 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 82.0 p -65.03 79.71 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 109.973 179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.615 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 36.2 m -154.14 109.72 3.19 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.407 -0.808 . . . . 0.0 110.701 -179.634 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.433 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 149.7 -170.69 29.84 Favored Glycine 0 N--CA 1.488 2.115 0 C-N-CA 118.915 -1.612 . . . . 0.0 111.088 179.102 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 8.5 mm-40 -111.34 -22.14 11.49 Favored 'General case' 0 C--N 1.304 -1.384 0 O-C-N 121.697 -0.884 . . . . 0.0 110.23 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.869 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.1 tt -96.58 105.84 25.7 Favored Pre-proline 0 N--CA 1.489 1.522 0 C-N-CA 118.709 -1.196 . . . . 0.0 109.758 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.459 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.4 Cg_endo -64.51 131.94 31.52 Favored 'Trans proline' 0 C--N 1.313 -1.311 0 O-C-N 123.366 1.193 . . . . 0.0 110.807 -179.174 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.437 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.3 t80 -122.13 -165.76 1.31 Allowed 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.581 -0.699 . . . . 0.0 110.625 -179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.512 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 36.7 m-85 -58.04 81.44 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.938 0 O-C-N 121.443 -0.785 . . . . 0.0 111.378 -179.324 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 71.14 2.52 48.04 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.572 -1.011 . . . . 0.0 110.572 179.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.684 ' CB ' HD23 ' A' ' 15' ' ' LEU . 16.6 mmtp -130.49 156.75 44.28 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.909 -1.348 . . . . 0.0 109.301 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.615 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -110.37 107.77 17.59 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.974 -1.079 . . . . 0.0 109.649 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.869 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.5 mt -67.79 113.62 15.55 Favored Pre-proline 0 C--N 1.301 -1.542 0 O-C-N 121.392 -0.817 . . . . 0.0 110.984 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.856 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.9 Cg_endo -69.54 127.47 14.82 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 N-CA-C 106.924 -1.991 . . . . 0.0 106.924 175.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.606 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -55.85 -19.08 10.39 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 120.844 -1.16 . . . . 0.0 110.785 -177.487 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.0 pt-20 -59.84 -16.11 26.19 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.75 -1.219 . . . . 0.0 110.491 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.1 -25.22 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.744 0 O-C-N 120.949 -1.094 . . . . 0.0 110.967 -179.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 41.4 pt -117.32 -16.48 8.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 120.998 -1.064 . . . . 0.0 110.624 -179.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.576 ' HB2' HD11 ' A' ' 60' ' ' ILE . 3.5 tptm -96.38 148.22 23.0 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.853 -1.155 . . . . 0.0 110.175 179.409 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.49 -3.33 56.36 Favored Glycine 0 N--CA 1.483 1.823 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.2 -161.32 26.53 Favored Glycine 0 N--CA 1.494 2.525 0 C-N-CA 118.881 -1.628 . . . . 0.0 110.883 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.462 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 3.6 mtt85 -97.16 128.47 44.09 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.497 -1.002 . . . . 0.0 110.492 -179.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.582 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 77.3 m-70 -136.57 145.07 44.55 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.084 -1.01 . . . . 0.0 110.748 -179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.511 ' HB2' ' CD2' ' A' ' 96' ' ' PHE . 27.8 tp -107.21 113.63 27.17 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.378 -0.826 . . . . 0.0 109.977 179.635 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.948 HD12 HG12 ' A' ' 83' ' ' VAL . 36.0 mt -96.42 129.24 46.77 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.222 -0.924 . . . . 0.0 109.452 179.429 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.7 m-85 -94.86 123.76 38.51 Favored 'General case' 0 C--N 1.292 -1.927 0 O-C-N 121.169 -0.957 . . . . 0.0 109.728 -179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.68 159.71 21.82 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.193 -0.942 . . . . 0.0 111.031 -179.364 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.512 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 0.6 OUTLIER -112.29 6.9 19.14 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.505 -0.747 . . . . 0.0 110.087 178.952 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.408 ' OG ' ' HB3' ' A' ' 47' ' ' LYS . 3.9 p -138.2 137.18 37.34 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.044 -1.035 . . . . 0.0 110.675 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.458 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 15.0 tttt -71.6 -40.58 69.74 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.422 -0.799 . . . . 0.0 110.197 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.61 -36.77 79.4 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.368 -0.832 . . . . 0.0 110.25 -179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.423 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -72.29 -35.59 68.73 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.378 -0.826 . . . . 0.0 109.573 179.983 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 5.5 m -60.34 -33.74 72.84 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.425 -0.797 . . . . 0.0 109.551 179.672 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.83 -49.06 61.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.236 -0.915 . . . . 0.0 110.464 179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.418 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 5.5 mt-10 -71.67 -43.28 66.32 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.297 -0.877 . . . . 0.0 110.541 -179.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.849 HD12 HG11 ' A' ' 83' ' ' VAL . 0.9 OUTLIER -56.54 -41.58 77.04 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.408 -0.807 . . . . 0.0 110.972 -179.04 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.402 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -75.94 -51.39 12.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.965 -1.084 . . . . 0.0 110.583 -179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.57 -42.03 98.26 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 120.903 -1.123 . . . . 0.0 109.616 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.494 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.8 OUTLIER -57.63 -46.13 84.54 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.324 -0.86 . . . . 0.0 109.916 179.66 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.726 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.04 -41.47 71.44 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.458 -0.777 . . . . 0.0 109.649 179.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.7 t -56.15 -31.16 31.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.083 -1.011 . . . . 0.0 108.59 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.494 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.54 -32.93 60.62 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.602 -0.686 . . . . 0.0 109.982 179.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.484 HD13 ' HA ' ' A' ' 58' ' ' LEU . 4.2 mm? -71.87 -25.92 62.14 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.313 -0.867 . . . . 0.0 109.528 179.659 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.06 7.28 8.6 Favored Glycine 0 N--CA 1.493 2.456 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.434 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.606 ' CD1' HD22 ' A' ' 30' ' ' LEU . 34.6 mt -108.77 143.28 19.34 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.374 -1.074 . . . . 0.0 110.305 -179.477 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.584 ' ND2' HD11 ' A' ' 74' ' ' ILE . 24.0 t-20 -86.45 107.02 17.87 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 178.012 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.619 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.51 143.91 48.31 Favored 'General case' 0 C--N 1.296 -1.721 0 C-N-CA 118.932 -1.107 . . . . 0.0 111.431 -177.591 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.5 t -132.13 150.82 34.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 C-N-CA 119.846 -0.742 . . . . 0.0 109.191 179.349 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.41 126.54 55.46 Favored 'General case' 0 C--N 1.297 -1.686 0 C-N-CA 119.199 -1.0 . . . . 0.0 110.083 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.603 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.4 t80 -118.29 122.55 43.18 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.259 -0.9 . . . . 0.0 110.432 179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.913 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.1 p90 -154.12 -179.73 8.17 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.411 -0.805 . . . . 0.0 109.652 179.647 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -51.97 125.24 14.81 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.15 -0.969 . . . . 0.0 110.947 -179.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 75.12 44.73 22.38 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.218 -1.153 . . . . 0.0 110.218 179.316 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.913 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.77 156.46 28.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.092 -1.24 . . . . 0.0 110.119 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.899 ' N ' HD13 ' A' ' 69' ' ' LEU . 6.7 m-20 -94.49 148.97 21.7 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.249 -0.907 . . . . 0.0 110.732 -179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.8 m -62.41 111.15 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 C-N-CA 119.224 -0.991 . . . . 0.0 109.311 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.52 ' O ' HG23 ' A' ' 74' ' ' ILE . 7.0 m -133.62 -32.61 1.13 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.369 -0.832 . . . . 0.0 110.992 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 30.5 t -55.98 138.77 16.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.177 -0.952 . . . . 0.0 109.952 -179.598 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.622 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -137.1 92.12 14.26 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 121.116 -0.99 . . . . 0.0 111.105 -179.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.408 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.1 Cg_endo -87.73 50.94 1.99 Allowed 'Trans proline' 0 C--N 1.31 -1.457 0 O-C-N 123.617 1.325 . . . . 0.0 109.715 178.847 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.3 p -122.44 -25.64 4.74 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.136 -0.977 . . . . 0.0 111.283 -179.028 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 50.7 m-20 -158.1 160.34 37.22 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.884 -1.135 . . . . 0.0 110.699 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 59.99 160.47 0.07 OUTLIER Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 37.5 m-20 -78.28 111.08 13.89 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.238 . . . . 0.0 110.072 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 7.4 p -117.28 133.93 62.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 CA-C-O 121.937 0.875 . . . . 0.0 110.365 -179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.58 HG22 HG22 ' A' ' 60' ' ' ILE . 7.9 m -112.64 123.88 68.76 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 O-C-N 121.346 -0.846 . . . . 0.0 108.731 178.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.727 HG22 HG13 ' A' ' 73' ' ' VAL . 4.1 t -96.8 116.43 38.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.09 -1.006 . . . . 0.0 110.354 -177.769 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.948 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -108.97 100.23 10.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 C-N-CA 118.882 -1.127 . . . . 0.0 108.763 179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.472 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.82 162.99 34.11 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.745 -1.222 . . . . 0.0 111.102 -177.959 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.523 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -92.08 -130.98 0.12 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.537 -0.727 . . . . 0.0 109.434 179.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.523 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -90.96 34.8 0.91 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.655 -1.278 . . . . 0.0 110.191 179.58 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.426 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -98.91 -30.46 12.37 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.149 -0.969 . . . . 0.0 110.355 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.0 tp -62.62 -36.56 83.15 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.099 -1.0 . . . . 0.0 109.151 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.477 ' C ' HG22 ' A' ' 90' ' ' THR . 0.6 OUTLIER 46.05 43.93 11.18 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.549 -0.719 . . . . 0.0 110.667 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.668 ' OG1' HG22 ' A' ' 93' ' ' THR . 1.8 t 35.34 -119.06 0.11 Allowed 'General case' 0 N--CA 1.504 2.227 0 O-C-N 122.171 -0.331 . . . . 0.0 111.691 179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.413 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 79.92 -58.42 4.54 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 109.121 -1.591 . . . . 0.0 109.121 -179.65 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.0 p90 -122.13 20.16 10.67 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.277 -1.131 . . . . 0.0 110.139 179.628 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.668 HG22 ' OG1' ' A' ' 90' ' ' THR . 8.3 t -94.35 -171.46 2.52 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.268 -0.895 . . . . 0.0 110.214 179.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 124' ' ' ARG . . . 119.62 5.63 10.99 Favored Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.788 -1.196 . . . . 0.0 110.512 179.375 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -125.82 58.56 1.32 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.684 -1.48 . . . . 0.0 110.464 179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.511 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 28.3 m-85 -120.52 152.17 38.41 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.838 -1.163 . . . . 0.0 110.77 -179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.442 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 11.3 m-20 -89.53 -28.74 19.41 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.535 -0.728 . . . . 0.0 109.404 179.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.451 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 7.4 p -161.02 163.77 31.42 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.363 -0.835 . . . . 0.0 110.75 179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.49 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -125.77 119.21 54.17 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.037 0 O-C-N 121.308 -0.87 . . . . 0.0 110.277 179.567 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.768 HG21 ' CD1' ' A' ' 28' ' ' ILE . 37.9 mm -95.92 111.25 25.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.668 0 O-C-N 121.191 -0.943 . . . . 0.0 108.888 179.086 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.435 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -118.9 161.06 20.82 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.891 -1.131 . . . . 0.0 111.731 -178.858 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.474 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 28.4 p -99.94 -0.28 39.75 Favored 'General case' 0 C--N 1.301 -1.504 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 6.4 m-20 50.48 18.6 0.47 Allowed 'General case' 0 N--CA 1.496 1.86 0 O-C-N 121.3 -0.875 . . . . 0.0 112.182 179.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.469 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -144.68 120.81 10.79 Favored 'General case' 0 C--N 1.305 -1.328 0 O-C-N 120.696 -1.252 . . . . 0.0 109.403 179.859 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.43 ' N ' ' O ' ' A' ' 108' ' ' LYS . 10.2 p -102.39 141.57 35.01 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.262 -0.899 . . . . 0.0 110.3 179.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t70 52.29 28.32 5.57 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.276 -0.89 . . . . 0.0 110.566 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.19 -13.27 57.94 Favored Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.222 -1.151 . . . . 0.0 110.222 -179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 104' ' ' THR . 14.6 mttt -96.6 156.65 36.45 Favored Pre-proline 0 N--CA 1.49 1.559 0 O-C-N 120.999 -1.294 . . . . 0.0 109.962 179.94 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.1 Cg_endo -63.45 130.03 27.11 Favored 'Trans proline' 0 C--N 1.309 -1.534 0 O-C-N 123.594 1.313 . . . . 0.0 110.63 -179.841 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 1.9 pp0? -49.26 168.08 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.502 -0.749 . . . . 0.0 111.176 -179.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.529 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -102.68 161.57 13.63 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.553 -0.717 . . . . 0.0 110.301 179.701 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.648 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -42.29 -56.51 2.92 Favored 'General case' 0 N--CA 1.498 1.961 0 O-C-N 121.584 -0.698 . . . . 0.0 112.372 -178.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.529 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -64.26 -29.81 48.36 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.818 0 O-C-N 120.717 -1.239 . . . . 0.0 111.262 -178.717 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.415 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.74 -56.36 7.52 Favored 'General case' 0 N--CA 1.498 1.95 0 O-C-N 121.085 -1.009 . . . . 0.0 110.499 -179.253 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.442 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.0 OUTLIER -66.72 -33.74 76.3 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.131 -0.981 . . . . 0.0 108.866 178.89 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 54.1 m -60.98 -50.12 74.68 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.091 -1.006 . . . . 0.0 108.333 178.486 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.98 -38.71 64.07 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.41 -0.806 . . . . 0.0 110.141 178.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 45.1 mtt-85 -71.89 -44.33 63.91 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.226 -0.921 . . . . 0.0 111.329 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.537 ' HD3' ' CE1' ' A' ' 7' ' ' HIS . 6.9 ttp180 -62.1 -40.43 95.85 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 120.895 -1.128 . . . . 0.0 110.257 -179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -63.45 75.28 0.04 OUTLIER Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.982 -1.247 . . . . 0.0 109.982 -179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.534 ' NE ' HG21 ' A' ' 93' ' ' THR . 0.7 OUTLIER -149.04 -47.35 0.14 Allowed 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.475 -1.015 . . . . 0.0 108.735 179.595 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.57 HG23 ' HA3' ' A' ' 128' ' ' GLY . 13.1 t -96.18 143.44 27.29 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 178.774 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.459 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.78 17.82 4.54 Favored Glycine 0 N--CA 1.489 2.17 0 C-N-CA 119.153 -1.499 . . . . 0.0 110.438 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.432 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 10.8 mmt180 -91.73 82.78 5.23 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.085 -1.244 . . . . 0.0 109.976 -179.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 121.88 -31.73 4.85 Favored Glycine 0 N--CA 1.493 2.488 0 N-CA-C 108.56 -1.816 . . . . 0.0 108.56 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.474 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 1.0 OUTLIER -144.17 -169.7 0.22 Allowed Pre-proline 0 C--N 1.301 -1.507 0 N-CA-C 108.108 -1.071 . . . . 0.0 108.108 179.43 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.9 Cg_endo -85.33 114.99 1.58 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 122.964 0.981 . . . . 0.0 110.448 -179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.57 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -78.79 166.32 51.94 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.356 -1.497 . . . . 0.0 109.356 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.564 HG21 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 mt -119.99 140.09 45.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.092 -1.24 . . . . 0.0 109.062 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.49 ' HD1' HG23 ' A' ' 99' ' ' VAL . 6.8 t80 -122.69 114.52 20.69 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.941 -1.104 . . . . 0.0 110.219 179.549 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.6 ' HB2' HD13 ' A' ' 100' ' ' ILE . 24.3 mtt180 -108.15 126.81 53.21 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.618 -0.676 . . . . 0.0 109.309 179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.454 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 35.9 p90 -126.91 156.94 40.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.056 -1.028 . . . . 0.0 110.907 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.517 HG22 HD23 ' A' ' 15' ' ' LEU . 7.0 t -78.1 -69.29 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.307 -0.87 . . . . 0.0 108.944 178.854 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.431 ' N ' HG12 ' A' ' 133' ' ' VAL . . . 54.47 83.3 0.23 Allowed Pre-proline 0 N--CA 1.489 1.495 0 O-C-N 121.653 -0.654 . . . . 0.0 110.85 179.752 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -83.39 7.84 4.97 Favored 'Trans proline' 0 C--N 1.31 -1.471 0 O-C-N 123.688 1.362 . . . . 0.0 110.581 179.335 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 132.02 -124.62 4.02 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.663 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -161.07 155.19 22.73 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 179.559 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.263 -179.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 30.0 t -109.35 141.74 41.26 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.358 -1.084 . . . . 0.0 110.342 -179.919 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.666 ' O ' HG13 ' A' ' 3' ' ' VAL . 10.6 p -113.43 104.59 17.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.305 -0.872 . . . . 0.0 109.745 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 70.0 p -66.52 145.54 55.53 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.287 -0.883 . . . . 0.0 110.749 -179.615 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.515 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -72.71 149.93 90.72 Favored Pre-proline 0 N--CA 1.492 1.643 0 O-C-N 121.294 -0.879 . . . . 0.0 109.751 179.606 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.517 ' O ' ' CD2' ' A' ' 7' ' ' HIS . 40.4 Cg_endo -79.62 -64.88 0.02 OUTLIER 'Trans proline' 0 C--N 1.311 -1.446 0 O-C-N 124.159 1.61 . . . . 0.0 112.533 -179.854 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.539 ' CG ' ' O ' ' A' ' 7' ' ' HIS . 15.3 p80 42.88 88.78 0.1 OUTLIER Pre-proline 0 N--CA 1.491 1.623 0 CA-C-O 121.564 0.697 . . . . 0.0 110.405 -177.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -72.39 2.4 5.13 Favored 'Trans proline' 0 C--N 1.315 -1.203 0 O-C-N 123.526 1.277 . . . . 0.0 112.319 -178.446 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.423 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 24.4 t-20 -51.56 -25.09 6.15 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 120.653 -1.279 . . . . 0.0 109.261 179.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.54 HD12 ' HG2' ' A' ' 119' ' ' ARG . 20.0 mt -105.72 132.99 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.465 0 O-C-N 121.452 -0.78 . . . . 0.0 109.146 178.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -84.19 127.56 34.02 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.063 -1.023 . . . . 0.0 109.303 179.126 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.2 mt-10 -89.57 126.37 35.58 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.176 -0.953 . . . . 0.0 110.036 -179.475 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.563 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 6.4 t -116.13 154.53 17.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.372 -0.83 . . . . 0.0 110.402 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -102.82 105.03 15.35 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.3 -0.875 . . . . 0.0 109.63 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.512 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -55.46 132.34 48.16 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.368 -0.833 . . . . 0.0 109.805 -179.84 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.415 ' O ' ' N ' ' A' ' 18' ' ' THR . 69.7 p -135.86 172.26 13.28 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.194 -0.941 . . . . 0.0 110.3 -179.972 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.7 p -64.92 78.31 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.298 -0.876 . . . . 0.0 110.236 -179.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.68 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 26.1 m -151.31 108.57 3.59 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 110.702 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 147.04 -167.29 28.36 Favored Glycine 0 N--CA 1.487 2.091 0 C-N-CA 119.027 -1.559 . . . . 0.0 110.733 179.25 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 2.3 mm-40 -114.8 -18.48 11.33 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.665 -0.903 . . . . 0.0 110.32 179.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.8 tt -100.54 104.27 29.5 Favored Pre-proline 0 N--CA 1.491 1.589 0 C-N-CA 118.886 -1.126 . . . . 0.0 110.284 -179.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.442 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.3 Cg_endo -62.97 148.69 93.2 Favored 'Trans proline' 0 C--N 1.31 -1.461 0 O-C-N 123.347 1.183 . . . . 0.0 109.918 179.796 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.532 ' CZ ' ' CE2' ' A' ' 24' ' ' TYR . 89.4 t80 -162.24 95.68 0.95 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.152 -0.967 . . . . 0.0 111.12 -178.179 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.573 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 21.4 m-85 59.21 66.73 0.99 Allowed 'General case' 0 N--CA 1.5 2.034 0 O-C-N 121.381 -0.825 . . . . 0.0 111.372 179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.92 14.94 11.14 Favored Glycine 0 N--CA 1.493 2.493 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 30.3 mmtm -130.6 156.95 44.0 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.05 -1.265 . . . . 0.0 109.106 179.559 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.68 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -117.21 107.25 14.22 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 120.862 -1.149 . . . . 0.0 109.706 179.947 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.6 mt -69.95 114.35 24.47 Favored Pre-proline 0 C--N 1.3 -1.563 0 O-C-N 121.351 -0.843 . . . . 0.0 109.929 -179.855 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.829 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.4 Cg_endo -69.01 129.7 18.88 Favored 'Trans proline' 0 C--N 1.303 -1.844 0 N-CA-C 107.036 -1.948 . . . . 0.0 107.036 176.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.678 HD22 ' CD1' ' A' ' 60' ' ' ILE . 12.9 mt -56.5 -16.93 6.78 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.831 -1.168 . . . . 0.0 111.015 -177.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.439 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -62.01 -15.91 47.69 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.819 -1.176 . . . . 0.0 110.255 179.397 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.081 HG23 HG23 ' A' ' 33' ' ' ILE . 12.9 m -92.57 -25.16 5.13 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.776 0 O-C-N 121.007 -1.058 . . . . 0.0 111.241 -179.231 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.081 HG23 HG23 ' A' ' 32' ' ' VAL . 12.0 pt -120.45 -23.26 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.016 -1.052 . . . . 0.0 110.789 -179.456 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.658 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.03 147.82 22.66 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.906 -1.121 . . . . 0.0 110.694 -179.853 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.414 ' N ' ' CE ' ' A' ' 34' ' ' LYS . . . 99.69 -3.5 57.57 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 -179.651 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.94 -155.74 13.6 Favored Glycine 0 N--CA 1.494 2.536 0 C-N-CA 119.023 -1.56 . . . . 0.0 110.718 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 30.4 mtt180 -104.97 131.08 52.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.416 -1.05 . . . . 0.0 110.106 -179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.545 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.78 152.38 45.17 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.188 -0.945 . . . . 0.0 111.075 -179.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.452 HD12 ' O ' ' A' ' 82' ' ' VAL . 43.1 tp -112.3 115.62 29.07 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.405 -0.809 . . . . 0.0 110.306 179.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.832 HD12 ' CG1' ' A' ' 83' ' ' VAL . 29.6 mt -100.3 128.56 52.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.172 -0.955 . . . . 0.0 109.842 179.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.458 ' CD2' ' HG2' ' A' ' 118' ' ' ARG . 6.2 m-85 -97.05 123.67 40.84 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.093 -1.004 . . . . 0.0 110.059 179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.0 m -115.54 159.62 21.0 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.303 -0.873 . . . . 0.0 110.566 -179.577 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.573 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 17.9 p80 -106.64 5.07 28.58 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.353 -0.842 . . . . 0.0 109.992 179.115 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.1 p -137.02 135.99 38.05 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.111 -0.993 . . . . 0.0 110.605 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.484 ' CG ' ' CD1' ' A' ' 66' ' ' TYR . 14.5 ttpt -71.54 -31.34 66.92 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.523 -0.736 . . . . 0.0 110.364 179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 3.3 mtpm? -71.01 -30.02 66.12 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.35 -0.844 . . . . 0.0 110.247 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -73.09 -37.01 66.9 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.393 -0.817 . . . . 0.0 109.623 179.914 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.889 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 62.1 m -61.13 -37.33 82.44 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.323 -0.861 . . . . 0.0 109.383 179.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -62.48 -49.93 73.45 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.138 -0.976 . . . . 0.0 109.997 179.604 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 2.7 mt-10 -72.63 -47.0 51.25 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 121.34 -0.85 . . . . 0.0 110.328 179.727 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.697 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.0 tm? -56.55 -40.07 74.52 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.5 -0.75 . . . . 0.0 110.754 -179.263 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.22 -51.37 13.49 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.052 -1.03 . . . . 0.0 110.194 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.35 -42.23 98.36 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.176 -0.953 . . . . 0.0 109.796 179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.52 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.39 -45.23 84.72 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.267 -0.896 . . . . 0.0 109.514 179.452 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.87 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.07 -42.12 72.38 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.527 -0.733 . . . . 0.0 109.62 179.921 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 71.3 t -56.1 -33.28 36.03 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.21 -0.931 . . . . 0.0 109.087 179.171 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.69 -31.32 59.67 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.426 -0.796 . . . . 0.0 110.222 179.268 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.649 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.26 -26.37 62.87 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.316 -0.865 . . . . 0.0 109.44 179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.29 5.4 8.71 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.589 -1.405 . . . . 0.0 109.589 -179.612 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.678 ' CD1' HD22 ' A' ' 30' ' ' LEU . 67.8 mt -108.17 143.82 17.9 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.33 -1.1 . . . . 0.0 110.32 -179.582 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 57.3 t30 -88.73 106.48 18.38 Favored 'General case' 0 C--N 1.306 -1.316 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 177.863 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.689 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.48 142.9 46.27 Favored 'General case' 0 C--N 1.297 -1.69 0 C-N-CA 118.934 -1.106 . . . . 0.0 111.895 -177.017 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 84.0 t -123.01 148.84 26.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.889 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.46 117.15 29.58 Favored 'General case' 0 C--N 1.3 -1.584 0 C-N-CA 119.265 -0.974 . . . . 0.0 109.267 178.269 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.48 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.6 OUTLIER -107.93 135.36 49.44 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.264 -0.898 . . . . 0.0 110.98 -179.203 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.966 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 15.4 p90 -167.94 177.31 5.72 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.497 -0.752 . . . . 0.0 109.848 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 20.2 ttp-105 -51.47 126.04 16.15 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.068 -1.02 . . . . 0.0 110.695 -179.36 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 74.86 45.13 22.49 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 110.199 -1.16 . . . . 0.0 110.199 179.474 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.966 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.5 tm? -117.27 153.61 32.62 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.259 . . . . 0.0 109.877 179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.778 ' N ' HD13 ' A' ' 69' ' ' LEU . 15.9 m-20 -91.21 149.48 21.76 Favored 'General case' 0 N--CA 1.495 1.798 0 O-C-N 121.301 -0.874 . . . . 0.0 110.602 -179.2 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.7 m -62.44 111.1 0.77 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.109 179.112 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.672 ' O ' HG23 ' A' ' 74' ' ' ILE . 15.0 m -133.9 -34.39 1.0 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.402 -0.811 . . . . 0.0 110.841 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 92.3 t -49.46 129.47 6.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.727 0 O-C-N 121.126 -0.984 . . . . 0.0 110.08 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.672 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -138.36 94.72 10.66 Favored Pre-proline 0 N--CA 1.494 1.74 0 O-C-N 121.134 -0.979 . . . . 0.0 110.988 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.59 ' HA ' HG11 ' A' ' 80' ' ' VAL . 48.7 Cg_endo -78.73 58.01 6.63 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 O-C-N 123.691 1.364 . . . . 0.0 110.012 179.192 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 8.9 t -165.29 41.91 0.07 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.322 -0.861 . . . . 0.0 110.408 -179.763 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.451 ' HB2' HD12 ' A' ' 74' ' ' ILE . 5.4 m120 -141.03 29.36 1.85 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.154 -0.966 . . . . 0.0 110.424 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 106.76 -89.03 0.57 Allowed Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 38.8 m-20 -140.51 102.86 4.42 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.153 -1.204 . . . . 0.0 110.262 179.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.59 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.2 p -116.96 135.24 57.97 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-O 122.011 0.91 . . . . 0.0 109.878 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 13.6 m -112.61 124.63 69.47 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.248 0 O-C-N 121.288 -0.882 . . . . 0.0 109.335 179.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.834 HG11 HD13 ' A' ' 88' ' ' LEU . 12.9 t -97.17 119.13 44.82 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 O-C-N 120.952 -1.092 . . . . 0.0 110.357 -178.284 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.832 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.3 m -111.87 99.25 8.29 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 C-N-CA 119.009 -1.077 . . . . 0.0 108.792 179.325 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.425 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -133.31 159.45 40.24 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.596 -1.315 . . . . 0.0 110.77 -178.474 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 13.2 t -91.04 -28.55 17.9 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.343 -0.848 . . . . 0.0 110.728 -179.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER 178.87 -31.34 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.945 0 O-C-N 121.059 -1.026 . . . . 0.0 110.767 -179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.475 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -46.91 -37.58 9.15 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.197 -0.939 . . . . 0.0 111.085 -179.519 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.834 HD13 HG11 ' A' ' 82' ' ' VAL . 0.6 OUTLIER -70.22 -33.43 71.67 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.143 -0.973 . . . . 0.0 110.698 -179.682 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.403 ' O ' HD23 ' A' ' 88' ' ' LEU . 2.3 tpt 53.43 -144.14 0.68 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.085 -1.01 . . . . 0.0 109.356 -179.303 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.487 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.5 OUTLIER -155.55 24.86 0.4 Allowed 'General case' 0 N--CA 1.49 1.549 0 O-C-N 120.923 -1.111 . . . . 0.0 110.416 179.468 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.02 -62.46 5.92 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 108.964 -1.654 . . . . 0.0 108.964 179.5 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 52.1 p90 -101.19 36.21 2.05 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.365 -1.079 . . . . 0.0 108.633 178.47 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.646 HG22 ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -133.75 -167.54 1.96 Allowed 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.712 -0.617 . . . . 0.0 110.073 -179.439 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.434 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 120.64 -24.18 7.67 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.9 t70 -84.42 73.21 10.53 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.003 -1.292 . . . . 0.0 110.213 -179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.646 ' CE2' HG22 ' A' ' 93' ' ' THR . 38.5 m-85 -119.8 152.73 36.81 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.181 -0.949 . . . . 0.0 110.156 179.681 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 53.1 m-20 -84.82 -29.28 25.49 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.488 -0.757 . . . . 0.0 109.74 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.422 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 4.7 p -161.16 163.52 31.2 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.21 -0.931 . . . . 0.0 110.855 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.414 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.32 116.33 28.54 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.941 0 O-C-N 121.312 -0.867 . . . . 0.0 109.971 179.654 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.817 HG21 HD11 ' A' ' 28' ' ' ILE . 4.2 mp -94.59 111.27 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.039 -1.038 . . . . 0.0 108.968 179.153 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' HB2' ' CE1' ' A' ' 130' ' ' TYR . 3.5 t0 -114.35 161.11 18.34 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.207 -0.933 . . . . 0.0 111.754 -178.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 28.6 p -104.36 9.67 35.7 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 178.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.45 ' CB ' ' HB3' ' A' ' 134' ' ' ALA . 2.7 m120 46.17 27.35 0.54 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.271 -0.893 . . . . 0.0 110.92 -179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.582 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.1 p -144.31 133.42 22.87 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.14 -0.975 . . . . 0.0 110.449 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 62.9 p -113.42 128.6 56.51 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.311 -0.868 . . . . 0.0 109.392 179.482 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.0 t70 55.73 -141.58 0.83 Allowed 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.048 -1.032 . . . . 0.0 109.533 -179.305 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -88.34 18.43 41.66 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 109.97 -1.252 . . . . 0.0 109.97 179.64 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -134.77 156.99 78.13 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.099 -1.236 . . . . 0.0 109.597 179.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.582 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.0 Cg_endo -63.25 158.33 45.1 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.514 1.271 . . . . 0.0 110.436 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 103' ' ' ASN . 0.5 OUTLIER -64.83 164.79 11.71 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.296 -0.877 . . . . 0.0 111.198 -178.786 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.501 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -100.56 161.76 13.38 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.56 -0.712 . . . . 0.0 110.113 179.596 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.464 ' HA ' ' CZ ' ' A' ' 115' ' ' ARG . . . -41.38 -61.58 1.02 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.481 -0.762 . . . . 0.0 112.153 -178.881 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.501 HG22 ' OD1' ' A' ' 111' ' ' ASP . 13.0 m -59.82 -28.84 41.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.762 -1.211 . . . . 0.0 111.432 -178.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.433 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.2 OUTLIER -47.73 -57.14 5.92 Favored 'General case' 0 N--CA 1.498 1.962 0 O-C-N 120.923 -1.111 . . . . 0.0 110.948 -178.74 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 112' ' ' ALA . 2.6 ptp180 -66.47 -34.62 78.33 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.045 -1.034 . . . . 0.0 108.512 179.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 50.3 m -59.87 -48.86 80.0 Favored 'General case' 0 N--CA 1.486 1.347 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 178.306 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -73.57 -40.16 64.12 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.508 -0.745 . . . . 0.0 110.107 178.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.458 ' HG2' ' CD2' ' A' ' 41' ' ' PHE . 0.4 OUTLIER -69.42 -44.59 71.04 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.015 -1.053 . . . . 0.0 110.346 -179.702 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.54 ' HG2' HD12 ' A' ' 10' ' ' ILE . 41.9 ttp180 -61.6 -36.01 79.48 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.088 -1.007 . . . . 0.0 109.336 179.19 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.12 66.73 0.35 Allowed Glycine 0 N--CA 1.492 2.375 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' HE ' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -143.74 -51.4 0.33 Allowed 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.454 -1.027 . . . . 0.0 108.855 179.784 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.532 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.2 t -92.09 142.44 27.51 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.377 -0.827 . . . . 0.0 108.956 178.858 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.449 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 124.59 17.06 2.95 Favored Glycine 0 N--CA 1.493 2.464 0 C-N-CA 119.274 -1.441 . . . . 0.0 110.604 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.434 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.2 mmt180 -95.15 82.42 3.76 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 120.949 -1.324 . . . . 0.0 109.995 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 119.38 -51.48 0.76 Allowed Glycine 0 N--CA 1.493 2.448 0 N-CA-C 108.392 -1.883 . . . . 0.0 108.392 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.449 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 14.6 ptpt -125.82 166.41 21.42 Favored Pre-proline 0 N--CA 1.491 1.587 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.437 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 38.2 Cg_endo -63.6 117.73 4.69 Favored 'Trans proline' 0 C--N 1.307 -1.611 0 O-C-N 123.296 1.156 . . . . 0.0 110.123 -179.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.532 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.84 172.24 54.79 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.985 -1.246 . . . . 0.0 109.985 -179.38 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.426 HG23 ' CG2' ' A' ' 13' ' ' VAL . 5.1 mt -126.13 142.06 43.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.304 -1.115 . . . . 0.0 108.996 179.008 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.414 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.5 t80 -131.11 115.24 16.15 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.329 -0.948 . . . . 0.0 110.266 179.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.563 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.0 mtp180 -99.84 147.72 25.21 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.511 -0.743 . . . . 0.0 109.384 179.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 25.1 p90 -138.15 150.31 46.68 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.046 -1.034 . . . . 0.0 110.224 -179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.512 HG22 HD23 ' A' ' 15' ' ' LEU . 34.4 t -86.98 -41.09 14.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.148 -0.97 . . . . 0.0 109.446 179.452 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.45 ' HB3' ' CB ' ' A' ' 103' ' ' ASN . . . -91.14 113.07 57.06 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.301 -0.875 . . . . 0.0 109.962 179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.442 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 45.4 Cg_endo -71.5 -22.98 23.98 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.481 1.253 . . . . 0.0 110.751 -179.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 157.33 148.16 5.02 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 179.976 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 11.2 tt0 -90.67 -32.41 16.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.257 -1.143 . . . . 0.0 110.181 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.684 0 CA-C-O 117.986 -1.007 . . . . 0.0 110.146 -179.962 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 62.0 m -89.9 105.96 18.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.233 -1.157 . . . . 0.0 110.178 179.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 3' ' ' VAL . 31.3 m -112.84 104.46 17.07 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.408 0 O-C-N 121.346 -0.846 . . . . 0.0 109.619 179.624 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.474 HG21 ' HD3' ' A' ' 115' ' ' ARG . 43.8 p -90.03 143.36 26.85 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.194 -0.941 . . . . 0.0 110.82 -179.497 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.466 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.71 148.46 98.03 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.392 -0.817 . . . . 0.0 109.476 179.448 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.466 ' HD2' HG23 ' A' ' 5' ' ' VAL . 39.5 Cg_endo -67.57 -167.02 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 124.013 1.533 . . . . 0.0 111.104 179.33 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.557 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 176.31 83.2 0.1 OUTLIER Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 121.712 -0.618 . . . . 0.0 109.341 -179.714 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.8 Cg_endo -67.71 -9.6 26.01 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.91 1.479 . . . . 0.0 111.094 -179.635 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 9.9 t-20 -77.94 -29.45 49.94 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.923 -1.111 . . . . 0.0 109.633 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.515 HD13 HG22 ' A' ' 122' ' ' THR . 16.4 mt -106.82 132.43 54.16 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.042 -1.036 . . . . 0.0 109.504 179.269 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 4.1 tt0 -83.86 127.3 33.73 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.1 -1.0 . . . . 0.0 109.291 179.186 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.4 mt-10 -89.69 128.48 36.09 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.181 -0.949 . . . . 0.0 110.019 -179.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.411 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 9.8 t -124.46 158.1 31.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.444 -0.785 . . . . 0.0 110.188 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -112.03 110.95 21.53 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.259 -0.901 . . . . 0.0 109.731 179.361 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.464 HD23 HG22 ' A' ' 133' ' ' VAL . 12.7 tp -53.47 134.48 40.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.287 -0.883 . . . . 0.0 110.303 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 41.7 p -135.49 177.78 7.56 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.284 -0.885 . . . . 0.0 110.154 -179.909 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 3.1 p -71.35 65.34 0.42 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.239 -0.913 . . . . 0.0 109.924 179.698 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.485 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 22.1 m -137.13 110.51 7.92 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.344 -0.848 . . . . 0.0 110.351 -179.714 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.443 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.02 -163.91 27.98 Favored Glycine 0 N--CA 1.488 2.127 0 C-N-CA 118.981 -1.581 . . . . 0.0 110.723 179.391 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 67.6 mm-40 -119.7 -21.0 7.45 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.654 -0.909 . . . . 0.0 110.349 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.922 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.3 tt -96.85 108.7 44.82 Favored Pre-proline 0 N--CA 1.488 1.461 0 C-N-CA 118.646 -1.221 . . . . 0.0 110.171 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.433 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.5 Cg_endo -65.48 149.8 87.45 Favored 'Trans proline' 0 C--N 1.312 -1.358 0 O-C-N 123.411 1.217 . . . . 0.0 110.276 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.511 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 46.1 t80 -169.06 108.16 0.45 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.251 -0.906 . . . . 0.0 110.991 -178.767 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.47 ' OH ' ' CE1' ' A' ' 43' ' ' HIS . 17.6 m-85 56.17 60.76 3.03 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 121.25 -0.906 . . . . 0.0 111.173 179.257 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 54.5 17.15 7.98 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.86 -1.296 . . . . 0.0 109.86 -179.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.511 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 10.3 mttt -130.5 157.25 43.17 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.111 -1.229 . . . . 0.0 109.101 179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.485 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.77 107.25 14.82 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 120.844 -1.16 . . . . 0.0 110.248 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.922 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.4 mt -68.25 114.47 21.52 Favored Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 121.289 -0.882 . . . . 0.0 110.132 179.867 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.801 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.7 Cg_endo -69.14 128.42 16.57 Favored 'Trans proline' 0 C--N 1.303 -1.862 0 N-CA-C 106.549 -2.135 . . . . 0.0 106.549 175.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.654 HD22 ' CD1' ' A' ' 60' ' ' ILE . 11.0 mt -55.87 -17.62 6.84 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.687 -1.258 . . . . 0.0 111.037 -177.229 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -59.62 -16.0 22.82 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.681 -1.262 . . . . 0.0 110.646 179.855 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.062 HG23 HG23 ' A' ' 33' ' ' ILE . 16.3 m -91.36 -25.41 5.31 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.018 -1.051 . . . . 0.0 111.202 -179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.062 HG23 HG23 ' A' ' 32' ' ' VAL . 25.0 pt -119.82 -16.93 6.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.605 0 O-C-N 120.985 -1.072 . . . . 0.0 110.667 -179.2 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.612 ' HB2' HD11 ' A' ' 60' ' ' ILE . 1.9 tptt -98.82 147.85 24.5 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 120.769 -1.207 . . . . 0.0 110.042 179.424 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.86 -5.43 50.61 Favored Glycine 0 N--CA 1.485 1.913 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.573 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.31 -151.2 9.53 Favored Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.059 -1.543 . . . . 0.0 110.525 -179.987 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.44 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -107.02 131.9 53.55 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.457 -1.025 . . . . 0.0 110.395 -179.437 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.564 ' HB2' HG12 ' A' ' 81' ' ' VAL . 95.6 m-70 -138.4 151.54 47.57 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.156 -0.965 . . . . 0.0 110.99 -179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.589 HD12 ' O ' ' A' ' 82' ' ' VAL . 46.2 tp -111.55 119.27 38.17 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.441 -0.787 . . . . 0.0 110.068 179.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.926 HD12 HG12 ' A' ' 83' ' ' VAL . 31.4 mt -103.83 126.3 58.39 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.307 -0.871 . . . . 0.0 109.18 179.32 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -94.99 123.75 38.64 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.207 -0.933 . . . . 0.0 110.325 -179.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . 0.403 ' CB ' ' SG ' ' A' ' 48' ' ' CYS . 1.7 m -117.26 160.08 21.66 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.371 -0.83 . . . . 0.0 110.689 -179.825 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.47 ' CE1' ' OH ' ' A' ' 24' ' ' TYR . 5.4 p-80 -105.12 -4.73 21.52 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.348 -0.845 . . . . 0.0 110.406 179.433 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . 0.421 ' HB3' ' CD2' ' A' ' 43' ' ' HIS . 66.2 p -136.12 145.79 46.25 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.985 -1.072 . . . . 0.0 111.235 -179.385 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 23.7 tttt -72.07 -40.85 67.98 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.656 -0.653 . . . . 0.0 110.701 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 7.8 mttt -58.82 -34.95 72.11 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.125 -0.985 . . . . 0.0 110.693 -179.418 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 12.3 tppt? -71.57 -40.5 69.9 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.115 -0.99 . . . . 0.0 109.468 179.931 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.884 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 67.2 m -61.81 -37.17 83.41 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.377 -0.827 . . . . 0.0 110.073 179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -60.97 -50.23 74.25 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.992 -1.067 . . . . 0.0 110.579 -179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 0.8 OUTLIER -72.24 -44.2 63.23 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.131 -0.98 . . . . 0.0 110.257 179.898 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.705 HD12 HG11 ' A' ' 83' ' ' VAL . 1.7 tm? -56.63 -42.07 78.2 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.527 -0.733 . . . . 0.0 111.196 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -74.37 -50.9 16.76 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.865 -1.147 . . . . 0.0 110.346 -179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.36 -42.1 98.15 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.147 -0.971 . . . . 0.0 109.823 179.783 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.517 ' O ' ' HB3' ' A' ' 57' ' ' ALA . 0.2 OUTLIER -57.97 -45.78 86.18 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.263 -0.898 . . . . 0.0 109.809 179.683 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.653 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.2 OUTLIER -54.58 -42.25 70.82 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.42 -0.8 . . . . 0.0 109.493 179.804 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 74.2 t -56.84 -30.65 33.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.167 -0.958 . . . . 0.0 108.62 178.587 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.517 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.6 -33.93 60.58 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.546 -0.721 . . . . 0.0 110.011 179.202 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.538 HD12 HD11 ' A' ' 30' ' ' LEU . 4.4 mm? -71.45 -25.75 62.43 Favored 'General case' 0 N--CA 1.488 1.463 0 CA-C-O 121.818 0.818 . . . . 0.0 109.553 179.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.58 7.36 8.96 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.299 -1.52 . . . . 0.0 109.299 -179.304 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.654 ' CD1' HD22 ' A' ' 30' ' ' LEU . 40.3 mt -108.02 143.28 18.74 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.3 -1.118 . . . . 0.0 109.961 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.452 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 38.3 t30 -87.18 107.06 18.3 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 107.17 -1.418 . . . . 0.0 107.17 178.256 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.653 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.92 145.11 48.03 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 119.098 -1.041 . . . . 0.0 111.393 -177.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.895 HG21 ' HA ' ' A' ' 73' ' ' VAL . 6.6 t -133.03 143.07 40.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 C-N-CA 119.689 -0.804 . . . . 0.0 109.578 179.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.884 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -107.12 123.49 48.32 Favored 'General case' 0 C--N 1.299 -1.592 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.834 179.322 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.499 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.7 t80 -113.18 119.03 36.36 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.327 -0.858 . . . . 0.0 110.381 -179.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.926 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 6.8 p90 -146.73 174.48 11.42 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.562 -0.711 . . . . 0.0 109.751 179.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.84 120.62 5.48 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.179 -0.951 . . . . 0.0 110.788 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 87.0 35.74 9.6 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.904 -1.278 . . . . 0.0 109.904 179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.95 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.0 tm? -117.16 155.87 28.62 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.182 -1.187 . . . . 0.0 110.089 -179.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.95 ' N ' HD13 ' A' ' 69' ' ' LEU . 37.2 m-20 -95.37 149.41 21.4 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.348 -0.845 . . . . 0.0 110.219 -179.612 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.657 HG23 ' O ' ' A' ' 71' ' ' VAL . 27.2 m -61.84 110.24 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.51 0 C-N-CA 118.952 -1.099 . . . . 0.0 109.144 179.457 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 7.3 m -132.09 -20.83 2.42 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.526 -0.734 . . . . 0.0 111.067 -179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.895 ' HA ' HG21 ' A' ' 63' ' ' VAL . 13.5 t -65.37 131.89 31.13 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.094 -1.004 . . . . 0.0 109.329 -179.723 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.633 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -126.27 96.94 35.41 Favored Pre-proline 0 N--CA 1.495 1.811 0 O-C-N 121.236 -0.915 . . . . 0.0 110.966 -179.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.55 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.5 Cg_endo -82.29 54.04 4.78 Favored 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.681 1.359 . . . . 0.0 109.913 179.196 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.4 HG23 ' OD1' ' A' ' 77' ' ' ASN . 9.4 t -157.0 42.45 0.34 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.245 -0.91 . . . . 0.0 110.476 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.421 ' CG ' HD13 ' A' ' 74' ' ' ILE . 3.9 m120 -141.48 -164.95 1.87 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.166 -0.959 . . . . 0.0 110.175 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.44 -73.4 0.36 Allowed Glycine 0 N--CA 1.495 2.586 0 N-CA-C 109.662 -1.375 . . . . 0.0 109.662 179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 51.6 m-20 -149.86 111.66 4.55 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.291 -1.123 . . . . 0.0 110.123 179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.55 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.6 p -117.43 134.56 60.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.726 0 CA-C-O 122.086 0.946 . . . . 0.0 110.397 -179.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.651 HG11 ' HB ' ' A' ' 33' ' ' ILE . 5.8 m -113.27 124.69 70.15 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.182 0 O-C-N 121.36 -0.837 . . . . 0.0 108.931 178.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.777 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.0 t -97.33 119.88 45.94 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 121.126 -0.984 . . . . 0.0 110.053 -178.031 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.926 HG12 HD12 ' A' ' 40' ' ' ILE . 3.8 m -114.48 101.02 11.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.048 -1.033 . . . . 0.0 108.573 179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.499 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -145.39 164.25 32.09 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 120.693 -1.254 . . . . 0.0 111.791 -177.492 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.694 HG23 ' H ' ' A' ' 87' ' ' ALA . 6.4 t -94.3 -147.18 0.26 Allowed 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.644 -0.66 . . . . 0.0 109.399 179.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.14 -15.33 56.43 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.936 -1.102 . . . . 0.0 110.236 179.75 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.694 ' H ' HG23 ' A' ' 85' ' ' THR . . . -49.33 -44.56 44.61 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.099 -1.0 . . . . 0.0 110.254 179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.5 tp -63.63 -26.83 68.85 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.214 -0.929 . . . . 0.0 108.96 179.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.499 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 5.6 tpt 45.17 32.47 0.94 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.729 -0.607 . . . . 0.0 111.171 179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.451 ' HA ' ' CG2' ' A' ' 93' ' ' THR . 48.2 p 44.12 36.73 1.57 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.718 -0.614 . . . . 0.0 111.221 179.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.0 -63.99 4.65 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 179.934 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 44.2 p90 -122.28 41.1 3.49 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.383 -1.069 . . . . 0.0 109.884 179.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.541 ' HG1' ' HE2' ' A' ' 96' ' ' PHE . 15.4 t -91.19 -159.39 0.63 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.369 -0.832 . . . . 0.0 110.765 -179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 96.48 -36.88 3.64 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 179.686 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -84.44 55.03 3.21 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 120.97 -1.312 . . . . 0.0 110.511 -179.608 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.541 ' HE2' ' HG1' ' A' ' 93' ' ' THR . 40.9 m-85 -119.93 147.96 44.1 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.931 -1.106 . . . . 0.0 110.307 179.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.485 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.0 m-20 -76.44 -28.76 56.7 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.379 -0.826 . . . . 0.0 110.149 179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.2 p -160.35 163.58 33.13 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.217 -0.927 . . . . 0.0 110.77 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.499 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -128.87 117.82 45.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.912 0 O-C-N 121.352 -0.842 . . . . 0.0 110.579 179.969 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.83 HG21 HD11 ' A' ' 28' ' ' ILE . 4.6 mp -98.2 110.81 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.117 -1.068 . . . . 0.0 108.117 178.305 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 7.8 t0 -119.15 158.86 25.09 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.088 -1.007 . . . . 0.0 111.772 -178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.2 p -95.83 3.69 53.49 Favored 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.437 ' CB ' ' OE1' ' A' ' 110' ' ' GLN . 3.2 m-20 52.87 27.7 5.73 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.219 -0.926 . . . . 0.0 111.128 179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.9 p -147.25 130.83 16.82 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.144 -0.972 . . . . 0.0 110.202 179.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.415 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.0 p -112.86 127.84 56.29 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.266 -0.896 . . . . 0.0 109.868 179.763 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER 55.45 26.95 9.47 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.312 -0.867 . . . . 0.0 110.526 -179.961 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 97.15 -37.79 3.32 Favored Glycine 0 N--CA 1.493 2.482 0 N-CA-C 109.877 -1.289 . . . . 0.0 109.877 179.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.415 ' O ' ' N ' ' A' ' 105' ' ' SER . 15.8 mttt -77.05 156.54 82.09 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.267 -1.137 . . . . 0.0 110.069 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.9 Cg_endo -65.92 132.63 30.87 Favored 'Trans proline' 0 C--N 1.31 -1.453 0 O-C-N 123.647 1.341 . . . . 0.0 109.902 179.771 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.466 ' NE2' ' N ' ' A' ' 110' ' ' GLN . 0.0 OUTLIER -49.68 171.15 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.256 -0.902 . . . . 0.0 110.972 -179.039 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.8 p30 -99.69 160.79 14.04 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.302 -0.874 . . . . 0.0 110.256 179.678 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -43.35 -53.45 5.28 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.484 -0.76 . . . . 0.0 112.316 -178.776 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.7 m -69.76 -29.38 40.67 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.87 0 O-C-N 120.844 -1.16 . . . . 0.0 111.527 -178.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.32 -56.5 6.71 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.118 -0.989 . . . . 0.0 110.611 -179.094 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.474 ' HD3' HG21 ' A' ' 4' ' ' THR . 1.8 ptm180 -69.1 -34.71 75.51 Favored 'General case' 0 N--CA 1.486 1.352 0 O-C-N 121.31 -0.869 . . . . 0.0 108.797 178.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.43 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 25.7 m -59.48 -49.78 76.48 Favored 'General case' 0 C--N 1.305 -1.33 0 N-CA-C 108.373 -0.973 . . . . 0.0 108.373 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.0 tt0 -73.7 -37.55 65.15 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.479 -0.763 . . . . 0.0 110.044 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.404 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 36.3 mtt-85 -71.89 -45.63 60.63 Favored 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.187 -0.946 . . . . 0.0 111.711 -179.221 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.557 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 27.6 ttp85 -59.36 -51.63 69.1 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.103 -0.998 . . . . 0.0 109.899 -179.56 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.42 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -43.28 -27.39 0.71 Allowed Glycine 0 N--CA 1.501 2.972 0 N-CA-C 111.08 -0.808 . . . . 0.0 111.08 -179.251 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.51 ' HD2' HG21 ' A' ' 93' ' ' THR . 0.0 OUTLIER -45.71 -33.23 2.87 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.253 -1.145 . . . . 0.0 111.627 -179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.515 HG22 HD13 ' A' ' 10' ' ' ILE . 14.9 t -100.63 144.07 30.05 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.882 -1.136 . . . . 0.0 110.901 -179.604 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.437 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 103.99 14.6 24.32 Favored Glycine 0 N--CA 1.489 2.179 0 C-N-CA 119.731 -1.224 . . . . 0.0 110.398 178.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.42 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 0.3 OUTLIER -70.66 84.3 0.63 Allowed 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.167 -1.196 . . . . 0.0 109.776 179.7 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 110.51 -26.4 13.25 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 108.922 -1.671 . . . . 0.0 108.922 -179.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.49 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -137.92 -168.66 0.19 Allowed Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.501 -1.0 . . . . 0.0 108.691 179.652 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.49 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 51.3 Cg_endo -87.35 110.94 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.539 0 O-C-N 123.132 1.07 . . . . 0.0 110.7 179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.463 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -82.46 170.54 50.6 Favored Glycine 0 N--CA 1.495 2.614 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.957 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 49.0 mt -126.43 142.64 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.531 -0.982 . . . . 0.0 108.44 178.692 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.499 ' HD1' HG23 ' A' ' 99' ' ' VAL . 8.4 t80 -128.78 114.75 16.96 Favored 'General case' 0 C--N 1.3 -1.551 0 C-N-CA 118.801 -1.16 . . . . 0.0 110.718 179.823 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.44 ' HD3' HG11 ' A' ' 32' ' ' VAL . 18.2 mtp180 -105.23 122.84 46.77 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.398 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.424 ' HB2' ' OD1' ' A' ' 103' ' ' ASN . 32.1 p90 -121.7 158.04 29.6 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.023 -1.048 . . . . 0.0 110.694 -179.204 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.619 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 32.1 t -94.68 -56.99 4.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.257 -0.902 . . . . 0.0 109.438 179.244 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.619 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 69.07 145.17 0.1 Allowed Pre-proline 0 N--CA 1.496 1.87 0 O-C-N 121.732 -0.605 . . . . 0.0 110.353 -179.537 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_endo -78.34 -55.97 0.04 OUTLIER 'Trans proline' 0 C--N 1.312 -1.386 0 O-C-N 123.783 1.412 . . . . 0.0 110.49 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 136.81 -32.47 2.44 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.466 -1.454 . . . . 0.0 109.466 -179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -147.29 -161.15 1.27 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.239 -1.153 . . . . 0.0 110.262 -179.941 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 9.7 ttt-85 . . . . . 0 N--CA 1.491 1.586 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.135 179.92 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 1.5 t -77.36 108.33 10.42 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.246 -1.149 . . . . 0.0 110.287 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.542 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.1 m -113.39 104.29 16.77 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.257 -0.902 . . . . 0.0 109.886 179.628 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 22.1 p -63.57 139.91 58.82 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.329 -0.857 . . . . 0.0 110.508 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.457 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -69.81 148.38 96.47 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.358 -0.839 . . . . 0.0 109.702 179.681 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.457 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.4 Cg_endo -71.97 -165.71 0.22 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 O-C-N 124.094 1.576 . . . . 0.0 110.914 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.52 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 174.61 80.6 0.06 OUTLIER Pre-proline 0 N--CA 1.499 1.992 0 O-C-N 121.513 -0.742 . . . . 0.0 109.507 -179.602 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -75.14 55.21 3.95 Favored 'Trans proline' 0 C--N 1.312 -1.343 0 O-C-N 123.747 1.393 . . . . 0.0 111.434 -179.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.4 m120 -139.04 4.72 2.28 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.027 -1.045 . . . . 0.0 110.947 179.552 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.681 HD11 ' O ' ' A' ' 122' ' ' THR . 30.5 mt -129.02 137.27 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 120.852 -1.155 . . . . 0.0 109.706 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.3 tt0 -82.72 127.82 33.79 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.088 -1.008 . . . . 0.0 109.224 179.521 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.3 mt-10 -89.92 139.32 30.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.26 -0.9 . . . . 0.0 110.533 -179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.781 HG11 ' NE ' ' A' ' 131' ' ' ARG . 11.2 t -131.77 156.56 42.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.251 -0.906 . . . . 0.0 110.103 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -107.37 109.86 21.7 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.26 -0.9 . . . . 0.0 110.116 179.539 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.699 HD23 ' CB ' ' A' ' 26' ' ' LYS . 9.8 tp -55.8 141.85 37.05 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.227 -0.921 . . . . 0.0 109.307 179.499 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 10.0 p -143.29 174.56 10.62 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.089 -1.007 . . . . 0.0 110.555 -179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -72.26 79.6 0.99 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.339 -0.851 . . . . 0.0 110.254 179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.719 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.0 m -155.66 109.33 2.79 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.209 -0.932 . . . . 0.0 110.472 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.434 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.45 -171.35 28.86 Favored Glycine 0 N--CA 1.488 2.163 0 C-N-CA 118.907 -1.616 . . . . 0.0 111.157 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 13.0 mm-40 -110.53 -22.6 11.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.766 -0.844 . . . . 0.0 110.473 179.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.917 HD12 HD13 ' A' ' 55' ' ' LEU . 9.9 tt -95.26 107.11 30.23 Favored Pre-proline 0 N--CA 1.488 1.448 0 C-N-CA 118.92 -1.112 . . . . 0.0 109.462 -179.746 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.1 Cg_endo -63.83 144.67 89.19 Favored 'Trans proline' 0 C--N 1.313 -1.293 0 O-C-N 123.295 1.155 . . . . 0.0 111.3 -178.37 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.431 ' O ' ' N ' ' A' ' 25' ' ' GLY . 2.9 t80 -135.71 -166.33 1.84 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.485 -0.759 . . . . 0.0 110.347 -179.469 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 36.8 m-85 -59.97 82.05 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.412 -0.805 . . . . 0.0 111.053 -179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 69.41 5.81 51.37 Favored Glycine 0 N--CA 1.492 2.384 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.699 ' CB ' HD23 ' A' ' 15' ' ' LEU . 14.4 mmtm -130.62 156.72 44.4 Favored 'General case' 0 N--CA 1.486 1.364 0 O-C-N 120.972 -1.311 . . . . 0.0 109.791 -179.989 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.719 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -111.8 107.59 16.7 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.111 -0.993 . . . . 0.0 109.128 179.67 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.045 HD11 HG21 ' A' ' 100' ' ' ILE . 6.2 mt -69.11 114.14 21.37 Favored Pre-proline 0 C--N 1.299 -1.612 0 O-C-N 121.335 -0.853 . . . . 0.0 110.793 -179.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.748 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.1 Cg_endo -69.7 132.13 22.78 Favored 'Trans proline' 0 C--N 1.306 -1.672 0 N-CA-C 107.136 -1.909 . . . . 0.0 107.136 176.151 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.79 HD11 HD12 ' A' ' 58' ' ' LEU . 13.2 mt -56.98 -14.93 4.03 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.894 -1.129 . . . . 0.0 111.212 -177.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 15.7 pt-20 -63.32 -16.18 59.58 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 120.516 -1.365 . . . . 0.0 110.5 179.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 10.5 m -93.81 -24.47 5.05 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 121.024 -1.048 . . . . 0.0 110.874 -179.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 48.2 pt -117.17 -27.77 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.469 -179.316 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.637 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -87.97 148.35 24.6 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.294 -0.879 . . . . 0.0 110.49 179.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.76 -5.15 46.9 Favored Glycine 0 N--CA 1.484 1.886 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -179.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.25 -147.7 7.8 Favored Glycine 0 N--CA 1.492 2.421 0 C-N-CA 119.118 -1.515 . . . . 0.0 110.421 179.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.434 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 6.1 mtt180 -108.78 132.44 53.98 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.411 -1.052 . . . . 0.0 110.47 -179.538 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.555 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.2 m-70 -140.72 149.0 41.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.223 -0.923 . . . . 0.0 110.629 179.841 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.574 HD12 ' O ' ' A' ' 82' ' ' VAL . 57.2 tp -110.96 113.6 26.27 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.433 -0.792 . . . . 0.0 109.841 179.502 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.898 HD12 HG12 ' A' ' 83' ' ' VAL . 29.1 mt -96.4 127.36 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 121.25 -0.907 . . . . 0.0 109.665 179.864 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 48.3 m-85 -95.09 122.63 37.96 Favored 'General case' 0 C--N 1.295 -1.801 0 O-C-N 121.272 -0.893 . . . . 0.0 110.277 -179.691 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.98 160.17 21.91 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 121.388 -0.82 . . . . 0.0 110.744 -179.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 3.4 p-80 -110.02 4.64 21.54 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.388 -0.82 . . . . 0.0 109.987 178.881 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -129.49 136.43 49.87 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.962 -1.086 . . . . 0.0 110.963 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.98 -36.88 69.94 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.65 -0.657 . . . . 0.0 110.834 -179.887 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -70.75 -36.7 73.24 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.279 -0.888 . . . . 0.0 110.892 -179.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -66.18 -35.38 80.32 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.34 -0.85 . . . . 0.0 109.553 -179.928 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.89 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 53.2 m -61.46 -33.84 74.43 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.552 -0.717 . . . . 0.0 109.785 179.215 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -67.2 -50.2 61.76 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.267 -0.896 . . . . 0.0 110.972 -179.389 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -72.25 -44.07 63.42 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.122 -0.986 . . . . 0.0 110.571 -179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.644 HD12 HG11 ' A' ' 83' ' ' VAL . 2.6 tm? -57.02 -38.29 72.93 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.553 -0.717 . . . . 0.0 111.253 -179.004 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.7 -51.08 13.52 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.888 -1.132 . . . . 0.0 110.633 -179.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -59.49 -40.06 85.79 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.144 -0.972 . . . . 0.0 110.089 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.685 ' CE ' HD21 ' A' ' 58' ' ' LEU . 0.4 OUTLIER -57.13 -46.0 83.03 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.325 -0.86 . . . . 0.0 109.797 179.76 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.917 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.11 -38.87 71.33 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.617 -0.677 . . . . 0.0 110.112 179.817 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 78.1 t -58.65 -34.38 51.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.202 -0.936 . . . . 0.0 109.17 179.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.28 -30.64 60.47 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.409 -0.807 . . . . 0.0 109.992 179.498 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.79 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -72.03 -25.7 61.91 Favored 'General case' 0 C--N 1.304 -1.405 0 O-C-N 121.399 -0.813 . . . . 0.0 109.781 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.14 5.89 10.31 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.174 -1.57 . . . . 0.0 109.174 -179.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.637 HD11 ' HB2' ' A' ' 34' ' ' LYS . 45.8 mt -108.04 143.24 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.331 0 O-C-N 121.317 -1.108 . . . . 0.0 109.792 -179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 51.8 t30 -89.82 106.4 18.44 Favored 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 177.986 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.705 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.22 142.61 46.6 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.873 -1.131 . . . . 0.0 111.67 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.926 HG21 ' HA ' ' A' ' 73' ' ' VAL . 57.6 t -125.53 149.42 30.22 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.695 -0.628 . . . . 0.0 109.716 179.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.89 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -116.72 118.99 34.06 Favored 'General case' 0 C--N 1.3 -1.553 0 C-N-CA 119.344 -0.943 . . . . 0.0 109.474 178.303 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.468 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.8 t80 -113.39 132.75 55.49 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.218 -0.926 . . . . 0.0 110.841 -179.526 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.745 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.5 p90 -166.92 176.83 6.73 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.524 -0.735 . . . . 0.0 109.75 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 2.9 tmm_? -52.16 125.36 15.5 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.07 -1.018 . . . . 0.0 110.699 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.69 37.4 19.97 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 110.072 -1.211 . . . . 0.0 110.072 179.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.844 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.48 157.23 26.63 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.052 -1.264 . . . . 0.0 110.08 -179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.844 ' N ' HD13 ' A' ' 69' ' ' LEU . 3.8 m-20 -96.55 149.22 22.01 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.297 -0.877 . . . . 0.0 110.544 -179.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.665 HG23 ' O ' ' A' ' 71' ' ' VAL . 30.3 m -62.59 111.4 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.185 -0.947 . . . . 0.0 109.114 179.013 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 58.7 m -132.85 -35.4 1.08 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.415 -0.803 . . . . 0.0 110.732 -179.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.926 ' HA ' HG21 ' A' ' 63' ' ' VAL . 59.9 t -48.45 120.34 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.387 -0.82 . . . . 0.0 110.302 -179.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.825 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.5 pp -137.48 110.03 8.84 Favored Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.201 -0.937 . . . . 0.0 110.623 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.644 ' HA ' HG11 ' A' ' 80' ' ' VAL . 50.2 Cg_endo -87.33 40.12 0.62 Allowed 'Trans proline' 0 C--N 1.313 -1.314 0 O-C-N 123.307 1.162 . . . . 0.0 110.644 179.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 7.3 p -136.4 26.25 3.16 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.063 -1.023 . . . . 0.0 110.201 -179.972 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 33.6 m-20 -135.47 27.33 3.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.237 -0.914 . . . . 0.0 110.163 -179.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 111.37 -156.46 15.54 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.888 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 13.3 m-20 -78.68 112.58 15.94 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.107 -1.231 . . . . 0.0 110.184 179.976 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.644 HG11 ' HA ' ' A' ' 75' ' ' PRO . 5.2 p -116.95 135.57 56.91 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 CA-C-O 122.119 0.961 . . . . 0.0 110.537 -179.775 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.625 HG22 HG22 ' A' ' 60' ' ' ILE . 12.0 m -112.86 119.95 61.73 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.115 0 O-C-N 121.272 -0.892 . . . . 0.0 108.815 178.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.687 HG22 HG13 ' A' ' 73' ' ' VAL . 3.7 t -96.45 119.88 45.08 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.893 -1.13 . . . . 0.0 110.276 -178.095 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.898 HG12 HD12 ' A' ' 40' ' ' ILE . 3.2 m -109.12 100.5 10.9 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.448 0 O-C-N 121.119 -0.988 . . . . 0.0 108.657 179.557 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.468 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.31 162.25 35.45 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 120.733 -1.23 . . . . 0.0 111.01 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.515 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -88.23 -131.29 0.07 Allowed 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.347 -0.846 . . . . 0.0 109.63 179.808 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.515 ' N ' HG23 ' A' ' 85' ' ' THR . 45.0 p30 -91.47 29.3 1.5 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 120.668 -1.27 . . . . 0.0 110.552 179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -101.66 -29.08 12.13 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.057 -1.027 . . . . 0.0 110.229 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -75.18 -33.43 61.45 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.155 -0.966 . . . . 0.0 109.773 179.664 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.404 ' O ' ' HB ' ' A' ' 90' ' ' THR . 1.6 mmt 51.03 -106.77 0.26 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.283 -0.886 . . . . 0.0 109.988 -179.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.741 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.76 41.59 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.835 0 O-C-N 120.637 -1.29 . . . . 0.0 110.424 179.74 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -54.25 -32.43 51.12 Favored Glycine 0 N--CA 1.493 2.459 0 N-CA-C 108.604 -1.798 . . . . 0.0 108.604 179.208 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.494 ' N ' ' CD1' ' A' ' 92' ' ' PHE . 14.2 p90 -145.48 38.32 1.13 Allowed 'General case' 0 C--N 1.305 -1.359 0 O-C-N 121.66 -0.906 . . . . 0.0 109.798 179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.741 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -126.91 -162.41 1.15 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.324 -0.86 . . . . 0.0 110.197 -179.631 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.679 ' N ' HG23 ' A' ' 93' ' ' THR . . . 123.48 -40.44 1.98 Allowed Glycine 0 N--CA 1.491 2.3 0 C-N-CA 119.814 -1.184 . . . . 0.0 110.343 179.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 41.9 t0 -84.45 81.09 8.99 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.135 -1.214 . . . . 0.0 110.82 -179.263 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.49 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 15.0 m-85 -119.75 147.99 43.95 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.121 -0.987 . . . . 0.0 110.105 179.231 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.501 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.5 m-20 -71.12 -35.13 71.65 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.395 -0.815 . . . . 0.0 109.372 179.437 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.463 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.3 p -162.05 163.62 28.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.232 -0.917 . . . . 0.0 111.143 179.784 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.712 HG22 HG21 ' A' ' 122' ' ' THR . 1.3 m -129.38 118.1 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.513 -0.742 . . . . 0.0 110.094 179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.045 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -92.59 111.97 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -118.15 160.24 21.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.12 -0.988 . . . . 0.0 111.679 -178.173 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.542 ' HB3' ' CD2' ' A' ' 24' ' ' TYR . 29.4 p -103.25 6.31 38.07 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 109.164 -0.68 . . . . 0.0 109.164 178.136 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.454 ' HA ' ' NE2' ' A' ' 110' ' ' GLN . 2.5 m120 47.06 25.44 0.5 Allowed 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.265 -0.897 . . . . 0.0 110.875 179.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.656 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -147.76 129.38 15.05 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.281 -0.887 . . . . 0.0 110.38 179.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 24.5 p -113.35 132.17 55.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.258 -0.901 . . . . 0.0 109.61 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . 0.416 ' OD1' ' N ' ' A' ' 106' ' ' ASP . 1.5 m-20 54.47 -141.9 0.83 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.095 -1.003 . . . . 0.0 109.637 -179.63 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.76 18.09 41.22 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 110.046 -1.222 . . . . 0.0 110.046 179.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 2.0 mmtp -133.79 156.3 79.54 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.089 -1.242 . . . . 0.0 109.713 179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.656 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.4 Cg_endo -64.67 159.79 43.43 Favored 'Trans proline' 0 C--N 1.309 -1.516 0 O-C-N 123.625 1.329 . . . . 0.0 110.164 179.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.454 ' NE2' ' HA ' ' A' ' 103' ' ' ASN . 2.8 pt20 -57.17 153.32 12.01 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.219 -0.926 . . . . 0.0 110.706 -179.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.534 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.7 p30 -90.74 160.77 15.64 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.342 -0.849 . . . . 0.0 110.257 179.826 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.412 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.33 -52.28 4.59 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.559 -0.713 . . . . 0.0 112.324 -178.724 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.534 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.3 m -70.78 -29.25 36.98 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.793 -1.192 . . . . 0.0 111.226 -178.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.442 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.44 -56.2 7.45 Favored 'General case' 0 N--CA 1.498 1.929 0 O-C-N 121.111 -0.993 . . . . 0.0 110.499 -179.366 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.416 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.4 OUTLIER -68.81 -34.53 75.66 Favored 'General case' 0 N--CA 1.487 1.38 0 O-C-N 121.151 -0.968 . . . . 0.0 108.777 178.654 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.442 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 31.4 m -60.02 -49.97 75.59 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 178.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.1 tp60 -73.57 -39.98 64.27 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.49 -0.756 . . . . 0.0 109.693 178.867 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.416 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 4.1 mtt180 -66.16 -44.76 83.14 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.216 -0.928 . . . . 0.0 110.028 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.52 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 13.4 ttm180 -64.05 -34.09 77.24 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.186 -0.946 . . . . 0.0 110.295 179.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.454 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -70.31 11.99 1.98 Allowed Glycine 0 N--CA 1.497 2.732 0 O-C-N 121.104 -0.998 . . . . 0.0 112.291 -179.065 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.494 ' CZ ' HG21 ' A' ' 90' ' ' THR . 1.1 mmt85 -101.29 -5.18 25.81 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 120.301 -1.705 . . . . 0.0 109.443 178.644 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.712 HG21 HG22 ' A' ' 99' ' ' VAL . 0.5 OUTLIER -121.43 142.23 50.23 Favored 'General case' 0 N--CA 1.496 1.848 0 O-C-N 121.266 -0.896 . . . . 0.0 109.398 179.769 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.421 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 78.4 26.48 59.31 Favored Glycine 0 N--CA 1.488 2.155 0 C-N-CA 119.799 -1.191 . . . . 0.0 110.177 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.454 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 1.0 OUTLIER -57.0 -44.31 82.62 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.112 -1.228 . . . . 0.0 110.119 179.906 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . -126.57 24.91 5.46 Favored Glycine 0 N--CA 1.491 2.35 0 N-CA-C 109.231 -1.548 . . . . 0.0 109.231 179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -174.26 -169.36 0.11 Allowed Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.52 -0.988 . . . . 0.0 109.092 -179.658 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.474 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 46.4 Cg_endo -84.43 99.6 0.76 Allowed 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.191 1.101 . . . . 0.0 109.533 179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.431 ' HA3' ' OG1' ' A' ' 122' ' ' THR . . . -83.88 176.6 52.11 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.695 -1.241 . . . . 0.0 110.05 -179.141 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.446 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.1 mt -123.46 143.96 34.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.709 0 O-C-N 121.449 -1.03 . . . . 0.0 109.97 -179.788 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.53 ' CD2' HG21 ' A' ' 99' ' ' VAL . 9.7 t80 -129.41 116.92 19.74 Favored 'General case' 0 C--N 1.304 -1.406 0 C-N-CA 119.06 -1.056 . . . . 0.0 111.202 179.669 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.781 ' NE ' HG11 ' A' ' 13' ' ' VAL . 11.3 mmt180 -99.22 137.91 37.06 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.588 -0.695 . . . . 0.0 109.186 179.045 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.467 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 23.8 p90 -137.79 153.96 49.61 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.918 -1.113 . . . . 0.0 110.739 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 24.0 t -83.86 -46.72 18.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.294 -0.878 . . . . 0.0 109.41 179.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -119.19 160.97 39.15 Favored Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.272 -0.892 . . . . 0.0 110.247 179.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.43 -27.36 16.02 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.791 1.416 . . . . 0.0 110.545 -179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 137.44 79.83 0.08 OUTLIER Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.698 -1.361 . . . . 0.0 109.698 179.918 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.9 tt0 -175.92 143.37 0.56 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.278 -1.131 . . . . 0.0 110.187 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.184 -179.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 109.652 -1.379 . . . . 0.0 109.652 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.5 m -93.06 150.92 20.19 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.205 -1.174 . . . . 0.0 110.383 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.543 HG23 ' O ' ' A' ' 3' ' ' VAL . 21.2 m -113.32 104.69 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.412 0 O-C-N 121.366 -0.834 . . . . 0.0 110.039 179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.809 HG22 ' OG1' ' A' ' 116' ' ' THR . 6.2 p -66.08 145.04 56.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.336 -0.853 . . . . 0.0 110.346 -179.902 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.673 HG22 ' HD1' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -70.19 147.85 95.62 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.257 -0.902 . . . . 0.0 109.828 179.845 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.533 ' HD2' HG23 ' A' ' 5' ' ' VAL . 38.6 Cg_endo -73.14 -64.64 0.03 OUTLIER 'Trans proline' 0 C--N 1.31 -1.485 0 O-C-N 124.13 1.594 . . . . 0.0 112.47 -179.963 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.673 ' HD1' HG22 ' A' ' 5' ' ' VAL . 47.8 p-80 41.25 87.29 0.12 Allowed Pre-proline 0 N--CA 1.492 1.674 0 CA-C-O 121.262 0.553 . . . . 0.0 111.226 -178.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -74.91 0.74 8.49 Favored 'Trans proline' 0 C--N 1.313 -1.336 0 O-C-N 123.454 1.239 . . . . 0.0 111.567 -179.255 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 12.3 m120 -52.41 -22.17 4.41 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 120.805 -1.184 . . . . 0.0 110.427 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.459 HD11 ' O ' ' A' ' 122' ' ' THR . 31.0 mt -111.89 135.27 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 O-C-N 120.942 -1.099 . . . . 0.0 110.252 179.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -85.2 129.1 34.87 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.22 -0.925 . . . . 0.0 109.71 179.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 8.9 mt-10 -89.26 135.45 33.57 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.056 -1.027 . . . . 0.0 110.506 -179.441 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.708 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 17.1 t -125.68 158.03 34.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 O-C-N 121.412 -0.805 . . . . 0.0 109.962 -179.644 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.94 114.92 29.41 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.161 -0.962 . . . . 0.0 110.384 179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.537 HD23 HG22 ' A' ' 133' ' ' VAL . 12.3 tp -63.15 135.62 57.27 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.178 -0.951 . . . . 0.0 109.665 179.546 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.2 p -134.78 171.6 14.14 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.086 -1.009 . . . . 0.0 110.623 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.2 p -68.27 76.27 0.25 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.866 . . . . 0.0 110.055 179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.517 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -149.22 112.67 5.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.337 -0.852 . . . . 0.0 110.359 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.32 -161.67 27.28 Favored Glycine 0 N--CA 1.489 2.191 0 C-N-CA 118.887 -1.625 . . . . 0.0 110.705 179.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 27.4 mm-40 -122.05 -22.31 5.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.672 -0.899 . . . . 0.0 110.873 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.946 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.9 tt -93.55 112.87 58.53 Favored Pre-proline 0 N--CA 1.488 1.429 0 C-N-CA 118.602 -1.239 . . . . 0.0 110.291 -179.383 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.4 Cg_endo -64.9 141.24 70.27 Favored 'Trans proline' 0 C--N 1.31 -1.456 0 O-C-N 123.55 1.289 . . . . 0.0 109.98 -179.741 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.454 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 78.9 t80 -153.9 89.0 1.28 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.12 -0.988 . . . . 0.0 111.761 -178.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.572 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 32.3 m-85 59.05 67.77 0.88 Allowed 'General case' 0 N--CA 1.499 1.995 0 O-C-N 121.526 -0.734 . . . . 0.0 111.597 178.814 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.72 12.07 26.0 Favored Glycine 0 N--CA 1.494 2.525 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.469 ' CB ' HD23 ' A' ' 15' ' ' LEU . 10.2 mmtt -129.92 156.6 44.15 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.037 -1.273 . . . . 0.0 109.243 179.685 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.517 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -113.58 106.91 15.1 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 120.922 -1.111 . . . . 0.0 108.932 179.371 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.946 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -70.85 114.95 31.09 Favored Pre-proline 0 C--N 1.297 -1.716 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.065 -179.394 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.865 ' O ' HG22 ' A' ' 32' ' ' VAL . 38.9 Cg_endo -67.49 130.32 22.04 Favored 'Trans proline' 0 C--N 1.302 -1.893 0 N-CA-C 107.478 -1.778 . . . . 0.0 107.478 176.848 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.757 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.33 -16.43 5.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 120.936 -1.102 . . . . 0.0 110.633 -178.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 12.3 pt-20 -63.18 -16.22 59.42 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.624 -1.297 . . . . 0.0 110.581 179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.053 HG23 HG23 ' A' ' 33' ' ' ILE . 15.3 m -92.64 -25.26 5.09 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 120.972 -1.08 . . . . 0.0 111.115 -179.204 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.053 HG23 HG23 ' A' ' 32' ' ' VAL . 30.7 pt -116.38 -29.75 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.209 -0.932 . . . . 0.0 109.839 -179.356 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.618 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -88.39 148.18 24.36 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.29 -0.881 . . . . 0.0 110.365 179.444 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 103.13 -5.25 49.47 Favored Glycine 0 N--CA 1.485 1.901 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.482 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.13 -152.49 11.2 Favored Glycine 0 N--CA 1.493 2.479 0 C-N-CA 119.121 -1.514 . . . . 0.0 110.509 179.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.432 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 8.8 mtt85 -103.24 128.58 50.2 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.411 -1.052 . . . . 0.0 110.404 -179.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.65 ' HB2' HG12 ' A' ' 81' ' ' VAL . 54.5 m80 -139.45 149.94 44.63 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.098 -1.001 . . . . 0.0 110.461 179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.56 HD12 ' HB ' ' A' ' 82' ' ' VAL . 19.9 tp -111.92 117.29 32.35 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.412 -0.805 . . . . 0.0 110.384 -179.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.902 ' CG1' HG12 ' A' ' 83' ' ' VAL . 11.6 mm -96.02 127.15 48.35 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 O-C-N 121.248 -0.907 . . . . 0.0 108.961 179.431 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.429 ' CZ ' ' HG2' ' A' ' 118' ' ' ARG . 5.8 m-85 -94.85 122.0 37.04 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.962 -1.086 . . . . 0.0 110.036 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.36 159.36 23.55 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.376 -0.827 . . . . 0.0 110.477 179.862 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.572 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 1.7 p-80 -112.08 4.65 18.14 Favored 'General case' 0 C--N 1.301 -1.523 0 O-C-N 121.423 -0.798 . . . . 0.0 109.612 178.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.3 p -133.54 141.33 47.68 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.1 -1.0 . . . . 0.0 110.447 179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.482 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 0.5 OUTLIER -72.07 -35.68 69.34 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.519 -0.738 . . . . 0.0 110.579 -179.942 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 20.3 mttt -64.12 -45.39 88.76 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.315 -0.865 . . . . 0.0 110.651 -179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 2.6 tptt -61.16 -38.28 85.91 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.361 -0.837 . . . . 0.0 109.632 -179.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.948 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.25 -34.12 74.63 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.513 -0.742 . . . . 0.0 109.566 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -66.27 -48.67 69.7 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.174 -0.954 . . . . 0.0 110.788 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.435 ' O ' ' HB2' ' A' ' 54' ' ' LYS . 2.6 mt-10 -71.22 -44.61 65.02 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.209 -0.932 . . . . 0.0 110.498 -179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 1.053 HD12 HG11 ' A' ' 83' ' ' VAL . 0.3 OUTLIER -55.72 -44.63 77.66 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.34 -0.85 . . . . 0.0 111.009 -179.105 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.448 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -72.19 -51.41 21.28 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.048 -1.032 . . . . 0.0 110.456 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.07 -43.45 98.54 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.216 -0.928 . . . . 0.0 110.086 -179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.619 ' O ' HD23 ' A' ' 58' ' ' LEU . 4.4 tmtt? -57.21 -46.12 83.2 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.193 -0.942 . . . . 0.0 109.535 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.745 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.1 OUTLIER -55.78 -40.96 73.36 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.529 -0.732 . . . . 0.0 110.179 179.93 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 51.8 t -57.35 -35.28 48.6 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.032 -1.042 . . . . 0.0 108.998 179.428 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.85 -31.26 59.25 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.373 -0.829 . . . . 0.0 110.223 179.52 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.757 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.31 -25.82 62.59 Favored 'General case' 0 N--CA 1.488 1.469 0 CA-C-O 121.926 0.869 . . . . 0.0 109.714 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.44 5.75 10.1 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.154 -1.579 . . . . 0.0 109.154 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.668 ' CD1' HD22 ' A' ' 30' ' ' LEU . 38.0 mt -108.03 143.31 18.71 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.43 -1.041 . . . . 0.0 110.074 -179.511 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.506 ' ND2' HD11 ' A' ' 74' ' ' ILE . 45.8 t30 -89.55 106.61 18.57 Favored 'General case' 0 C--N 1.307 -1.256 0 N-CA-C 106.817 -1.549 . . . . 0.0 106.817 177.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.745 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.76 144.41 46.29 Favored 'General case' 0 C--N 1.299 -1.624 0 C-N-CA 118.997 -1.081 . . . . 0.0 111.685 -177.287 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.915 HG21 ' HA ' ' A' ' 73' ' ' VAL . 48.7 t -127.8 145.9 34.32 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.741 0 C-N-CA 119.941 -0.704 . . . . 0.0 109.682 179.252 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.948 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -110.12 119.39 39.12 Favored 'General case' 0 C--N 1.301 -1.535 0 C-N-CA 119.171 -1.012 . . . . 0.0 109.868 178.8 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.511 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 4.1 t80 -116.41 127.27 54.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.246 -0.909 . . . . 0.0 110.655 -179.676 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.848 ' CE1' HD23 ' A' ' 69' ' ' LEU . 1.2 p90 -153.24 -171.39 3.9 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.369 -0.832 . . . . 0.0 109.997 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 9.3 ttp180 -52.57 126.91 21.09 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.286 -0.884 . . . . 0.0 111.308 -179.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 66.18 50.87 48.51 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 110.612 -0.995 . . . . 0.0 110.612 179.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.848 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.5 tm? -117.75 155.06 30.66 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.037 -1.272 . . . . 0.0 109.963 179.551 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.3 m-20 -90.81 149.54 21.94 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.351 -0.843 . . . . 0.0 110.667 -179.148 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.684 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.3 m -62.49 110.89 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.522 0 O-C-N 121.131 -0.981 . . . . 0.0 109.587 179.397 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.428 ' O ' HG23 ' A' ' 74' ' ' ILE . 34.4 m -132.14 -23.78 2.16 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.377 -0.827 . . . . 0.0 111.151 -179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.915 ' HA ' HG21 ' A' ' 63' ' ' VAL . 22.6 t -60.12 138.71 20.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.118 -0.989 . . . . 0.0 110.058 -179.478 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.506 HD11 ' ND2' ' A' ' 61' ' ' ASN . 1.2 pp -137.1 100.49 9.61 Favored Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.24 -0.913 . . . . 0.0 110.572 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.646 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.6 Cg_endo -88.16 36.87 0.43 Allowed 'Trans proline' 0 C--N 1.311 -1.404 0 O-C-N 123.636 1.335 . . . . 0.0 110.53 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -128.43 16.41 6.54 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.045 -1.035 . . . . 0.0 110.67 -179.62 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.44 ' HB2' HD12 ' A' ' 74' ' ' ILE . 1.8 m-80 -116.14 -165.39 1.04 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.057 -1.027 . . . . 0.0 110.09 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -51.78 -87.58 0.01 OUTLIER Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.563 -1.415 . . . . 0.0 109.563 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 79.3 m-20 -131.83 114.97 15.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.185 -1.186 . . . . 0.0 110.391 179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.646 HG11 ' HA ' ' A' ' 75' ' ' PRO . 7.1 p -116.83 133.74 62.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 CA-C-O 122.08 0.943 . . . . 0.0 110.42 179.893 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.65 HG12 ' HB2' ' A' ' 38' ' ' HIS . 6.1 m -113.54 123.53 69.29 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.168 0 O-C-N 121.455 -0.778 . . . . 0.0 109.034 179.075 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.713 HG22 HG13 ' A' ' 73' ' ' VAL . 3.6 t -97.49 118.03 43.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.654 0 O-C-N 120.907 -1.121 . . . . 0.0 110.675 -177.88 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 1.053 HG11 HD12 ' A' ' 51' ' ' LEU . 3.4 m -106.62 100.46 10.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 120.967 -1.083 . . . . 0.0 108.626 179.059 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.511 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -144.2 162.4 36.44 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 120.679 -1.263 . . . . 0.0 111.26 -178.067 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.451 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.8 t -92.95 -138.16 0.19 Allowed 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.495 -0.753 . . . . 0.0 108.982 179.234 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.451 ' N ' HG23 ' A' ' 85' ' ' THR . 0.1 OUTLIER -86.34 50.04 1.91 Allowed 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.727 -1.233 . . . . 0.0 109.936 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -117.64 -18.65 9.63 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.271 -0.893 . . . . 0.0 110.572 -179.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.492 HD12 ' HA ' ' A' ' 88' ' ' LEU . 14.2 tp -62.44 -23.53 66.93 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.072 -1.018 . . . . 0.0 109.704 179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.548 ' C ' HG22 ' A' ' 90' ' ' THR . 0.4 OUTLIER 46.3 28.36 0.69 Allowed 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.466 -0.771 . . . . 0.0 110.731 179.721 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.772 ' OG1' HG22 ' A' ' 93' ' ' THR . 5.8 t 35.1 -126.34 0.11 Allowed 'General case' 0 N--CA 1.5 2.049 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 178.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.44 ' N ' HG23 ' A' ' 90' ' ' THR . . . 90.72 -51.22 3.25 Favored Glycine 0 N--CA 1.489 2.185 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -178.918 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 51.7 p90 -133.17 23.67 4.15 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.572 -0.958 . . . . 0.0 109.428 179.066 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.772 HG22 ' OG1' ' A' ' 90' ' ' THR . 3.7 t -98.92 -156.28 0.54 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.415 -0.803 . . . . 0.0 110.696 -179.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.538 ' N ' HG23 ' A' ' 93' ' ' THR . . . 94.08 -25.01 24.13 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 110.211 -1.156 . . . . 0.0 110.211 179.277 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -87.17 60.94 6.44 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.025 -1.279 . . . . 0.0 110.814 -179.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.484 ' CE2' ' OG1' ' A' ' 93' ' ' THR . 20.8 m-85 -119.64 146.56 45.45 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.032 -1.043 . . . . 0.0 110.381 179.283 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -76.3 -34.79 59.06 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.489 -0.757 . . . . 0.0 109.505 179.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.431 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 3.7 p -160.91 163.07 32.19 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.24 -0.912 . . . . 0.0 110.745 179.78 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.554 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.32 118.13 45.07 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.948 0 O-C-N 121.229 -0.92 . . . . 0.0 110.11 179.397 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.714 HG21 ' CD1' ' A' ' 28' ' ' ILE . 3.2 mp -95.94 117.69 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.368 -0.833 . . . . 0.0 109.468 179.649 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.43 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 18.7 t0 -124.47 161.37 26.21 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.13 -0.981 . . . . 0.0 111.858 -178.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 24.7 t -96.9 -6.81 34.86 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.141 -0.688 . . . . 0.0 109.141 177.73 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 55.75 15.33 1.57 Allowed 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.304 -0.872 . . . . 0.0 111.65 179.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.508 HG23 ' C ' ' A' ' 107' ' ' GLY . 1.1 m -143.42 120.14 11.17 Favored 'General case' 0 C--N 1.308 -1.214 0 O-C-N 120.755 -1.216 . . . . 0.0 109.534 -179.961 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.485 ' N ' ' O ' ' A' ' 108' ' ' LYS . 8.9 p -96.91 121.72 39.1 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.311 -0.868 . . . . 0.0 110.334 179.868 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 13.5 t0 60.79 32.88 20.19 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 121.271 -0.893 . . . . 0.0 110.727 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . 0.508 ' C ' HG23 ' A' ' 104' ' ' THR . . . 92.26 -28.2 9.26 Favored Glycine 0 N--CA 1.492 2.382 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 179.401 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.485 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -88.42 155.77 51.21 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.064 -1.256 . . . . 0.0 110.137 -179.768 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -63.85 128.44 22.02 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.512 1.269 . . . . 0.0 110.779 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.413 ' HG2' ' HB3' ' A' ' 114' ' ' SER . 0.0 OUTLIER -46.35 168.73 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.569 -0.707 . . . . 0.0 111.133 -179.451 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.518 ' OD1' HG22 ' A' ' 113' ' ' VAL . 3.0 p30 -87.79 161.0 17.81 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.355 -0.841 . . . . 0.0 110.265 179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . . . . . . . . . . . -48.63 -59.14 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.351 -0.843 . . . . 0.0 111.826 -178.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.518 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.5 m -60.69 -29.72 45.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.864 0 O-C-N 120.917 -1.114 . . . . 0.0 111.785 -178.308 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.35 -56.06 7.6 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.084 -1.01 . . . . 0.0 110.444 -179.151 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.472 ' HG2' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -69.33 -32.88 72.27 Favored 'General case' 0 C--N 1.305 -1.368 0 O-C-N 121.207 -0.933 . . . . 0.0 108.9 178.766 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.809 ' OG1' HG22 ' A' ' 4' ' ' THR . 25.3 m -61.11 -49.82 75.76 Favored 'General case' 0 C--N 1.307 -1.247 0 O-C-N 121.099 -1.001 . . . . 0.0 108.417 178.968 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -73.96 -36.29 64.58 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.546 -0.721 . . . . 0.0 109.832 178.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.433 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 49.1 mtt-85 -71.71 -44.43 64.17 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.201 -0.937 . . . . 0.0 111.111 -179.475 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.477 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 19.6 ttm180 -56.77 -40.97 76.79 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.871 -1.143 . . . . 0.0 109.93 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.07 71.45 0.19 Allowed Glycine 0 N--CA 1.493 2.452 0 N-CA-C 109.884 -1.286 . . . . 0.0 109.884 -179.822 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.444 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -144.75 -45.13 0.24 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.558 -0.966 . . . . 0.0 108.846 179.435 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.53 HG23 ' HA3' ' A' ' 128' ' ' GLY . 9.2 t -101.14 143.06 31.71 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.617 -0.677 . . . . 0.0 109.337 178.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.473 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 114.5 3.96 22.07 Favored Glycine 0 N--CA 1.486 2.021 0 C-N-CA 119.49 -1.338 . . . . 0.0 110.167 179.862 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.404 ' HB2' ' O ' ' A' ' 94' ' ' GLY . 0.3 OUTLIER -70.98 85.39 0.7 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.962 -1.316 . . . . 0.0 109.842 179.945 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 104.1 9.77 35.97 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.473 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 3.6 pttt -174.96 -173.79 0.22 Allowed Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 121.334 -1.098 . . . . 0.0 108.637 -179.712 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.457 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 49.8 Cg_endo -88.19 105.35 0.51 Allowed 'Trans proline' 0 C--N 1.309 -1.517 0 O-C-N 123.194 1.102 . . . . 0.0 110.296 179.451 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.53 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.36 170.44 53.54 Favored Glycine 0 N--CA 1.493 2.489 0 N-CA-C 110.098 -1.201 . . . . 0.0 110.098 -179.836 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.431 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.5 mp -126.81 142.57 42.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.519 -0.989 . . . . 0.0 108.847 179.174 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.554 ' CD2' HG23 ' A' ' 99' ' ' VAL . 6.3 t80 -129.36 115.18 17.16 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.03 -1.044 . . . . 0.0 110.562 179.711 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.708 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.3 mtt180 -98.67 122.83 42.39 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.488 -0.757 . . . . 0.0 109.323 179.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' O ' ' CD1' ' A' ' 132' ' ' PHE . 23.9 p90 -121.38 148.68 44.05 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.081 -1.012 . . . . 0.0 110.293 -179.465 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.537 HG22 HD23 ' A' ' 15' ' ' LEU . 46.2 t -74.6 -31.74 27.89 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.126 -0.984 . . . . 0.0 109.546 179.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -127.67 134.01 25.72 Favored Pre-proline 0 N--CA 1.492 1.627 0 O-C-N 121.177 -0.952 . . . . 0.0 110.061 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -74.51 -18.77 19.77 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 O-C-N 123.549 1.289 . . . . 0.0 110.692 -179.931 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . 0.431 ' O ' ' N ' ' A' ' 138' ' ' ARG . . . 108.09 -42.62 1.89 Allowed Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.359 -1.496 . . . . 0.0 109.359 -179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.6 mt-10 55.1 -88.23 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.486 -1.008 . . . . 0.0 110.546 179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.431 ' N ' ' O ' ' A' ' 136' ' ' GLY . 9.8 ptt85 . . . . . 0 N--CA 1.492 1.628 0 O-C-N 120.975 -1.078 . . . . 0.0 110.277 -179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.8 m -117.06 140.15 49.85 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.241 -1.153 . . . . 0.0 110.3 -179.955 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.625 ' O ' HG13 ' A' ' 3' ' ' VAL . 7.1 p -112.83 104.8 17.61 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.397 0 O-C-N 121.303 -0.873 . . . . 0.0 109.769 179.64 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 72.2 p -62.85 141.75 58.53 Favored 'General case' 0 C--N 1.298 -1.64 0 O-C-N 121.34 -0.85 . . . . 0.0 110.376 -179.657 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.462 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -66.86 148.88 98.71 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.319 -0.863 . . . . 0.0 109.301 179.792 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.462 ' HD2' HG23 ' A' ' 5' ' ' VAL . 43.3 Cg_endo -69.1 -171.98 0.47 Allowed 'Trans proline' 0 C--N 1.306 -1.658 0 O-C-N 124.03 1.542 . . . . 0.0 110.93 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.544 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.2 OUTLIER 175.66 75.15 0.07 OUTLIER Pre-proline 0 N--CA 1.495 1.788 0 O-C-N 121.535 -0.728 . . . . 0.0 109.51 -179.721 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -70.71 -13.49 32.33 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 O-C-N 123.861 1.453 . . . . 0.0 110.691 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.447 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 8.5 m120 -59.85 -18.11 41.73 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.049 -1.032 . . . . 0.0 110.171 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.456 ' CD1' ' O ' ' A' ' 119' ' ' ARG . 40.7 mt -117.5 136.42 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.059 -1.026 . . . . 0.0 110.522 -179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 22.0 tp10 -84.05 129.47 34.91 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.311 -0.868 . . . . 0.0 109.146 178.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -88.24 129.2 35.42 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.05 -1.031 . . . . 0.0 110.387 -179.033 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.472 ' O ' ' CD2' ' A' ' 132' ' ' PHE . 15.7 t -124.47 156.28 32.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.408 -0.808 . . . . 0.0 110.066 -179.681 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 111.45 23.95 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.249 -0.907 . . . . 0.0 110.209 179.696 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.448 HD23 ' CB ' ' A' ' 26' ' ' LYS . 11.5 tp -55.07 136.15 48.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.335 -0.853 . . . . 0.0 109.865 179.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 18' ' ' THR . 12.6 p -136.96 173.82 11.28 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.147 -0.97 . . . . 0.0 110.242 -179.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 4.0 p -67.56 74.29 0.16 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.214 -0.929 . . . . 0.0 109.875 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.626 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 17.9 m -145.57 109.58 4.86 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.358 -0.839 . . . . 0.0 110.339 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.44 -160.68 27.92 Favored Glycine 0 N--CA 1.488 2.128 0 C-N-CA 119.024 -1.56 . . . . 0.0 110.676 179.522 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 58.3 mm-40 -122.05 -24.97 5.02 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.716 -0.873 . . . . 0.0 110.575 -179.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.9 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.7 tt -93.91 111.37 52.66 Favored Pre-proline 0 N--CA 1.489 1.477 0 C-N-CA 118.608 -1.237 . . . . 0.0 110.172 -179.561 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.2 Cg_endo -64.81 142.99 78.55 Favored 'Trans proline' 0 C--N 1.311 -1.411 0 O-C-N 123.456 1.24 . . . . 0.0 110.151 -179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.446 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 85.6 t80 -155.23 94.83 1.65 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.231 -0.918 . . . . 0.0 111.319 -178.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.434 ' CZ ' ' CE1' ' A' ' 43' ' ' HIS . 23.8 m-85 57.68 67.04 1.01 Allowed 'General case' 0 N--CA 1.499 2.02 0 O-C-N 121.527 -0.733 . . . . 0.0 111.613 179.091 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.53 13.3 16.43 Favored Glycine 0 N--CA 1.494 2.501 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.448 ' CB ' HD23 ' A' ' 15' ' ' LEU . 22.2 mmtm -130.56 157.0 43.9 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.077 -1.249 . . . . 0.0 109.176 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.626 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -112.62 107.5 16.22 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.87 -1.144 . . . . 0.0 109.801 -179.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.9 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.5 mt -70.01 113.38 17.2 Favored Pre-proline 0 C--N 1.301 -1.522 0 O-C-N 121.35 -0.844 . . . . 0.0 109.927 -179.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.79 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.0 Cg_endo -68.92 128.85 17.44 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 N-CA-C 107.038 -1.947 . . . . 0.0 107.038 176.442 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.581 HD11 HD12 ' A' ' 58' ' ' LEU . 6.3 mt -56.54 -16.07 5.4 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.853 -1.155 . . . . 0.0 111.128 -177.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.406 ' OE2' ' HB2' ' A' ' 29' ' ' PRO . 9.7 pt-20 -64.4 -16.42 62.3 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.677 -1.264 . . . . 0.0 110.859 -179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.083 HG23 HG23 ' A' ' 33' ' ' ILE . 15.1 m -89.67 -26.45 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.902 0 O-C-N 120.907 -1.121 . . . . 0.0 111.168 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.083 HG23 HG23 ' A' ' 32' ' ' VAL . 43.4 pt -116.97 -23.71 3.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.139 -0.976 . . . . 0.0 110.095 -179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.599 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.1 OUTLIER -92.56 148.33 22.17 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.133 -0.98 . . . . 0.0 110.6 179.977 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.21 -4.25 51.74 Favored Glycine 0 N--CA 1.486 1.99 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -179.23 -151.64 9.9 Favored Glycine 0 N--CA 1.492 2.429 0 C-N-CA 119.206 -1.473 . . . . 0.0 110.224 -179.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.452 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 4.2 mtp180 -106.56 130.68 54.28 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.4 -1.059 . . . . 0.0 110.225 -179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.566 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 71.0 m80 -140.75 148.8 41.25 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.162 -0.961 . . . . 0.0 110.973 -179.678 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 20.2 tp -109.72 123.18 49.07 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.251 -0.906 . . . . 0.0 109.956 179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.939 HD12 ' CG1' ' A' ' 83' ' ' VAL . 37.6 mt -104.76 128.76 58.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.528 0 O-C-N 121.291 -0.881 . . . . 0.0 108.891 179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.423 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 15.7 m-85 -94.31 122.84 37.28 Favored 'General case' 0 C--N 1.293 -1.883 0 O-C-N 121.307 -0.871 . . . . 0.0 110.349 -179.34 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.82 160.03 22.06 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.331 -0.856 . . . . 0.0 110.812 -179.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.434 ' CE1' ' CZ ' ' A' ' 24' ' ' TYR . 3.9 p-80 -115.5 5.26 14.42 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.512 -0.742 . . . . 0.0 109.813 178.695 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.5 p -133.72 138.19 45.67 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.045 -1.035 . . . . 0.0 110.888 -179.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 1.0 OUTLIER -71.75 -43.29 66.05 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.747 -0.596 . . . . 0.0 110.551 -179.93 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.1 mptt -60.71 -34.52 74.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.293 -0.879 . . . . 0.0 110.555 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 5.6 ttmt -73.14 -38.24 66.33 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.213 -0.929 . . . . 0.0 109.916 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.951 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 61.6 m -61.43 -34.42 75.37 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.496 -0.752 . . . . 0.0 109.898 179.981 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.26 -49.69 58.84 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.14 -0.975 . . . . 0.0 110.381 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -72.02 -46.38 57.37 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.234 -0.916 . . . . 0.0 110.288 179.977 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.809 ' CD2' HD11 ' A' ' 21' ' ' ILE . 3.3 tm? -56.92 -42.65 80.39 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 121.549 -0.719 . . . . 0.0 110.973 -179.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.468 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -73.39 -50.86 19.64 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.981 -1.075 . . . . 0.0 110.607 -179.854 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -63.1 -40.43 97.6 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.079 -1.013 . . . . 0.0 109.769 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.533 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.2 OUTLIER -57.29 -43.04 82.8 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.314 -0.866 . . . . 0.0 109.457 179.341 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.734 HD23 ' CB ' ' A' ' 62' ' ' ALA . 0.3 OUTLIER -55.42 -42.81 74.64 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.393 -0.817 . . . . 0.0 109.741 179.595 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.8 t -56.13 -32.65 34.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 108.701 179.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.445 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.46 -32.11 60.51 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.561 -0.712 . . . . 0.0 110.032 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.581 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.49 -26.27 62.61 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.338 -0.852 . . . . 0.0 109.59 179.807 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.32 5.45 9.45 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.599 HD11 ' HB2' ' A' ' 34' ' ' LYS . 51.9 mt -108.25 143.14 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.432 0 O-C-N 121.304 -1.115 . . . . 0.0 110.042 -179.754 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 36.7 t30 -86.63 107.02 17.99 Favored 'General case' 0 N--CA 1.485 1.278 0 N-CA-C 107.273 -1.38 . . . . 0.0 107.273 178.346 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.734 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -122.07 147.79 45.66 Favored 'General case' 0 C--N 1.298 -1.669 0 C-N-CA 119.163 -1.015 . . . . 0.0 111.516 -177.585 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.939 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.8 t -135.75 142.41 39.29 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.812 0 C-N-CA 119.81 -0.756 . . . . 0.0 109.497 179.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.951 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -105.33 135.08 47.36 Favored 'General case' 0 C--N 1.3 -1.56 0 C-N-CA 119.234 -0.986 . . . . 0.0 109.914 179.273 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.458 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 1.9 t80 -127.64 131.3 49.88 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.161 -0.962 . . . . 0.0 110.812 -179.885 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.672 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.6 p90 -166.22 175.32 8.42 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.644 -0.66 . . . . 0.0 109.526 179.679 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -51.77 114.94 1.43 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.256 -0.903 . . . . 0.0 110.807 -179.313 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 94.73 31.43 7.8 Favored Glycine 0 N--CA 1.494 2.518 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.528 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.924 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.3 tm? -117.51 157.32 26.51 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.132 -1.216 . . . . 0.0 110.081 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.924 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -96.88 149.39 21.92 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.198 -0.939 . . . . 0.0 110.548 -179.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.672 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.4 m -62.62 111.26 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 O-C-N 121.182 -0.949 . . . . 0.0 109.153 179.233 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.644 ' O ' HG23 ' A' ' 74' ' ' ILE . 4.6 m -133.63 -32.18 1.15 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.304 -0.873 . . . . 0.0 111.086 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.939 HG22 ' HB ' ' A' ' 63' ' ' VAL . 20.4 t -53.68 137.93 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.187 -0.945 . . . . 0.0 109.821 -179.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.644 HG23 ' O ' ' A' ' 72' ' ' SER . 1.2 pp -137.76 100.99 8.87 Favored Pre-proline 0 N--CA 1.495 1.812 0 O-C-N 121.248 -0.907 . . . . 0.0 111.2 -179.498 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_endo -82.05 53.4 4.55 Favored 'Trans proline' 0 C--N 1.31 -1.459 0 O-C-N 123.487 1.257 . . . . 0.0 110.12 178.985 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 5.9 p -149.62 22.39 0.91 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.041 -1.037 . . . . 0.0 110.925 -179.328 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 3.0 m120 -123.19 -165.85 1.38 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.038 -1.038 . . . . 0.0 110.145 -179.982 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.64 -91.05 0.01 OUTLIER Glycine 0 N--CA 1.493 2.454 0 N-CA-C 109.451 -1.459 . . . . 0.0 109.451 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 93.5 m-20 -126.36 113.03 16.36 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.16 -1.2 . . . . 0.0 110.168 179.537 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 12.0 p -117.84 133.15 65.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.86 0 CA-C-O 122.101 0.953 . . . . 0.0 110.125 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.587 HG22 HG22 ' A' ' 60' ' ' ILE . 4.8 m -113.83 125.47 71.12 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.354 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.056 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.694 HG22 ' CG1' ' A' ' 73' ' ' VAL . 9.2 t -97.21 121.17 47.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.001 -1.062 . . . . 0.0 110.109 -178.44 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.939 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.2 m -114.85 100.05 9.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.759 -1.213 . . . . 0.0 108.625 179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.458 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -146.26 164.0 33.69 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 120.662 -1.274 . . . . 0.0 111.638 -177.627 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.484 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.8 t -84.12 -138.59 0.06 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.569 -0.707 . . . . 0.0 109.585 179.632 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.484 ' N ' HG23 ' A' ' 85' ' ' THR . 0.7 OUTLIER -87.52 14.45 8.22 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.762 -1.211 . . . . 0.0 110.621 179.828 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.462 ' H ' HG23 ' A' ' 85' ' ' THR . . . -86.62 -21.76 26.6 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.004 -1.06 . . . . 0.0 110.171 179.866 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -76.58 -24.51 53.5 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.164 -0.96 . . . . 0.0 110.159 179.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.415 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 52.56 -157.03 0.15 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.26 -0.9 . . . . 0.0 109.365 -179.209 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.609 ' CB ' HG22 ' A' ' 93' ' ' THR . 0.1 OUTLIER -147.72 29.14 0.93 Allowed 'General case' 0 N--CA 1.492 1.636 0 O-C-N 120.991 -1.068 . . . . 0.0 110.066 179.706 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -53.6 -39.55 60.89 Favored Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 55.1 p90 -130.03 25.15 5.27 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.427 -1.043 . . . . 0.0 110.436 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.609 HG22 ' CB ' ' A' ' 90' ' ' THR . 0.5 OUTLIER -108.31 -171.06 1.79 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.186 -0.946 . . . . 0.0 109.843 179.666 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.556 ' N ' HG23 ' A' ' 93' ' ' THR . . . 121.76 -26.9 6.39 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.972 -1.251 . . . . 0.0 109.972 179.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -83.95 65.81 8.85 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.909 -1.348 . . . . 0.0 110.24 -179.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.476 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 24.1 m-85 -119.38 144.42 46.9 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.239 -0.913 . . . . 0.0 110.309 179.694 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.416 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 6.5 m-20 -78.98 -31.7 45.0 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.303 -0.873 . . . . 0.0 109.703 179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB2' ' HB ' ' A' ' 129' ' ' ILE . 4.9 p -161.58 163.14 30.27 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.278 -0.889 . . . . 0.0 110.744 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.518 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.05 119.38 49.1 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.029 0 O-C-N 121.248 -0.907 . . . . 0.0 110.117 179.296 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.867 HG21 HD11 ' A' ' 28' ' ' ILE . 3.0 mp -93.38 119.17 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.301 -0.874 . . . . 0.0 109.128 179.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.4 ' OD2' ' HB2' ' A' ' 41' ' ' PHE . 2.4 t70 -128.45 160.59 31.81 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.138 -0.976 . . . . 0.0 111.577 -178.769 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.443 ' HA ' ' CG2' ' A' ' 133' ' ' VAL . 42.3 t -98.98 -5.18 31.0 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.433 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 56.21 13.99 1.39 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.277 -0.89 . . . . 0.0 111.74 179.963 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.405 HG23 ' O ' ' A' ' 108' ' ' LYS . 1.3 m -141.6 127.91 19.88 Favored 'General case' 0 C--N 1.307 -1.273 0 O-C-N 120.697 -1.252 . . . . 0.0 109.056 179.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -109.18 124.46 50.87 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.299 -0.876 . . . . 0.0 110.618 -179.599 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER 58.19 34.78 24.47 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.328 -0.857 . . . . 0.0 111.257 179.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 92.8 -33.9 4.8 Favored Glycine 0 N--CA 1.492 2.407 0 C-N-CA 119.864 -1.16 . . . . 0.0 110.308 179.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.472 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -86.22 155.31 57.56 Favored Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.161 -1.199 . . . . 0.0 110.05 -179.862 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -64.9 138.49 57.85 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 O-C-N 123.415 1.218 . . . . 0.0 110.76 -179.863 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -50.3 156.67 0.8 Allowed 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.528 -0.733 . . . . 0.0 110.948 -179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.51 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.7 p-10 -73.81 162.89 28.64 Favored 'General case' 0 N--CA 1.496 1.849 0 O-C-N 121.55 -0.718 . . . . 0.0 110.283 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.45 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.27 -44.76 92.43 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.897 -1.127 . . . . 0.0 111.597 -179.024 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.51 HG22 ' OD2' ' A' ' 111' ' ' ASP . 7.7 m -72.77 -30.7 33.92 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.842 0 O-C-N 120.672 -1.267 . . . . 0.0 112.727 -178.324 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.432 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 2.6 p -53.6 -55.25 27.43 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 120.388 -1.445 . . . . 0.0 110.148 -178.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.45 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.1 OUTLIER -60.65 -35.3 75.87 Favored 'General case' 0 N--CA 1.487 1.403 0 C-N-CA 118.533 -1.267 . . . . 0.0 108.06 178.423 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.408 ' HB ' ' O ' ' A' ' 113' ' ' VAL . 26.1 m -62.08 -50.3 72.5 Favored 'General case' 0 N--CA 1.483 1.198 0 C-N-CA 119.387 -0.925 . . . . 0.0 108.61 178.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.9 tt0 -74.3 -46.83 38.54 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.307 -0.871 . . . . 0.0 109.958 178.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 60.2 mtt180 -61.26 -45.34 94.9 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.259 -0.901 . . . . 0.0 110.978 -179.768 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.544 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 11.9 ttm180 -55.51 -38.71 69.55 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 120.704 -1.248 . . . . 0.0 109.476 179.732 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.83 71.81 0.28 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.569 -1.413 . . . . 0.0 109.569 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.445 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.5 OUTLIER -145.63 -50.76 0.24 Allowed 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.45 -1.03 . . . . 0.0 108.639 179.66 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.492 HG23 ' HA3' ' A' ' 128' ' ' GLY . 11.9 t -94.8 142.33 27.59 Favored 'General case' 0 C--N 1.303 -1.429 0 N-CA-C 109.014 -0.735 . . . . 0.0 109.014 178.7 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.465 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 112.26 5.41 24.84 Favored Glycine 0 N--CA 1.485 1.906 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.58 179.396 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.441 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -62.17 86.16 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.64 0 O-C-N 120.898 -1.354 . . . . 0.0 109.907 -179.976 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 103.88 -43.02 1.75 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 108.731 -1.748 . . . . 0.0 108.731 -179.334 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.465 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 12.9 mttt -111.01 -171.67 0.22 Allowed Pre-proline 0 N--CA 1.487 1.42 0 O-C-N 121.597 -0.943 . . . . 0.0 109.46 179.553 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.465 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -90.74 107.75 0.32 Allowed 'Trans proline' 0 C--N 1.31 -1.477 0 O-C-N 123.587 1.309 . . . . 0.0 109.773 179.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.492 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.31 166.05 50.94 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.884 -1.287 . . . . 0.0 109.884 -179.675 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.419 ' HB ' ' HB2' ' A' ' 98' ' ' SER . 3.9 mt -119.53 140.54 43.18 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 O-C-N 121.299 -1.118 . . . . 0.0 109.193 179.23 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.518 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 6.5 t80 -128.74 114.95 17.24 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.209 -0.996 . . . . 0.0 110.147 179.419 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.42 ' NE ' HG11 ' A' ' 13' ' ' VAL . 4.8 mtt180 -99.41 134.27 42.52 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.582 -0.699 . . . . 0.0 109.665 179.991 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.472 ' CD2' ' O ' ' A' ' 13' ' ' VAL . 27.7 p90 -128.14 148.25 50.58 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.15 -0.969 . . . . 0.0 109.84 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.443 ' CG2' ' HA ' ' A' ' 102' ' ' CYS . 78.5 t -79.86 -54.16 11.65 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 121.052 -1.03 . . . . 0.0 110.073 179.934 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -89.49 134.98 31.53 Favored Pre-proline 0 N--CA 1.492 1.645 0 O-C-N 121.233 -0.917 . . . . 0.0 110.132 179.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.23 -51.85 0.13 Allowed 'Trans proline' 0 C--N 1.312 -1.38 0 O-C-N 123.527 1.278 . . . . 0.0 110.4 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 143.29 -69.29 0.42 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 53.49 96.25 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.214 -1.168 . . . . 0.0 110.114 -179.886 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.6 ptp180 . . . . . 0 N--CA 1.491 1.598 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.191 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 2.2 m -115.06 128.35 56.19 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.237 -1.155 . . . . 0.0 110.18 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 63.2 t -113.18 104.2 16.63 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 121.248 -0.907 . . . . 0.0 110.201 179.679 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.516 HG22 ' OG1' ' A' ' 116' ' ' THR . 69.1 p -72.18 146.15 47.57 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.495 -0.753 . . . . 0.0 110.109 179.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.65 HG22 ' HD2' ' A' ' 7' ' ' HIS . 0.2 OUTLIER -66.46 148.45 98.6 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 121.235 -0.916 . . . . 0.0 109.74 -179.859 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.542 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.8 Cg_endo -80.33 -59.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.311 -1.447 0 O-C-N 124.244 1.655 . . . . 0.0 112.413 -179.485 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.65 ' HD2' HG22 ' A' ' 5' ' ' VAL . 20.4 p80 39.31 89.25 0.08 OUTLIER Pre-proline 0 N--CA 1.493 1.683 0 CA-C-O 121.025 0.44 . . . . 0.0 111.459 -178.379 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 46.4 Cg_endo -74.68 57.29 4.31 Favored 'Trans proline' 0 C--N 1.311 -1.433 0 O-C-N 123.317 1.167 . . . . 0.0 110.9 -179.63 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 31.8 m120 -119.99 -18.78 8.07 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.242 -0.911 . . . . 0.0 110.289 179.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.843 HD13 HG23 ' A' ' 122' ' ' THR . 62.1 mt -108.8 136.61 44.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.086 -1.009 . . . . 0.0 110.133 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -83.4 127.93 34.09 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.209 -0.932 . . . . 0.0 109.238 179.162 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 24.9 mt-10 -89.71 135.68 33.48 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.158 -0.964 . . . . 0.0 110.204 -179.257 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.479 ' O ' ' CE2' ' A' ' 132' ' ' PHE . 11.7 t -137.24 156.37 33.58 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.277 -0.89 . . . . 0.0 110.431 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.3 113.84 27.0 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 109.841 179.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 ' CB ' ' A' ' 26' ' ' LYS . 8.8 tp -52.79 142.58 18.52 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.185 -0.947 . . . . 0.0 110.106 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 47.7 p -138.25 174.37 10.63 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.194 -0.941 . . . . 0.0 110.261 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.8 p -74.21 71.87 1.71 Allowed 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.272 -0.892 . . . . 0.0 109.952 179.841 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.743 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.4 m -144.14 110.13 5.37 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.316 -0.865 . . . . 0.0 110.513 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.423 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.8 -171.42 26.78 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.83 179.297 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.402 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -108.92 -26.23 10.34 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.695 -0.885 . . . . 0.0 110.396 179.93 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.945 HD12 HD13 ' A' ' 55' ' ' LEU . 8.1 tt -95.26 101.55 7.73 Favored Pre-proline 0 N--CA 1.488 1.425 0 C-N-CA 118.949 -1.101 . . . . 0.0 110.355 -179.373 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.431 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 36.6 Cg_endo -61.26 155.23 52.84 Favored 'Trans proline' 0 C--N 1.311 -1.415 0 O-C-N 123.462 1.243 . . . . 0.0 110.208 -179.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.582 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 81.8 t80 -166.73 94.5 0.5 Allowed 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.095 -1.003 . . . . 0.0 111.349 -178.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE2' ' CE1' ' A' ' 23' ' ' PHE . 16.8 m-85 59.98 68.33 0.79 Allowed 'General case' 0 N--CA 1.501 2.096 0 O-C-N 121.411 -0.806 . . . . 0.0 111.642 178.806 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.13 14.55 11.52 Favored Glycine 0 N--CA 1.493 2.484 0 N-CA-C 110.283 -1.127 . . . . 0.0 110.283 179.59 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.662 ' CB ' HD23 ' A' ' 15' ' ' LEU . 21.3 mmtt -130.75 156.69 44.54 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 121.058 -1.26 . . . . 0.0 109.186 179.744 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.743 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.22 108.05 16.09 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 120.942 -1.099 . . . . 0.0 109.106 179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 1.037 HD11 HG21 ' A' ' 100' ' ' ILE . 5.1 mt -71.29 113.34 18.53 Favored Pre-proline 0 C--N 1.299 -1.592 0 C-N-CA 119.569 -0.853 . . . . 0.0 110.115 -179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.896 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.7 Cg_endo -71.09 129.68 16.56 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 N-CA-C 107.0 -1.962 . . . . 0.0 107.0 176.754 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.491 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.9 mt -55.75 -18.83 9.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 120.813 -1.179 . . . . 0.0 110.548 -177.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.442 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.5 OUTLIER -59.71 -16.0 23.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.643 -1.286 . . . . 0.0 110.308 179.316 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.054 HG23 HG23 ' A' ' 33' ' ' ILE . 16.1 m -93.35 -25.39 4.92 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.795 0 O-C-N 120.909 -1.119 . . . . 0.0 111.075 -179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.054 HG23 HG23 ' A' ' 32' ' ' VAL . 21.5 pt -117.84 -16.23 8.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.959 -1.088 . . . . 0.0 110.934 -179.17 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.569 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.4 OUTLIER -97.78 148.45 23.36 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.84 -1.162 . . . . 0.0 110.086 179.542 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 102.22 -4.16 51.66 Favored Glycine 0 N--CA 1.485 1.929 0 N-CA-C 109.398 -1.481 . . . . 0.0 109.398 -179.435 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.62 -159.04 23.32 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.338 -1.41 . . . . 0.0 110.094 -179.996 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.459 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 2.3 mtt180 -99.92 133.47 44.23 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.321 -1.105 . . . . 0.0 110.502 -179.702 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.556 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 83.4 m-70 -139.77 146.96 40.15 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.121 -0.987 . . . . 0.0 110.705 -179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.595 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.2 tp -108.51 113.72 26.98 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.413 -0.805 . . . . 0.0 110.004 179.625 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.791 HD12 HG12 ' A' ' 83' ' ' VAL . 26.1 mt -96.57 126.89 49.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.321 -0.862 . . . . 0.0 109.399 179.318 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.503 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 34.1 m-85 -95.2 123.79 38.89 Favored 'General case' 0 C--N 1.291 -1.946 0 O-C-N 121.369 -0.832 . . . . 0.0 109.978 -179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.02 160.22 21.3 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.199 -0.938 . . . . 0.0 110.604 -179.665 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.537 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 4.3 p-80 -107.18 -3.78 19.49 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.407 -0.808 . . . . 0.0 110.181 179.082 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 3.1 p -130.25 137.64 50.12 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.061 -1.024 . . . . 0.0 110.792 -179.553 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.55 -41.39 69.16 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.779 -0.575 . . . . 0.0 110.608 -179.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 1.3 mttp -58.79 -35.27 72.55 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.155 -0.966 . . . . 0.0 110.081 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -73.25 -34.88 66.09 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.378 -0.827 . . . . 0.0 109.446 179.667 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.837 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 91.8 m -60.7 -34.26 74.09 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.423 -0.798 . . . . 0.0 109.556 179.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -68.03 -49.12 63.36 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.174 -0.954 . . . . 0.0 110.295 179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.419 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 3.0 mt-10 -71.78 -42.63 66.89 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.278 -0.889 . . . . 0.0 110.572 -179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.757 HD12 HG11 ' A' ' 83' ' ' VAL . 1.1 tm? -57.26 -41.1 78.99 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.397 -0.815 . . . . 0.0 111.277 -179.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.97 -51.43 12.4 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.865 -1.147 . . . . 0.0 110.545 -179.588 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.86 -39.57 89.64 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.011 -1.056 . . . . 0.0 109.503 179.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.537 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.08 -45.71 86.7 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.484 -0.76 . . . . 0.0 109.536 179.366 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.945 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -55.87 -41.99 75.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.424 -0.798 . . . . 0.0 109.891 179.703 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 73.5 t -56.32 -33.76 38.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.119 -0.988 . . . . 0.0 109.183 179.407 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.21 -32.01 61.05 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.364 -0.835 . . . . 0.0 109.874 179.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.537 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.68 -26.23 62.43 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.831 0.824 . . . . 0.0 109.529 179.62 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.53 6.15 8.9 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.624 HG22 HG22 ' A' ' 81' ' ' VAL . 30.6 mt -108.26 143.69 18.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.434 0 O-C-N 121.222 -1.163 . . . . 0.0 110.149 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.614 ' ND2' HD11 ' A' ' 74' ' ' ILE . 19.3 t30 -87.03 107.26 18.34 Favored 'General case' 0 C--N 1.307 -1.26 0 N-CA-C 106.857 -1.534 . . . . 0.0 106.857 178.282 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.609 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -121.19 147.31 45.78 Favored 'General case' 0 C--N 1.296 -1.75 0 C-N-CA 118.969 -1.093 . . . . 0.0 111.781 -177.29 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.86 ' HB ' HG22 ' A' ' 73' ' ' VAL . 3.6 t -134.74 149.96 29.88 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.887 0 C-N-CA 119.944 -0.702 . . . . 0.0 109.358 179.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.837 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.42 136.39 52.83 Favored 'General case' 0 C--N 1.301 -1.541 0 C-N-CA 119.111 -1.035 . . . . 0.0 110.019 179.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.561 ' CD1' HD12 ' A' ' 69' ' ' LEU . 7.1 t80 -123.51 128.18 49.41 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.271 -0.893 . . . . 0.0 110.714 -179.777 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.85 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.9 p90 -155.15 -179.93 8.55 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.527 -0.733 . . . . 0.0 109.825 179.628 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -51.89 123.72 10.98 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.232 -0.918 . . . . 0.0 111.001 -179.244 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 73.75 47.79 19.17 Favored Glycine 0 N--CA 1.492 2.431 0 N-CA-C 110.235 -1.146 . . . . 0.0 110.235 179.338 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.85 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.9 tm? -117.0 152.99 33.43 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.052 -1.263 . . . . 0.0 109.623 179.554 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.835 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.4 m-20 -89.59 148.27 23.46 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.256 -0.902 . . . . 0.0 110.963 -178.891 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.68 HG23 ' O ' ' A' ' 71' ' ' VAL . 35.5 m -63.15 111.41 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.183 -0.948 . . . . 0.0 109.245 179.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.691 ' O ' HG23 ' A' ' 74' ' ' ILE . 18.1 m -132.55 -38.32 1.04 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.255 -0.903 . . . . 0.0 110.495 -179.486 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.86 HG22 ' HB ' ' A' ' 63' ' ' VAL . 64.8 t -48.27 137.31 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.359 -0.838 . . . . 0.0 110.461 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.691 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -137.0 91.79 14.69 Favored Pre-proline 0 N--CA 1.492 1.654 0 O-C-N 121.264 -0.898 . . . . 0.0 110.296 179.945 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.515 ' HA ' HG11 ' A' ' 80' ' ' VAL . 53.0 Cg_endo -79.86 55.73 5.76 Favored 'Trans proline' 0 C--N 1.309 -1.528 0 O-C-N 123.716 1.377 . . . . 0.0 110.345 179.816 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 10.8 t -156.13 31.89 0.34 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.175 -0.953 . . . . 0.0 110.457 -179.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -128.97 -164.77 1.43 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.15 -0.969 . . . . 0.0 110.034 179.95 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -49.64 -73.58 0.35 Allowed Glycine 0 N--CA 1.495 2.589 0 N-CA-C 109.598 -1.401 . . . . 0.0 109.598 179.784 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 5.1 m-20 -149.26 109.36 4.12 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.179 -1.189 . . . . 0.0 110.036 179.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.546 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.1 p -117.03 134.77 59.56 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 CA-C-O 121.959 0.885 . . . . 0.0 110.382 179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.624 HG22 HG22 ' A' ' 60' ' ' ILE . 11.4 m -112.6 125.75 69.91 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.221 0 O-C-N 121.365 -0.834 . . . . 0.0 109.018 179.136 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.803 HG22 HG13 ' A' ' 73' ' ' VAL . 12.2 t -97.38 118.31 43.63 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.69 0 O-C-N 120.961 -1.087 . . . . 0.0 110.08 -178.303 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.791 HG12 HD12 ' A' ' 40' ' ' ILE . 4.4 m -112.6 100.08 9.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.022 -1.049 . . . . 0.0 108.798 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.522 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -142.02 162.27 35.89 Favored 'General case' 0 C--N 1.299 -1.626 0 O-C-N 120.592 -1.318 . . . . 0.0 111.53 -178.117 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.687 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -87.03 -143.98 0.12 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.655 -0.653 . . . . 0.0 109.367 179.423 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.411 ' N ' HG23 ' A' ' 85' ' ' THR . 3.2 p30 -73.9 -4.56 35.77 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 120.916 -1.115 . . . . 0.0 110.791 179.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.687 ' H ' HG23 ' A' ' 85' ' ' THR . . . -61.64 -40.05 93.5 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.895 -1.128 . . . . 0.0 110.505 -179.774 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.69 -47.0 64.77 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.102 -0.999 . . . . 0.0 109.82 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.456 ' O ' ' N ' ' A' ' 91' ' ' GLY . 0.4 OUTLIER 53.11 21.89 2.33 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.311 -0.868 . . . . 0.0 110.075 -179.743 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.408 HG22 ' N ' ' A' ' 94' ' ' GLY . 0.2 OUTLIER 62.36 -72.78 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.589 -0.694 . . . . 0.0 110.708 179.999 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.456 ' N ' ' O ' ' A' ' 89' ' ' MET . . . 54.66 -98.7 0.05 OUTLIER Glycine 0 N--CA 1.493 2.471 0 N-CA-C 109.425 -1.47 . . . . 0.0 109.425 179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.515 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 46.6 p90 -88.89 48.42 1.63 Allowed 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.26 -1.141 . . . . 0.0 109.602 179.274 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.424 ' CG2' ' CE2' ' A' ' 96' ' ' PHE . 0.2 OUTLIER -151.64 -146.15 0.19 Allowed 'General case' 0 C--N 1.303 -1.418 0 O-C-N 121.336 -0.853 . . . . 0.0 109.941 -179.64 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.408 ' N ' HG22 ' A' ' 90' ' ' THR . . . 111.47 -30.61 7.74 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 179.582 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -85.11 80.97 9.06 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.192 -1.181 . . . . 0.0 110.428 -179.731 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.439 ' CD2' ' HB2' ' A' ' 39' ' ' LEU . 21.9 m-85 -119.41 144.62 46.82 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.156 -0.965 . . . . 0.0 109.727 179.385 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.444 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.8 OUTLIER -62.97 -35.58 80.65 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.192 -0.943 . . . . 0.0 109.095 179.497 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.476 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 10.4 p -160.92 163.55 31.82 Favored 'General case' 0 N--CA 1.489 1.489 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.853 179.943 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.738 HG23 ' CD1' ' A' ' 130' ' ' TYR . 0.4 OUTLIER -130.1 117.6 41.12 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.867 0 O-C-N 121.385 -0.822 . . . . 0.0 110.556 179.845 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 1.037 HG21 HD11 ' A' ' 28' ' ' ILE . 2.9 mp -93.09 112.57 26.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 N-CA-C 108.135 -1.061 . . . . 0.0 108.135 178.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 2.9 t0 -120.28 161.08 21.73 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.12 -0.987 . . . . 0.0 111.935 -178.086 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 24' ' ' TYR . 30.0 p -102.83 6.57 39.28 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 178.1 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 3.2 m120 45.82 25.44 0.29 Allowed 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.255 -0.903 . . . . 0.0 111.345 179.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.513 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.9 p -146.91 128.91 15.49 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.197 -0.939 . . . . 0.0 110.038 179.471 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 16.3 p -114.37 134.6 54.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.099 -1.001 . . . . 0.0 110.406 179.854 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 29.0 t0 54.03 27.02 6.97 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.245 -0.91 . . . . 0.0 110.416 179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.4 -31.51 6.35 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -78.72 155.91 78.0 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.164 -1.198 . . . . 0.0 110.132 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.513 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.3 Cg_endo -66.59 133.5 32.23 Favored 'Trans proline' 0 C--N 1.311 -1.443 0 O-C-N 123.659 1.347 . . . . 0.0 110.336 -179.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.428 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -47.94 163.98 0.05 Allowed 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.351 -0.843 . . . . 0.0 110.648 -179.453 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.516 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -96.38 160.28 14.5 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.281 -0.887 . . . . 0.0 110.384 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.423 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -48.4 -48.3 37.11 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 121.413 -0.805 . . . . 0.0 111.976 -178.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.516 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.2 m -71.1 -29.59 37.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 120.803 -1.185 . . . . 0.0 110.86 -178.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.435 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.53 -56.31 7.36 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.189 -0.944 . . . . 0.0 110.348 -179.46 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.432 ' O ' ' CB ' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -68.67 -34.8 76.31 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.268 -0.895 . . . . 0.0 108.686 178.726 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.516 ' OG1' HG22 ' A' ' 4' ' ' THR . 42.9 m -59.77 -49.84 76.16 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.07 -1.019 . . . . 0.0 108.574 178.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 3.3 tp-100 -73.86 -38.86 64.32 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.468 -0.77 . . . . 0.0 109.924 179.009 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 82.8 mtt180 -70.2 -44.25 69.06 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.243 -0.911 . . . . 0.0 110.572 -179.737 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.587 ' O ' HG23 ' A' ' 122' ' ' THR . 34.5 ttm180 -54.47 -36.58 64.27 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.201 -0.937 . . . . 0.0 110.552 179.978 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.414 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -55.96 -15.84 11.18 Favored Glycine 0 N--CA 1.494 2.523 0 O-C-N 120.965 -1.084 . . . . 0.0 111.513 -179.172 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -71.73 -3.58 22.71 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 120.671 -1.487 . . . . 0.0 111.515 -179.262 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.843 HG23 HD13 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -120.95 143.53 48.95 Favored 'General case' 0 N--CA 1.498 1.957 0 O-C-N 120.773 -1.204 . . . . 0.0 110.905 -179.681 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.477 ' N ' ' HA3' ' A' ' 128' ' ' GLY . . . 74.94 12.22 83.36 Favored Glycine 0 N--CA 1.487 2.094 0 C-N-CA 119.824 -1.179 . . . . 0.0 110.862 178.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.414 ' NE ' ' O ' ' A' ' 120' ' ' GLY . 8.3 mtt180 -61.27 88.02 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.067 -1.254 . . . . 0.0 109.011 179.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 95.35 16.66 39.51 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.968 -1.653 . . . . 0.0 108.968 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.459 ' O ' ' CA ' ' A' ' 123' ' ' GLY . 0.2 OUTLIER -175.46 -176.44 0.26 Allowed Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.454 -1.027 . . . . 0.0 108.796 -179.658 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.453 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.2 Cg_endo -88.26 105.41 0.5 Allowed 'Trans proline' 0 C--N 1.309 -1.536 0 O-C-N 123.165 1.087 . . . . 0.0 110.012 179.408 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.477 ' HA3' ' N ' ' A' ' 123' ' ' GLY . . . -100.27 173.81 25.58 Favored Glycine 0 N--CA 1.492 2.424 0 C-N-CA 119.517 -1.325 . . . . 0.0 110.185 -179.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -123.24 142.93 38.04 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.522 -0.987 . . . . 0.0 109.6 179.952 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.738 ' CD1' HG23 ' A' ' 99' ' ' VAL . 1.1 t80 -130.38 114.93 16.18 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 120.759 -1.213 . . . . 0.0 110.433 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.444 ' HG2' ' HB ' ' A' ' 13' ' ' VAL . 29.2 mtp85 -99.56 145.71 27.22 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.491 -0.756 . . . . 0.0 109.457 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 19.6 p90 -137.87 157.11 47.09 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.935 -1.103 . . . . 0.0 110.329 -180.0 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 45.1 t -87.09 -34.78 7.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.133 -0.98 . . . . 0.0 109.632 179.45 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -128.06 159.78 65.06 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.22 -0.925 . . . . 0.0 110.329 -179.844 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -73.67 -40.98 1.24 Allowed 'Trans proline' 0 C--N 1.313 -1.325 0 O-C-N 123.74 1.389 . . . . 0.0 110.441 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 67.06 88.78 0.06 OUTLIER Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 -179.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 3.3 tt0 -78.47 130.77 36.43 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.234 -1.156 . . . . 0.0 110.335 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 13.3 mtt-85 . . . . . 0 N--CA 1.492 1.651 0 CA-C-O 117.999 -1.0 . . . . 0.0 110.316 179.941 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 74.5 m -111.58 155.31 23.53 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.246 -1.149 . . . . 0.0 110.219 180.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.598 HG23 ' O ' ' A' ' 3' ' ' VAL . 27.5 m -113.29 104.0 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.264 -0.897 . . . . 0.0 109.889 179.629 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.544 HG22 ' OG1' ' A' ' 116' ' ' THR . 10.5 p -64.22 138.09 58.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.436 -0.79 . . . . 0.0 110.607 -179.923 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.446 HG12 ' H ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -67.58 147.8 98.67 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.316 -0.865 . . . . 0.0 109.606 179.601 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.433 ' HD2' HG23 ' A' ' 5' ' ' VAL . 41.6 Cg_endo -69.88 -169.28 0.32 Allowed 'Trans proline' 0 C--N 1.308 -1.602 0 O-C-N 124.1 1.579 . . . . 0.0 111.096 179.508 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.547 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 6.9 p80 -177.43 82.48 0.24 Allowed Pre-proline 0 C--N 1.302 -1.476 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 179.595 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -63.83 89.24 0.15 Allowed 'Trans proline' 0 C--N 1.308 -1.586 0 O-C-N 123.658 1.346 . . . . 0.0 110.496 -179.463 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.502 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.3 t-20 -177.22 -33.97 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.76 -0.587 . . . . 0.0 109.908 -179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.489 HD13 HG22 ' A' ' 122' ' ' THR . 19.9 mt -105.3 134.84 45.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 120.843 -1.161 . . . . 0.0 110.04 179.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 tt0 -84.93 128.25 34.54 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.336 -0.853 . . . . 0.0 108.861 178.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 14.4 mt-10 -89.4 142.76 27.37 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.05 -1.031 . . . . 0.0 110.231 -179.193 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.607 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 13.2 t -136.55 157.27 36.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.41 -0.806 . . . . 0.0 109.972 -179.447 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -109.36 108.71 19.36 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.23 -0.919 . . . . 0.0 109.869 179.461 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.603 HD23 HG22 ' A' ' 133' ' ' VAL . 11.2 tp -55.03 134.36 49.04 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.32 -0.862 . . . . 0.0 109.759 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 63.3 p -137.96 -179.35 5.72 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.296 -0.878 . . . . 0.0 110.181 -179.683 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 42.4 p -74.51 60.77 0.9 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.232 -0.917 . . . . 0.0 110.027 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.451 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 4.9 m -131.76 111.42 11.63 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.334 -0.854 . . . . 0.0 110.198 179.955 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.469 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 144.54 -162.6 27.97 Favored Glycine 0 N--CA 1.488 2.14 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.959 179.593 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -119.37 -21.61 7.4 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.714 -0.874 . . . . 0.0 110.45 -179.995 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.89 HG23 ' HB ' ' A' ' 28' ' ' ILE . 7.0 tt -97.41 107.13 37.09 Favored Pre-proline 0 N--CA 1.489 1.512 0 C-N-CA 118.79 -1.164 . . . . 0.0 110.255 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.44 ' HD2' ' NZ ' ' A' ' 54' ' ' LYS . 37.4 Cg_endo -63.64 154.98 65.86 Favored 'Trans proline' 0 C--N 1.313 -1.338 0 O-C-N 123.367 1.193 . . . . 0.0 109.503 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.475 ' CZ ' ' SG ' ' A' ' 102' ' ' CYS . 34.8 t80 -169.08 91.62 0.25 Allowed 'General case' 0 N--CA 1.487 1.392 0 O-C-N 121.034 -1.041 . . . . 0.0 111.532 -178.114 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.506 ' CZ ' ' NE2' ' A' ' 43' ' ' HIS . 24.9 m-85 59.78 67.26 0.89 Allowed 'General case' 0 N--CA 1.499 2.008 0 O-C-N 121.529 -0.732 . . . . 0.0 111.405 178.92 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.72 13.52 18.4 Favored Glycine 0 N--CA 1.495 2.627 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.655 ' HG3' HG13 ' A' ' 133' ' ' VAL . 6.5 mmtt -130.79 156.19 45.41 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.093 -1.24 . . . . 0.0 109.138 179.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.451 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -119.76 106.96 12.62 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.892 -1.13 . . . . 0.0 109.206 179.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.89 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.0 mt -68.52 115.15 27.15 Favored Pre-proline 0 C--N 1.299 -1.618 0 O-C-N 121.464 -0.773 . . . . 0.0 110.585 -179.284 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.915 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.0 Cg_endo -68.46 126.79 14.66 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 N-CA-C 107.381 -1.815 . . . . 0.0 107.381 176.267 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.578 HD11 HD12 ' A' ' 58' ' ' LEU . 5.6 mt -56.08 -20.73 18.39 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.966 -1.084 . . . . 0.0 110.835 -177.459 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 5.2 pt-20 -59.95 -16.07 27.08 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 120.696 -1.252 . . . . 0.0 110.464 179.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.059 HG23 HG23 ' A' ' 33' ' ' ILE . 15.4 m -91.56 -25.36 5.28 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.79 0 O-C-N 120.991 -1.068 . . . . 0.0 110.95 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.059 HG23 HG23 ' A' ' 32' ' ' VAL . 14.7 pt -117.84 -15.57 8.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.968 -1.082 . . . . 0.0 110.914 -179.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.589 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.5 tptm -98.16 147.78 24.24 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.815 -1.178 . . . . 0.0 110.502 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 97.37 -3.14 61.39 Favored Glycine 0 N--CA 1.485 1.954 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 -179.713 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -175.07 -159.45 21.27 Favored Glycine 0 N--CA 1.492 2.412 0 C-N-CA 119.216 -1.468 . . . . 0.0 110.381 179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 70.3 mtt85 -104.33 134.71 47.09 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.394 -1.062 . . . . 0.0 110.548 -179.527 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.563 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 84.7 m-70 -141.09 147.92 39.33 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.25 -0.907 . . . . 0.0 110.879 -179.833 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 82' ' ' VAL . 40.2 tp -109.19 116.21 31.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.346 -0.846 . . . . 0.0 110.272 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 HG12 ' A' ' 83' ' ' VAL . 34.4 mt -99.88 127.78 52.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.536 0 O-C-N 121.138 -0.976 . . . . 0.0 109.729 179.448 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 6.8 m-85 -95.7 124.03 39.54 Favored 'General case' 0 C--N 1.294 -1.846 0 O-C-N 121.342 -0.849 . . . . 0.0 109.906 179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 3.9 m -116.67 159.73 21.78 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.235 -0.916 . . . . 0.0 110.817 -179.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.506 ' NE2' ' CZ ' ' A' ' 24' ' ' TYR . 27.2 p80 -104.42 -8.62 19.02 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 121.525 -0.734 . . . . 0.0 109.956 179.094 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.4 p -127.11 138.99 53.29 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.981 -1.074 . . . . 0.0 110.982 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HG2' ' CG ' ' A' ' 66' ' ' TYR . 0.0 OUTLIER -71.94 -40.35 68.78 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.317 0.579 . . . . 0.0 110.779 -179.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 2.3 mttp -59.97 -36.48 77.23 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.366 -0.834 . . . . 0.0 111.027 -179.326 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.01 -35.27 71.98 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.301 -0.874 . . . . 0.0 109.874 -179.493 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.87 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 84.4 m -61.27 -36.29 79.62 Favored 'General case' 0 C--N 1.303 -1.413 0 O-C-N 121.269 -0.894 . . . . 0.0 109.308 179.331 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.73 -50.52 66.58 Favored 'General case' 0 N--CA 1.491 1.607 0 C-N-CA 119.296 -0.962 . . . . 0.0 110.248 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -72.99 -46.0 54.7 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.288 -0.882 . . . . 0.0 110.279 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.626 ' O ' HD13 ' A' ' 51' ' ' LEU . 3.2 tm? -56.99 -39.69 75.16 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.56 -0.713 . . . . 0.0 111.28 -178.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.486 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.87 -51.13 13.2 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.89 -1.131 . . . . 0.0 110.565 -179.849 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -60.05 -40.11 88.3 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.109 -0.995 . . . . 0.0 109.631 179.766 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.497 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.6 OUTLIER -57.2 -44.65 83.83 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.381 -0.825 . . . . 0.0 109.542 179.404 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.875 HD13 HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -54.94 -42.57 72.44 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.424 -0.797 . . . . 0.0 109.5 179.678 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 76.8 t -56.18 -30.97 30.85 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 120.982 -1.074 . . . . 0.0 108.767 178.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.493 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.05 -32.7 61.61 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.533 -0.729 . . . . 0.0 109.92 179.307 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.578 HD12 HD11 ' A' ' 30' ' ' LEU . 4.3 mm? -72.09 -26.16 62.04 Favored 'General case' 0 N--CA 1.49 1.545 0 CA-C-O 121.83 0.824 . . . . 0.0 109.699 179.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.31 6.01 9.15 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.327 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.608 HG22 HG22 ' A' ' 81' ' ' VAL . 44.7 mt -107.53 143.26 18.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.277 -1.131 . . . . 0.0 109.87 -179.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 49.9 t30 -87.61 106.86 18.3 Favored 'General case' 0 C--N 1.306 -1.318 0 N-CA-C 106.798 -1.556 . . . . 0.0 106.798 178.368 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.656 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -117.63 145.01 44.64 Favored 'General case' 0 C--N 1.297 -1.701 0 C-N-CA 118.818 -1.153 . . . . 0.0 111.83 -177.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.911 HG21 ' HA ' ' A' ' 73' ' ' VAL . 92.1 t -126.02 148.12 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.703 -0.623 . . . . 0.0 109.819 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.87 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -117.78 117.67 29.97 Favored 'General case' 0 C--N 1.3 -1.556 0 C-N-CA 119.301 -0.96 . . . . 0.0 109.453 178.319 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.504 ' HB3' ' HB1' ' A' ' 84' ' ' ALA . 3.5 t80 -108.13 131.23 54.85 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.288 -0.882 . . . . 0.0 110.891 -179.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.857 ' CE1' HD23 ' A' ' 69' ' ' LEU . 3.1 p90 -155.35 -168.67 2.91 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.572 -0.705 . . . . 0.0 109.988 179.488 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 15.8 ttt180 -55.99 123.69 15.21 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 111.202 -179.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 64.58 59.03 8.73 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 110.432 -1.067 . . . . 0.0 110.432 179.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.857 HD23 ' CE1' ' A' ' 66' ' ' TYR . 2.7 tm? -117.72 152.04 36.06 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.107 -1.231 . . . . 0.0 109.666 179.414 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.73 ' N ' HD13 ' A' ' 69' ' ' LEU . 5.2 m-20 -85.85 149.01 25.54 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.23 -0.919 . . . . 0.0 110.602 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.9 m -62.54 110.8 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 C-N-CA 119.107 -1.037 . . . . 0.0 109.113 179.216 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.707 ' O ' HG23 ' A' ' 74' ' ' ILE . 69.2 m -131.36 -32.16 1.57 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.362 -0.836 . . . . 0.0 110.642 -179.369 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.911 ' HA ' HG21 ' A' ' 63' ' ' VAL . 94.9 t -52.96 131.27 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.137 -0.977 . . . . 0.0 109.449 179.994 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.707 HG23 ' O ' ' A' ' 72' ' ' SER . 1.0 OUTLIER -134.04 103.78 11.72 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.133 -0.98 . . . . 0.0 110.792 -179.266 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -87.07 43.66 1.01 Allowed 'Trans proline' 0 C--N 1.31 -1.474 0 O-C-N 123.523 1.275 . . . . 0.0 110.304 179.233 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 1.5 p -136.66 4.59 2.84 Favored 'General case' 0 N--CA 1.493 1.71 0 O-C-N 120.998 -1.063 . . . . 0.0 111.091 -179.438 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.495 ' HB2' HD12 ' A' ' 74' ' ' ILE . 1.6 m-80 -100.77 -169.15 1.67 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.892 -1.13 . . . . 0.0 110.282 -179.938 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -54.42 -70.45 0.95 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 109.574 -1.41 . . . . 0.0 109.574 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 28.1 m-20 -144.91 113.64 6.76 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.164 -1.198 . . . . 0.0 110.29 179.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.623 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -117.39 132.47 67.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.747 0 CA-C-O 122.061 0.934 . . . . 0.0 110.47 179.979 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.611 HG11 ' HB ' ' A' ' 33' ' ' ILE . 11.3 m -112.51 122.05 66.0 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.135 0 O-C-N 121.372 -0.83 . . . . 0.0 108.957 179.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.83 HG22 HG13 ' A' ' 73' ' ' VAL . 16.1 t -96.96 120.91 46.91 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 120.984 -1.073 . . . . 0.0 110.606 -177.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.92 HG12 HD12 ' A' ' 40' ' ' ILE . 3.3 m -112.4 100.38 10.61 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.014 -1.054 . . . . 0.0 108.659 179.303 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.504 ' HB1' ' HB3' ' A' ' 65' ' ' TYR . . . -139.51 162.71 34.41 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.569 -1.332 . . . . 0.0 111.693 -177.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.552 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.9 t -93.23 -136.69 0.18 Allowed 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 109.1 -0.704 . . . . 0.0 109.1 179.18 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.516 ' N ' HG23 ' A' ' 85' ' ' THR . 3.3 p30 -77.0 -6.2 51.69 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 120.678 -1.264 . . . . 0.0 111.044 179.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.552 ' H ' HG23 ' A' ' 85' ' ' THR . . . -60.7 -41.5 95.32 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.866 -1.146 . . . . 0.0 110.049 179.945 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.4 tp -64.48 -32.21 73.75 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.106 -0.996 . . . . 0.0 108.581 179.194 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.477 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 43.83 34.84 0.95 Allowed 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.249 0.547 . . . . 0.0 110.914 179.592 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.58 HG21 ' NH1' ' A' ' 121' ' ' ARG . 22.5 p 47.26 -130.32 1.49 Allowed 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.675 -0.641 . . . . 0.0 110.459 179.591 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . 92.96 -85.11 1.13 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 108.983 -1.647 . . . . 0.0 108.983 -179.691 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 27.1 p90 -94.43 16.98 13.86 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.259 -1.142 . . . . 0.0 109.785 179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.51 ' HG1' ' HE1' ' A' ' 96' ' ' PHE . 14.9 t -92.53 -151.2 0.28 Allowed 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.316 -0.865 . . . . 0.0 110.298 -179.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.443 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 94.05 -31.89 6.3 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.249 -1.141 . . . . 0.0 110.249 179.291 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -83.6 57.26 3.97 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.99 -1.3 . . . . 0.0 110.285 -179.585 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.51 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 63.8 m-85 -120.27 152.8 37.27 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.245 -0.91 . . . . 0.0 110.309 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.492 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.6 m-20 -82.58 -28.35 30.95 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.417 -0.802 . . . . 0.0 109.846 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.492 ' HG ' ' HD1' ' A' ' 38' ' ' HIS . 4.5 p -160.69 163.62 32.29 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.243 -0.91 . . . . 0.0 110.681 179.885 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.505 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -129.94 128.15 64.63 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.983 0 O-C-N 121.383 -0.823 . . . . 0.0 110.146 179.418 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.887 HG21 HD11 ' A' ' 28' ' ' ILE . 4.0 mp -105.99 111.11 33.69 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.178 -0.951 . . . . 0.0 108.622 178.825 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.422 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.6 t0 -115.84 161.28 19.0 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.106 -0.996 . . . . 0.0 111.985 -178.301 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.475 ' SG ' ' CZ ' ' A' ' 23' ' ' PHE . 59.9 m -96.83 -2.93 43.07 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.039 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.43 ' ND2' ' O ' ' A' ' 134' ' ' ALA . 2.4 m120 53.87 21.47 2.8 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.111 -0.993 . . . . 0.0 110.218 -179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.745 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -144.1 126.02 15.32 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.313 -0.867 . . . . 0.0 110.137 179.652 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 27.2 p -112.67 139.21 48.46 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.145 -0.972 . . . . 0.0 109.582 179.486 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.5 t70 54.8 -143.55 0.73 Allowed 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.051 -1.031 . . . . 0.0 109.581 -179.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -91.74 26.44 12.52 Favored Glycine 0 N--CA 1.493 2.468 0 N-CA-C 109.67 -1.372 . . . . 0.0 109.67 179.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -141.12 156.78 67.87 Favored Pre-proline 0 N--CA 1.49 1.572 0 O-C-N 121.21 -1.171 . . . . 0.0 109.821 -179.931 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.745 ' HA ' HG22 ' A' ' 104' ' ' THR . 40.1 Cg_endo -65.85 162.11 36.35 Favored 'Trans proline' 0 C--N 1.309 -1.508 0 O-C-N 123.644 1.339 . . . . 0.0 110.494 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.412 ' NE2' ' O ' ' A' ' 111' ' ' ASP . 0.0 OUTLIER -64.91 168.12 6.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.302 -0.874 . . . . 0.0 110.862 -179.307 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.487 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.0 p30 -105.58 161.84 14.01 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.498 -0.752 . . . . 0.0 110.285 179.79 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.408 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -42.81 -59.86 1.8 Allowed 'General case' 0 N--CA 1.498 1.927 0 O-C-N 121.361 -0.837 . . . . 0.0 112.163 -178.858 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.487 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.5 m -64.3 -29.25 46.82 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.863 0 O-C-N 120.744 -1.222 . . . . 0.0 111.773 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.43 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.41 -56.53 6.75 Favored 'General case' 0 N--CA 1.498 1.943 0 O-C-N 121.028 -1.045 . . . . 0.0 110.587 -179.026 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.459 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -68.52 -34.75 76.43 Favored 'General case' 0 C--N 1.304 -1.408 0 C-N-CA 119.321 -0.951 . . . . 0.0 108.744 178.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.544 ' OG1' HG22 ' A' ' 4' ' ' THR . 29.7 m -59.14 -49.24 78.63 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.007 -1.058 . . . . 0.0 108.271 178.397 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.417 ' O ' ' NH1' ' A' ' 121' ' ' ARG . 6.0 tt0 -73.49 -37.0 65.86 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.511 -0.743 . . . . 0.0 109.885 178.753 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.436 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 5.1 mtt180 -71.73 -44.62 63.81 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.085 -1.01 . . . . 0.0 111.186 -179.633 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.547 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -57.4 -41.61 80.65 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.833 -1.167 . . . . 0.0 109.813 179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.417 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -67.06 63.84 0.21 Allowed Glycine 0 N--CA 1.495 2.582 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -179.427 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.58 ' NH1' HG21 ' A' ' 90' ' ' THR . 10.9 mmp_? -135.35 -44.67 0.69 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.483 -1.01 . . . . 0.0 108.504 178.924 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.515 HG23 ' HA3' ' A' ' 128' ' ' GLY . 12.0 t -93.6 144.05 25.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.709 -0.619 . . . . 0.0 109.713 179.024 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 107.03 3.3 36.21 Favored Glycine 0 N--CA 1.486 2.033 0 C-N-CA 119.54 -1.314 . . . . 0.0 110.645 179.082 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.443 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 2.8 mmt180 -62.76 87.72 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.689 0 O-C-N 120.953 -1.322 . . . . 0.0 109.524 179.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.403 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.47 19.13 33.41 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.055 -1.618 . . . . 0.0 109.055 -178.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.464 ' O ' ' HA2' ' A' ' 123' ' ' GLY . 16.4 ptpt -176.25 -178.3 0.31 Allowed Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.474 -1.016 . . . . 0.0 108.532 -179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.502 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.6 Cg_endo -89.2 105.3 0.4 Allowed 'Trans proline' 0 C--N 1.308 -1.56 0 O-C-N 123.23 1.121 . . . . 0.0 110.432 179.574 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.583 ' C ' HD12 ' A' ' 129' ' ' ILE . . . -80.84 176.69 54.6 Favored Glycine 0 N--CA 1.497 2.719 0 C-N-CA 119.963 -1.113 . . . . 0.0 110.728 -179.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.583 HD12 ' C ' ' A' ' 128' ' ' GLY . 3.5 mp -132.52 143.41 39.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.758 -0.848 . . . . 0.0 109.063 179.234 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.505 ' HD1' HG23 ' A' ' 99' ' ' VAL . 9.5 t80 -129.98 115.5 17.23 Favored 'General case' 0 C--N 1.303 -1.45 0 C-N-CA 118.87 -1.132 . . . . 0.0 111.22 179.834 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.607 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mtt180 -106.0 131.44 53.29 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.526 -0.734 . . . . 0.0 109.424 179.326 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.422 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 46.0 p90 -129.63 157.3 42.49 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.037 -1.039 . . . . 0.0 110.371 -179.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.655 HG13 ' HG3' ' A' ' 26' ' ' LYS . 42.7 t -76.08 -60.41 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.098 -1.001 . . . . 0.0 109.912 179.769 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.43 ' O ' ' ND2' ' A' ' 103' ' ' ASN . . . -111.15 146.83 35.34 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.19 -0.944 . . . . 0.0 110.316 -179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_endo -73.97 -51.05 0.15 Allowed 'Trans proline' 0 C--N 1.312 -1.387 0 O-C-N 123.795 1.418 . . . . 0.0 110.426 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 62.69 85.6 0.05 OUTLIER Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 -179.901 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -94.9 82.02 3.81 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.219 -1.165 . . . . 0.0 110.294 -179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.605 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.286 179.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.2 139.31 50.09 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.224 -1.163 . . . . 0.0 110.217 -179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 59.5 t -112.85 104.32 16.85 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.371 0 O-C-N 121.266 -0.896 . . . . 0.0 109.83 179.783 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.616 HG22 ' OG1' ' A' ' 116' ' ' THR . 18.1 p -69.13 138.25 54.06 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.435 -0.79 . . . . 0.0 110.181 -179.919 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.407 HG12 ' H ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -67.79 146.25 98.32 Favored Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.246 -0.909 . . . . 0.0 109.529 179.702 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.434 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 45.9 Cg_endo -72.71 -174.3 1.45 Allowed 'Trans proline' 0 C--N 1.307 -1.643 0 O-C-N 123.997 1.525 . . . . 0.0 110.53 179.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.515 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 175.87 76.78 0.08 OUTLIER Pre-proline 0 N--CA 1.497 1.879 0 O-C-N 121.452 -0.78 . . . . 0.0 109.859 -179.626 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.23 53.96 3.6 Favored 'Trans proline' 0 C--N 1.31 -1.462 0 O-C-N 123.763 1.402 . . . . 0.0 111.096 179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.435 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.1 m-80 -138.41 8.31 2.64 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.999 -1.063 . . . . 0.0 110.358 179.556 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.625 HD11 ' O ' ' A' ' 122' ' ' THR . 36.1 mt -128.05 137.95 56.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.201 -0.937 . . . . 0.0 109.431 179.864 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.4 tt0 -81.93 128.44 34.07 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.083 -1.011 . . . . 0.0 109.289 179.743 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 10.1 mt-10 -89.09 133.08 34.5 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.229 -0.919 . . . . 0.0 110.473 -178.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.538 HG11 ' HE ' ' A' ' 131' ' ' ARG . 16.5 t -128.68 156.14 40.96 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.39 -0.819 . . . . 0.0 109.988 -179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -110.63 110.93 21.82 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.259 -0.901 . . . . 0.0 109.963 179.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.714 HD23 HG22 ' A' ' 133' ' ' VAL . 11.7 tp -58.82 134.17 56.64 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.238 -0.913 . . . . 0.0 109.577 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 14.0 p -138.73 -175.14 4.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.21 -0.932 . . . . 0.0 110.277 -179.641 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 81.8 p -77.79 81.29 4.22 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.885 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.622 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 27.9 m -153.65 109.56 3.27 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.317 -0.864 . . . . 0.0 110.642 -179.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.431 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.69 -165.12 28.05 Favored Glycine 0 N--CA 1.487 2.06 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.534 179.466 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -117.69 -21.81 8.32 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.633 -0.922 . . . . 0.0 110.277 179.796 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.85 HG23 ' HB ' ' A' ' 28' ' ' ILE . 6.6 tt -96.22 110.68 53.53 Favored Pre-proline 0 N--CA 1.488 1.439 0 C-N-CA 118.804 -1.158 . . . . 0.0 109.892 -179.889 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.454 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 38.3 Cg_endo -64.61 155.33 67.36 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.619 1.326 . . . . 0.0 110.271 -179.533 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.577 ' CE1' ' CE2' ' A' ' 24' ' ' TYR . 58.5 t80 -169.49 94.08 0.28 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.094 -1.004 . . . . 0.0 111.512 -178.941 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.582 ' CE1' ' CE1' ' A' ' 43' ' ' HIS . 24.9 m-85 58.4 67.88 0.89 Allowed 'General case' 0 N--CA 1.5 2.037 0 O-C-N 121.44 -0.787 . . . . 0.0 111.492 179.124 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 56.39 14.85 9.6 Favored Glycine 0 N--CA 1.495 2.573 0 N-CA-C 110.43 -1.068 . . . . 0.0 110.43 179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.479 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 29.9 mmtm -130.82 156.78 44.43 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.002 -1.293 . . . . 0.0 109.38 179.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.622 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -114.71 107.4 15.41 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.001 -1.062 . . . . 0.0 109.477 179.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.85 ' HB ' HG23 ' A' ' 21' ' ' ILE . 4.4 mt -69.58 113.89 20.4 Favored Pre-proline 0 C--N 1.299 -1.613 0 O-C-N 121.377 -0.827 . . . . 0.0 110.197 -179.538 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.916 ' O ' HG22 ' A' ' 32' ' ' VAL . 42.8 Cg_endo -70.25 129.77 17.63 Favored 'Trans proline' 0 C--N 1.306 -1.679 0 N-CA-C 107.188 -1.889 . . . . 0.0 107.188 176.86 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.819 HD11 HD12 ' A' ' 58' ' ' LEU . 17.6 mt -56.37 -18.19 10.23 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.885 -1.134 . . . . 0.0 110.9 -177.663 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -59.48 -16.49 24.49 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.611 -1.306 . . . . 0.0 110.071 179.414 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.066 HG23 HG23 ' A' ' 33' ' ' ILE . 14.3 m -93.97 -24.94 4.89 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.174 -0.954 . . . . 0.0 110.989 -179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.066 HG23 HG23 ' A' ' 32' ' ' VAL . 40.8 pt -118.14 -22.82 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.924 -1.11 . . . . 0.0 110.846 -178.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.588 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.3 OUTLIER -92.9 148.29 22.13 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.91 -1.119 . . . . 0.0 110.202 179.53 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.99 -5.25 59.39 Favored Glycine 0 N--CA 1.483 1.797 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 -179.678 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -177.23 -162.58 27.82 Favored Glycine 0 N--CA 1.494 2.507 0 C-N-CA 118.933 -1.603 . . . . 0.0 110.678 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.43 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 14.8 mtt85 -97.18 129.33 44.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.497 -1.002 . . . . 0.0 110.393 -179.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.584 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 88.6 m-70 -138.9 145.62 40.1 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.222 -0.924 . . . . 0.0 110.601 179.987 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.58 HD12 ' O ' ' A' ' 82' ' ' VAL . 38.3 tp -108.06 117.17 33.44 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.428 -0.795 . . . . 0.0 110.279 179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.923 ' CG1' HG12 ' A' ' 83' ' ' VAL . 10.5 mm -94.0 125.71 46.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.261 -0.9 . . . . 0.0 108.606 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.477 ' CZ ' ' CD2' ' A' ' 39' ' ' LEU . 11.4 m-85 -94.25 121.87 36.21 Favored 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.111 -0.993 . . . . 0.0 109.619 -179.9 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -118.48 150.68 39.19 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.32 -0.862 . . . . 0.0 110.819 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.582 ' CE1' ' CE1' ' A' ' 24' ' ' TYR . 2.4 p-80 -103.73 3.57 34.32 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.34 -0.85 . . . . 0.0 109.698 178.441 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 1.9 p -132.57 135.42 45.91 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.169 -0.957 . . . . 0.0 110.185 179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.443 ' HG3' ' CG ' ' A' ' 66' ' ' TYR . 7.5 ttpt -71.32 -37.16 71.76 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.583 -0.698 . . . . 0.0 110.721 -179.652 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 44.2 mttp -60.77 -37.05 80.56 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.263 -0.898 . . . . 0.0 110.695 -179.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.409 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 4.3 tptm -72.55 -36.3 68.23 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.37 -0.832 . . . . 0.0 110.055 -179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.706 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 71.2 m -60.44 -34.17 73.6 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.354 -0.841 . . . . 0.0 109.493 179.688 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -69.73 -49.07 56.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.116 -0.99 . . . . 0.0 110.591 179.83 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.442 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 2.3 mm-40 -71.46 -41.71 69.05 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.169 -0.957 . . . . 0.0 110.584 -179.685 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.928 HD12 HG11 ' A' ' 83' ' ' VAL . 1.8 tm? -56.56 -43.93 80.46 Favored 'General case' 0 N--CA 1.496 1.836 0 O-C-N 121.545 -0.722 . . . . 0.0 111.24 -178.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -69.08 -51.0 43.23 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 120.911 -1.118 . . . . 0.0 110.169 -179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -56.94 -31.69 65.23 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.234 -0.916 . . . . 0.0 109.132 179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.587 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -62.89 -47.06 84.96 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.848 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -60.98 -41.41 96.38 Favored 'General case' 0 C--N 1.297 -1.685 0 O-C-N 121.318 -0.864 . . . . 0.0 111.066 -179.332 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.1 t -56.37 -33.93 39.42 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 120.874 -1.141 . . . . 0.0 109.244 179.486 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.81 -34.77 60.15 Favored 'General case' 0 N--CA 1.497 1.921 0 O-C-N 121.32 -0.862 . . . . 0.0 110.494 179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.819 HD12 HD11 ' A' ' 30' ' ' LEU . 4.2 mm? -71.31 -25.57 62.48 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-O 121.8 0.81 . . . . 0.0 109.826 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 120.26 8.92 8.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.4 -1.48 . . . . 0.0 109.4 -179.485 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.746 ' CD1' HD22 ' A' ' 30' ' ' LEU . 36.5 mt -108.33 143.7 18.25 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.356 -1.085 . . . . 0.0 109.703 -179.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 24.6 t30 -90.04 106.77 18.7 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 178.269 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.578 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.62 145.96 45.97 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 119.132 -1.027 . . . . 0.0 111.53 -176.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.874 HG21 ' HA ' ' A' ' 73' ' ' VAL . 4.3 t -131.7 149.37 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 C-N-CA 119.77 -0.772 . . . . 0.0 109.483 179.243 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.706 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -113.43 128.26 56.39 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.155 -1.018 . . . . 0.0 109.714 178.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.611 ' CD1' HD12 ' A' ' 69' ' ' LEU . 12.8 t80 -119.92 134.67 55.17 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.392 -0.818 . . . . 0.0 110.117 -179.901 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.7 p90 -167.73 -178.27 3.8 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.534 -0.729 . . . . 0.0 109.733 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -58.11 116.79 3.76 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.168 -0.958 . . . . 0.0 110.595 -179.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 89.62 36.12 7.54 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 109.806 -1.318 . . . . 0.0 109.806 179.769 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.893 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.1 tm? -117.64 156.9 27.38 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -1.21 . . . . 0.0 110.112 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.769 ' N ' HD13 ' A' ' 69' ' ' LEU . 33.8 m-20 -97.44 149.04 22.59 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.289 -0.882 . . . . 0.0 110.074 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.676 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.0 m -62.44 111.25 0.8 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 C-N-CA 119.271 -0.972 . . . . 0.0 109.215 179.25 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.442 ' HB2' ' CG1' ' A' ' 63' ' ' VAL . 27.7 m -130.16 -34.41 1.66 Allowed 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.321 -0.862 . . . . 0.0 110.747 -179.432 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.874 ' HA ' HG21 ' A' ' 63' ' ' VAL . 50.3 t -49.9 151.74 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.767 0 O-C-N 121.249 -0.907 . . . . 0.0 109.438 179.67 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.438 HG13 HG21 ' A' ' 80' ' ' VAL . 1.0 OUTLIER -131.29 100.34 16.9 Favored Pre-proline 0 N--CA 1.495 1.823 0 O-C-N 120.842 -1.161 . . . . 0.0 111.493 -178.963 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -81.68 59.8 7.36 Favored 'Trans proline' 0 C--N 1.311 -1.396 0 O-C-N 123.609 1.321 . . . . 0.0 109.902 179.012 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.431 HG23 ' O ' ' A' ' 76' ' ' THR . 4.7 t -135.86 61.85 1.64 Allowed 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.443 -0.785 . . . . 0.0 109.288 179.905 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.425 ' HB2' ' O ' ' A' ' 76' ' ' THR . 3.2 m-20 62.7 -154.14 0.34 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.812 -0.555 . . . . 0.0 110.03 -179.349 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 63.69 151.34 0.05 OUTLIER Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.531 -1.828 . . . . 0.0 108.531 -179.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -80.4 94.04 6.1 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 120.941 -1.329 . . . . 0.0 110.238 -179.648 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 4.9 p -117.25 131.09 70.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.836 0 CA-C-O 122.051 0.929 . . . . 0.0 110.065 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.603 HG11 ' HB ' ' A' ' 33' ' ' ILE . 6.2 m -112.93 121.34 64.98 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.334 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 178.333 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 11.0 t -96.77 118.54 43.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 O-C-N 121.135 -0.978 . . . . 0.0 110.411 -177.694 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.928 HG11 HD12 ' A' ' 51' ' ' LEU . 2.9 m -109.44 100.32 10.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 121.047 -1.033 . . . . 0.0 108.814 179.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.482 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -142.96 161.61 37.67 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 120.606 -1.309 . . . . 0.0 111.144 -178.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.778 HG23 ' H ' ' A' ' 87' ' ' ALA . 8.8 t -85.38 -136.95 0.07 Allowed 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.523 -0.735 . . . . 0.0 109.167 179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.504 ' N ' HG23 ' A' ' 85' ' ' THR . 6.1 m-20 -82.53 -13.63 56.3 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.671 -1.268 . . . . 0.0 110.434 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.778 ' H ' HG23 ' A' ' 85' ' ' THR . . . -52.61 -41.99 64.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.069 -1.02 . . . . 0.0 110.353 179.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.436 HD12 ' CD2' ' A' ' 65' ' ' TYR . 2.4 tp -64.06 -47.87 78.46 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.122 -0.986 . . . . 0.0 109.776 179.836 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.441 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.0 OUTLIER 54.2 20.61 2.66 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 109.943 -179.742 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.654 HG22 ' HB ' ' A' ' 93' ' ' THR . 0.1 OUTLIER 46.85 54.65 8.81 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.393 -0.817 . . . . 0.0 110.805 179.837 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -66.55 -67.94 1.83 Allowed Glycine 0 N--CA 1.492 2.422 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 179.568 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 10.6 p90 -93.12 21.74 5.63 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.308 -1.113 . . . . 0.0 109.617 178.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.654 ' HB ' HG22 ' A' ' 90' ' ' THR . 0.0 OUTLIER -127.99 -167.69 1.79 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.433 -0.792 . . . . 0.0 109.806 -179.922 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.426 ' HA3' ' NH1' ' A' ' 124' ' ' ARG . . . 150.76 -51.02 0.53 Allowed Glycine 0 N--CA 1.489 2.195 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.408 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.1 p-10 -87.31 97.41 10.78 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.238 -1.154 . . . . 0.0 110.589 -179.819 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.543 ' CZ ' HG21 ' A' ' 93' ' ' THR . 10.5 m-85 -116.68 151.7 35.79 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.283 -0.886 . . . . 0.0 109.491 179.195 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 -69.54 -32.96 72.1 Favored 'General case' 0 C--N 1.299 -1.628 0 C-N-CA 119.378 -0.929 . . . . 0.0 109.287 179.473 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.427 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.7 p -162.36 163.54 27.81 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.314 -0.867 . . . . 0.0 111.138 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.604 HG22 HG21 ' A' ' 122' ' ' THR . 0.3 OUTLIER -130.88 112.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.845 0 O-C-N 121.521 -0.737 . . . . 0.0 109.888 179.329 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.593 HG21 HD11 ' A' ' 28' ' ' ILE . 3.2 mp -94.47 115.34 33.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.21 -0.931 . . . . 0.0 109.128 179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.407 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.9 t0 -128.03 161.09 29.99 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.15 -0.969 . . . . 0.0 111.523 -178.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.458 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 42.7 t -90.92 -9.04 47.64 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.159 -0.682 . . . . 0.0 109.159 177.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.9 m-20 57.35 13.68 1.86 Allowed 'General case' 0 N--CA 1.496 1.825 0 O-C-N 121.28 -0.887 . . . . 0.0 111.676 179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.479 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.2 m -144.01 109.93 5.32 Favored 'General case' 0 C--N 1.305 -1.339 0 O-C-N 120.795 -1.19 . . . . 0.0 108.98 179.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.464 ' N ' ' O ' ' A' ' 108' ' ' LYS . 3.6 p -86.81 128.73 35.04 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.319 -0.863 . . . . 0.0 111.071 -179.331 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 3.9 t70 54.38 34.29 20.42 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.413 -0.805 . . . . 0.0 111.288 179.198 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 86.65 -14.96 54.3 Favored Glycine 0 N--CA 1.494 2.535 0 C-N-CA 119.856 -1.164 . . . . 0.0 110.301 179.715 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 104' ' ' THR . 10.6 mttt -98.02 156.57 35.77 Favored Pre-proline 0 N--CA 1.49 1.565 0 O-C-N 120.986 -1.302 . . . . 0.0 109.788 179.84 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -62.51 127.29 20.42 Favored 'Trans proline' 0 C--N 1.307 -1.653 0 O-C-N 123.512 1.27 . . . . 0.0 110.508 -179.987 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -44.49 157.43 0.06 Allowed 'General case' 0 N--CA 1.496 1.855 0 CA-C-O 121.58 0.705 . . . . 0.0 111.25 -179.313 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.538 ' OD2' HG22 ' A' ' 113' ' ' VAL . 4.3 p-10 -73.28 162.52 29.28 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.521 -0.737 . . . . 0.0 109.97 179.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -59.19 -42.56 91.17 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 120.886 -1.134 . . . . 0.0 111.65 -178.701 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.538 HG22 ' OD2' ' A' ' 111' ' ' ASP . 6.6 m -72.62 -30.81 35.02 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.873 0 O-C-N 120.738 -1.226 . . . . 0.0 113.07 -178.055 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.452 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 0.3 OUTLIER -52.76 -55.8 20.24 Favored 'General case' 0 N--CA 1.497 1.881 0 O-C-N 120.483 -1.386 . . . . 0.0 110.251 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.415 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 0.3 OUTLIER -62.84 -34.74 77.96 Favored 'General case' 0 C--N 1.302 -1.478 0 C-N-CA 118.738 -1.185 . . . . 0.0 108.201 178.363 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.616 ' OG1' HG22 ' A' ' 4' ' ' THR . 24.5 m -61.48 -50.68 71.79 Favored 'General case' 0 N--CA 1.485 1.298 0 N-CA-C 108.59 -0.892 . . . . 0.0 108.59 178.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -73.88 -46.9 41.82 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.362 -0.836 . . . . 0.0 109.591 178.777 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.426 ' HD2' ' HB2' ' A' ' 114' ' ' SER . 25.2 mtt180 -59.62 -45.11 92.92 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 110.422 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.515 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 20.1 ttm180 -62.7 -34.59 77.46 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.783 -1.198 . . . . 0.0 110.086 179.361 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.425 ' O ' ' NE ' ' A' ' 124' ' ' ARG . . . -66.73 -5.42 31.06 Favored Glycine 0 N--CA 1.49 2.256 0 O-C-N 120.969 -1.082 . . . . 0.0 111.098 -179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.506 ' HG3' HG21 ' A' ' 90' ' ' THR . 0.0 OUTLIER -87.89 -5.0 58.79 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.633 -1.51 . . . . 0.0 110.981 -179.813 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.625 ' O ' HD11 ' A' ' 10' ' ' ILE . 0.5 OUTLIER -118.7 140.34 50.09 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 120.86 -1.15 . . . . 0.0 109.468 179.557 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 92.02 19.63 39.05 Favored Glycine 0 N--CA 1.486 2.032 0 N-CA-C 109.754 -1.338 . . . . 0.0 109.754 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.426 ' NH1' ' HA3' ' A' ' 94' ' ' GLY . 10.2 mmt85 -69.42 85.99 0.42 Allowed 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.066 -1.256 . . . . 0.0 109.799 179.73 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 97.29 6.12 57.79 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.475 ' HB2' ' HD2' ' A' ' 127' ' ' PRO . 16.6 ptmt -166.43 -174.84 0.39 Allowed Pre-proline 0 N--CA 1.491 1.591 0 O-C-N 121.118 -1.225 . . . . 0.0 109.02 -179.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.475 ' HD2' ' HB2' ' A' ' 126' ' ' LYS . 47.0 Cg_endo -85.22 103.29 0.8 Allowed 'Trans proline' 0 C--N 1.309 -1.514 0 O-C-N 123.341 1.18 . . . . 0.0 109.46 179.474 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.428 ' O ' ' HA ' ' A' ' 10' ' ' ILE . . . -86.96 173.21 44.73 Favored Glycine 0 N--CA 1.489 2.205 0 C-N-CA 119.648 -1.263 . . . . 0.0 110.044 -179.096 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.427 ' O ' ' HA ' ' A' ' 98' ' ' SER . 3.4 mt -122.16 142.89 36.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.473 -1.016 . . . . 0.0 109.567 179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.549 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 25.6 t80 -127.0 115.31 19.03 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.139 -0.975 . . . . 0.0 110.182 179.424 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.538 ' HE ' HG11 ' A' ' 13' ' ' VAL . 10.6 mtt85 -105.63 135.29 47.3 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.415 -0.803 . . . . 0.0 109.511 -179.917 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.466 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 40.5 p90 -137.23 146.97 45.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.113 -0.992 . . . . 0.0 110.515 -179.597 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.714 HG22 HD23 ' A' ' 15' ' ' LEU . 54.6 t -69.18 -55.61 14.77 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.677 0 O-C-N 121.222 -0.924 . . . . 0.0 109.864 179.707 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -118.87 159.29 45.13 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.184 -0.947 . . . . 0.0 110.299 179.946 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.446 ' HG2' ' CB ' ' A' ' 138' ' ' ARG . 44.9 Cg_endo -72.16 -23.12 21.62 Favored 'Trans proline' 0 C--N 1.311 -1.401 0 O-C-N 123.697 1.367 . . . . 0.0 110.395 179.98 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 115.5 -64.61 0.31 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.908 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 20.2 tt0 -83.64 -48.96 9.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.207 -1.172 . . . . 0.0 110.215 -179.975 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . 0.446 ' CB ' ' HG2' ' A' ' 135' ' ' PRO . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 118.01 -0.995 . . . . 0.0 110.128 179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 48.8 p -104.04 106.87 17.52 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.216 -1.167 . . . . 0.0 110.268 -179.913 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.558 ' O ' HG13 ' A' ' 3' ' ' VAL . 4.8 p -113.3 103.95 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.311 -0.868 . . . . 0.0 109.88 179.597 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.414 HG22 ' O ' ' A' ' 112' ' ' ALA . 18.1 p -75.24 142.67 43.35 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.243 -0.911 . . . . 0.0 110.309 179.953 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.461 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -68.76 146.89 97.82 Favored Pre-proline 0 N--CA 1.49 1.543 0 O-C-N 121.208 -0.933 . . . . 0.0 109.623 179.601 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.461 ' HD2' HG23 ' A' ' 5' ' ' VAL . 46.3 Cg_endo -71.98 -168.58 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.691 0 O-C-N 124.116 1.588 . . . . 0.0 110.447 179.169 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.555 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.6 OUTLIER -173.66 81.9 0.38 Allowed Pre-proline 0 C--N 1.303 -1.449 0 O-C-N 121.52 -0.737 . . . . 0.0 109.543 179.546 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.409 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 40.1 Cg_endo -67.06 87.83 0.3 Allowed 'Trans proline' 0 C--N 1.31 -1.498 0 O-C-N 123.38 1.2 . . . . 0.0 111.021 -179.161 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.46 ' ND2' ' N ' ' A' ' 9' ' ' ASN . 0.1 OUTLIER 171.79 -5.82 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.373 0 O-C-N 121.523 -0.736 . . . . 0.0 112.481 179.3 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.522 ' HB ' ' CE1' ' A' ' 7' ' ' HIS . 12.7 mt -124.32 135.58 63.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.148 -1.595 . . . . 0.0 109.564 179.364 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -84.83 128.75 34.76 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.306 -0.871 . . . . 0.0 109.821 179.312 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -89.37 140.92 29.02 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.145 -0.972 . . . . 0.0 109.888 -179.857 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.417 ' HB ' ' HG2' ' A' ' 131' ' ' ARG . 6.5 t -134.77 153.98 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.245 -0.909 . . . . 0.0 110.451 -179.156 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -104.47 107.54 18.52 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.301 -0.875 . . . . 0.0 109.591 179.075 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.512 HD11 HG12 ' A' ' 28' ' ' ILE . 10.8 tp -56.05 136.67 52.15 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.291 -0.881 . . . . 0.0 109.788 -179.944 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 54.4 p -134.44 -167.56 1.99 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.73 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 49.5 p -88.3 73.26 8.88 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.217 -0.927 . . . . 0.0 109.861 179.755 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.633 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.2 m -146.07 112.32 5.8 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.483 -179.703 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 145.4 -165.32 27.9 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.84 -1.647 . . . . 0.0 110.819 179.231 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.3 mm-40 -116.6 -21.63 9.05 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.684 -0.892 . . . . 0.0 110.147 -179.982 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.892 HG23 ' HB ' ' A' ' 28' ' ' ILE . 9.1 tt -98.82 105.69 32.65 Favored Pre-proline 0 N--CA 1.487 1.422 0 C-N-CA 118.897 -1.121 . . . . 0.0 110.185 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.436 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.5 Cg_endo -62.99 154.99 63.45 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 O-C-N 123.248 1.13 . . . . 0.0 109.694 179.822 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.461 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 61.1 t80 -167.49 93.65 0.42 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.028 -1.045 . . . . 0.0 111.539 -178.126 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.476 ' OH ' ' CD2' ' A' ' 43' ' ' HIS . 25.5 m-85 59.36 67.04 0.94 Allowed 'General case' 0 N--CA 1.501 2.09 0 O-C-N 121.516 -0.74 . . . . 0.0 111.577 179.056 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 58.1 13.78 15.8 Favored Glycine 0 N--CA 1.495 2.569 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 179.552 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.461 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 38.3 mmtm -130.8 156.94 44.14 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.126 -1.22 . . . . 0.0 109.031 179.723 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.633 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -118.11 107.87 14.51 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.829 -1.17 . . . . 0.0 109.646 179.871 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.987 HD11 HG21 ' A' ' 100' ' ' ILE . 4.5 mt -70.86 114.12 24.35 Favored Pre-proline 0 C--N 1.299 -1.614 0 O-C-N 121.412 -0.805 . . . . 0.0 110.663 -179.426 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.839 ' O ' HG22 ' A' ' 32' ' ' VAL . 39.5 Cg_endo -68.9 128.4 16.76 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 N-CA-C 106.93 -1.989 . . . . 0.0 106.93 176.176 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.551 HD11 HD12 ' A' ' 58' ' ' LEU . 6.9 mt -55.89 -18.92 10.12 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.882 -1.136 . . . . 0.0 110.689 -177.587 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -59.52 -16.28 23.67 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.669 -1.269 . . . . 0.0 110.287 179.584 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.046 HG23 HG23 ' A' ' 33' ' ' ILE . 13.2 m -92.25 -25.46 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.781 0 O-C-N 120.941 -1.099 . . . . 0.0 111.233 -179.524 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.046 HG23 HG23 ' A' ' 32' ' ' VAL . 8.9 pt -117.87 -18.54 6.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 120.946 -1.097 . . . . 0.0 110.631 -179.492 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.515 ' HB2' HD11 ' A' ' 60' ' ' ILE . 9.7 tptt -96.3 148.94 22.23 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 120.948 -1.095 . . . . 0.0 110.41 179.567 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 100.37 -3.82 56.7 Favored Glycine 0 N--CA 1.484 1.834 0 N-CA-C 109.484 -1.447 . . . . 0.0 109.484 -179.831 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.78 -159.24 21.83 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.246 -1.454 . . . . 0.0 110.103 179.956 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.448 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 64.5 mtt85 -100.6 130.66 46.69 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.427 -1.043 . . . . 0.0 110.559 -179.567 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.571 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 79.1 m-70 -140.39 147.22 39.42 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.2 -0.938 . . . . 0.0 110.561 -179.976 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.622 HD12 ' HB ' ' A' ' 82' ' ' VAL . 14.0 tp -109.48 120.96 44.12 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.32 -0.862 . . . . 0.0 110.292 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.926 ' CG1' HG12 ' A' ' 83' ' ' VAL . 12.3 mm -99.71 125.57 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.259 -0.901 . . . . 0.0 109.281 179.474 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.493 ' CE2' ' HG2' ' A' ' 118' ' ' ARG . 5.1 m-85 -95.29 123.06 38.61 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.101 -1.0 . . . . 0.0 109.685 179.656 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.27 157.88 25.31 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.266 -0.896 . . . . 0.0 110.837 -179.422 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.476 ' CD2' ' OH ' ' A' ' 24' ' ' TYR . 0.7 OUTLIER -105.76 8.2 32.79 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.446 -0.784 . . . . 0.0 109.965 178.95 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 4.2 p -137.51 139.68 40.68 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.18 -0.95 . . . . 0.0 110.342 -179.86 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HG2' ' CB ' ' A' ' 66' ' ' TYR . 0.1 OUTLIER -71.95 -38.09 69.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.621 -0.674 . . . . 0.0 110.802 -179.675 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 18.8 mtpt -63.94 -37.26 86.74 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.295 -0.878 . . . . 0.0 110.726 -179.523 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.1 OUTLIER -64.98 -35.92 82.73 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.369 -0.832 . . . . 0.0 109.753 -179.827 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.739 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 66.6 m -60.27 -34.3 73.53 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.365 -0.835 . . . . 0.0 108.998 179.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -68.01 -48.83 64.63 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.217 -0.927 . . . . 0.0 110.29 179.714 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.434 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 4.9 mt-10 -71.47 -45.57 62.2 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.216 -0.928 . . . . 0.0 110.614 -179.791 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.993 HD12 HG11 ' A' ' 83' ' ' VAL . 0.5 OUTLIER -56.44 -41.36 76.33 Favored 'General case' 0 N--CA 1.496 1.866 0 O-C-N 121.388 -0.82 . . . . 0.0 111.329 -178.924 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.462 ' HA ' ' CB ' ' A' ' 62' ' ' ALA . . . -75.42 -50.88 14.48 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.873 -1.142 . . . . 0.0 110.367 -179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.58 99.26 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.094 -1.004 . . . . 0.0 109.484 179.529 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.565 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -58.45 -46.11 87.2 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.372 -0.83 . . . . 0.0 109.438 179.343 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.746 HD13 HD12 ' A' ' 21' ' ' ILE . 0.1 OUTLIER -56.41 -42.99 78.89 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.481 -0.762 . . . . 0.0 110.218 179.841 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 53.7 t -55.86 -33.43 34.78 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.05 -1.031 . . . . 0.0 109.198 179.477 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.59 -31.55 59.99 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.332 -0.855 . . . . 0.0 109.975 179.304 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD23 ' O ' ' A' ' 54' ' ' LYS . 3.9 mm? -72.04 -26.53 62.23 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.341 -0.849 . . . . 0.0 109.591 179.825 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 122.05 6.28 8.45 Favored Glycine 0 N--CA 1.493 2.491 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 -179.551 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.589 HG22 HG22 ' A' ' 81' ' ' VAL . 35.2 mt -107.86 143.84 17.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.257 -1.143 . . . . 0.0 110.147 -179.8 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.629 ' ND2' HD11 ' A' ' 74' ' ' ILE . 15.8 t30 -88.01 106.46 18.15 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.84 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.594 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -116.68 141.66 47.91 Favored 'General case' 0 C--N 1.296 -1.723 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.657 -177.2 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.922 HG21 ' HA ' ' A' ' 73' ' ' VAL . 87.5 t -124.28 147.9 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 C-N-CA 119.986 -0.685 . . . . 0.0 109.664 179.653 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.739 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -115.47 127.05 55.05 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.152 -1.019 . . . . 0.0 109.83 178.5 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.476 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 11.0 t80 -119.45 118.69 31.8 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.232 -0.917 . . . . 0.0 110.569 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.865 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 4.6 p90 -147.78 175.06 11.23 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.63 -0.669 . . . . 0.0 109.613 179.726 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.6 ttt180 -51.52 120.66 5.35 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.283 -0.885 . . . . 0.0 110.809 -179.288 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 84.92 37.22 10.36 Favored Glycine 0 N--CA 1.493 2.466 0 N-CA-C 109.928 -1.269 . . . . 0.0 109.928 179.579 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.877 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.5 tm? -117.31 155.9 28.74 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.153 -1.204 . . . . 0.0 109.978 -179.968 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.877 ' N ' HD13 ' A' ' 69' ' ' LEU . 32.6 m-20 -95.62 149.23 21.68 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.256 -0.903 . . . . 0.0 110.434 -179.461 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.663 HG23 ' O ' ' A' ' 71' ' ' VAL . 33.4 m -61.83 110.1 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 C-N-CA 118.928 -1.109 . . . . 0.0 108.977 179.233 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.6 m -132.12 -9.72 3.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.532 -0.73 . . . . 0.0 110.967 -179.257 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.922 ' HA ' HG21 ' A' ' 63' ' ' VAL . 40.0 t -72.26 135.16 28.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.078 -1.013 . . . . 0.0 109.284 -179.576 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.871 HD13 ' OD1' ' A' ' 77' ' ' ASN . 1.3 pp -137.19 104.11 8.75 Favored Pre-proline 0 N--CA 1.493 1.713 0 O-C-N 121.168 -0.957 . . . . 0.0 111.224 -179.011 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.4 Cg_endo -89.33 35.6 0.36 Allowed 'Trans proline' 0 C--N 1.312 -1.346 0 O-C-N 123.655 1.345 . . . . 0.0 110.589 179.341 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . 0.698 HG23 ' ND2' ' A' ' 77' ' ' ASN . 6.9 t -127.81 -11.14 5.48 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 120.855 -1.153 . . . . 0.0 111.533 -179.167 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.871 ' OD1' HD13 ' A' ' 74' ' ' ILE . 8.1 m120 -104.85 -150.36 0.43 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.86 -1.15 . . . . 0.0 110.358 -179.776 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -53.04 174.98 0.23 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.887 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 69.6 m-20 -54.88 115.81 2.39 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.139 -1.212 . . . . 0.0 110.1 -179.915 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.681 HG11 ' O ' ' A' ' 74' ' ' ILE . 7.3 p -116.05 135.44 56.21 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.765 0 CA-C-O 121.967 0.889 . . . . 0.0 110.327 -179.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.589 HG22 HG22 ' A' ' 60' ' ' ILE . 19.0 m -111.9 126.86 69.33 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.111 0 O-C-N 121.455 -0.778 . . . . 0.0 109.248 179.57 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.771 HG22 HG13 ' A' ' 73' ' ' VAL . 7.5 t -97.62 116.9 41.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 120.816 -1.177 . . . . 0.0 110.501 -177.883 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.993 HG11 HD12 ' A' ' 51' ' ' LEU . 3.9 m -110.68 100.06 9.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.912 -1.118 . . . . 0.0 108.693 179.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.476 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -139.54 162.46 35.01 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.563 -1.335 . . . . 0.0 111.213 -178.099 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.3 t -90.84 -133.39 0.12 Allowed 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.535 -0.728 . . . . 0.0 109.082 179.542 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.491 ' N ' HG23 ' A' ' 85' ' ' THR . 49.5 p-10 -89.93 41.66 1.06 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.632 -1.293 . . . . 0.0 110.165 179.468 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -112.85 -32.13 6.49 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.296 -0.877 . . . . 0.0 109.681 179.808 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 0.6 OUTLIER -78.58 -34.28 47.01 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.243 -0.911 . . . . 0.0 108.938 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.42 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.7 OUTLIER 46.4 -96.15 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.713 -0.617 . . . . 0.0 110.526 179.73 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.677 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.5 OUTLIER 177.1 57.1 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.864 0 O-C-N 120.779 -1.201 . . . . 0.0 110.713 179.924 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.03 -50.2 67.79 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 108.458 -1.857 . . . . 0.0 108.458 179.175 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.423 ' CD2' ' O ' ' A' ' 92' ' ' PHE . 51.8 p90 -137.49 38.72 2.46 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.566 -0.961 . . . . 0.0 109.889 179.725 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.688 HG23 ' N ' ' A' ' 94' ' ' GLY . 1.3 t -98.37 -153.74 0.44 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.211 -0.93 . . . . 0.0 110.659 -179.449 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.688 ' N ' HG23 ' A' ' 93' ' ' THR . . . 109.74 7.54 27.44 Favored Glycine 0 N--CA 1.49 2.269 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.61 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -124.74 68.89 1.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.771 -1.429 . . . . 0.0 110.795 -179.902 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.502 ' CZ ' ' OG1' ' A' ' 93' ' ' THR . 22.7 m-85 -119.37 151.08 39.09 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 120.973 -1.079 . . . . 0.0 110.288 179.335 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.9 -28.38 20.35 Favored 'General case' 0 C--N 1.301 -1.536 0 O-C-N 121.356 -0.84 . . . . 0.0 109.403 179.102 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.417 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 5.8 p -160.9 163.3 32.04 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.396 -0.815 . . . . 0.0 110.69 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.422 HG23 ' HD1' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.12 115.4 29.51 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.876 0 O-C-N 121.343 -0.848 . . . . 0.0 110.105 179.718 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.987 HG21 HD11 ' A' ' 28' ' ' ILE . 3.4 mp -95.49 111.24 25.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.095 -1.003 . . . . 0.0 108.637 178.936 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.433 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 2.7 t0 -119.64 161.19 21.09 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.175 -0.953 . . . . 0.0 111.762 -178.434 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.431 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 36.2 t -101.85 8.47 41.27 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.705 -0.622 . . . . 0.0 109.456 178.235 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.426 ' OD1' ' HB2' ' A' ' 132' ' ' PHE . 3.5 m-20 51.68 23.8 2.12 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.137 -0.977 . . . . 0.0 111.288 179.989 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.412 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.3 p -145.15 128.7 17.05 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.12 -0.987 . . . . 0.0 109.976 179.147 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.408 ' O ' ' HB2' ' A' ' 108' ' ' LYS . 3.8 p -113.11 134.52 54.5 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.351 -0.843 . . . . 0.0 110.201 -179.716 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER 54.14 41.53 31.97 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.163 -0.961 . . . . 0.0 110.329 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 65.09 19.77 66.31 Favored Glycine 0 N--CA 1.492 2.421 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 179.933 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.408 ' HB2' ' O ' ' A' ' 105' ' ' SER . 1.0 OUTLIER -126.55 157.56 70.41 Favored Pre-proline 0 N--CA 1.492 1.666 0 O-C-N 121.206 -1.173 . . . . 0.0 109.719 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -62.61 123.65 12.75 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 123.629 1.331 . . . . 0.0 110.213 -179.749 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.503 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 2.5 tt0 -48.61 147.37 2.55 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.535 -0.728 . . . . 0.0 111.095 -179.191 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.455 ' OD2' HG22 ' A' ' 113' ' ' VAL . 6.9 p-10 -88.47 161.12 17.19 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.308 -0.87 . . . . 0.0 110.326 179.773 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.422 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -46.02 -54.97 7.51 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 112.976 0.732 . . . . 0.0 112.976 -178.28 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.479 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 5.8 m -71.64 -31.93 43.79 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.007 0 O-C-N 120.575 -1.328 . . . . 0.0 112.686 -177.551 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.503 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.5 OUTLIER -48.47 -56.18 8.96 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.954 -1.091 . . . . 0.0 110.443 -179.242 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.469 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.4 OUTLIER -66.71 -35.53 80.35 Favored 'General case' 0 C--N 1.306 -1.285 0 C-N-CA 119.169 -1.012 . . . . 0.0 108.291 178.734 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.479 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 61.3 m -58.46 -49.13 78.43 Favored 'General case' 0 N--CA 1.488 1.438 0 C-N-CA 119.372 -0.931 . . . . 0.0 108.526 178.831 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -71.1 -35.57 71.85 Favored 'General case' 0 N--CA 1.486 1.359 0 O-C-N 121.404 -0.81 . . . . 0.0 109.554 178.806 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.493 ' HG2' ' CE2' ' A' ' 41' ' ' PHE . 1.2 mtt180 -72.11 -45.19 61.58 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 121.225 -0.922 . . . . 0.0 110.958 -179.784 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.555 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 14.4 ttt180 -54.09 -45.19 71.72 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.992 -1.067 . . . . 0.0 109.949 179.964 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -67.55 64.19 0.28 Allowed Glycine 0 N--CA 1.494 2.521 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -179.205 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.435 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -136.76 -44.66 0.59 Allowed 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.546 -0.973 . . . . 0.0 108.445 178.776 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.495 HG23 ' HA3' ' A' ' 128' ' ' GLY . 10.9 t -96.15 142.87 27.81 Favored 'General case' 0 N--CA 1.486 1.353 0 O-C-N 121.592 -0.693 . . . . 0.0 109.463 178.823 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.456 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 106.17 8.73 33.16 Favored Glycine 0 N--CA 1.486 2.002 0 C-N-CA 119.481 -1.342 . . . . 0.0 110.936 178.892 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.427 ' CG ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -61.32 87.26 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.0 -1.294 . . . . 0.0 109.404 179.608 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 123' ' ' GLY . . . 94.91 -8.35 70.44 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 -178.931 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.47 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -142.0 -174.71 0.42 Allowed Pre-proline 0 N--CA 1.49 1.556 0 O-C-N 121.199 -1.177 . . . . 0.0 109.237 -179.805 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 48.4 Cg_endo -89.05 97.49 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.455 0 O-C-N 123.346 1.182 . . . . 0.0 110.597 179.58 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.495 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -74.22 171.13 52.95 Favored Glycine 0 N--CA 1.493 2.496 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 179.996 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.417 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.7 mp -126.85 142.15 44.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.472 -1.017 . . . . 0.0 109.28 179.346 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.422 ' HD1' HG23 ' A' ' 99' ' ' VAL . 10.4 t80 -128.63 115.22 17.72 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.155 -0.965 . . . . 0.0 110.355 179.63 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.437 ' HD2' ' HB ' ' A' ' 32' ' ' VAL . 4.1 mtp180 -104.7 122.78 46.38 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.475 -0.766 . . . . 0.0 109.178 179.785 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.433 ' HA ' ' O ' ' A' ' 101' ' ' ASP . 29.9 p90 -121.51 157.54 30.44 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.077 -1.014 . . . . 0.0 110.402 -179.578 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.558 ' O ' ' HB3' ' A' ' 134' ' ' ALA . 18.2 t -94.98 -56.03 5.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.285 -0.884 . . . . 0.0 109.347 179.339 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.558 ' HB3' ' O ' ' A' ' 133' ' ' VAL . . . 63.29 146.87 0.09 OUTLIER Pre-proline 0 N--CA 1.494 1.759 0 O-C-N 121.662 -0.649 . . . . 0.0 110.227 -179.611 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.29 -52.05 0.19 Allowed 'Trans proline' 0 C--N 1.312 -1.347 0 O-C-N 123.711 1.374 . . . . 0.0 110.433 -179.774 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 160.19 -151.69 22.35 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 -179.917 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 4.8 mm-40 -86.44 159.19 19.41 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.27 -1.135 . . . . 0.0 110.161 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.6 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.142 -179.916 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 3.3 t -83.84 146.42 28.11 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.253 -1.145 . . . . 0.0 110.408 -179.921 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.685 ' O ' HG13 ' A' ' 3' ' ' VAL . 12.8 p -113.12 104.67 17.39 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.312 -0.867 . . . . 0.0 109.589 179.321 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 16.2 p -80.13 145.63 32.26 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.31 -0.869 . . . . 0.0 110.732 -179.565 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.547 HG13 HG23 ' A' ' 116' ' ' THR . 0.2 OUTLIER -74.98 148.98 85.0 Favored Pre-proline 0 N--CA 1.49 1.541 0 O-C-N 121.422 -0.799 . . . . 0.0 109.425 179.348 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.524 ' O ' ' CG ' ' A' ' 7' ' ' HIS . 40.2 Cg_endo -71.16 -43.59 1.5 Allowed 'Trans proline' 0 C--N 1.308 -1.568 0 O-C-N 124.144 1.602 . . . . 0.0 112.843 -179.622 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.524 ' CG ' ' O ' ' A' ' 6' ' ' PRO . 13.4 p-80 41.26 85.35 0.16 Allowed Pre-proline 0 N--CA 1.497 1.924 0 O-C-N 122.13 -0.356 . . . . 0.0 110.786 -177.207 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.483 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 41.7 Cg_endo -68.29 -161.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.308 -1.565 0 O-C-N 123.842 1.443 . . . . 0.0 110.132 -179.845 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.483 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 1.0 OUTLIER 78.09 -35.89 0.2 Allowed 'General case' 0 N--CA 1.508 2.466 0 O-C-N 121.66 -0.65 . . . . 0.0 111.047 -179.159 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.5 HD13 HG22 ' A' ' 122' ' ' THR . 12.5 mt -95.76 124.89 48.59 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 120.579 -1.326 . . . . 0.0 109.915 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 11.4 tt0 -86.58 128.04 34.95 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.147 -0.971 . . . . 0.0 109.509 179.354 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -89.99 132.96 35.08 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 109.993 -179.657 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.73 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 16.7 t -122.07 149.94 25.47 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.256 -0.902 . . . . 0.0 110.469 -179.352 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -97.63 108.86 21.66 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.292 -0.88 . . . . 0.0 109.711 179.336 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.902 HD23 ' HB2' ' A' ' 26' ' ' LYS . 9.0 tp -53.5 141.09 26.25 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.255 -0.903 . . . . 0.0 109.906 -179.965 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . 0.459 ' HA ' ' HD2' ' A' ' 26' ' ' LYS . 28.4 p -136.1 -178.46 5.16 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.257 -0.902 . . . . 0.0 110.512 -179.565 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.9 p -79.72 71.16 6.35 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.348 -0.845 . . . . 0.0 109.924 179.873 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.683 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 5.9 m -146.11 112.73 5.95 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.325 -0.859 . . . . 0.0 110.405 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.435 ' CA ' ' HA ' ' A' ' 29' ' ' PRO . . . 147.26 -167.79 28.43 Favored Glycine 0 N--CA 1.487 2.07 0 C-N-CA 118.763 -1.684 . . . . 0.0 111.182 179.207 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -114.17 -21.59 10.41 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.782 -0.834 . . . . 0.0 110.342 179.963 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.901 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -97.16 107.98 41.35 Favored Pre-proline 0 N--CA 1.489 1.521 0 C-N-CA 118.677 -1.209 . . . . 0.0 110.064 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.429 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 38.6 Cg_endo -65.07 117.46 4.57 Favored 'Trans proline' 0 C--N 1.313 -1.323 0 O-C-N 123.442 1.233 . . . . 0.0 110.647 -179.383 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.42 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.9 t80 -105.52 -170.82 1.8 Allowed 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.651 -0.656 . . . . 0.0 110.583 -179.48 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.481 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 55.7 m-85 -57.73 82.29 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.55 -0.719 . . . . 0.0 111.601 -179.448 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 75.12 -1.85 53.99 Favored Glycine 0 N--CA 1.493 2.451 0 C-N-CA 120.244 -0.979 . . . . 0.0 110.716 179.422 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.902 ' HB2' HD23 ' A' ' 15' ' ' LEU . 12.0 mmtm -130.12 156.18 44.97 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 120.866 -1.373 . . . . 0.0 109.511 179.967 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.683 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.86 107.16 18.01 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 120.977 -1.077 . . . . 0.0 109.435 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.901 ' HB ' HG23 ' A' ' 21' ' ' ILE . 3.9 mt -68.37 112.95 12.53 Favored Pre-proline 0 C--N 1.301 -1.526 0 O-C-N 121.334 -0.854 . . . . 0.0 110.783 -179.32 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.767 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.2 Cg_endo -68.25 127.79 16.39 Favored 'Trans proline' 0 C--N 1.308 -1.559 0 N-CA-C 106.991 -1.965 . . . . 0.0 106.991 175.701 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.836 HD11 HD12 ' A' ' 58' ' ' LEU . 12.4 mt -56.71 -16.65 6.77 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 120.859 -1.151 . . . . 0.0 110.672 -177.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.2 pp20? -60.85 -15.91 35.63 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.668 -1.27 . . . . 0.0 110.288 179.331 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.044 HG23 HG23 ' A' ' 33' ' ' ILE . 12.0 m -91.8 -25.69 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.854 0 O-C-N 120.969 -1.082 . . . . 0.0 111.23 -179.432 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.044 HG23 HG23 ' A' ' 32' ' ' VAL . 27.5 pt -118.52 -25.27 2.92 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 120.99 -1.069 . . . . 0.0 110.214 -179.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.617 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.0 OUTLIER -91.45 148.17 22.49 Favored 'General case' 0 C--N 1.3 -1.581 0 O-C-N 121.14 -0.975 . . . . 0.0 110.628 179.842 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 99.65 -3.86 57.76 Favored Glycine 0 N--CA 1.484 1.884 0 N-CA-C 109.413 -1.475 . . . . 0.0 109.413 -179.63 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -176.43 -151.23 8.71 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.147 -1.501 . . . . 0.0 110.315 -179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.445 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 81.2 mtt85 -109.76 132.31 54.26 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.525 -0.986 . . . . 0.0 110.101 -179.725 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.576 ' HB2' HG12 ' A' ' 81' ' ' VAL . 90.9 m-70 -140.75 152.97 45.67 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.117 -0.989 . . . . 0.0 110.992 -179.766 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.673 HD12 ' O ' ' A' ' 82' ' ' VAL . 54.9 tp -112.07 114.19 26.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.413 -0.804 . . . . 0.0 109.976 179.605 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.829 HD12 ' CG1' ' A' ' 83' ' ' VAL . 32.9 mt -98.33 129.18 48.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.223 -0.923 . . . . 0.0 109.592 179.531 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 12.0 m-85 -94.42 123.84 38.08 Favored 'General case' 0 C--N 1.294 -1.83 0 O-C-N 121.329 -0.857 . . . . 0.0 109.765 -179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.83 158.83 23.3 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.23 -0.919 . . . . 0.0 110.81 -179.66 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.481 ' NE2' ' CE1' ' A' ' 24' ' ' TYR . 23.1 p80 -110.16 4.26 20.91 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.501 -0.749 . . . . 0.0 110.033 179.185 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.5 p -137.14 137.05 38.8 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.096 -1.003 . . . . 0.0 110.616 -179.766 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.473 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 13.5 tttt -71.61 -42.83 67.19 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.516 -0.74 . . . . 0.0 110.18 179.864 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 25.1 mttm -59.84 -39.21 84.37 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.288 -0.883 . . . . 0.0 110.418 -179.928 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -68.72 -35.14 76.76 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.332 -0.855 . . . . 0.0 109.369 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.894 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 1.7 m -61.17 -34.11 74.52 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.578 -0.702 . . . . 0.0 109.466 179.248 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.74 -49.39 62.8 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.262 -0.899 . . . . 0.0 110.283 -179.987 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -71.82 -44.66 63.54 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.225 -0.922 . . . . 0.0 110.115 179.908 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.714 HD21 HD11 ' A' ' 21' ' ' ILE . 2.6 tm? -57.13 -41.63 79.4 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.464 -0.772 . . . . 0.0 110.852 -179.365 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' HB2' ' HB2' ' A' ' 64' ' ' ALA . . . -75.03 -51.2 14.16 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.005 -1.059 . . . . 0.0 110.36 -179.711 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -61.27 -41.01 96.2 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.148 -0.97 . . . . 0.0 109.688 179.726 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.555 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.17 -44.92 83.98 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.334 -0.854 . . . . 0.0 109.56 179.449 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.699 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.3 OUTLIER -55.08 -42.7 73.16 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.512 -0.743 . . . . 0.0 109.893 179.909 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 42.7 t -56.37 -32.07 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.056 -1.028 . . . . 0.0 108.835 178.888 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.427 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.42 -30.87 60.18 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.42 -0.8 . . . . 0.0 109.598 179.011 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.836 HD12 HD11 ' A' ' 30' ' ' LEU . 4.1 mm? -71.65 -26.15 62.42 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.853 0.835 . . . . 0.0 109.497 179.6 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.03 7.44 10.28 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.133 -1.587 . . . . 0.0 109.133 -179.273 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.617 HD11 ' HB2' ' A' ' 34' ' ' LYS . 56.3 mt -108.3 143.21 19.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 O-C-N 121.325 -1.103 . . . . 0.0 110.362 -179.628 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.478 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 0.3 OUTLIER -85.88 107.51 17.73 Favored 'General case' 0 N--CA 1.485 1.312 0 N-CA-C 106.452 -1.685 . . . . 0.0 106.452 177.937 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.639 ' HB2' HD23 ' A' ' 55' ' ' LEU . . . -121.98 144.61 48.78 Favored 'General case' 0 C--N 1.299 -1.598 0 C-N-CA 119.038 -1.065 . . . . 0.0 111.682 -177.546 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.894 HG21 ' HA ' ' A' ' 73' ' ' VAL . 45.0 t -130.3 143.55 40.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.608 -0.682 . . . . 0.0 109.533 179.102 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.894 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -109.49 118.32 36.3 Favored 'General case' 0 C--N 1.3 -1.561 0 C-N-CA 119.214 -0.995 . . . . 0.0 109.949 179.126 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.457 ' HB3' ' CB ' ' A' ' 84' ' ' ALA . 16.3 t80 -113.63 134.69 54.58 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.285 -0.884 . . . . 0.0 110.606 -179.583 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.755 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 2.2 p90 -167.28 -173.51 2.29 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.501 -0.749 . . . . 0.0 109.752 179.767 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.0 ttt180 -58.28 127.17 30.75 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.156 -0.965 . . . . 0.0 110.802 -179.459 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 77.36 35.33 37.77 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.925 -1.27 . . . . 0.0 109.925 179.467 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.895 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.4 tm? -117.12 155.81 28.69 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.127 -1.219 . . . . 0.0 110.082 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.895 ' N ' HD13 ' A' ' 69' ' ' LEU . 1.5 m-20 -96.64 149.18 22.09 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.314 -0.866 . . . . 0.0 110.589 -179.367 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.678 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.7 m -62.02 110.34 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 C-N-CA 119.104 -1.038 . . . . 0.0 108.988 179.229 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 18.0 m -132.79 -15.41 2.68 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.487 -0.758 . . . . 0.0 111.374 -178.977 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.894 ' HA ' HG21 ' A' ' 63' ' ' VAL . 19.3 t -68.92 138.08 23.04 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 O-C-N 121.076 -1.015 . . . . 0.0 109.437 -179.376 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.687 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.6 pp -137.35 98.8 9.96 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.254 -0.904 . . . . 0.0 110.997 -179.353 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.657 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.8 Cg_endo -81.59 51.6 3.93 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 O-C-N 123.578 1.304 . . . . 0.0 110.421 179.261 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 2.9 p -141.91 8.94 1.92 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 120.976 -1.078 . . . . 0.0 111.072 -179.694 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -108.61 -165.48 1.03 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 120.897 -1.127 . . . . 0.0 109.923 179.962 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.1 -91.84 0.01 OUTLIER Glycine 0 N--CA 1.493 2.46 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 179.752 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . 0.419 ' O ' ' HB3' ' A' ' 61' ' ' ASN . 87.6 m-20 -124.26 113.72 18.64 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.151 -1.206 . . . . 0.0 109.983 179.457 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.657 HG11 ' HA ' ' A' ' 75' ' ' PRO . 8.2 p -115.06 130.93 68.75 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.792 0 CA-C-O 122.09 0.948 . . . . 0.0 110.404 -179.658 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.599 HG22 HG22 ' A' ' 60' ' ' ILE . 6.8 m -113.04 123.04 68.29 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.286 0 O-C-N 121.379 -0.826 . . . . 0.0 109.067 179.08 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.673 ' O ' HD12 ' A' ' 39' ' ' LEU . 4.7 t -97.1 118.08 42.89 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 O-C-N 121.053 -1.029 . . . . 0.0 110.125 -177.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.829 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.9 m -111.2 100.31 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.111 -0.993 . . . . 0.0 108.836 179.762 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.457 ' CB ' ' HB3' ' A' ' 65' ' ' TYR . . . -141.48 162.63 35.0 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 120.746 -1.221 . . . . 0.0 111.082 -178.206 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.403 HG23 ' N ' ' A' ' 86' ' ' ASP . 8.9 t -90.12 -139.24 0.14 Allowed 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.564 -0.71 . . . . 0.0 109.391 179.755 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.413 ' OD1' ' NH2' ' A' ' 118' ' ' ARG . 0.2 OUTLIER -85.99 48.02 1.54 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.802 -1.187 . . . . 0.0 109.983 179.668 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.465 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -120.27 -19.15 7.77 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.183 -0.948 . . . . 0.0 110.623 -179.661 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 3.1 tp -62.53 -23.49 66.99 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 120.994 -1.066 . . . . 0.0 109.644 179.808 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.514 ' C ' HG22 ' A' ' 90' ' ' THR . 32.3 mmt 49.81 37.26 12.94 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.406 -0.809 . . . . 0.0 110.941 179.567 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.514 HG22 ' C ' ' A' ' 89' ' ' MET . 3.2 t 32.7 42.66 0.03 OUTLIER 'General case' 0 N--CA 1.503 2.198 0 N-CA-C 112.561 0.578 . . . . 0.0 112.561 178.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -68.13 -38.52 88.19 Favored Glycine 0 N--CA 1.489 2.18 0 N-CA-C 108.903 -1.679 . . . . 0.0 108.903 179.567 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 42.1 p90 -136.21 12.43 3.3 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.455 -1.026 . . . . 0.0 110.76 -179.753 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.495 ' HA ' ' CE2' ' A' ' 96' ' ' PHE . 14.9 t -67.43 -158.99 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.96 -1.087 . . . . 0.0 110.468 -179.834 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.453 ' CA ' ' HG3' ' A' ' 124' ' ' ARG . . . 90.35 -50.93 3.34 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 179.07 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 21.7 t0 -84.22 60.23 5.82 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.057 -1.261 . . . . 0.0 110.938 -179.248 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.495 ' CE2' ' HA ' ' A' ' 93' ' ' THR . 20.4 m-85 -119.75 144.84 47.05 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.07 -1.019 . . . . 0.0 109.911 178.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.499 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 1.1 m-20 -74.2 -33.44 63.4 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.693 -0.803 . . . . 0.0 109.497 179.348 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 129' ' ' ILE . 6.0 p -162.87 163.55 26.37 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.26 -0.9 . . . . 0.0 110.943 179.92 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.583 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -127.19 116.58 44.74 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.905 0 O-C-N 121.332 -0.855 . . . . 0.0 110.086 179.061 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.876 HG21 HD11 ' A' ' 28' ' ' ILE . 4.1 mp -93.36 118.41 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.676 0 O-C-N 121.226 -0.921 . . . . 0.0 109.086 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 t0 -126.85 160.81 29.84 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.155 -0.965 . . . . 0.0 111.474 -178.601 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.415 ' HA ' ' HB ' ' A' ' 133' ' ' VAL . 36.9 t -101.57 7.31 42.29 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.705 -0.622 . . . . 0.0 109.42 178.184 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.4 m120 49.06 33.17 4.49 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.153 -0.967 . . . . 0.0 111.111 179.939 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.437 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 1.8 p -147.49 130.37 16.18 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.941 -1.099 . . . . 0.0 110.808 179.818 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.446 ' N ' ' O ' ' A' ' 108' ' ' LYS . 22.7 p -113.97 127.67 56.06 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.304 -0.872 . . . . 0.0 109.916 179.309 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 26.9 t70 54.98 28.96 11.4 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.229 -0.92 . . . . 0.0 110.488 -179.935 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 94.92 -36.13 3.93 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.759 -1.336 . . . . 0.0 109.759 179.772 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.446 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.1 OUTLIER -76.87 156.6 82.44 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.321 -1.105 . . . . 0.0 109.918 179.873 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -64.8 138.97 60.57 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.52 1.274 . . . . 0.0 109.968 -179.986 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.424 ' NE2' ' O ' ' A' ' 110' ' ' GLN . 1.2 pm0 -49.76 150.63 2.04 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.274 -0.892 . . . . 0.0 110.843 -178.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.503 ' OD1' HG22 ' A' ' 113' ' ' VAL . 2.7 p30 -80.7 161.47 24.6 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.167 -0.958 . . . . 0.0 109.724 179.814 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.447 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -45.33 -57.07 4.28 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.22 -0.925 . . . . 0.0 111.845 -178.742 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.503 HG22 ' OD1' ' A' ' 111' ' ' ASP . 11.6 m -66.17 -28.31 43.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 120.807 -1.183 . . . . 0.0 111.739 -178.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.434 ' HB2' ' O ' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.1 -56.33 6.75 Favored 'General case' 0 N--CA 1.499 2.023 0 O-C-N 121.015 -1.053 . . . . 0.0 110.717 -179.045 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.462 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 0.1 OUTLIER -68.5 -35.91 78.16 Favored 'General case' 0 C--N 1.305 -1.354 0 C-N-CA 119.246 -0.982 . . . . 0.0 108.843 178.919 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.547 HG23 HG13 ' A' ' 5' ' ' VAL . 88.0 m -59.27 -49.49 77.62 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.122 -0.986 . . . . 0.0 108.604 178.823 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 4.1 tt0 -73.69 -35.51 65.17 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.487 -0.758 . . . . 0.0 109.786 178.808 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.462 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 58.9 mtt-85 -71.6 -44.81 63.78 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.129 -0.982 . . . . 0.0 110.813 -179.54 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.5 ' CD ' ' NE2' ' A' ' 7' ' ' HIS . 2.8 ttm180 -55.01 -37.94 67.27 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.915 -1.116 . . . . 0.0 109.754 179.782 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . 0.418 ' O ' ' NE ' ' A' ' 121' ' ' ARG . . . -66.54 77.23 0.13 Allowed Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.876 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.424 ' HG2' HD23 ' A' ' 39' ' ' LEU . 0.0 OUTLIER -153.37 -49.07 0.1 Allowed 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.49 -1.006 . . . . 0.0 108.555 179.512 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.544 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.7 t -93.16 143.33 26.35 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 178.394 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 118.2 15.96 5.88 Favored Glycine 0 N--CA 1.489 2.195 0 C-N-CA 119.258 -1.449 . . . . 0.0 110.439 179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.453 ' HG3' ' CA ' ' A' ' 94' ' ' GLY . 25.3 mmt180 -92.9 83.01 4.69 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.109 -1.23 . . . . 0.0 110.11 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 123.11 -26.83 6.02 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 108.763 -1.735 . . . . 0.0 108.763 -179.52 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.489 ' CB ' ' CD ' ' A' ' 127' ' ' PRO . 15.1 pttt -154.28 -166.55 0.15 Allowed Pre-proline 0 N--CA 1.488 1.439 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.726 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.489 ' CD ' ' CB ' ' A' ' 126' ' ' LYS . 47.1 Cg_endo -82.54 115.0 2.46 Favored 'Trans proline' 0 C--N 1.309 -1.545 0 O-C-N 122.99 0.995 . . . . 0.0 110.536 -179.946 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.544 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -79.0 172.08 55.22 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.89 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.41 ' O ' ' HA ' ' A' ' 98' ' ' SER . 1.8 mp -132.77 142.57 42.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.249 -1.147 . . . . 0.0 109.385 179.328 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.499 ' CD2' HG23 ' A' ' 99' ' ' VAL . 7.7 t80 -129.22 115.19 17.27 Favored 'General case' 0 C--N 1.301 -1.519 0 C-N-CA 119.337 -0.945 . . . . 0.0 110.351 179.564 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.73 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 0.4 OUTLIER -100.65 122.57 43.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.403 -0.811 . . . . 0.0 109.196 179.514 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . . . . . . . . . 50.3 p90 -117.48 149.72 40.12 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.011 -1.056 . . . . 0.0 110.216 -179.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.415 ' HB ' ' HA ' ' A' ' 102' ' ' CYS . 48.7 t -78.45 -61.12 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.701 0 O-C-N 121.197 -0.94 . . . . 0.0 110.045 179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.624 ' HB1' ' HD2' ' A' ' 135' ' ' PRO . . . -115.97 170.75 5.35 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.258 -0.901 . . . . 0.0 110.437 -179.713 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.624 ' HD2' ' HB1' ' A' ' 134' ' ' ALA . 49.0 Cg_endo -74.69 -50.35 0.14 Allowed 'Trans proline' 0 C--N 1.311 -1.403 0 O-C-N 123.735 1.387 . . . . 0.0 110.327 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 112.03 87.07 1.67 Allowed Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.516 -1.434 . . . . 0.0 109.516 179.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 37.4 mt-10 -85.08 -164.75 1.04 Allowed 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.234 -1.157 . . . . 0.0 110.315 -179.943 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 117.992 -1.004 . . . . 0.0 110.264 179.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.332 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.23 138.02 31.91 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.212 -1.169 . . . . 0.0 110.01 179.884 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.9 m -113.2 104.1 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.18 -0.95 . . . . 0.0 109.959 179.712 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . . . . . . . . . 18.0 p -73.46 135.8 44.14 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.309 -0.869 . . . . 0.0 110.23 179.922 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.411 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.12 147.56 99.0 Favored Pre-proline 0 N--CA 1.488 1.462 0 O-C-N 121.248 -0.908 . . . . 0.0 109.175 179.604 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.43 ' C ' ' CG ' ' A' ' 7' ' ' HIS . 49.6 Cg_endo -73.66 -168.91 0.48 Allowed 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.021 1.537 . . . . 0.0 110.635 179.901 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CD2' ' HD3' ' A' ' 119' ' ' ARG . 0.3 OUTLIER 173.71 81.27 0.05 OUTLIER Pre-proline 0 N--CA 1.498 1.933 0 O-C-N 121.633 -0.667 . . . . 0.0 109.22 -179.764 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -71.49 -5.86 17.94 Favored 'Trans proline' 0 C--N 1.312 -1.364 0 O-C-N 123.805 1.424 . . . . 0.0 111.236 -179.296 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.47 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 3.2 m120 -69.58 -14.24 62.74 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 120.888 -1.132 . . . . 0.0 110.449 -179.977 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.496 HD13 HG22 ' A' ' 122' ' ' THR . 33.8 mt -119.64 136.17 57.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 120.957 -1.09 . . . . 0.0 110.381 -179.819 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 3.9 tp10 -83.78 128.87 34.85 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.313 -0.867 . . . . 0.0 109.582 179.382 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.3 mt-10 -89.28 132.42 34.92 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.151 -0.968 . . . . 0.0 110.341 -179.386 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.79 HG11 ' NH1' ' A' ' 131' ' ' ARG . 29.6 t -122.65 157.67 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.392 -0.817 . . . . 0.0 110.251 -179.673 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -106.99 110.64 22.84 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.217 -0.927 . . . . 0.0 109.835 179.419 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.573 HD23 HG22 ' A' ' 133' ' ' VAL . 12.1 tp -62.67 134.79 56.85 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.319 -0.863 . . . . 0.0 109.648 179.738 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 20.4 p -133.7 179.49 6.19 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.25 -0.906 . . . . 0.0 110.131 -179.683 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 1.1 p -75.88 74.43 2.8 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.168 -0.957 . . . . 0.0 109.637 179.588 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.682 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 7.5 m -144.55 111.6 5.89 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.342 -0.849 . . . . 0.0 110.555 -179.458 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.449 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 142.47 -159.31 27.18 Favored Glycine 0 N--CA 1.488 2.165 0 C-N-CA 119.114 -1.517 . . . . 0.0 110.543 179.433 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -119.93 -24.77 6.0 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.638 -0.919 . . . . 0.0 110.578 -179.977 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.942 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.9 tt -95.84 108.71 42.23 Favored Pre-proline 0 N--CA 1.488 1.442 0 C-N-CA 118.616 -1.234 . . . . 0.0 110.499 -179.39 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.467 ' HD2' ' HE2' ' A' ' 54' ' ' LYS . 37.7 Cg_endo -64.34 154.51 70.89 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.325 1.171 . . . . 0.0 109.888 179.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.502 ' O ' ' HB2' ' A' ' 26' ' ' LYS . 87.4 t80 -167.78 95.05 0.43 Allowed 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.185 -0.947 . . . . 0.0 110.85 -178.295 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.434 ' HB2' ' O ' ' A' ' 23' ' ' PHE . 66.8 m-85 60.38 65.49 1.06 Allowed 'General case' 0 N--CA 1.502 2.129 0 O-C-N 121.49 -0.756 . . . . 0.0 111.151 179.649 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 57.11 15.88 16.44 Favored Glycine 0 N--CA 1.493 2.49 0 N-CA-C 110.123 -1.191 . . . . 0.0 110.123 179.782 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.57 ' HG3' HG13 ' A' ' 133' ' ' VAL . 3.6 mmtt -130.54 157.29 43.1 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.189 -1.183 . . . . 0.0 109.376 179.769 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.682 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -115.99 107.44 14.97 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 120.813 -1.179 . . . . 0.0 109.674 179.988 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.969 HD11 HG21 ' A' ' 100' ' ' ILE . 3.8 mt -69.93 114.04 22.12 Favored Pre-proline 0 C--N 1.301 -1.528 0 O-C-N 121.299 -0.875 . . . . 0.0 110.468 -179.605 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.756 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.1 Cg_endo -69.15 130.12 19.5 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 N-CA-C 106.595 -2.117 . . . . 0.0 106.595 175.966 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.478 HD22 ' CD1' ' A' ' 60' ' ' ILE . 7.6 mt -56.14 -18.33 9.69 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.802 -1.186 . . . . 0.0 110.553 -177.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.428 ' CG ' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.3 -15.9 18.71 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.669 -1.269 . . . . 0.0 110.767 179.649 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.064 HG23 HG23 ' A' ' 33' ' ' ILE . 12.2 m -92.47 -25.17 5.14 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.908 -1.12 . . . . 0.0 110.962 -179.571 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.064 HG23 HG23 ' A' ' 32' ' ' VAL . 10.3 pt -116.85 -22.83 4.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.013 -1.054 . . . . 0.0 110.486 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.548 ' HB2' HD11 ' A' ' 60' ' ' ILE . 2.0 tptt -92.62 148.49 22.03 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 120.983 -1.073 . . . . 0.0 109.96 179.232 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.68 -5.65 43.86 Favored Glycine 0 N--CA 1.486 2.003 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 -179.634 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 179.58 -152.64 11.19 Favored Glycine 0 N--CA 1.491 2.35 0 C-N-CA 119.238 -1.458 . . . . 0.0 110.1 -179.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 18.4 mtt85 -105.53 131.42 52.95 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.366 -1.079 . . . . 0.0 110.262 -179.861 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.557 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 91.7 m-70 -136.38 153.69 51.04 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.143 -0.973 . . . . 0.0 110.997 -179.618 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.535 ' HB3' HG12 ' A' ' 99' ' ' VAL . 65.5 tp -114.47 118.33 33.49 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.402 -0.811 . . . . 0.0 110.265 179.733 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.878 HD12 ' CG1' ' A' ' 83' ' ' VAL . 30.4 mt -104.43 127.9 58.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.123 -0.986 . . . . 0.0 109.653 179.423 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 25.1 m-85 -95.73 122.76 38.85 Favored 'General case' 0 C--N 1.294 -1.837 0 O-C-N 121.252 -0.905 . . . . 0.0 110.119 -179.963 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -117.81 159.01 23.76 Favored 'General case' 0 N--CA 1.494 1.774 0 O-C-N 121.216 -0.927 . . . . 0.0 110.529 179.911 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.422 ' ND1' ' OH ' ' A' ' 24' ' ' TYR . 0.0 OUTLIER -108.72 10.35 26.83 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.39 -0.819 . . . . 0.0 110.377 179.16 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.2 p -137.79 136.36 37.16 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.07 -1.019 . . . . 0.0 110.897 -179.624 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.466 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 10.9 tttt -71.87 -40.01 69.23 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.526 -0.734 . . . . 0.0 110.256 179.796 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -64.32 -36.46 84.19 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.253 -0.904 . . . . 0.0 110.431 -179.914 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -69.8 -36.44 75.69 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.245 -0.91 . . . . 0.0 109.555 179.997 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.913 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 98.6 m -61.65 -34.11 75.13 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.471 -0.768 . . . . 0.0 109.673 179.456 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -67.31 -49.44 64.14 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.146 -0.971 . . . . 0.0 109.977 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.42 ' O ' ' CB ' ' A' ' 54' ' ' LYS . 1.8 mt-10 -71.72 -45.7 60.95 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.306 -0.871 . . . . 0.0 110.117 179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.665 ' O ' HD13 ' A' ' 51' ' ' LEU . 2.1 tm? -56.46 -41.7 76.93 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.458 -0.776 . . . . 0.0 110.59 -179.428 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.418 ' O ' ' HB3' ' A' ' 62' ' ' ALA . . . -76.0 -51.41 12.4 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.08 -1.013 . . . . 0.0 110.212 179.897 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . 0.402 ' O ' ' HB ' ' A' ' 56' ' ' VAL . . . -61.46 -42.02 98.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.008 -1.057 . . . . 0.0 109.65 179.794 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.524 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.11 -44.37 83.17 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.236 -0.915 . . . . 0.0 109.651 179.623 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.777 HD13 HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.12 -41.53 71.83 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.379 -0.826 . . . . 0.0 109.633 179.707 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.402 ' HB ' ' O ' ' A' ' 53' ' ' ALA . 78.7 t -56.28 -33.19 37.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.136 -0.978 . . . . 0.0 108.822 179.034 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -76.01 -32.04 59.2 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.522 -0.736 . . . . 0.0 110.134 179.233 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.524 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.0 mm? -71.57 -26.43 62.61 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.345 -0.847 . . . . 0.0 109.737 -179.979 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 123.48 4.02 8.39 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -179.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.619 HG22 HG22 ' A' ' 81' ' ' VAL . 49.2 mt -108.14 143.93 17.69 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.238 -1.154 . . . . 0.0 110.374 -179.697 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.793 HD22 HG23 ' A' ' 80' ' ' VAL . 1.3 t30 -86.81 107.1 18.14 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 106.977 -1.49 . . . . 0.0 106.977 178.142 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.59 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -120.82 147.7 45.01 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 119.075 -1.05 . . . . 0.0 111.639 -177.259 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.902 ' HB ' HG22 ' A' ' 73' ' ' VAL . 2.9 t -136.13 148.67 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.717 0 C-N-CA 119.716 -0.794 . . . . 0.0 109.491 179.313 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.913 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -111.35 126.98 55.49 Favored 'General case' 0 C--N 1.299 -1.625 0 C-N-CA 119.261 -0.976 . . . . 0.0 110.078 179.534 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.485 ' O ' ' HB1' ' A' ' 84' ' ' ALA . 5.4 t80 -117.47 125.91 51.72 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.303 -0.873 . . . . 0.0 110.684 -179.626 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.893 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.5 p90 -157.74 -174.84 5.05 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.369 -0.832 . . . . 0.0 110.138 179.634 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -52.61 123.65 11.7 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.44 -0.787 . . . . 0.0 111.241 -179.227 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 71.68 47.7 32.29 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.06 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.949 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.26 155.66 29.09 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.05 -1.265 . . . . 0.0 109.812 179.612 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.949 ' N ' HD13 ' A' ' 69' ' ' LEU . 7.7 m-20 -92.08 148.63 22.03 Favored 'General case' 0 N--CA 1.496 1.845 0 O-C-N 121.197 -0.94 . . . . 0.0 110.846 -179.213 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.656 HG23 ' O ' ' A' ' 71' ' ' VAL . 29.8 m -62.86 111.25 0.84 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.021 -1.05 . . . . 0.0 109.308 179.091 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.746 ' O ' HG23 ' A' ' 74' ' ' ILE . 10.6 m -134.59 -35.92 0.88 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.343 -0.848 . . . . 0.0 110.884 -179.573 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.902 HG22 ' HB ' ' A' ' 63' ' ' VAL . 24.8 t -51.37 135.85 11.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.02 -1.05 . . . . 0.0 110.024 -179.666 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.746 HG23 ' O ' ' A' ' 72' ' ' SER . 1.4 pp -136.15 95.02 13.66 Favored Pre-proline 0 N--CA 1.494 1.751 0 O-C-N 121.223 -0.923 . . . . 0.0 110.722 -179.452 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.694 ' HA ' HG11 ' A' ' 80' ' ' VAL . 52.7 Cg_endo -81.39 52.81 4.43 Favored 'Trans proline' 0 C--N 1.311 -1.417 0 O-C-N 123.622 1.328 . . . . 0.0 110.887 179.889 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 9.7 t -149.98 17.73 0.87 Allowed 'General case' 0 N--CA 1.495 1.78 0 O-C-N 120.982 -1.073 . . . . 0.0 110.652 179.905 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.4 ' HB2' ' CD1' ' A' ' 74' ' ' ILE . 3.0 m120 -112.54 -165.83 1.03 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.121 -0.987 . . . . 0.0 110.173 179.973 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -52.08 -66.35 2.66 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.904 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 58.6 m-20 -151.79 110.91 3.89 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.218 -1.166 . . . . 0.0 110.216 179.748 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.793 HG23 HD22 ' A' ' 61' ' ' ASN . 7.6 p -117.31 133.27 64.6 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.736 0 CA-C-O 122.012 0.911 . . . . 0.0 110.373 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.619 HG22 HG22 ' A' ' 60' ' ' ILE . 9.6 m -111.9 124.18 68.39 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.211 0 O-C-N 121.254 -0.904 . . . . 0.0 108.772 178.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.733 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -97.25 120.99 47.3 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.691 0 O-C-N 121.113 -0.992 . . . . 0.0 110.298 -177.903 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.878 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.6 m -116.49 100.47 10.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 120.969 -1.082 . . . . 0.0 108.711 179.581 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.485 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -138.35 162.21 34.97 Favored 'General case' 0 C--N 1.299 -1.621 0 O-C-N 120.614 -1.304 . . . . 0.0 111.489 -177.944 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.601 HG23 ' N ' ' A' ' 86' ' ' ASP . 9.1 t -87.2 -132.26 0.07 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.654 -0.653 . . . . 0.0 109.725 -179.885 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.601 ' N ' HG23 ' A' ' 85' ' ' THR . 3.7 p30 -91.54 32.83 1.04 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 120.8 -1.188 . . . . 0.0 110.577 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.471 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -102.52 -32.95 9.69 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.159 -0.963 . . . . 0.0 109.881 179.924 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 2.2 tp -76.25 -45.47 32.68 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.32 -0.862 . . . . 0.0 109.255 179.188 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.434 ' CE ' ' HA ' ' A' ' 89' ' ' MET . 0.6 OUTLIER 53.22 20.74 1.96 Allowed 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.615 -0.678 . . . . 0.0 110.713 179.642 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.513 HG23 ' HB ' ' A' ' 93' ' ' THR . 0.7 OUTLIER 48.09 32.7 3.08 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.207 -0.933 . . . . 0.0 110.527 179.559 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -52.91 -67.84 1.91 Allowed Glycine 0 N--CA 1.494 2.509 0 N-CA-C 109.518 -1.433 . . . . 0.0 109.518 -179.928 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.441 ' O ' ' CD1' ' A' ' 92' ' ' PHE . 53.2 p90 -96.68 33.96 1.75 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.336 -1.097 . . . . 0.0 109.155 179.087 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.513 ' HB ' HG23 ' A' ' 90' ' ' THR . 0.2 OUTLIER -131.22 -151.64 0.47 Allowed 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.553 -0.717 . . . . 0.0 110.303 -179.37 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' ARG . . . 124.42 -35.76 3.11 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 179.577 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 11.9 p-10 -84.61 80.1 9.36 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.956 -1.32 . . . . 0.0 110.872 -179.463 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.512 ' CZ ' HG21 ' A' ' 93' ' ' THR . 27.2 m-85 -119.09 148.16 43.35 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.162 -0.961 . . . . 0.0 109.887 179.012 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.425 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 3.5 m-20 -74.94 -32.22 61.7 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.304 -0.872 . . . . 0.0 109.501 179.298 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 4.0 p -162.55 163.8 27.16 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.238 -0.914 . . . . 0.0 111.174 -179.987 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.576 HG23 ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -131.63 113.55 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.004 0 O-C-N 121.445 -0.785 . . . . 0.0 110.289 179.321 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.969 HG21 HD11 ' A' ' 28' ' ' ILE . 3.1 mp -92.91 117.75 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.269 -0.894 . . . . 0.0 108.781 179.166 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -118.7 161.18 20.53 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.054 -1.029 . . . . 0.0 112.105 -178.399 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 29.1 p -92.19 -11.65 34.9 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 109.028 -0.731 . . . . 0.0 109.028 177.596 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . 0.422 ' O ' ' NE2' ' A' ' 110' ' ' GLN . 3.7 m120 55.55 12.32 0.76 Allowed 'General case' 0 N--CA 1.498 1.959 0 O-C-N 121.32 -0.862 . . . . 0.0 112.516 179.13 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.429 ' HA ' ' O ' ' A' ' 108' ' ' LYS . 1.0 OUTLIER -147.44 122.14 9.88 Favored 'General case' 0 C--N 1.306 -1.313 0 O-C-N 120.517 -1.364 . . . . 0.0 109.553 -179.982 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.459 ' N ' ' O ' ' A' ' 108' ' ' LYS . 33.0 p -102.6 131.53 49.3 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.299 -0.876 . . . . 0.0 110.219 179.848 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER 55.97 30.73 16.62 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.334 -0.854 . . . . 0.0 111.032 179.611 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . 93.35 -29.7 8.01 Favored Glycine 0 N--CA 1.493 2.44 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.349 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . 0.459 ' O ' ' N ' ' A' ' 105' ' ' SER . 0.0 OUTLIER -85.27 154.43 59.97 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.057 -1.261 . . . . 0.0 110.14 -179.977 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.2 Cg_endo -65.85 139.21 56.18 Favored 'Trans proline' 0 C--N 1.308 -1.571 0 O-C-N 123.535 1.281 . . . . 0.0 110.292 179.568 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.422 ' NE2' ' O ' ' A' ' 103' ' ' ASN . 0.2 OUTLIER -48.04 164.69 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.297 -0.877 . . . . 0.0 110.872 -179.449 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.539 ' OD1' HG22 ' A' ' 113' ' ' VAL . 1.6 p30 -88.93 160.38 17.2 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.294 -0.879 . . . . 0.0 109.871 179.519 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.409 ' O ' ' HG2' ' A' ' 115' ' ' ARG . . . -43.9 -51.06 7.82 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.466 -0.771 . . . . 0.0 112.319 -178.563 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.539 HG22 ' OD1' ' A' ' 111' ' ' ASP . 10.9 m -70.46 -29.66 39.63 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.811 0 O-C-N 120.759 -1.213 . . . . 0.0 111.457 -178.589 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.434 ' N ' ' OD1' ' A' ' 111' ' ' ASP . 0.1 OUTLIER -47.17 -56.47 6.58 Favored 'General case' 0 N--CA 1.498 1.946 0 O-C-N 121.103 -0.998 . . . . 0.0 110.373 -179.181 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.41 ' HA ' ' HB2' ' A' ' 118' ' ' ARG . 1.0 OUTLIER -69.46 -34.37 74.28 Favored 'General case' 0 C--N 1.304 -1.386 0 O-C-N 121.327 -0.858 . . . . 0.0 108.709 178.741 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.454 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 22.4 m -59.3 -49.99 75.7 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 108.45 -0.944 . . . . 0.0 108.45 178.821 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 1.3 tt0 -73.88 -39.54 63.84 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.474 -0.766 . . . . 0.0 109.752 178.651 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . 0.41 ' HB2' ' HA ' ' A' ' 115' ' ' ARG . 2.2 mtt180 -67.46 -44.33 78.9 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.152 -0.967 . . . . 0.0 110.532 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD3' ' CD2' ' A' ' 7' ' ' HIS . 7.0 ttm180 -60.5 -39.08 86.44 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.005 -1.059 . . . . 0.0 110.009 179.773 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.69 66.64 0.43 Allowed Glycine 0 N--CA 1.493 2.434 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.919 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.453 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.0 OUTLIER -143.02 -46.57 0.31 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.556 -0.967 . . . . 0.0 108.665 179.436 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.524 HG23 ' HA3' ' A' ' 128' ' ' GLY . 15.0 t -94.49 142.2 27.71 Favored 'General case' 0 C--N 1.304 -1.379 0 O-C-N 121.407 -0.808 . . . . 0.0 109.149 178.62 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 111.85 10.02 19.57 Favored Glycine 0 N--CA 1.487 2.061 0 C-N-CA 119.336 -1.411 . . . . 0.0 110.612 179.437 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.43 ' HG3' ' O ' ' A' ' 94' ' ' GLY . 12.0 mmt85 -69.25 86.91 0.41 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.986 -1.303 . . . . 0.0 109.711 179.85 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 91.24 22.15 33.15 Favored Glycine 0 N--CA 1.492 2.418 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 -179.373 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.463 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -176.8 -178.26 0.29 Allowed Pre-proline 0 N--CA 1.491 1.625 0 O-C-N 121.556 -0.967 . . . . 0.0 108.684 -179.491 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.47 ' HA ' ' O ' ' A' ' 9' ' ' ASN . 47.1 Cg_endo -89.76 104.01 0.35 Allowed 'Trans proline' 0 C--N 1.31 -1.478 0 O-C-N 123.242 1.128 . . . . 0.0 110.091 179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.524 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -77.59 156.83 45.12 Favored Glycine 0 N--CA 1.492 2.397 0 C-N-CA 119.898 -1.144 . . . . 0.0 110.595 -179.305 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 39.0 mt -111.03 142.06 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 121.411 -1.052 . . . . 0.0 109.054 178.88 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.576 ' CD2' HG23 ' A' ' 99' ' ' VAL . 5.4 t80 -132.13 118.95 20.28 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.11 -0.994 . . . . 0.0 110.78 -179.991 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.79 ' NH1' HG11 ' A' ' 13' ' ' VAL . 0.6 OUTLIER -101.51 124.01 46.49 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.458 -0.776 . . . . 0.0 109.458 179.196 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.476 ' CE2' ' O ' ' A' ' 13' ' ' VAL . 27.4 p90 -118.04 155.84 29.64 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.074 -1.016 . . . . 0.0 110.257 -179.591 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.573 HG22 HD23 ' A' ' 15' ' ' LEU . 71.1 t -95.34 -24.09 4.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.139 -0.976 . . . . 0.0 109.872 179.611 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . . . . . . . . . . . -148.04 124.65 5.47 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.266 -0.896 . . . . 0.0 110.186 179.924 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.46 -50.76 0.1 Allowed 'Trans proline' 0 C--N 1.313 -1.296 0 O-C-N 123.511 1.269 . . . . 0.0 110.367 -179.93 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 66.75 113.11 0.01 OUTLIER Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -179.839 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -100.77 83.89 2.63 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.203 -1.175 . . . . 0.0 110.281 -179.958 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 69.4 ttt180 . . . . . 0 N--CA 1.491 1.604 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.196 -179.948 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.291 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . 0.555 ' OG ' ' HB2' ' A' ' 112' ' ' ALA . 2.5 t -84.16 106.28 15.67 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.197 -1.179 . . . . 0.0 110.319 -179.985 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 3' ' ' VAL . 19.4 m -113.13 104.41 16.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.324 -0.86 . . . . 0.0 110.076 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.77 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 50.5 p -88.57 136.33 33.04 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.304 -0.872 . . . . 0.0 110.221 179.696 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.409 HG23 ' HD2' ' A' ' 6' ' ' PRO . 0.2 OUTLIER -67.62 147.28 98.71 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.248 -0.908 . . . . 0.0 109.654 179.654 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.409 ' HD2' HG23 ' A' ' 5' ' ' VAL . 55.7 Cg_endo -82.01 -169.33 0.74 Allowed 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 124.106 1.582 . . . . 0.0 110.862 179.358 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.536 ' CE1' ' CD ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER 169.74 80.84 0.03 OUTLIER Pre-proline 0 N--CA 1.497 1.889 0 N-CA-C 109.049 -0.723 . . . . 0.0 109.049 179.158 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . . . . . . . . . 39.0 Cg_endo -65.7 108.82 1.32 Allowed 'Trans proline' 0 C--N 1.312 -1.367 0 O-C-N 123.844 1.444 . . . . 0.0 110.884 -179.51 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.462 ' O ' ' HA ' ' A' ' 127' ' ' PRO . 10.9 t-20 179.69 -32.49 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.756 0 CA-C-O 121.508 0.67 . . . . 0.0 109.436 179.996 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.538 HD13 HG22 ' A' ' 122' ' ' THR . 33.3 mt -103.49 136.35 36.79 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 110.102 179.776 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.8 tt0 -82.92 129.43 35.02 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.265 -0.897 . . . . 0.0 109.3 179.536 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -87.9 125.73 34.65 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.16 -0.963 . . . . 0.0 110.301 -179.008 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.45 HG11 ' NE ' ' A' ' 131' ' ' ARG . 20.3 t -117.86 155.01 19.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.622 -0.674 . . . . 0.0 110.007 -179.421 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.15 106.88 17.58 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.19 -0.944 . . . . 0.0 109.961 179.485 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.662 HD23 HG22 ' A' ' 133' ' ' VAL . 12.5 tp -57.62 132.2 52.52 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.322 -0.861 . . . . 0.0 109.601 179.859 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 11.9 p -135.9 -166.95 1.95 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.21 -0.932 . . . . 0.0 110.551 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 5.1 p -82.51 83.42 7.56 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.413 -0.804 . . . . 0.0 109.935 179.921 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.699 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 11.0 m -156.91 110.04 2.57 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.295 -0.878 . . . . 0.0 110.518 -179.568 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.453 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 146.61 -163.33 28.52 Favored Glycine 0 N--CA 1.488 2.11 0 C-N-CA 118.892 -1.623 . . . . 0.0 110.966 179.386 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.405 ' O ' ' HD3' ' A' ' 22' ' ' PRO . 0.6 OUTLIER -117.49 -24.72 7.22 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.795 -0.826 . . . . 0.0 110.416 -179.888 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.911 HG23 ' HB ' ' A' ' 28' ' ' ILE . 8.0 tt -93.83 103.47 10.33 Favored Pre-proline 0 N--CA 1.485 1.286 0 C-N-CA 118.497 -1.281 . . . . 0.0 110.012 -179.338 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.446 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.58 118.7 5.6 Favored 'Trans proline' 0 C--N 1.313 -1.333 0 O-C-N 123.656 1.345 . . . . 0.0 110.549 -179.572 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.427 ' O ' ' N ' ' A' ' 25' ' ' GLY . 3.1 t80 -108.58 -168.73 1.39 Allowed 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.732 -0.605 . . . . 0.0 110.722 -178.912 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.43 ' CE1' ' NE2' ' A' ' 43' ' ' HIS . 45.6 m-85 -57.07 81.8 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.827 0 O-C-N 121.531 -0.73 . . . . 0.0 111.702 -179.347 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 74.36 -1.64 49.44 Favored Glycine 0 N--CA 1.495 2.583 0 C-N-CA 120.197 -1.001 . . . . 0.0 110.805 179.355 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.459 ' HB2' ' CD2' ' A' ' 15' ' ' LEU . 4.4 mmtt -130.15 156.44 44.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.879 -1.365 . . . . 0.0 109.292 179.978 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.699 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -105.24 107.1 17.9 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 120.878 -1.139 . . . . 0.0 109.001 179.404 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.936 HD11 HG21 ' A' ' 100' ' ' ILE . 4.0 mt -67.35 113.54 14.39 Favored Pre-proline 0 C--N 1.302 -1.481 0 O-C-N 121.193 -0.942 . . . . 0.0 110.631 -179.302 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.803 ' O ' HG22 ' A' ' 32' ' ' VAL . 41.2 Cg_endo -68.79 127.34 15.22 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 N-CA-C 106.827 -2.028 . . . . 0.0 106.827 175.805 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.565 HD11 HD12 ' A' ' 58' ' ' LEU . 8.7 mt -55.91 -18.01 7.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.856 -1.152 . . . . 0.0 110.798 -177.584 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -59.71 -16.34 26.33 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.691 -1.256 . . . . 0.0 110.288 179.671 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.124 HG23 HG23 ' A' ' 33' ' ' ILE . 12.3 m -90.98 -25.3 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 120.989 -1.069 . . . . 0.0 110.875 -179.707 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.124 HG23 HG23 ' A' ' 32' ' ' VAL . 20.3 pt -117.45 -18.67 6.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.979 -1.076 . . . . 0.0 110.605 -179.531 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.615 ' HB2' HD11 ' A' ' 60' ' ' ILE . 0.6 OUTLIER -97.58 148.26 23.45 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.871 -1.143 . . . . 0.0 110.164 179.55 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.07 -5.99 36.68 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 109.287 -1.525 . . . . 0.0 109.287 -179.413 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 178.19 -143.66 6.09 Favored Glycine 0 N--CA 1.492 2.42 0 C-N-CA 119.342 -1.409 . . . . 0.0 110.109 179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.473 ' HG2' HG12 ' A' ' 80' ' ' VAL . 9.0 mtt85 -111.23 134.62 52.68 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.369 -1.077 . . . . 0.0 110.326 -179.876 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.587 ' HB2' HG12 ' A' ' 81' ' ' VAL . 66.3 m80 -141.17 150.71 43.12 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.071 -1.018 . . . . 0.0 111.043 -179.91 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.661 HD12 ' O ' ' A' ' 82' ' ' VAL . 60.8 tp -110.01 115.05 29.07 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.474 -0.766 . . . . 0.0 110.017 179.625 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.817 HD12 ' CG1' ' A' ' 83' ' ' VAL . 26.4 mt -98.81 127.31 51.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.164 -0.96 . . . . 0.0 109.823 179.665 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . 0.421 ' CZ ' HD21 ' A' ' 39' ' ' LEU . 29.4 m-85 -95.35 124.71 39.53 Favored 'General case' 0 C--N 1.294 -1.822 0 O-C-N 121.453 -0.779 . . . . 0.0 110.05 -179.959 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.8 m -116.69 157.73 24.96 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.153 -0.967 . . . . 0.0 110.629 -179.715 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.435 ' HB3' ' O ' ' A' ' 104' ' ' THR . 15.0 p80 -101.94 -2.93 28.71 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.325 -0.859 . . . . 0.0 110.304 179.288 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 2.7 p -132.38 136.57 46.89 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.072 -1.017 . . . . 0.0 110.291 179.878 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 19.6 tttt -70.66 -37.45 73.71 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.409 -0.807 . . . . 0.0 110.727 -179.663 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.58 -36.07 77.64 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.191 -0.943 . . . . 0.0 110.278 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . 0.422 ' O ' ' HB2' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -71.61 -32.77 68.37 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.413 -0.804 . . . . 0.0 109.278 179.83 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.687 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 72.4 m -60.41 -34.7 74.31 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.376 -0.828 . . . . 0.0 109.099 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.94 -48.85 64.77 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.167 -0.958 . . . . 0.0 110.382 179.55 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 4.2 mt-10 -71.82 -44.4 63.97 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 121.232 -0.918 . . . . 0.0 110.623 -179.726 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.741 HD12 HG11 ' A' ' 83' ' ' VAL . 0.8 OUTLIER -56.84 -38.92 73.35 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.399 -0.813 . . . . 0.0 111.202 -178.925 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -75.86 -51.35 12.71 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 120.89 -1.131 . . . . 0.0 110.581 -179.701 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -62.24 -40.76 97.22 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.022 -1.049 . . . . 0.0 109.7 179.772 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.535 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.1 OUTLIER -57.34 -45.93 83.81 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.283 -0.885 . . . . 0.0 109.551 179.426 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.751 ' CD1' HD12 ' A' ' 21' ' ' ILE . 0.2 OUTLIER -55.36 -40.98 71.94 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.494 -0.754 . . . . 0.0 109.992 179.914 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.2 t -56.28 -33.83 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.098 -1.001 . . . . 0.0 108.923 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . . . . . . . . . . . -75.44 -30.04 59.87 Favored 'General case' 0 N--CA 1.496 1.858 0 O-C-N 121.372 -0.83 . . . . 0.0 110.04 179.366 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.565 HD12 HD11 ' A' ' 30' ' ' LEU . 4.0 mm? -71.5 -25.92 62.46 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.332 -0.855 . . . . 0.0 109.428 179.618 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 119.97 5.71 10.59 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 -179.129 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.615 HD11 ' HB2' ' A' ' 34' ' ' LYS . 33.5 mt -108.45 143.5 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.46 -1.024 . . . . 0.0 110.242 -179.581 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.655 HD22 HG23 ' A' ' 80' ' ' VAL . 0.6 OUTLIER -87.97 106.91 18.44 Favored 'General case' 0 N--CA 1.484 1.271 0 N-CA-C 106.884 -1.524 . . . . 0.0 106.884 178.056 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.691 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -118.59 146.94 44.22 Favored 'General case' 0 C--N 1.297 -1.682 0 C-N-CA 118.716 -1.194 . . . . 0.0 111.94 -177.185 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.921 HG21 ' HA ' ' A' ' 73' ' ' VAL . 19.7 t -129.31 149.36 33.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 C-N-CA 120.159 -0.616 . . . . 0.0 109.861 179.627 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.687 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -114.04 123.85 50.7 Favored 'General case' 0 C--N 1.301 -1.509 0 C-N-CA 119.236 -0.986 . . . . 0.0 109.844 178.648 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.443 ' HA ' ' HG ' ' A' ' 69' ' ' LEU . 0.3 OUTLIER -114.02 134.71 54.68 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 110.992 -179.327 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.994 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 5.1 p90 -171.02 -179.82 2.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.461 -0.775 . . . . 0.0 110.138 179.391 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -52.27 126.28 18.49 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.235 -0.915 . . . . 0.0 111.022 -179.258 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 72.12 46.53 35.03 Favored Glycine 0 N--CA 1.492 2.413 0 N-CA-C 110.099 -1.201 . . . . 0.0 110.099 179.329 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.994 HD23 ' CZ ' ' A' ' 66' ' ' TYR . 2.7 tm? -117.51 154.71 30.99 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.118 -1.225 . . . . 0.0 109.893 179.777 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.828 ' N ' HD13 ' A' ' 69' ' ' LEU . 4.1 m-20 -93.13 149.81 20.96 Favored 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.238 -0.914 . . . . 0.0 110.667 -179.234 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.69 HG23 ' O ' ' A' ' 71' ' ' VAL . 34.1 m -61.7 111.14 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 C-N-CA 119.039 -1.064 . . . . 0.0 108.816 179.126 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.92 ' O ' HG23 ' A' ' 74' ' ' ILE . 74.1 m -132.41 -34.64 1.2 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.288 -0.882 . . . . 0.0 110.797 -179.01 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.921 ' HA ' HG21 ' A' ' 63' ' ' VAL . 58.4 t -47.75 125.19 2.05 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.93 0 O-C-N 121.259 -0.901 . . . . 0.0 109.602 179.757 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.92 HG23 ' O ' ' A' ' 72' ' ' SER . 1.1 pp -136.68 113.33 10.02 Favored Pre-proline 0 N--CA 1.496 1.857 0 O-C-N 121.062 -1.023 . . . . 0.0 111.771 -178.37 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.456 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.3 Cg_endo -89.31 40.97 0.51 Allowed 'Trans proline' 0 C--N 1.314 -1.289 0 O-C-N 123.566 1.298 . . . . 0.0 110.357 178.722 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 3.0 p -142.57 47.67 1.56 Allowed 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.068 -1.02 . . . . 0.0 110.652 -179.492 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . 0.51 ' ND2' HD13 ' A' ' 74' ' ' ILE . 5.5 m-80 -148.45 27.38 0.92 Allowed 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.139 -0.976 . . . . 0.0 110.275 179.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 99.71 -94.6 1.39 Allowed Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.229 -1.548 . . . . 0.0 109.229 -179.956 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 55.6 m-20 -128.27 111.68 13.66 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.189 -1.183 . . . . 0.0 110.097 179.675 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.655 HG23 HD22 ' A' ' 61' ' ' ASN . 8.0 p -117.23 134.99 59.08 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.861 0 CA-C-O 122.159 0.98 . . . . 0.0 110.056 179.981 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.595 HG22 HG22 ' A' ' 60' ' ' ILE . 5.3 m -114.01 122.08 67.42 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.26 0 O-C-N 121.343 -0.848 . . . . 0.0 109.234 179.547 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.776 HG22 HG13 ' A' ' 73' ' ' VAL . 5.7 t -96.83 117.88 42.19 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.604 0 O-C-N 120.922 -1.111 . . . . 0.0 110.323 -178.071 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.817 ' CG1' HD12 ' A' ' 40' ' ' ILE . 3.7 m -108.83 99.71 9.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 C-N-CA 119.26 -0.976 . . . . 0.0 108.936 179.555 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.428 ' HB2' ' CB ' ' A' ' 65' ' ' TYR . . . -132.41 162.0 32.22 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 120.677 -1.264 . . . . 0.0 110.64 -178.688 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . . . . . . . . . 15.3 t -91.05 -34.51 15.08 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.263 -0.898 . . . . 0.0 110.717 -179.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -177.97 -29.6 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.119 -0.988 . . . . 0.0 111.091 -179.911 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.504 ' HB2' ' HA ' ' A' ' 66' ' ' TYR . . . -44.85 -34.07 2.19 Favored 'General case' 0 N--CA 1.497 1.905 0 O-C-N 121.183 -0.948 . . . . 0.0 111.071 -179.517 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.44 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.7 tp -67.04 -33.86 76.45 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.13 -0.981 . . . . 0.0 109.746 179.496 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . 0.538 ' C ' HG22 ' A' ' 90' ' ' THR . 4.5 mmt 55.09 -87.48 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.606 -0.684 . . . . 0.0 110.505 179.801 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.538 HG22 ' C ' ' A' ' 89' ' ' MET . 0.0 OUTLIER -179.5 -91.76 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.871 0 O-C-N 120.944 -1.097 . . . . 0.0 110.46 -179.833 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . 0.418 ' N ' ' OG1' ' A' ' 90' ' ' THR . . . 70.09 -65.38 0.71 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.853 -1.299 . . . . 0.0 109.853 179.975 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . 0.41 ' N ' ' O ' ' A' ' 90' ' ' THR . 38.3 p90 -128.22 13.93 6.68 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -1.213 . . . . 0.0 110.858 -179.637 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.534 HG22 ' OG1' ' A' ' 90' ' ' THR . 14.6 t -75.47 -167.25 0.63 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.1 -1.0 . . . . 0.0 110.408 -179.716 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.431 ' O ' ' CD ' ' A' ' 124' ' ' ARG . . . 113.11 -37.58 3.57 Favored Glycine 0 N--CA 1.491 2.343 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 179.345 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.4 t0 -84.43 65.41 8.91 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.941 -1.329 . . . . 0.0 110.733 -179.415 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.471 ' CD1' ' N ' ' A' ' 96' ' ' PHE . 22.0 m-85 -119.84 149.13 42.57 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.16 -0.963 . . . . 0.0 110.077 179.309 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.457 ' HB2' ' NE2' ' A' ' 38' ' ' HIS . 12.5 m-20 -83.69 -29.31 27.69 Favored 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.463 -0.773 . . . . 0.0 109.989 179.86 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 5.2 p -161.69 163.6 29.67 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.157 -0.964 . . . . 0.0 111.345 -179.645 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.521 ' CG2' ' CD2' ' A' ' 130' ' ' TYR . 0.0 OUTLIER -132.16 114.41 23.85 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.922 0 O-C-N 121.433 -0.792 . . . . 0.0 109.96 179.097 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.936 HG21 HD11 ' A' ' 28' ' ' ILE . 3.7 mp -93.01 115.67 32.36 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.23 -0.919 . . . . 0.0 109.267 179.563 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -122.94 160.92 25.18 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.209 -0.932 . . . . 0.0 111.547 -178.617 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' CD2' ' A' ' 24' ' ' TYR . 13.7 t -100.66 3.78 42.73 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.632 -0.668 . . . . 0.0 109.477 178.144 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 2.7 m120 48.54 23.87 0.68 Allowed 'General case' 0 N--CA 1.494 1.741 0 O-C-N 121.241 -0.912 . . . . 0.0 111.22 -179.934 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.901 HG22 ' HA ' ' A' ' 109' ' ' PRO . 0.8 OUTLIER -146.76 135.76 22.44 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.019 -1.051 . . . . 0.0 110.485 179.299 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.6 p -114.78 132.68 56.38 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.298 -0.876 . . . . 0.0 109.938 179.8 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 2.3 t0 52.52 -142.65 0.75 Allowed 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.025 -1.047 . . . . 0.0 109.832 -179.858 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -87.17 17.31 43.22 Favored Glycine 0 N--CA 1.492 2.408 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.491 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 5.6 mmtp -129.42 156.29 78.76 Favored Pre-proline 0 N--CA 1.488 1.458 0 O-C-N 121.102 -1.234 . . . . 0.0 109.43 -179.965 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.901 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.8 Cg_endo -64.35 167.1 15.44 Favored 'Trans proline' 0 C--N 1.308 -1.575 0 O-C-N 123.595 1.313 . . . . 0.0 110.465 179.966 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.513 ' CG ' ' HB3' ' A' ' 114' ' ' SER . 13.9 tt0 -70.79 154.88 41.43 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.457 -0.777 . . . . 0.0 110.91 -178.83 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 114' ' ' SER . 6.3 p-10 -88.31 161.51 17.1 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.577 -0.702 . . . . 0.0 110.09 179.66 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.77 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -52.33 -61.8 2.04 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.351 -0.843 . . . . 0.0 112.287 -178.599 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.424 ' HA ' ' HB ' ' A' ' 116' ' ' THR . 7.3 m -58.09 -29.77 37.51 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.957 0 O-C-N 120.805 -1.185 . . . . 0.0 112.043 -177.952 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.513 ' HB3' ' CG ' ' A' ' 110' ' ' GLN . 0.3 OUTLIER -47.83 -56.18 8.05 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 120.946 -1.096 . . . . 0.0 110.478 -179.301 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.441 ' O ' ' HB2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -66.55 -33.85 76.6 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.208 -0.932 . . . . 0.0 108.942 178.964 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.424 ' HB ' ' HA ' ' A' ' 113' ' ' VAL . 88.6 m -60.27 -49.84 76.01 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.02 -1.05 . . . . 0.0 108.453 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 2.5 tt0 -73.94 -37.98 64.39 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.457 -0.777 . . . . 0.0 110.23 179.004 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 40.5 mtt85 -72.17 -44.88 62.38 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.2 -0.938 . . . . 0.0 111.46 -179.262 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.536 ' CD ' ' CE1' ' A' ' 7' ' ' HIS . 12.2 ttm180 -54.64 -45.35 73.75 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.758 -1.214 . . . . 0.0 109.508 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -62.26 81.68 0.03 OUTLIER Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.757 -1.337 . . . . 0.0 109.757 179.699 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.451 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.1 OUTLIER -156.23 -50.69 0.08 Allowed 'General case' 0 N--CA 1.49 1.54 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 179.639 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.538 HG22 HD13 ' A' ' 10' ' ' ILE . 8.7 t -93.19 143.51 26.19 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 178.269 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.478 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 116.57 1.62 19.77 Favored Glycine 0 N--CA 1.487 2.071 0 C-N-CA 119.314 -1.422 . . . . 0.0 110.625 179.513 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.431 ' CD ' ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -70.18 85.85 0.56 Allowed 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.926 -1.337 . . . . 0.0 110.159 -179.817 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 120.09 -37.95 2.92 Favored Glycine 0 N--CA 1.493 2.444 0 N-CA-C 108.696 -1.762 . . . . 0.0 108.696 -179.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.492 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.1 OUTLIER -136.9 -166.85 0.13 Allowed Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.471 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.492 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 49.3 Cg_endo -86.36 114.8 1.3 Allowed 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.084 1.044 . . . . 0.0 109.642 179.212 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.516 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -75.41 167.91 54.81 Favored Glycine 0 N--CA 1.493 2.468 0 C-N-CA 119.86 -1.162 . . . . 0.0 110.498 -179.308 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . . . . . . . . . 3.7 mt -119.85 138.75 49.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.473 -1.016 . . . . 0.0 108.613 178.728 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.521 ' CD2' ' CG2' ' A' ' 99' ' ' VAL . 7.5 t80 -129.28 118.8 22.89 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.112 -0.992 . . . . 0.0 110.548 179.868 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.475 ' HD2' HG11 ' A' ' 32' ' ' VAL . 8.4 mtt180 -106.28 127.17 53.05 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.492 -0.755 . . . . 0.0 109.889 179.944 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.468 ' CD1' ' O ' ' A' ' 134' ' ' ALA . 10.4 p90 -118.9 158.49 25.59 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.138 -0.976 . . . . 0.0 109.835 179.768 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . 0.662 HG22 HD23 ' A' ' 15' ' ' LEU . 7.1 t -82.92 -50.6 15.57 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.093 -1.004 . . . . 0.0 110.256 179.802 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.468 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -49.52 162.64 0.42 Allowed Pre-proline 0 N--CA 1.494 1.764 0 O-C-N 121.371 -0.831 . . . . 0.0 111.513 -178.888 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -76.38 -53.87 0.08 OUTLIER 'Trans proline' 0 C--N 1.312 -1.361 0 O-C-N 123.596 1.314 . . . . 0.0 110.163 179.819 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . 117.89 177.72 17.27 Favored Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.511 -1.436 . . . . 0.0 109.511 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 1.3 tm-20 -74.26 -34.39 63.58 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.295 -1.121 . . . . 0.0 110.203 179.989 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.165 -179.941 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.553 -1.419 . . . . 0.0 109.553 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -75.06 106.37 6.54 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.257 -1.143 . . . . 0.0 110.064 179.867 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.597 ' O ' HG23 ' A' ' 3' ' ' VAL . 27.5 m -112.99 104.17 16.6 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.285 -0.884 . . . . 0.0 110.024 179.765 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' THR . . . . . 0.867 ' CG2' ' HB1' ' A' ' 112' ' ' ALA . 18.0 p -66.96 141.18 57.7 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 121.331 -0.856 . . . . 0.0 109.894 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.456 HG13 ' CG2' ' A' ' 116' ' ' THR . 0.2 OUTLIER -66.63 147.58 98.95 Favored Pre-proline 0 N--CA 1.489 1.484 0 O-C-N 121.163 -0.961 . . . . 0.0 109.381 179.856 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' PRO . . . . . 0.424 ' HD2' HG23 ' A' ' 5' ' ' VAL . 42.3 Cg_endo -67.86 -168.33 0.19 Allowed 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 124.189 1.626 . . . . 0.0 110.675 179.637 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' HIS . . . . . 0.529 ' CE1' ' HD2' ' A' ' 119' ' ' ARG . 0.3 OUTLIER -179.81 81.24 0.19 Allowed Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.472 -0.768 . . . . 0.0 109.987 -179.818 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' PRO . . . . . 0.453 ' O ' ' CB ' ' A' ' 9' ' ' ASN . 42.5 Cg_endo -69.78 -170.73 0.41 Allowed 'Trans proline' 0 C--N 1.308 -1.597 0 O-C-N 123.73 1.384 . . . . 0.0 109.831 179.644 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.453 ' CB ' ' O ' ' A' ' 8' ' ' PRO . 6.5 m120 76.84 -14.04 0.87 Allowed 'General case' 0 N--CA 1.508 2.457 0 O-C-N 121.854 -0.529 . . . . 0.0 111.264 -179.497 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . 0.497 ' HA ' ' O ' ' A' ' 128' ' ' GLY . 14.2 mt -116.6 135.37 57.11 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 120.607 -1.308 . . . . 0.0 109.484 179.047 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.446 ' N ' ' O ' ' A' ' 128' ' ' GLY . 1.5 tm-20 -86.13 127.22 34.66 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.21 -0.931 . . . . 0.0 109.804 179.335 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.41 ' HG2' ' NH2' ' A' ' 119' ' ' ARG . 47.6 mt-10 -90.48 136.64 32.93 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.104 -0.998 . . . . 0.0 109.999 -179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.499 HG11 ' CZ ' ' A' ' 131' ' ' ARG . 5.1 t -133.17 157.67 42.87 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 O-C-N 121.21 -0.931 . . . . 0.0 110.072 -179.527 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -105.57 112.21 25.22 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.222 -0.924 . . . . 0.0 110.039 179.549 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . 0.757 HD23 ' HB2' ' A' ' 26' ' ' LYS . 8.6 tp -54.85 147.38 15.26 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.237 -0.914 . . . . 0.0 109.264 179.391 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 7.2 p -148.63 -179.52 7.04 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.076 -1.015 . . . . 0.0 110.502 -179.437 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 2.5 p -78.19 74.61 4.73 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.343 -0.848 . . . . 0.0 109.978 179.698 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' THR . . . . . 0.808 ' N ' ' HB3' ' A' ' 27' ' ' ALA . 9.3 m -152.41 108.83 3.42 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.298 -0.876 . . . . 0.0 110.756 -179.663 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 29' ' ' PRO . . . 148.53 -167.17 29.17 Favored Glycine 0 N--CA 1.488 2.152 0 C-N-CA 118.98 -1.581 . . . . 0.0 110.884 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' GLU . . . . . 0.461 ' HB3' HD11 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -112.27 -24.81 9.59 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.687 -0.89 . . . . 0.0 110.451 -179.957 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ILE . . . . . 0.978 HD12 HD13 ' A' ' 55' ' ' LEU . 9.4 tt -95.12 101.94 8.37 Favored Pre-proline 0 C--N 1.306 -1.325 0 C-N-CA 118.743 -1.183 . . . . 0.0 109.746 -179.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.452 ' HD2' ' HA ' ' A' ' 21' ' ' ILE . 37.0 Cg_endo -61.46 127.36 21.63 Favored 'Trans proline' 0 C--N 1.313 -1.295 0 O-C-N 123.518 1.273 . . . . 0.0 111.051 -178.993 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' PHE . . . . . 0.416 ' O ' ' N ' ' A' ' 25' ' ' GLY . 6.4 t80 -117.21 -171.87 2.11 Favored 'General case' 0 N--CA 1.489 1.521 0 CA-C-O 121.522 0.677 . . . . 0.0 110.671 -179.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' TYR . . . . . 0.566 ' CZ ' ' CD2' ' A' ' 43' ' ' HIS . 36.6 m-85 -57.59 83.62 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.469 -0.77 . . . . 0.0 111.707 -179.418 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' A' ' 23' ' ' PHE . . . 77.0 -4.62 53.4 Favored Glycine 0 N--CA 1.494 2.529 0 C-N-CA 120.399 -0.905 . . . . 0.0 110.94 178.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' LYS . . . . . 0.757 ' HB2' HD23 ' A' ' 15' ' ' LEU . 28.3 mmtt -130.09 156.34 44.7 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.828 -1.395 . . . . 0.0 109.865 -179.92 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . 0.808 ' HB3' ' N ' ' A' ' 18' ' ' THR . . . -106.22 108.02 19.31 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.051 -1.03 . . . . 0.0 108.913 179.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' ILE . . . . . 0.924 ' HB ' HG23 ' A' ' 21' ' ' ILE . 5.1 mt -68.19 112.94 12.32 Favored Pre-proline 0 C--N 1.299 -1.589 0 O-C-N 121.241 -0.912 . . . . 0.0 110.726 -179.046 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' PRO . . . . . 0.729 ' O ' HG22 ' A' ' 32' ' ' VAL . 40.5 Cg_endo -68.43 130.04 20.25 Favored 'Trans proline' 0 C--N 1.307 -1.635 0 N-CA-C 107.051 -1.942 . . . . 0.0 107.051 176.106 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.581 ' CD2' HD11 ' A' ' 33' ' ' ILE . 12.9 mt -56.56 -17.22 7.75 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.82 -1.175 . . . . 0.0 110.804 -177.968 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.426 ' HG2' ' HB2' ' A' ' 29' ' ' PRO . 0.0 OUTLIER -59.28 -16.07 19.5 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.695 -1.253 . . . . 0.0 110.484 179.98 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 1.073 HG23 HG23 ' A' ' 33' ' ' ILE . 10.0 m -95.16 -24.26 4.83 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.852 0 O-C-N 120.976 -1.077 . . . . 0.0 110.753 179.961 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 1.073 HG23 HG23 ' A' ' 32' ' ' VAL . 46.4 pt -116.56 -12.22 11.59 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.15 -0.969 . . . . 0.0 110.908 -179.255 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' LYS . . . . . 0.627 ' HB2' HD11 ' A' ' 60' ' ' ILE . 8.9 tptm -102.09 148.33 25.52 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 120.843 -1.161 . . . . 0.0 110.204 179.695 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 107.02 -5.29 36.25 Favored Glycine 0 N--CA 1.485 1.933 0 N-CA-C 109.298 -1.521 . . . . 0.0 109.298 -179.323 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . 177.97 -138.77 3.9 Favored Glycine 0 N--CA 1.491 2.348 0 C-N-CA 119.368 -1.396 . . . . 0.0 110.06 179.907 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' ARG . . . . . 0.439 ' HA ' ' O ' ' A' ' 80' ' ' VAL . 0.1 OUTLIER -116.51 135.94 53.4 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.315 -1.109 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' HIS . . . . . 0.569 ' CG ' ' HA ' ' A' ' 33' ' ' ILE . 93.5 m-70 -140.03 153.45 46.82 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.302 -0.874 . . . . 0.0 111.172 -179.455 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.636 ' HB3' HG12 ' A' ' 99' ' ' VAL . 60.6 tp -113.49 116.45 29.6 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.43 -0.794 . . . . 0.0 110.301 179.981 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.92 HD12 ' CG1' ' A' ' 83' ' ' VAL . 33.8 mt -100.95 128.1 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.2 -0.938 . . . . 0.0 109.571 179.36 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' PHE . . . . . . . . . . . . . 20.8 m-85 -95.12 123.76 38.79 Favored 'General case' 0 C--N 1.294 -1.813 0 O-C-N 121.439 -0.788 . . . . 0.0 110.232 -179.727 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' CYS . . . . . . . . . . . . . 1.7 m -116.9 159.91 21.69 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.247 -0.908 . . . . 0.0 110.691 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.566 ' CD2' ' CZ ' ' A' ' 24' ' ' TYR . 24.3 p80 -105.59 -4.45 21.14 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.394 -0.816 . . . . 0.0 110.341 179.333 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' SER . . . . . . . . . . . . . 8.4 p -132.14 138.51 48.08 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.948 -1.095 . . . . 0.0 110.687 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.502 ' HD2' ' CD1' ' A' ' 66' ' ' TYR . 4.1 ttpm? -71.21 -41.19 70.55 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.462 -0.774 . . . . 0.0 110.629 -179.912 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -58.93 -34.76 72.1 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.25 -0.906 . . . . 0.0 110.622 -179.707 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -73.44 -37.35 65.89 Favored 'General case' 0 C--N 1.301 -1.525 0 O-C-N 121.347 -0.846 . . . . 0.0 109.932 -179.807 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' CYS . . . . . 0.878 ' HB3' ' HB1' ' A' ' 64' ' ' ALA . 73.9 m -61.1 -34.37 74.84 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.308 -0.87 . . . . 0.0 109.833 179.665 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . 0.408 ' OD1' ' CE2' ' A' ' 66' ' ' TYR . 3.1 m-20 -67.68 -50.07 59.55 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.226 -0.921 . . . . 0.0 110.592 -179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' A' ' 54' ' ' LYS . 11.7 mt-10 -72.37 -40.55 67.22 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.265 -0.897 . . . . 0.0 110.402 -179.763 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.803 HD21 HD11 ' A' ' 21' ' ' ILE . 3.4 tm? -60.89 -42.67 98.45 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.609 -0.682 . . . . 0.0 111.578 -178.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -68.68 -51.12 45.2 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.83 -1.168 . . . . 0.0 110.27 -179.741 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ALA . . . . . . . . . . . . . . . -57.19 -34.4 68.45 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.099 -1.001 . . . . 0.0 109.185 179.538 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.527 ' O ' HD23 ' A' ' 58' ' ' LEU . 0.0 OUTLIER -57.26 -47.94 80.15 Favored 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.188 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 55' ' ' LEU . . . . . 0.978 HD13 HD12 ' A' ' 21' ' ' ILE . 0.0 OUTLIER -57.06 -42.42 80.53 Favored 'General case' 0 C--N 1.298 -1.638 0 O-C-N 121.567 -0.708 . . . . 0.0 110.92 -179.978 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 55.1 t -55.72 -28.31 23.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.951 -1.093 . . . . 0.0 108.742 179.487 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 57' ' ' ALA . . . . . 0.484 ' HB3' ' O ' ' A' ' 54' ' ' LYS . . . -75.58 -35.38 60.6 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.496 -0.753 . . . . 0.0 110.286 179.395 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 58' ' ' LEU . . . . . 0.527 HD23 ' O ' ' A' ' 54' ' ' LYS . 4.6 mm? -72.38 -26.06 61.75 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.221 -0.924 . . . . 0.0 109.839 179.945 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 59' ' ' GLY . . . . . . . . . . . . . . . 121.36 8.03 7.97 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.31 -1.516 . . . . 0.0 109.31 -179.215 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.627 HD11 ' HB2' ' A' ' 34' ' ' LYS . 50.5 mt -106.33 143.0 17.94 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.417 0 O-C-N 121.321 -1.105 . . . . 0.0 109.663 179.986 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 61' ' ' ASN . . . . . 0.443 ' O ' ' HA ' ' A' ' 80' ' ' VAL . 13.6 t30 -87.41 106.55 18.03 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 178.408 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.58 ' CB ' HD23 ' A' ' 55' ' ' LEU . . . -119.49 146.0 45.81 Favored 'General case' 0 C--N 1.296 -1.746 0 C-N-CA 119.223 -0.991 . . . . 0.0 111.007 -177.677 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.689 ' HB ' HG13 ' A' ' 73' ' ' VAL . 6.1 t -138.67 149.98 23.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 C-N-CA 119.847 -0.741 . . . . 0.0 109.342 179.919 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.878 ' HB1' ' HB3' ' A' ' 48' ' ' CYS . . . -112.01 134.8 53.35 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.116 -1.034 . . . . 0.0 110.701 179.925 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 65' ' ' TYR . . . . . 0.654 ' CD1' HD12 ' A' ' 69' ' ' LEU . 20.3 t80 -124.92 129.25 50.0 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.406 -0.809 . . . . 0.0 110.302 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.81 ' CZ ' HD23 ' A' ' 69' ' ' LEU . 3.0 p90 -154.71 -171.25 3.78 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.585 -0.697 . . . . 0.0 109.648 179.846 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -63.86 124.88 22.66 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.145 -0.972 . . . . 0.0 110.728 -179.45 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 68' ' ' GLY . . . . . . . . . . . . . . . 80.34 34.06 30.21 Favored Glycine 0 N--CA 1.493 2.487 0 N-CA-C 109.733 -1.347 . . . . 0.0 109.733 179.786 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 69' ' ' LEU . . . . . 0.928 HD13 ' N ' ' A' ' 70' ' ' ASP . 2.7 tm? -117.33 157.13 26.65 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.191 -1.182 . . . . 0.0 110.078 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.928 ' N ' HD13 ' A' ' 69' ' ' LEU . 2.2 m-20 -95.41 148.12 22.8 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.167 -0.958 . . . . 0.0 110.799 -179.275 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.692 ' O ' HG23 ' A' ' 71' ' ' VAL . 28.3 m -62.92 111.27 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.088 -1.007 . . . . 0.0 109.06 178.902 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.432 ' CB ' HG11 ' A' ' 63' ' ' VAL . 4.1 m -131.14 -11.83 3.66 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.117 -0.99 . . . . 0.0 111.516 -179.341 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 73' ' ' VAL . . . . . 0.956 ' CG1' HG22 ' A' ' 82' ' ' VAL . 0.1 OUTLIER -94.28 136.2 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 120.757 -1.214 . . . . 0.0 109.511 179.836 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 74' ' ' ILE . . . . . 0.506 ' O ' HD12 ' A' ' 74' ' ' ILE . 1.2 pp -136.93 92.13 14.55 Favored Pre-proline 0 N--CA 1.497 1.888 0 O-C-N 121.144 -0.972 . . . . 0.0 110.497 -179.924 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.439 ' HA ' HG11 ' A' ' 80' ' ' VAL . 51.4 Cg_endo -77.0 58.1 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.47 0 O-C-N 123.428 1.225 . . . . 0.0 110.52 179.745 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 76' ' ' THR . . . . . . . . . . . . . 4.4 p -119.43 -32.0 4.47 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.163 -0.961 . . . . 0.0 110.337 -179.998 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 77' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 -150.82 160.65 43.74 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.258 -0.901 . . . . 0.0 110.169 179.997 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . 65.01 166.65 1.38 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.238 -1.545 . . . . 0.0 109.238 -179.837 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 79' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -89.09 102.97 15.62 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.1 -1.235 . . . . 0.0 110.171 -179.949 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.443 ' HA ' ' O ' ' A' ' 61' ' ' ASN . 5.8 p -117.07 135.1 58.56 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.711 0 CA-C-O 121.9 0.857 . . . . 0.0 110.328 -179.957 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 HG22 ' A' ' 60' ' ' ILE . 7.2 m -112.91 122.5 67.18 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.189 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.545 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.956 HG22 ' CG1' ' A' ' 73' ' ' VAL . 4.5 t -96.8 117.68 41.77 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.042 -1.036 . . . . 0.0 110.073 -177.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 83' ' ' VAL . . . . . 0.92 ' CG1' HD12 ' A' ' 40' ' ' ILE . 5.3 m -111.46 99.79 9.41 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.057 -1.027 . . . . 0.0 108.804 179.687 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 84' ' ' ALA . . . . . 0.484 ' HB1' ' O ' ' A' ' 65' ' ' TYR . . . -139.18 159.88 41.11 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 120.603 -1.311 . . . . 0.0 111.252 -178.218 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 85' ' ' THR . . . . . 0.496 HG23 ' N ' ' A' ' 86' ' ' ASP . 7.8 t -82.36 -130.44 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.564 -0.71 . . . . 0.0 109.496 179.775 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 86' ' ' ASP . . . . . 0.496 ' N ' HG23 ' A' ' 85' ' ' THR . 0.3 OUTLIER -93.8 27.81 2.6 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 120.628 -1.295 . . . . 0.0 110.246 179.917 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . 0.476 ' CB ' ' HA ' ' A' ' 66' ' ' TYR . . . -94.14 -35.81 12.35 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.885 . . . . 0.0 110.066 179.848 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.429 ' O ' ' N ' ' A' ' 90' ' ' THR . 1.3 tp -69.29 -33.0 72.52 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.19 -0.944 . . . . 0.0 109.654 179.639 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 89' ' ' MET . . . . . . . . . . . . . 4.2 mmt 54.06 -89.94 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.585 -0.697 . . . . 0.0 110.144 179.93 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 90' ' ' THR . . . . . 0.519 ' OG1' HG22 ' A' ' 93' ' ' THR . 0.4 OUTLIER 177.84 41.71 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 120.896 -1.127 . . . . 0.0 110.097 179.843 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 91' ' ' GLY . . . . . . . . . . . . . . . -62.78 -48.65 79.46 Favored Glycine 0 N--CA 1.489 2.182 0 N-CA-C 109.126 -1.59 . . . . 0.0 109.126 179.61 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 92' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -128.56 32.63 4.79 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.46 -1.024 . . . . 0.0 110.51 -179.893 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 93' ' ' THR . . . . . 0.559 HG23 ' N ' ' A' ' 94' ' ' GLY . 5.6 t -95.1 -152.92 0.37 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.096 -1.003 . . . . 0.0 110.217 -179.98 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.559 ' N ' HG23 ' A' ' 93' ' ' THR . . . 97.35 -10.29 65.18 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.642 179.117 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 95' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -124.92 65.0 1.12 Allowed 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.748 -1.442 . . . . 0.0 110.893 -179.69 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.425 ' HE1' ' HG1' ' A' ' 93' ' ' THR . 48.3 m-85 -120.08 151.58 38.83 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.081 -1.012 . . . . 0.0 110.286 179.337 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 97' ' ' ASP . . . . . 0.45 ' HB2' ' CE1' ' A' ' 38' ' ' HIS . 0.6 OUTLIER -81.47 -30.95 33.19 Favored 'General case' 0 C--N 1.298 -1.631 0 C-N-CA 119.65 -0.82 . . . . 0.0 109.297 179.012 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.459 ' CB ' ' HB ' ' A' ' 129' ' ' ILE . 8.2 p -161.96 163.94 28.7 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 111.217 179.884 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 99' ' ' VAL . . . . . 0.636 HG12 ' HB3' ' A' ' 39' ' ' LEU . 0.0 OUTLIER -130.44 115.36 31.54 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.824 0 O-C-N 121.528 -0.733 . . . . 0.0 109.792 179.066 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 100' ' ' ILE . . . . . 0.874 HG21 HD11 ' A' ' 28' ' ' ILE . 2.7 mp -93.13 117.6 36.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.712 0 O-C-N 121.24 -0.912 . . . . 0.0 109.1 179.515 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.442 ' O ' ' HA ' ' A' ' 132' ' ' PHE . 3.9 t0 -122.51 161.15 24.15 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.175 -0.953 . . . . 0.0 111.568 -178.507 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 20.6 t -103.43 8.38 37.96 Favored 'General case' 0 C--N 1.302 -1.496 0 O-C-N 121.578 -0.701 . . . . 0.0 109.125 177.935 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 103' ' ' ASN . . . . . . . . . . . . . 4.0 m-20 52.3 22.31 1.97 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.282 -0.886 . . . . 0.0 110.681 -179.987 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.654 HG22 ' HA ' ' A' ' 109' ' ' PRO . 1.3 p -142.88 133.66 25.36 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.174 -0.954 . . . . 0.0 110.728 -179.869 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.6 p -113.86 132.42 55.91 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.363 -0.836 . . . . 0.0 109.431 179.246 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 106' ' ' ASP . . . . . . . . . . . . . 14.7 m-20 54.53 -141.95 0.83 Allowed 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.021 -1.049 . . . . 0.0 109.49 -179.361 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 107' ' ' GLY . . . . . . . . . . . . . . . -90.36 24.7 15.37 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.77 -1.332 . . . . 0.0 109.77 179.514 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 108' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -139.84 157.21 70.11 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.262 -1.14 . . . . 0.0 109.641 -179.837 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.654 ' HA ' HG22 ' A' ' 104' ' ' THR . 38.9 Cg_endo -64.67 166.31 18.24 Favored 'Trans proline' 0 C--N 1.31 -1.499 0 O-C-N 123.574 1.302 . . . . 0.0 110.212 -179.759 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -73.07 162.89 28.93 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.213 -0.929 . . . . 0.0 110.8 -179.24 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 111' ' ' ASP . . . . . 0.578 ' OD2' HG22 ' A' ' 113' ' ' VAL . 3.6 p-10 -92.67 162.58 14.1 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.478 -0.764 . . . . 0.0 110.376 179.959 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 112' ' ' ALA . . . . . 0.867 ' HB1' ' CG2' ' A' ' 4' ' ' THR . . . -50.53 -49.38 55.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.841 -1.162 . . . . 0.0 111.924 -178.734 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 113' ' ' VAL . . . . . 0.578 HG22 ' OD2' ' A' ' 111' ' ' ASP . 5.7 m -72.6 -30.63 34.57 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.904 0 O-C-N 120.636 -1.29 . . . . 0.0 113.326 -177.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 114' ' ' SER . . . . . 0.45 ' OG ' ' O ' ' A' ' 111' ' ' ASP . 1.2 p -53.87 -54.75 34.19 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 120.26 -1.525 . . . . 0.0 110.091 -178.686 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.433 ' HG2' ' O ' ' A' ' 112' ' ' ALA . 3.3 ptm180 -61.26 -35.94 78.63 Favored 'General case' 0 N--CA 1.488 1.464 0 C-N-CA 118.358 -1.337 . . . . 0.0 108.201 178.376 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.456 ' CG2' HG13 ' A' ' 5' ' ' VAL . 82.8 m -60.8 -49.94 75.48 Favored 'General case' 0 C--N 1.308 -1.199 0 C-N-CA 119.273 -0.971 . . . . 0.0 108.428 178.737 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.4 ' HA ' ' NE2' ' A' ' 117' ' ' GLN . 7.6 tp60 -73.66 -46.51 46.14 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.397 -0.814 . . . . 0.0 109.852 178.804 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 118' ' ' ARG . . . . . . . . . . . . . 56.1 mtt-85 -58.21 -46.07 86.5 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.229 -0.919 . . . . 0.0 110.528 179.979 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 119' ' ' ARG . . . . . 0.529 ' HD2' ' CE1' ' A' ' 7' ' ' HIS . 11.0 ttm180 -58.18 -39.86 79.98 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 120.828 -1.17 . . . . 0.0 109.509 179.417 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 120' ' ' GLY . . . . . . . . . . . . . . . -68.62 68.84 0.4 Allowed Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.932 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 121' ' ' ARG . . . . . 0.427 ' N ' ' O ' ' A' ' 119' ' ' ARG . 0.7 OUTLIER -146.21 -45.91 0.2 Allowed 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.443 -1.033 . . . . 0.0 108.789 179.477 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 122' ' ' THR . . . . . 0.558 HG23 ' HA3' ' A' ' 128' ' ' GLY . 14.9 t -94.36 142.38 27.49 Favored 'General case' 0 N--CA 1.487 1.414 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 178.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 123' ' ' GLY . . . . . 0.47 ' HA2' ' O ' ' A' ' 126' ' ' LYS . . . 119.36 5.7 11.21 Favored Glycine 0 N--CA 1.487 2.079 0 C-N-CA 119.35 -1.405 . . . . 0.0 110.55 179.856 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 124' ' ' ARG . . . . . 0.429 ' HD3' ' HA2' ' A' ' 94' ' ' GLY . 0.0 OUTLIER -76.25 84.58 3.05 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.952 -1.322 . . . . 0.0 110.137 -179.853 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 125' ' ' GLY . . . . . . . . . . . . . . . 114.91 -43.58 1.66 Allowed Glycine 0 N--CA 1.492 2.433 0 N-CA-C 109.034 -1.626 . . . . 0.0 109.034 -179.668 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 126' ' ' LYS . . . . . 0.48 ' HB2' ' CD ' ' A' ' 127' ' ' PRO . 0.0 OUTLIER -124.18 -169.32 0.17 Allowed Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.52 -0.988 . . . . 0.0 108.672 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.48 ' CD ' ' HB2' ' A' ' 126' ' ' LYS . 47.8 Cg_endo -87.75 110.68 0.72 Allowed 'Trans proline' 0 C--N 1.309 -1.512 0 O-C-N 123.237 1.124 . . . . 0.0 109.454 178.862 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 128' ' ' GLY . . . . . 0.558 ' HA3' HG23 ' A' ' 122' ' ' THR . . . -76.58 146.58 32.95 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.42 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 129' ' ' ILE . . . . . 0.481 HD12 ' N ' ' A' ' 129' ' ' ILE . 2.9 mp -106.35 141.17 22.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.865 -1.373 . . . . 0.0 109.273 179.293 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 130' ' ' TYR . . . . . 0.615 ' CD2' HG23 ' A' ' 99' ' ' VAL . 4.4 t80 -127.86 115.35 18.47 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.075 -1.015 . . . . 0.0 110.424 179.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 131' ' ' ARG . . . . . 0.499 ' CZ ' HG11 ' A' ' 13' ' ' VAL . 6.5 mmt180 -102.08 123.36 45.83 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.529 -0.732 . . . . 0.0 109.635 179.873 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 132' ' ' PHE . . . . . 0.443 ' CE1' ' HA ' ' A' ' 135' ' ' PRO . 25.8 p90 -115.23 157.8 23.2 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.041 -1.037 . . . . 0.0 110.095 -179.826 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 133' ' ' VAL . . . . . . . . . . . . . 25.4 t -88.96 -38.99 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.063 -1.023 . . . . 0.0 109.771 179.527 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 134' ' ' ALA . . . . . 0.417 ' O ' ' CD1' ' A' ' 132' ' ' PHE . . . -96.18 131.68 28.28 Favored Pre-proline 0 N--CA 1.492 1.673 0 O-C-N 121.201 -0.937 . . . . 0.0 110.212 -179.851 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 135' ' ' PRO . . . . . 0.443 ' HA ' ' CE1' ' A' ' 132' ' ' PHE . 49.7 Cg_endo -76.88 -19.66 13.89 Favored 'Trans proline' 0 C--N 1.314 -1.255 0 O-C-N 123.529 1.278 . . . . 0.0 110.624 -179.855 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 136' ' ' GLY . . . . . . . . . . . . . . . -52.19 105.37 0.24 Allowed Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.826 -1.31 . . . . 0.0 109.826 -179.817 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 137' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -135.03 -166.35 1.81 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.252 -1.146 . . . . 0.0 110.205 179.95 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 138' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 118.092 -0.956 . . . . 0.0 110.272 179.99 . . . . . . . . 1 1 . 1 stop_ save_